Index 256

2

February 2016

Volume 23 Number 0

Editor: Kaye Wilson email: enguiry@pharmac.govt.nz Telephone +64 4 460 4990 Facsimile +64 4 460 4995 Level 9. 40 Mercer Street PO Box 10 254 Wellington

Freephone Information Line 0800 66 00 50 (9am - 5pm weekdays)

Circulation

Published each April, August and December. Changes to the contents are published in monthly updates.

Accessible in an electronic format at no cost from the Health Professionals section of the PHARMAC website www.pharmac.govt.nz

You can register to have an electronic version of the Pharmaceutical Schedule (link to PDF copy) emailed to your nominated email address each month. Alternatively there is a nominal charge for an annual subscription to the printed Schedule publications. To access either of these subscriptions visit our subscription website www.schedule.co.nz.

Production

Typeset automatically from XML and TEX. XML version of the Schedule available from www.pharmac.govt.nz/schedule/archive/

Programmers

Anrik Drenth & John Geering email: texschedule@pharmac.govt.nz

© Pharmaceutical Management Agency



ISSN 1179-3686 pdf ISSN 1172-9376 print

This work is licensed under the Creative Commons Attribution 3.0 New Zealand licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to PHARMAC and abide by the other licence terms. To view a copy of this licence, visit:

creativecommons.org/licenses/by/3.0/nz/.

Attribution to PHARMAC should be in written form and not by reproduction of the PHARMAC logo. While care has been taken in compiling this Schedule, PHARMAC takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from.

Section /	4
-----------	---

Sectio

General Rules 6

n B	Alimentary Tract & Metabolism	20
	Blood & Blood Forming Organs	41

Cardiovascular System 50

Introducing PHARMAC

- Dermatologicals 62
- Genito Urinary System 73
- Hormone Preparations Systemic 79
- Infections Agents For Systemic Use 91
 - Musculoskeletal System 115
 - Nervous System 125
- Oncology Agents & Immunosuppressants 161
 - Respiratory System & Allergies 197
 - Sensory Organs 205

Various 210

Section C Extemporaneous Compounds (ECPs) 212

Section D Special Foods 219 Section E Practitioner's Supply Orders 239 Rural Areas 243 Section F Dispensing Period Exemptions 244

Section G

Section I National Immunisation Schedule 249

Safety Cap Medicines 246

Introducing PHARMAC

The Pharmaceutical Management Agency (PHARMAC) makes decisions that help control Government spending on pharmaceuticals. This includes community pharmaceuticals, hospital pharmaceuticals, vaccines and increasingly, hospital medical devices. PHARMAC negotiates prices, sets subsidy levels and conditions, and makes decisions on changes to the subsidised list. The funding for pharmaceuticals comes from District Health Boards.

PHARMAC's role:

"Secure for eligible people in need of pharmaceuticals, the best health outcomes that can reasonably be achieved, and from within the amount of funding provided."

New Zealand Public Health and Disability Act 2000

To ensure our decisions are as fair and robust as possible we use a decision-making process that incorporates clinical, economic and commercial issues. We also seek the views of users and the wider community through consultation. The processes we generally use are outlined in our Operating Policies and Procedures.

Further information about PHARMAC and the way we make funding decisions can be found on the PHARMAC website at http://www.pharmac.health.nz/about.

Purpose of the Pharmaceutical Schedule

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer's price and any access conditions that may apply;
- the Hospital Pharmaceuticals that may be used in DHB Hospitals, as well as any access conditions that may apply; and
- the Pharmaceuticals, including Medical Devices, used in DHB Hospitals for which national prices have been negotiated by PHARMAC.

The Schedule does not show the final cost to Government of subsidising each Community Pharmaceutical or to DHB Hospitals in purchasing each Pharmaceutical, since that will depend on any rebate and other arrangements PHARMAC has with the supplier and, for Pharmaceuticals used in DHB Hospitals, on any logistics arrangements put in place.

This book contains sections A through to G and Section I of the Pharmaceutical Schedule and lists the Pharmaceuticals funded for use in the community, including vaccines, as well as haemophilia and cancer treatments given in DHB hospitals. Section H lists the Pharmaceuticals that that can be used in DHB hospitals and is a separate publication.


The Pharmaceuticals in this book are listed by therapeutic group, which is based on the WHO Anatomical Therapeutic Chemical (ATC) system. The listings are displayed alphabetically under each heading.

The index lists both chemical entities and product brand names.

Explaining pharmaceutical entries

The Pharmaceutical Schedule lists pharmaceuticals subsidised by the Government, the subsidy, the supplier's price and the access conditions that may apply.

Example



Glossary

Units of Measure

gramg kilogramkg	milligrammg	m ur
international unitiu	millilitre ml	

millimole	mmol
unit	u

Abbreviations Ampoule ...

Ampoule	Amp	Gelatinous	Gel
Capsule	Сар	Granules	Gran
Cream		Infusion	Inf
Device	Dev	Injection	Inj
Dispersible	Disp	Liquid	Liq
Effervescent	Eff		LA
Emulsion	Emul	Ointment	Oint
Enteric Coated	EC	Sachet	Sach

Solution	Soln
Suppository	Supp
Tablet	Tab
Tincture	Tinc
Trans Dermal Delivery	
System	TDDS

BSO Bulk Supply Order.

CBS Cost Brand Source.

ECP Extemporaneously Compounded Preparation.

- Original Pack subsidy is rounded up to a multiple at whole packs. OP
- PSO Practitioner's Supply Order.

Sole Subsidised

Supplier Only brand of this medicine subsidised.

XPharm Pharmacies cannot claim subsidy because PHARMAC has made alternative distribution arrangements.

Three months supply may be dispensed at one time if the exempted medicine is endorsed 'certified exemption' by the practitioner or pharmacist.

- Three months dispensed all-at-once or, in the case of oral contraceptives, six months dispensed all-at-once, unless the * medicine meets the Dispensing Frequency Rule criteria.
- Safety cap required for oral liquid formulations, including extemporaneously compounded preparations. t
- Fully subsidised brand of a given medicine. Brands without the tick are not fully subsidised and may cost the patient a manufacturer's surcharge.
- S29 This medicine is an unapproved medication supplied under Section 29 of the Medicines Act 1981.
- HP3 Subsidised when dispensed from a pharmacy that has a contract to dispense Special Foods.
- HP4 Subsidised when dispensed from a pharmacy that has a contract to dispense from the Monitored Therapy Variation (for Clozapine Services).

Community Pharmaceutical costs met by the Government

Most of the cost of a subsidised prescription for a Community Pharmaceutical is met by the Government through the Combined Pharmaceutical Budget. The Government pays a subsidy for the Community Pharmaceutical to pharmacies, and a fee covering distribution and pharmacy dispensing services. The subsidy paid to pharmacies does not necessarily represent the final cost to Government of subsidising a particular Community Pharmaceutical. The final cost will depend on the nature of PHARMAC's contractual arrangements with the supplier. Fully subsidised medicines are identified with a V in the product's Schedule listing.

Patient costs

Everyone who is eligible for publicly funded health and disability services should in most circumstances pay only a \$5 co-payment for subsidised medicines, although co-payments can vary from \$0 to \$15. Where the price of a Pharmaceutical is higher than the subsidy, a patient may pay a manufacturer's surcharge in addition to the co-payment. A patient may also pay additional fees for services such as after-hours dispensing and special packaging.

Patients can check whether they are eligible for publicly funded health and disability services by referring to the Guide to eligibility on the Ministry of Health's website.

DHBs have a list of eligible providers in their respective regions. Any provider/prescriber not specifically listed by a DHB as an approved provider/prescriber should be regarded as not approved.

For more information on patient co-payments or eligibility please visit http://www.moh.govt.nz.

Special Authority Applications

Special Authority is an application process in which a prescriber requests government subsidy on a Community Pharmaceutical for a particular person.

Subsidy

Once approved, the applicant will be provided a Special Authority number which must appear on the prescription.

The authority number can provide access to subsidy, increased subsidy, or waive certain restrictions otherwise present on the Community Pharmaceutical.

Some approvals are dependent on the availability of funding from the Combined Pharmaceutical Budget.

Criteria

The criteria for approval of Special Authority applications are included below each Community Pharmaceutical listing, and on the application forms available on PHARMAC's website. For some Special Authority Community Pharmaceuticals, not all indications that have been approved by Medsafe are subsidised.

Making a Special Authority application

Application forms can be found at http://www.pharmac.govt.nz. Except where stated on the application form, applications are processed by the Ministry of Health, and are sent to:

Ministry of Health Sector Services, Fax: (06) 349 1983 or free fax 0800 100 131

Private Bag 3015, WANGANUI 4540

To register for submission of applications on-line - Contact the Ministry of Health on 0800 505 125 or email at

onlinehelpdesk@moh.govt.nz. For Special Authority approval numbers, applicants can phone the Ministry of Health Sector Services Call Centre, free phone 0800 243 666.

Named Patient Pharmaceutical Assessment policy

Named Patient Pharmaceutical Assessment (NPPA) provides a mechanism for individual patients to receive funding for medicines not listed in the Pharmaceutical Schedule (either at all or for their clinical circumstances). PHARMAC will assess applications that meet the prerequisites according to its Decision Criteria before deciding whether to approve applications for funding. The Decision Criteria will be used to assess both the individual clinical circumstances of each NPPA applicant, and the implications of each NPPA funding decision on PHARMAC's ability to carry out its legislative functions.

For more information on NPPA, or to apply, visit the PHARMAC website at

http://www.pharmac.health.nz/link/nppa, or call the Panel Coordinators at 0800 660 050 Option 2.

INTRODUCTION

Section A contains the restrictions and other general rules that apply to Subsidies on Community Pharmaceuticals. The amounts payable by the Funder to Contractors are currently determined by:

- the quantities, forms, and strengths, of subsidised Community Pharmaceuticals dispensed under valid prescription by each Contractor;
- the amount of the Subsidy on the Manufacturer's Price payable for each unit of the Community Pharmaceuticals dispensed by each Contractor and;
- the contractual arrangements between the Contractor and the Funder for the payment of the Contractor's dispensing services.

The Pharmaceutical Schedule shows the level of subsidy payable in respect of each Community Pharmaceutical so that the amount payable by the Government to Contractors, for each Community Pharmaceutical, can be calculated. The Pharmaceutical Schedule also shows the standard price (exclusive of GST) at which a Community Pharmaceutical is supplied ex-manufacturer to wholesalers if it differs from the subsidy. The manufacturer's surcharge to patients can be estimated using the subsidy and the standard manufacturer's price as set out in this Schedule.

The cost to Government of subsidising each Community Pharmaceutical and the manufacturer's prices may vary, in that suppliers may provide rebates to other stakeholders in the primary health care sector, including dispensers, wholesalers, and the Government. Rebates are not specified in the Pharmaceutical Schedule.

This Schedule is dated 1 February 2016 and is to be referred to as the Pharmaceutical Schedule Volume 23 Number 0, 2016. Distribution will be from 20 February 2016. This Schedule comes into force on 1 February 2016.

PART I INTERPRETATIONS AND DEFINITIONS

1.1 In this Schedule, unless the context otherwise requires:

"90 Day Lot", means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 90 consecutive days' treatment;

"180 Day Lot", means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 180 consecutive days' treatment;

"Access Exemption Criteria", means the criteria under which patients may receive greater than one Month's supply of a Community Pharmaceutical covered by Section F Part II (b) subsidised in one Lot. The specifics of these criteria are conveyed in the Ministry of Health guidelines, which are issued from time to time. The criteria the patient must meet are that they:

- a) have limited physical mobility;
- b) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;
- c) are relocating to another area;
- d) are travelling extensively and will be out of town when the repeat prescriptions are due.
- "Act", means the New Zealand Public Health and Disability Act 2000.

"Advisory Committee", means the Pharmaceutical Services Advisory Committee convened by the Ministry of Health under the terms of the Advice Notice issued to Contractors pursuant to Section 88 of the Act.

"Alternate Subsidy", means a higher level of subsidy that the Government will pay contractors for a particular community Pharmaceutical dispensed to a person who has either been granted a Special Authority for that pharmaceutical, or where the prescription is endorsed in accordance with the requirements of this Pharmaceutical Schedule.

"Annotation", means written annotation of a prescription by a dispensing pharmacist in the pharmacist's own handwriting following confirmation from the Prescriber if required, and "Annotated" has a corresponding meaning. The Annotation must include the details specified in the Schedule, including the date the prescriber was contacted (if applicable) and be initialled by the dispensing pharmacist.

"Authority to Substitute", means an authority for the dispensing pharmacist to change a prescribed medicine in accordance with regulation 42(4) of the Medicines Regulations 1984. An authority to substitute letter, which may be used by Practitioners, is available on the final page of the Schedule.

"Bulk Supply Order", means a written order, on a form supplied by the Ministry of Health, or approved by the Ministry of Health, made by the licensee or manager of an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001 for the supply of such Community Pharmaceuticals as are expected to be required for the treatment of persons who are under the medical or dental supervision of such a Private Hospital or institution.

"Class B Controlled Drug", means a Class B controlled drug within the meaning of the Misuse of Drugs Act 1975. "Community Pharmaceutical", means a Pharmaceutical listed in Sections A to G and Section I of the Pharmaceutical Schedule that is subsidised by the Funder from the Pharmaceutical Budget for use in the community.

"Contractor", means a person who is entitled to receive a payment from the Crown or a DHB under a notice issued by the Crown or a DHB under Section 88 of the Act or under a contract with the Ministry of Health or a DHB for the supply of Community Pharmaceuticals.

"Controlled Drug", means a controlled drug within the meaning of the Misuse of Drugs Act 1975 (other than a controlled drug specified in Part VI of the Third Schedule to that Act).

"Cost, Brand, Source of Supply", means that the Community Pharmaceutical is eligible for Subsidy on the basis of the Contractor's annotated purchase price, brand, and source of supply. Alternatively a copy of the invoice for the purchase of the Pharmaceutical may be attached to the prescription, in the place of an annotation, in order to be eligible for Subsidy.

"Dentist", means a person registered with the Dental Council, and who holds a current annual practising certificate, under the HPCA Act 2003.

"Diabetes Nurse Prescriber", means a nurse who is a Designated Prescriber—Registered Nurses Practising in Diabetes Health as determined by the Nursing Council of New Zealand to practice in diabetes health and has authority to prescribe specified diabetes medicines in accordance with regulations made under the Medicines Act 1981.

"Dietitian", means a person registered as a dietitian with the Dietitians Board, and who holds a current annual practicing certificate under the HPCA Act 2003.

"DHB", means an organisation established as a District Health Board by or under Section 19 of the Act.

"DHB Hospital", means a DHB, including its hospital or associated provider unit that the DHB purchases Hospital Pharmaceuticals for.

"Dispensing Frequency Rule", means the rule in Part IV, Section A of the Pharmaceutical Schedule that defines patient groups or medicines eligible for more frequent dispensing periods.

"Doctor", means a medical Practitioner registered with the Medical Council of New Zealand and, who holds a current annual practising certificate under the HPCA Act 2003.

"DV Limit", means, for a particular Hospital Pharmaceutical with HSS, the National DV Limit or the Individual DV Limit.

"DV Pharmaceutical", means a discretionary variance Pharmaceutical, that does not have HSS and which:

- a) is either listed in Section H Part II of the Schedule as being a DV Pharmaceutical in association with the relevant Hospital Pharmaceutical with HSS; or
- b) is the same chemical entity, at the same strength, and in the same or a similar presentation or form, as the relevant Hospital Pharmaceutical with HSS, but which is not yet listed as being a DV Pharmaceutical.

"Endorsements", - unless otherwise specified, endorsements should be either handwritten or computer generated by the practitioner prescribing the medication. The endorsement can be written as "certified condition", or state the condition of the patient, where that condition is specified for the Community Pharmaceutical in Section B of the Pharmaceutical Schedule. Where the practitioner writes "certified condition" as the endorsement, he/she is making a declaration that the patient meets the criteria as set out in Section B of the Pharmaceutical Schedule.

"Funder", means the body or bodies responsible, pursuant to the Act, for the funding of pharmaceuticals listed on the Schedule (which may be one or more DHBs and/or the Ministry of Health) and their successors.

"GST", means goods and services tax under the Goods and Services Tax Act 1985.

"Hospital Care Operator", means a person for the time being in charge of providing hospital care, in accordance with the Health and Disability Services (Safety) Act 2001.

"Hospital Pharmaceuticals", means the list of pharmaceuticals set out in Section H part II of the Schedule which includes some National Contract Pharmaceuticals.

"Hospital Pharmacy", means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to an person on the Prescription of a Practitioner.

"Hospital Pharmacy-Specialist", means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to an Outpatient either:

- a) on a Prescription signed by a Specialist, or
- b) where the treatment with the Community Pharmaceutical has been recommended by a Specialist, on the Prescription of a practitioner which is either:
 - endorsed with the words "recommended by [name of specialist and year of authorisation]" and signed by the Practitioner, or
 - ii) endorsed with the word 'protocol' which means "initiated in accordance with DHB hospital approved protocol",
 - iii) annotated by the dispensing pharmacist, following verbal confirmation from the Practitioner of the name of the Specialist and date of recommendation, with the words "recommended by [name of specialist and date of authorisation], confirmed by [practitioner]". Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly.

"As recommended by a Specialist" to be interpreted as either:

- i) follows a substantive consultation with an appropriate Specialist;
- ii) the consultation to relate to the Patient for whom the Prescription is written;
- iii) consultation to mean communication by referral, telephone, letter, facsimile or email;
- iv) except in emergencies consultation to precede annotation of the Prescription; and
- v) both the specialist and the General Practitioner must keep a written record of the consultation; or
- a) treatment with the Community Pharmaceutical has been initiated in accordance with a DHB hospital approved protocol.

For the purposes of the definition it makes no difference whether or not the Specialist is employed by a hospital.

"Hospital Pharmacy-Specialist Prescription", means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy:

- a) to an Outpatient; and
- b) on a Prescription signed by a Specialist.

For the purposes of this definition, a "specialist" means a doctor who holds a current annual practicing certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) of the definitions of Specialist below.

"HSS", means hospital supply status, the status of being the brand of the relevant Hospital Pharmaceutical listed in Section H Part II as HSS, that DHBs are obliged to purchase subject to any DV Limit for that Hospital Pharmaceutical for the period of hospital supply, as awarded under an agreement between PHARMAC and the relevant pharmaceutical supplier.

"In Combination", means that the Community Pharmaceutical is only subsidised when prescribed in combination with another subsidised pharmaceutical as specified in Section B or C of the Pharmaceutical Schedule.

"Individual DV Limit", means, for a particular Hospital Pharmaceutical with HSS and a particular DHB Hospital, the discretionary variance limit, being the specified percentage of that DHB Hospital's Total Market Volume up to which that DHB Hospital may purchase DV Pharmaceuticals of that Hospital Pharmaceutical.

"Licensed Hospital", means a place or institution that is certified to provide hospital care within the meaning of the Health and Disability Services (Safety) Act 2001.

"Lot", means a quantity of a Community Pharmaceutical supplied in one dispensing.

"Manufacturer's Price", means the standard price at which a Community Pharmaceutical is supplied to wholesalers (excluding GST), as notified to PHARMAC by the supplier.

"Maternity hospital", means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied pursuant to a Bulk Supply Order to a maternity hospital certified under the Health and Disability Services (Safety) Act 2001.

"Midwife", means a person registered as a midwife with the Midwifery Council, and who holds a current annual practising certificate under the HPCA Act 2003.

"Month", means a period of 30 consecutive days.

"Monthly Lot", means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 30 consecutive days' treatment;

"Named Patient Pharmaceutical Assessment Advisory Panel", means the panel of clinicians, appointed by the PHARMAC Board, that is responsible for advising, within its Terms of Reference, on Named Patient Pharmaceutical Assessment applications and Exceptional Circumstances renewal applications submitted after 1 March 2012 (EC renewal application form located at http://www.pharmac.govt.nz/healthpros/EC/ECForms)

"National Contract Pharmaceutical", means a Hospital Pharmaceutical for which PHARMAC has negotiated a

national contract and the Price.

"National DV Limit", means, for a particular Hospital Pharmaceutical with HSS, the discretionary variance limit, being the specified percentage of the Total Market Volume up to which all DHB Hospitals may collectively purchase DV Pharmaceuticals of that Hospital Pharmaceutical.

"National Immunisation Schedule", means Section I of the Pharmaceutical Schedule, which is a schedule administered by PHARMAC, being a schedule specifying a programme of vaccinations to promote immunity against the diseases specified in the schedule.

"Not In Combination", means that no Subsidy is available for any Prescription containing the Community Pharmaceutical in combination with other ingredients unless the particular combination of ingredients is separately specified in Section B or C of the Schedule, and then only to the extent specified.

"Nurse Prescriber", means a person who is a nurse practitioner in terms of the Medicines Act 1981, or a Diabetes Nurse Prescriber

"Optional Pharmaceuticals", means the list of National Contract Pharmaceuticals set out in Section H Part II of the Schedule

"Optometrist", means a person registered with the Optometrists and Dispensing Opticians Board with a scope of practice that includes prescribing medicines (TPA endorsement)

"Outpatient", in relation to a Community Pharmaceutical, means a person who, as part of treatment at a hospital or other institution under the control of a DHB, is prescribed the Community Pharmaceutical for consumption or use in the person's home.

"PCT", means Pharmaceutical Cancer Treatment in respect of which DHB hospital pharmacies and other Contractors can claim Subsidies.

"PCT only", means Pharmaceutical Cancer Treatment in respect of which only DHB hospital pharmacies can claim Subsidies.

"Penal Institution", means a penal institution, as that term is defined in The Penal Institutions Act 1954;

"PHARMAC", means the Pharmaceutical Management Agency established by Section 46 of the Act (PHARMAC). "Pharmaceutical", means a medicine, therapeutic medical device, or related product or related thing listed in Sections B to I of the Schedule.

"Pharmaceutical Benefits", means the right of:

- a) a person; and
- b) any member under 16 years of age of that person's family, to have made by the Government on his or her behalf, subject to any conditions for the time being specified in the Schedule, such payment in respect of any Community Pharmaceutical supplied to that person or family member under the order of a Practitioner in the course of his or her practice.

"Pharmaceutical Budget", means the pharmaceutical budget set for PHARMAC by the Crown for the subsidised supply of Community Pharmaceuticals and Pharmaceutical Cancer Treatments including for named patients in exceptional circumstances.

"Pharmaceutical Cancer Treatment", means Pharmaceuticals for the treatment of cancer, listed in Sections A to G of the Schedule and identified therein as a "PCT" or "PCT only" Pharmaceutical that DHBs must provide access to, for use in their hospitals, and/or in association with Outpatient services provided in their DHB Hospitals, in relation to the treatment of cancers.

"Pharmacist Prescriber", means a person registered with the Pharmacy Council of New Zealand, who holds a current annual practising certificate under the HPCA Act 2003, and is approved by the Pharmacy Council of New Zealand to prescribe specified prescription medicines relating to his/her scope of practice.

"Pharmacist", means a person registered with the Pharmacy Council of New Zealand and who holds a current annual practicing certificate under the HPCA Act 2003.

"Practitioner", means a Doctor, a Dentist, a Dietitian, a Midwife, a Nurse Prescriber, an Optometrist, a Quitcard Provider, or a Pharmacist Prescriber as those terms are defined in the Pharmaceutical Schedule.

"Practitioner's Supply Order", means a written order made by a Practitioner on a form supplied by the Ministry of Health, or approved by the Ministry of Health, for the supply of Community Pharmaceuticals to the Practitioner, which the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable.

"Prescription", means a quantity of a Community Pharmaceutical prescribed for a named person on a document signed by a Practitioner.

"Prescription Medicine", means any Pharmaceutical listed in Part I of Schedule 1 of the Medicines Regulations

1984.

"Private Hospital", means a hospital certified under the Health and Disability Services (Safety) Act 2001 that is not owned or operated by a DHB.

"Quitcard Provider", means a person registered with the Ministry of Health as a Quitcard Provider.

"Residential Disability Care Institution", means premises used to provide residential disability care in accordance with the Health and Disability Services (Safety) Act 2001.

"Rest Home", means premises used to provide rest home care in accordance with the Health and Disability Services (Safety) Act 2001.

"Restricted Medicine", means any Pharmaceutical listed in Part II of Schedule 1 of the Medicines Regulations 1984.

"Retail Pharmacy-Specialist", means that the Community Pharmaceutical is only eligible for Subsidy if it is either:

- a) supplied on a Prescription or Practitioner's Supply Order signed by a Specialist, or,
- b) in the case of treatment recommended by a Specialist, supplied on a Prescription or Practitioner's Supply Order and either:
 - endorsed with the words "recommended by [name of Specialist and year of authorisation]" and signed by the Practitioner, or
 - ii) endorsed with the word 'protocol' which means "initiated in accordance with DHB hospital approved protocol", or
 - iii) Annotated by the dispensing pharmacist, following verbal confirmation from the Practitioner of the name of the Specialist and date of recommendation, with the words "recommended by [name of specialist and year of authorisation], confirmed by [practitioner]". Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly.

"As recommended by a Specialist" to be interpreted as either:

- a) i) follows a substantive consultation with an appropriate Specialist;
 - ii) the consultation to relate to the Patient for whom the Prescription is written;
 - iii) consultation to mean communication by referral, telephone, letter, facsimile or email;
 - iv) except in emergencies consultation to precede annotation of the Prescription; and
 - v) both the Specialist and the General Practitioner must keep a written record of consultation; or
- b) treatment with the Community Pharmaceutical has been initiated in accordance with a DHB hospital approved protocol.

"Retail Pharmacy-Specialist Prescription", means that the Community Pharmaceutical is only eligible for Subsidy if it is supplied on a Prescription, or Practitioner's Supply Order, signed by a Specialist.

For the purposes of this definition, a "specialist" means a doctor who holds a current annual practicing certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) of the definitions of Specialist below.

"Safety Medicine", means a Community Pharmaceutical defined in Section A, Part IV of the Pharmaceutical Schedule.

"Schedule", means this Pharmaceutical Schedule and all its sections and appendices.

"Special Authority", means that the Community Pharmaceutical or Pharmaceutical Cancer Treatment is only eligible for Subsidy or additional Subsidy for a particular person if an application meeting the criteria specified in the Schedule has been approved, and the valid Special Authority number is present on the prescription.

"Specialist", in relation to a Prescription, means a doctor who holds a current annual practising certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) or (d) below:

- a) the doctor is vocationally registered in accordance with the criteria set out by the Medical Council of New Zealand and the HPCA Act 2003 and who has written the Prescription in the course of practising in that area of medicine; or
- b) the doctor is recognised by the Ministry of Health as a specialist for the purposes of this Schedule and receives remuneration from a DHB at a level which that DHB considers appropriate for specialists and who has written that prescription in the course of practising in that area of competency; or
- c) the doctor is recognised by the Ministry of Health as a specialist in relation to a particular area of medicine for the purpose of writing Prescriptions and who has written the Prescription in the course of practising in that area of competency; or
- d) the doctor writes the prescription on DHB stationery and is appropriately authorised by the relevant DHB to do so.

"Subsidy", means the maximum amount that the Government will pay Contractors for a Community Pharmaceutical dispensed to a person eligible for Pharmaceutical Benefits and is different from the cost to Government of subsidising that Community Pharmaceutical. For the purposes of a DHB hospital pharmacy claiming for Pharmaceutical Cancer Treatments, Subsidy refers to any payment made to the DHB hospital pharmacy or service provider to which that pharmacy serves, and does not relate to a specific payment that might be made on submission of a claim.

"Supply Order", means a Bulk Supply Order or a Practitioner's Supply Order.

"Unapproved Indication", means, for a Pharmaceutical, an indication for which it is not approved under the Medicines Act 1981. Practitioners prescribing Pharmaceuticals for Unapproved Indications should be aware of, and comply with, their obligations under Section 25 and/or Section 29 of the Medicines Act 1981 and as set out in Section A: General Rules, Part IV (Miscellaneous Provisions) rule 5.5.

"Unlisted Pharmaceutical", means a Pharmaceutical that is within the scope of a Hospital Pharmaceutical but is not listed in Section H part II

"Unusual Clinical Circumstances (UCC)", means the pathway under the Named Patient Pharmaceutical Assessment policy for funding consideration for named patients whose clinical circumstances are so unusual that PHARMAC is unlikely, for administrative reasons, to consider listing treatments for these circumstances on the Schedule.

"Urgent Assessment (UA)", means the pathway under the Named Patient Pharmaceutical Assessment policy for funding consideration for treatments for named patients where PHARMAC is also considering or is likely to consider the treatment for Schedule listing, but the patient's clinical circumstances justify urgent assessment, prior to a decision on Schedule listing.

- 1.2 In addition to the above interpretations and definitions, unless the content requires otherwise, a reference in the Schedule to:
 - a) the singular includes the plural; and
 - b) any legislation includes a modification and re-enactment of, legislation enacted in substitution for, and a regulation, Order in Council, and other instrument from time to time issued or made under that legislation, where that legislation, regulation, Order in Council or other instrument has an effect on the prescribing, dispensing or subsidising of Community Pharmaceuticals.

PART II COMMUNITY PHARMACEUTICALS SUBSIDY

- 2.1 Community Pharmaceuticals eligible for Subsidy include every medicine, therapeutic medical device or related product, or related thing listed in Sections B to G and I of the Schedule subject to:
 - 2.1.1 clauses 2.2 of the Schedule; and
 - 2.1.2 clauses 3.1 to 5.4 of the Schedule; and
 - 2.1.3 the conditions (if any) specified in Sections B to G and I of the Schedule;
- 2.2 No claim by a Contractor for payment in respect of the supply of Community Pharmaceuticals will be allowed unless the Community Pharmaceuticals so supplied:
 - 2.2.1 comply with the appropriate standards prescribed by regulations for the time being in force under the Medicines Act 1981; or
 - 2.2.2 in the absence of any such standards, comply with the appropriate standards for the time being prescribed by the British Pharmacopoeia; or
 - 2.2.3 in the absence of the standards prescribed in clauses 2.2.1 and 2.2.2, comply with the appropriate standards for the time being prescribed by the British Pharmaceutical Codex; or
 - 2.2.4 in the absence of the standards prescribed in clauses 2.2.1, 2.2.2 and 2.2.3 are of a grade and quality not lower than those usually applicable to Community Pharmaceuticals intended to be used for medical purposes.

PART III PERIOD AND QUANTITY OF SUPPLY

3.1 Doctors', Dentists', Dietitians', Midwives', Nurse Prescribers', Optometrists and Pharmacist Prescribers' Prescriptions (other than oral contraceptives) The following provisions apply to all Prescriptions, other than those for an oral contraceptive, written by a Doctor, Dentist, Dietitian, Midwife, Nurse Prescriber, an Optometrist, or a Pharmacist Prescriber unless specifically excluded:

- 3.1.1 For a Community Pharmaceutical other than a Class B Controlled Drug, only a quantity suffcient to provide treatment for a period not exceeding three Months will be subsidised.
- 3.1.2 For methylphenidate hydrochloride and dexamphetamine sulphate (except for Dentist prescriptions), only a quantity sufficient to provide treatment for a period not exceeding one Month will be subsidised.
- 3.1.3 For a Class B Controlled Drug:
 - a) other than Dentist prescriptions and methylphenidate hydrochloride and dexamphetamine sulphate, only a quantity:
 - i) sufficient to provide treatment for a period not exceeding 10 days; and
 - ii) which has been dispensed pursuant to a Prescription sufficient to provide treatment for a period not exceeding one Month, will be subsidised.
 - b) for a Dentist prescription only such quantity as is necessary to provide treatment for a period not exceeding five days will be subsidised.
- 3.1.4 Subject to clauses 3.1.3 and 3.1.7, for a Doctor, Dentist, Dietitian, Midwife or Nurse Prescriber and 3.1.7 for an Optometrist, where a practitioner has prescribed a quantity of a Community Pharmaceutical sufficient to provide treatment for:
 - A) one Month or less than one Month, but dispensed by the Contractor in quantities smaller than the quantity prescribed, the Community Pharmaceutical will only be subsidised as if that Community Pharmaceutical had been dispensed in a Monthly Lot;
 - B) more than one Month, the Community Pharmaceutical will be subsidised only if it is dispensed:
 - i) in a 90 Day Lot, where the Community Pharmaceutical is a Pharmaceutical covered by Section F Part I of the Pharmaceutical Schedule; or
 - ii) if the Community Pharmaceutical is not a Pharmaceutical referred to in Section F Part I of the Pharmaceutical Schedule, in Monthly Lots, unless:
 - a) the eligible person or his/her nominated representative endorses the back of the Prescription form with a statement identifying which Access Exemption Criterion (Criteria) applies and signs that statement to this effect; or
 - b) both:
 - the Practitioner endorses the Community Pharmaceutical on the Prescription with the words "certified exemption" written in the Practitioner's own handwriting, or signed or initialled by the Practitioner; and
 - every Community Pharmaceutical endorsed as "certified exemption" is covered by Section F Part II of the Pharmaceutical Schedule.
- 3.1.5 A Community Pharmaceutical is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor:
 - a) for a Class B Controlled Drug, within eight days of the date on which the Prescription was written; or
 - b) for any other Community Pharmaceutical, within three Months of the date on which the Prescription was written.
- 3.1.6 No subsidy will be paid for any Prescription, or part thereof, that is not fulfilled within:
 - a) in the case of a Prescription for a total supply of from one to three Months, three Months from the date the Community Pharmaceutical was first dispensed; or
 - b) in any other case, one Month from the date the Community Pharmaceutical was first dispensed. Only that part of any Prescription that is dispensed within the time frames specified above is eligible for Subsidy.
- 3.1.7 If a Community Pharmaceutical:
 - a) is stable for a limited period only, and the Practitioner has endorsed the Prescription with the words "unstable medicine" and has specified the maximum quantity that may be dispensed at any one time; or
 - b) is stable for a limited period only, and the Contractor has endorsed the Prescription with the words "unstable medicine" and has specified the maximum quantity that should be dispensed at any one time in all the circumstances of the particular case; or
 - c) is under the Dispensing Frequency Rule,

The actual quantity dispensed will be subsidised in accordance with any such specification.

3.2 Oral Contraceptives

The following provisions apply to all Prescriptions written by a Doctor, Midwife, Nurse Prescriber or a Pharmacist Prescriber for an oral contraceptive:

- 3.2.1 The prescribing Doctor, Midwife, Nurse Prescriber or a Pharmacist Prescriber must specify on the Prescription the period of treatment for which the Community Pharmaceutical is to be supplied. This period must not exceed six Months.
- 3.2.2 Where the period of treatment specified in the Prescription does not exceed six Months, the Community Pharmaceutical is to be dispensed:
 - a) in Lots as specified in the Prescription if the Community Pharmaceutical is under the Dispensing Frequency Rule; or
 - b) where no Lots are specified, in one Lot sufficient to provide treatment for the period prescribed.
- 3.2.3 An oral contraceptive is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor within three Months of the date on which it was written.
- 3.2.4 Where a Community Pharmaceutical on a Prescription is under the Dispensing Frequency Rule and a repeat on the Prescription remains unfulfilled after six Months from the date the Community Pharmaceutical was first dispensed only the actual quantity supplied by the Contractor within this time limit will be eligible for Subsidy.

3.3 Original Packs, Certain Antibiotics and Unapproved Medicines

- 3.3.1 Notwithstanding clauses 3.1 and 3.3 of the Schedule, if a Practitioner prescribes or orders a Community Pharmaceutical that is identified as an Original Pack (OP) on the Pharmaceutical Schedule and is packed in a container from which it is not practicable to dispense lesser amounts, every reference in those clauses to an amount or quantity eligible for Subsidy, is deemed to be a reference:
 - a) where an amount by weight or volume of the Community Pharmaceutical is specified in the Prescription, to the smallest container of the Community Pharmaceutical, or the smallest number of containers of the Community Pharmaceutical, sufficient to provide that amount; and
 - b) in every other case, to the amount contained in the smallest container of the Community Pharmaceutical that is manufactured in, or imported into, New Zealand.
- 3.3.2 If a Community Pharmaceutical is either:
 - a) the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing; or
 - b) an unapproved medicine supplied under Section 29 of the Medicines Act 1981, but excluding any medicine listed as Cost, Brand, Source of Supply, or
 - c) any other pharmaceutical that PHARMAC determines, from time to time and notes in the Pharmaceutical Schedule

and it is prescribed or ordered by a Practitioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will be paid for the amount prescribed or ordered by the Practitioner in accordance with either clause 3.1 or clause 3.3 of the Schedule, and for the balance of any pack or packs from which the Community Pharmaceutical has been dispensed. At the time of dispensing the Contractor must keep a record of the quantity discarded. To ensure wastage is reduced, the Contractor should reduce the amount dispensed to make it equal to the quantity contained in a whole pack where:

- a) the difference between the amount dispensed and the amount prescribed by the Practitioner is less than 10% (eg; if a prescription is for 105 mls then a 100ml pack would be dispensed); and
- b) in the reasonable opinion of the Contractor the difference would not affect the efficacy of the course of treatment prescribed by the Practitioner.

Note: For the purposes of audit and compliance it is an act of fraud to claim wastage and then use the wastage amount for any subsequent prescription.

3.4 Pharmacist Prescribers' Prescriptions

The following apply to every prescription written by a Pharmacist Prescriber

- 3.4.1 Prescriptions written by a Pharmacist Prescriber for a Community Pharmaceutical will only be subsidised where they are for either:
 - a) a Community Pharmaceutical classified as a Prescription Medicine and which a Pharmacist Prescriber is permitted under regulations to prescribe; or

- b) any other Community Pharmaceutical that is a Restricted Medicine (Pharmacist Only Medicine), a Pharmacy Only Medicine or a General Sales Medicine.
- 3.4.2 Any Pharmacist Prescribers' prescriptions for a medication requiring a Special Authority will only be subsidised if it is for a repeat prescription (ie after the initial prescription with Special Authority approval was dispensed).

3.5 Diabetes Nurse Prescribers' Prescriptions

- The following provisions apply to every Prescription written by a Diabetes Nurse Prescriber:
- 3.5.1 Prescriptions written by a Diabetes Nurse Prescriber for a Community Pharmaceutical will only be subsidised where they are for either:
 - a) a Community Pharmaceutical classified as a Prescription Medicine or a Restricted Medicine and which a Diabetes Nurse Prescribers is permitted under regulations to prescribe; or
 - b) any other Community Pharmaceutical listed below: aspirin, blood glucose diagnostic test meter, blood glucose diagnostic test strip, blood ketone diagnostic test meter, glucagon hydrochloride inj 1 mg syringe kit, insulin pen needles, insulin syringes disposable with attached needle, insulin pump accessories, insulin pump infusion set, insulin pump reservoir,

ketone blood beta-ketone electrodes test strip, nicotine, sodium nitroprusside test strip,

3.5.2 Any Diabetes Nurse Prescribers' prescription for a medication requiring a Special Authority will only be subsidised if it is for a repeat prescription (ie after the initial prescription with Special Authority approval was dispensed).

3.6 Quitcard Providers' Prescriptions

Prescriptions written by a Quitcard Provider will only be subsidised where they are:

- a) for any of the following Community Pharmaceuticals: nicotine patches, nicotine lozenges or nicotine gum; and
- b) written on a Quitcard.

PART IV DISPENSING FREQUENCY RULE

Rule 3.1.4 of the Pharmaceutical Schedule specifies, for community patients, a default period of supply for each Community Pharmaceutical (a Monthly Lot, 90 Day Lot or for oral contraceptives 180 Day Lot). This Dispensing Frequency Rule defines patient groups or medicines eligible for more frequent dispensing periods for Community Pharmaceuticals; and the conditions that must be met to enable any pharmacy to claim for payment of handling fees for the additional dispensings made. This Dispensing Frequency Rule relates to the circumstances in which a subsidy is payable for the Community Pharmaceutical; it does not override alternative dispensing frequencies as expressly stated in the Medicines Act, Medicines Regulations, Pharmacy Services Agreement or Pharmaceutical Schedule.

For the purposes of this Dispensing Frequency Rule:

"Frequent Dispensing" means:

- i) for a Community Pharmaceutical referred to in Section F Part I, (the Stat exemption) dispensing in quantities less than one 90 Day Lot (or for oral contraceptives, less than one 180 Day Lot); or
- ii) for any other Community Pharmaceutical dispensing in quantities less than a Monthly Lot

"Safety Medicine"

- i) an antidepressant listed under the "Cyclic and Related Agents" subheading;
- ii) an antipsychotic;
- iii) a benzodiazepine;
- iv) a Class B Controlled Drug;
- v) codeine (includes combination products);
- vi) buprenorphine with naloxone; or
- vii) zopiclone.

The Dispensing Frequency Rule covers 5 different circumstances where Frequent Dispensing for patients may be clinically or otherwise appropriate. These are:

- 1) Long Term Condition (LTC) patients and Core patients, or
- 2) Persons in residential care, or
- 3) Trial periods, or

- 4) Safety and co-prescribed medicines, or
- 5) Pharmaceutical Supply Management.
- 4.1 Frequent Dispensing for patients registered as Long Term Condition (LTC) or Core patients
 - If a Pharmacist considers Frequent Dispensing is required, then:
 - 4.1.1 For LTC registered patients, Frequent Dispensing can occur as often as the dispensing Pharmacist deems appropriate to meet that patient's compliance and adherence needs;
 - 4.1.2 For Core (non-LTC) patients, Frequent Dispensing should be no more often than a Monthly Lot. Pharmacists may authorise monthly dispensing on a Stat exemption Community Pharmaceutical without prescriber authority. If the Pharmacist considers more frequent (than monthly) dispensing is necessary, prescriber approval is required. Verbal approval from the prescriber is acceptable provided it is annotated by the Pharmacist on the Prescription and dated.

4.2 Frequent Dispensings for persons in residential care

- 4.2.1 Community Pharmaceuticals can be dispensed to:
 - any person whose placement in a Residential Disability Care Institution is funded by the Ministry of Health or a DHB; or
 - a person assessed as requiring long term residential care services and residing in an age related residential care facility;

on the request of the person, their agent or caregiver or community residential service provider via Frequent Dispensing, provided the following conditions are met:

- a) the quantity or period of supply to be dispensed at any one time is not less than:
 - i) 7 days' supply for a Class B Controlled Drug; or
 - ii) 7 days' supply for clozapine in accordance with a Clozapine Dispensing Protocol; or
 - 28 days' supply for any other Community Pharmaceutical (except under conditions outlined in 4.3 (Trial periods) below; and
- b) the prescribing Practitioner or dispensing Pharmacist has
 - i) included the name of the patient's residential placement or facility on the Prescription; and
 - ii) included the patient's NHI number on the Prescription; and
 - iii) specified the maximum quantity or period of supply to be dispensed at any one time.
- 4.2.2 Any person meeting the criteria above who is being initiated onto a new medicine or having their dose changed is able to have their medicine dispensed in accordance with 4.3 (Trial periods) below.

4.3 Frequent Dispensings for Trial Periods

Frequent Dispensing can occur when a Community Pharmaceutical has been prescribed for a patient who requires close monitoring due to recent initiation onto, or dose change for, the Community Pharmaceutical (applicable to the patient's first changed Prescription only) and the prescribing Practitioner has:

- endorsed each Community Pharmaceutical on the Prescription clearly with the words "Trial Period", or "Trial"; and
- specified the maximum quantity or period of supply to be dispensed for each Community Pharmaceutical at any one time.

Patients who reside in Penal Institutions are not eligible for Trial Periods.

4.4 Frequent Dispensing for Safety and co-prescribed medicines

- 4.4.1 For a Safety Medicine to be dispensed via Frequent Dispensing, both of the following conditions must be met:
 - a) The patient is not a resident in a Penal Institution, or one of the residential placements or facilities referenced in 4.2 on the previous page; and
 - b) The prescribing Practitioner has:
 - i) Assessed clinical risk and determined the patient requires increased Frequent Dispensing; and
 - ii) Specified the maximum quantity or period of supply to be dispensed for each Safety Medicine at each dispensing.
- 4.4.2 A Community Pharmaceutical that is co-prescribed with a Safety Medicine, which can be dispensed in accordance with rule 4.4.1 above, may be dispensed at the same frequency as the Safety Medicine if the dispensing pharmacist has:
 - Assessed clinical risk and determined the patient requires Frequent Dispensing of their co-dispensed medicines; and
 - Annotated the Prescription with the amended dispensing quantity and frequency.

4.5 Frequent Dispensing for Pharmaceutical Supply Management

- 4.5.1 Frequent Dispensing may be required from time to time to manage stock supply issues or emergency situations. Pharmacists may dispense more frequently than the Schedule would otherwise allow when all of the following conditions are met:
 - a) PHARMAC has approved and notified pharmacists to annotate Prescriptions for a specified Community Pharmaceutical(s) "out of stock" without prescriber endorsement for a specified time; and
 - b) the dispensing pharmacist has:
 - clearly annotated each of the approved Community Pharmaceuticals that appear on the Prescription with the words "out of stock" or "OOS"; and
 - ii) initialled the annotation in their own handwriting; and
 - iii) has complied with maximum quantity or period of supply to be dispensed at any one time, as specified by PHARMAC at the time of notification.

Note – no claim shall be made to any DHB for subsidised dispensing under this rule where dispensing occurs more frequently than specified by PHARMAC to manage the supply management issue.

PART V MISCELLANEOUS PROVISIONS

5.1 Bulk Supply Orders

The following provisions apply to the supply of Community Pharmaceuticals under Bulk Supply Orders:

- 5.1.1 No Community Pharmaceutical supplied under a Bulk Supply Order will be subsidised unless all the requirements in Section B, C or D of the Schedule applicable to that pharmaceutical are met.
- 5.1.2 The person who placed the Bulk Supply Order may be called upon by the Ministry of Health to justify the amount ordered.
- 5.1.3 Class B Controlled Drugs will be subsidised only if supplied under Bulk Supply Orders placed by an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001.
- 5.1.4 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Bulk Supply Order Controlled Drug Form supplied by the Ministry of Health.
- 5.1.5 Community Pharmaceuticals listed in Part I of the First Schedule to the Medicines Regulations 1984 will be subsidised only if supplied under a Bulk Supply Order placed by an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001 and:
 - a) that institution employs a registered general nurse, registered with the Nursing Council and who holds a current annual practicing certificate under the HPCA Act 2003; and
 - b) the Bulk Supply Order is supported by a written requisition signed by a Hospital Care Operator.
- 5.1.6 No Subsidy will be paid for any quantity of a Community Pharmaceutical supplied under a Bulk Supply Order in excess of what is a reasonable monthly allocation for the particular institution, after taking into account stock on hand.
- 5.1.7 The Ministry of Health may, at any time, by public notification, declare that any approved institution within its particular region, is not entitled to obtain supplies of Community Pharmaceuticals under Bulk Supply Orders

with effect from the date specified in that declaration. Any such notice may in like manner be revoked by the Ministry of Health at any time.

5.2 Practitioner's Supply Orders

The following provisions apply to the supply of Community Pharmaceuticals to Practitioners under a Practitioner's Supply Order:

- 5.2.1 Subject to clause 5.2.3 and 5.2.6, a Practitioner may only order under a Practitioner's Supply Order those Community Pharmaceuticals listed in Section E Part I and only in such quantities as set out in Section E Part I that the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable.
- 5.2.2 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Practitioner's Supply Order Controlled Drug Form supplied by the Ministry of Health.
- 5.2.3 A Practitioner may order such Community Pharmaceuticals as he or she expects to be required for personal administration to patients under the Practitioner's care if:
 - a) the Practitioner's normal practice is in the specified areas listed in Section E Part II of the Schedule, or if the Practitioner is a locum for a Practitioner whose normal practice is in such an area.
 - b) the quantities ordered are reasonable for up to one Month's supply under the conditions normally existing in the practice. (The Practitioner may be called on by the Ministry of Health to justify the amounts of Community Pharmaceuticals ordered.)
- 5.2.4 No Community Pharmaceutical ordered under a Practitioner's Supply order will be eligible for Subsidy unless:
 - a) the Practitioner's Supply Order is made on a form supplied for that purpose by the Ministry of Health, or approved by the Ministry of Health and which:
 - i) is personally signed and dated by the Practitioner; and
 - ii) sets out the Practitioner's address; and
 - iii) sets out the Community Pharmaceuticals and quantities, and;
 - b) all the requirements of Sections B and C of the Schedule applicable to that pharmaceutical are met.
- 5.2.5 The Ministry of Health may, at any time, on the recommendation of an Advisory Committee appointed by the Ministry of Health for that purpose, by public notification, declare that a Practitioner specified in such a notice is not entitled to obtain supplies of Community Pharmaceuticals under Practitioner's Supply Orders until such time as the Ministry of Health notifies otherwise.
- 5.2.6 A Practitioner working in the Rheumatic Fever Prevention Programme (RFPP) may order under a Practitioner's Supply Order such Community Pharmaceuticals (identified below) as he or she requires to ensure medical supplies are available for patients with suspected or confirmed Group A Streptococcal throat infections for the purposes of the RFPP in the following circumstances:
 - a) the RFPP provider name is written on the Practitioner's Supply Order; and
 - b) the total quantity ordered does not exceed a multiple of:
 - ten times the Practitioner's Supply Order current maximum listed in Section E Part I for amoxicillin grans for oral liq 250 mg per 5 ml, amoxicillin cap 250 mg and amoxicillin cap 500 mg; or
 - ii) two times the Practitioner's Supply Order current maximum listed in Section E Part I for phenoxymethyl penicillin grans for oral liquid 250 mg per 5 ml, phenoxymethyl penicillin cap 500 mg, erythromycin ethyl succinate grans for oral liq 200 mg per 5 ml and erythromycin ethyl succinate tab 400 mg; and
 - c) the practitioner must specify the order quantity in course-specific amounts on the Practitioner's Supply Order (e.g. 10 x 300 ml amoxicillin grans for oral liq 250 mg per 5 ml). This will enable the pharmacy to dispense each course separately and claim multiple service fees as per the Community Pharmacy Services Agreement.

5.3 Retail Pharmacy and Hospital Pharmacy-Specialist Restriction

The following provisions apply to Prescriptions for Community Pharmaceuticals eligible to be subsidised as "Retail Pharmacy-Specialist" and "Hospital Pharmacy-Specialist":

5.3.1 Record Keeping

It is expected that a record will be kept by both the General Practitioner and the Specialist of the fact of consultation and enough of the clinical details to justify the recommendation. This means referral by telephone will need to be followed up by written consultation.

5.3.2 Expiry

The recommendation expires at the end of two years and can be renewed by a further consultation.

- 5.3.3 The circulation by Specialists of the circumstances under which they are prepared to recommend a particular Community Pharmaceutical is acceptable as a guide. It must however be followed up by the procedure in subclauses 5.3.1 and 5.3.2, for the individual Patient.
- 5.3.4 The use of preprinted forms and named lists of Specialists (as circulated by some pharmaceutical companies) is regarded as inappropriate.
- 5.3.5 The Rules for Retail Pharmacy-Specialist and Hospital Pharmacy-Specialist will be audited as part of the Ministry of Health's routine auditing procedures.

5.4 Pharmaceutical Cancer Treatments

- 5.4.1 DHBs must provide access to Pharmaceutical Cancer Treatments for the treatment of cancers in their DHB hospitals, and/or in association with Outpatient services provided in their DHB hospitals.
- 5.4.2 DHBs must only provide access to Pharmaceuticals for the treatment of cancer that are listed as Pharmaceutical Cancer Treatments in Sections A to G of the Schedule, provided that DHBs may provide access to an unlisted pharmaceutical for the treatment of cancer where that unlisted pharmaceutical:
 - a) has Named Patient Pharmaceutical Assessment (NPPA) approval;
 - b) is being used as part of a bona fide clinical trial which has Ethics Committee approval;
 - c) is being used and funded as part of a paediatric oncology service; or
 - d) was being used to treat the patient in question prior to 1 July 2005.
- 5.4.3 A DHB hospital pharmacy that holds a claiming agreement for Pharmaceutical Cancer Treatements with the Funder may claim a Subsidy for a Pharmaceutical Cancer Treatment marked as "PCT" or "PCT only" in Sections A to G of this Schedule subject to that Pharmaceutical Cancer Treatment being dispensed in accordance with:
 - a) Part 1;
 - b) clauses 2.1 to 2.2;
 - c) clauses 3.1 to 3.4; and
 - d) clause 5.4,
 - of Section A of the Schedule
- 5.4.4 A Contractor (other than a DHB hospital pharmacy) may only claim a Subsidy for a Pharmaceutical Cancer Treatment marked as "PCT" in Sections A to G of the Schedule subject to that Pharmaceutical Cancer Treatment being dispensed in accordance with the rules applying to Sections A to G of the Schedule.
- 5.4.5 Some indications for Pharmaceutical Cancer Treatments listed in the Schedule are Unapproved Indications. Some of these formed part of the October 2001 decision by the Minister of Health as to pharmaceuticals and indications for which DHBs must provide access. As far as reasonably practicable, these Unapproved Indications are marked in the Schedule. However, PHARMAC makes no representation and gives no guarantee as to the accuracy of this information. Practitioners prescribing Pharmaceutical Cancer Treatments for such Unapproved Indications should:
 - a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under that act and the Medicines Regulations 1984;
 - b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
 - c) exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical Cancer Treatment or a Pharmaceutical Cancer Treatment for an Unapproved Indication.
- 5.4.6 Applications to add pharmaceuticals, and add or amend indications for Pharmaceutical Cancer Treatments, may be made in writing by pharmaceutical suppliers and/or clinicians to PHARMAC. Applications should follow the Guidelines for Funding Applications to PHARMAC 2010 and Recommended methods to derive clinical inputs for proposals to PHARMAC, copies of which are available from PHARMAC or PHARMAC's website.

5.5 Practitioners prescribing unapproved Pharmaceuticals

Practitioners should, where possible, prescribe Pharmaceuticals that are approved under the Medicines Act 1981. However, the access criteria under which a Pharmaceutical is listed on the Pharmaceutical Schedule may:

a) in some case, explicitly permit Government funded access to a Pharmaceutical that is not approved under

the Medicines Act 1981 or for an Unapproved Indication; or

b) not explicitly preclude Government funded access to a Pharmaceutical when it is used for an Unapproved Indication;

Accordingly, if Practitioners are planning on prescribing an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication, Practitioners should:

- a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under that Act and the Medicines Regulations 1984;
- b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
- c) exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication.

Practitioners should be aware that simply by listing a Pharmaceutical on the Pharmaceutical Schedule PHARMAC makes no representations about whether that Pharmaceutical has any form of approval or consent under, or whether the supply or use of the Pharmaceutical otherwise complies with, the Medicines Act 1981. Further, the Pharmaceutical Schedule does not constitute an advertisement, advertising material or a medical advertisement as defined in the Medicines Act or otherwise.

5.6 Substitution

Where a Practitioner has prescribed a brand of a Community Pharmaceutical that has no Subsidy or has a Manufacturer's Price that is greater than the Subsidy and there is an alternative fully subsidised Community Pharmaceutical available, a Contractor may dispense the fully subsidised Community Pharmaceutical, unless either or both of the following circumstances apply:

- a) there is a clinical reason why substitution should not occur; or
- b) the prescriber has marked the prescription with a statement such as 'no brand substitution permitted'

Such an Authority to Substitute is valid whether or not there is a financial implication for the Pharmaceutical Budget. When dispensing a subsidised alternative brand, the Contractor must annotate and sign the prescription and inform the patient of the brand change.

5.7 Alteration to Presentation of Pharmaceutical Dispensed

A Contractor, when dispensing a subsidised Community Pharmaceutical, may alter the presentation of a Pharmaceutical dispensed to another subsidised presentation but may not alter the dose, frequency and/or total daily dose. This may only occur when it is not practicable for the contractor to dispense the requested presentation. If the change will result in additional cost to the DHBs, then annotation of the prescription by the dispensing pharmacist must occur stating the reason for the change, and the Contractor must initial the change for the purposes of Audit.

5.8 Other DHB Funding

A DHB may fund a Community Pharmaceutical outside of the mechanisms established in the Pharmaceutical Schedule, provided that:

- a) specific prior agreement is obtained from PHARMAC for such funding;
- any funding restrictions set out in the Pharmaceutical Schedule for those Community Pharmaceuticals are applied; and
- c) a Contractor (including a DHB Hospital Pharmacy) may not claim a Subsidy for a Community Pharmaceutical dispensed and funded by the DHB via such an alternate mechanism.

5.9 Conflict in Provisions

If any rules in Sections B-G and Section I of this Schedule conflict with the rules in Section A, the rules in Sections B-G and Section I apply.

SECTION B: ALIMENTARY TRACT AND METABOLISM

	Subsidy		Fully Br	and or
	(Manufacturer's Pr \$	rice) S Per	Subsidised G	eneric anufacturer
Antacids and Antiflatulants				
Antacids and Reflux Barrier Agents				
ALGINIC ACID				
Sodium alginate 225 mg and magnesium alginate 87.5 mg per sachet		30	🖌 Gavis	scon Infant
SIMETHICONE				
 Oral liq aluminium hydroxide 200 mg with magnesium hydrox- ide 200 mg and activated simethicone 20 mg per 5 ml 		500 ml	Mylaı	nta P
SODIUM ALGINATE				
* Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg - peppermint flavour		60		con Double ength
* Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml		500 ml	Acide	X
Phosphate Binding Agents				
ALUMINIUM HYDROXIDE				
* Tab 600 mg		100	🖌 Alu-1	ab
CALCIUM CARBONATE				
Oral liq 1,250 mg per 5 ml (500 mg elemental per 5 ml) – Subsidy by endorsement Only when prescribed for children under 12 years of age endorsed accordingly.		500 ml nosphate bi	✓ Roxa nding agent a	
Antidiarrhoeals				
Agents Which Reduce Motility				
LOPERAMIDE HYDROCHLORIDE – Up to 30 cap available on a	N PSO			
* Tab 2 mg * Cap 2 mg		400 400	✓ Nodi	a ide Relief
Rectal and Colonic Anti-inflammatories				
BUDESONIDE				
Cap 3 mg – Special Authority see SA1155 below – Retail pharmacy		90	🖌 Ento	cort CIR
SA1155 Special Authority for Subsidy Initial application — (Crohn's disease) from any relevant pract following criteria: Both:	itioner. Approvals	s valid for 6	months for ap	oplications meeting th
 Mild to moderate ileal, ileocaecal or proximal Crohn's disc Any of the following: 	ease; and			

20

continued...

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- 2.1 Diabetes; or
- 2.2 Cushingoid habitus; or
- 2.3 Osteoporosis where there is significant risk of fracture; or
- 2.4 Severe acne following treatment with conventional corticosteroid therapy; or
- 2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
- 2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
- 2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

Initial application — (collagenous and lymphocytic colitis (microscopic colitis)) from any relevant practitioner. Approvals valid for 6 months where patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

Initial application — (gut Graft versus Host disease) from any relevant practitioner. Approvals valid for 6 months where patient has a gut Graft versus Host disease following allogenic bone marrow transplantation*.

Note: Indication marked with * is an Unapproved Indication.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Clinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate.

HYDROCORTISONE ACETATE

		Colifoam
MESALAZINE		
Tab 400 mg49.50	100	Asacol
Tab EC 500 mg49.50	100	Asamax
Tab long-acting 500 mg59.05	100	Pentasa
Tab 800 mg	90	Asacol
Modified release granules, 1 g	120 OP	Pentasa
Enema 1 g per 100 ml41.30	7	Pentasa
Suppos 500 mg	20	Asacol
Suppos 1 g	30	Pentasa
OLSALAZINE		
Tab 500 mg59.86	100	Dipentum
Cap 250 mg	100	 Dipentum
SODIUM CROMOGLYCATE		
Cap 100 mg92.91	100	Nalcrom
SULPHASALAZINE		
* Tab 500 mg – For sulphasalazine oral liquid formulation refer.		
page 213	100	 Salazopyrin
* Tab EC 500 mg12.89	100	✓ Salazopyrin E

Local preparations for Anal and Rectal Disorders

Antihaemorrhoidal Preparations

FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVALATE AND CINCHOCAINE

Oint 950 mcg, with fluocortolone pivalate 920 mcg, and cin-		
chocaine hydrochloride 5 mg per g6.35	30 g OP	 Ultraproct
Suppos 630 mcg, with fluocortolone pivalate 610 mcg, and		
cinchocaine hydrochloride 1 mg2.66	12	 Ultraproct

‡ safety cap *Three months or six months, as applicable, dispensed all-at-once EN

	Subsidy (Manufacturer's Pr \$	ice) Sub Per	Fully Brand or osidised Generic Manufacturer
HYDROCORTISONE WITH CINCHOCAINE Oint 5 mg with cinchocaine hydrochloride 5 mg per g Suppos 5 mg with cinchocaine hydrochloride 5 mg per g		30 g OP 12	✓ Proctosedyl✓ Proctosedyl
Management of Anal Fissures			
GLYCERYL TRINITRATE – Special Authority see SA1329 below * Oint 0.2% SA1329 Special Authority for Subsidy		y 30 g OP	✓ Rectogesic
Initial application from any relevant practitioner. Approvals valid chronic anal fissure that has persisted for longer than three week	d without further r s.	enewal unles	s notified where the patient has a
Antispasmodics and Other Agents Altering Gut	Motility		
GLYCOPYRRONIUM BROMIDE Inj 200 mcg per ml, 1 ml ampoule – Up to 10 inj available on			
	17.14	10	Max Health
HYOSCINE N-BUTYLBROMIDE * Tab 10 mg	2.18	20	✓ Gastrosoothe
* Inj 20 mg, 1 ml – Up to 5 inj available on a PSO	9.57	5	 Buscopan
MEBEVERINE HYDROCHLORIDE			
* Tab 135 mg		90	✓ Colofac
Antiulcerants			
Antisecretory and Cytoprotective			
MISOPROSTOL * Tab 200 mcg	56 92	120	✓ Cytotec
Helicobacter Pylori Eradication		120	• Cylotec
CLARITHROMYCIN			
Tab 500 mg – Subsidy by endorsement a) Maximum of 14 tab per prescription		14	✓ Apo-Clarithromycin
b) Subsidised only if prescribed for helicobacter pylori erac Note: the prescription is considered endorsed if clarithromycin is amoxicillin or metronidazole.			
H2 Antagonists			
RANITIDINE – Only on a prescription			
* Tab 150 mg* * Tab 300 mg		500 500	 ✓ <u>Ranitidine Relief</u> ✓ Ranitidine Relief

*	Tab 150 mg		500	Ranitidine Relief
*	Tab 300 mg	14.73	500	Ranitidine Relief
	Oral lig 150 mg per 10 ml		300 ml	Peptisoothe
*	Inj 25 mg per ml, 2 ml	8.75	5	✓ Zantac

(Subsidy (Manufacturer's Price) \$	Per	Full Subsidise	
Proton Pump Inhibitors				
ANSOPRAZOLE				
₭ Cap 15 mg	1.42	28	~	Solox
	5.08	100	~	Lanzol Relief
Lanzol Relief to be Sole Supply on 1 April 2016				
₭ Cap 30 mg	1.66	28	-	Solox
	5.93	100	~	Lanzol Relief
Lanzol Relief to be Sole Supply on 1 April 2016				
Solox Cap 15 mg to be delisted 1 April 2016)				
Solox Cap 30 mg to be delisted 1 April 2016)				
MEPRAZOLE				
For omeprazole suspension refer Standard Formulae, page 216	6			
⊱ Cap 10 mg	2.23	90	~	Omezol Relief
₭ Cap 20 mg		90	~	Omezol Relief
₭ Cap 40 mg	4.42	90	~	Omezol Relief
Powder – Only in combination		5 g	~	Midwest
Only in extemporaneously compounded omeprazole suspen		0		
🖌 Inj 40 mg		5	~	Dr Reddy's
, .				Omeprazole
ANTOPRAZOLE				•
K Tab EC 20 mg	2.69	100		Pantoprazole
	2.00	100	•	Actavis 20
✤ Tab EC 40 mg	3 54	100	~	Pantoprazole
		100	•	Actavis 40
O'lle Ducke allow Amerika				<u>A010110 40</u>
Site Protective Agents				
BISMUTH TRIOXIDE				
Tab 120 mg	32 50	112	~	De Nol S29
5		112	•	
SUCRALFATE				
Tab 1 g		120		o ()
	(48.28)			Carafate
Bile and Liver Therapy				
RIFAXIMIN – Special Authority see SA1461 below – Retail pharma				
Tab 550 mg		56	./	Xifaxan
un noc an	023.00	00	~	VIIdYall

►SA1461 Special Authority for Subsidy Initial application only from a gastroenterologist, hepatologist or Practitioner on the recommendation of a gastroenterologist or benatologist. Approvals valid for 6 months where the patient has benatic encentral path despite an adequate trial of maximum

hepatologist. Approvals valid for 6 months where the patient has hepatic encephalopathy despite an adequate trial of maximum tolerated doses of lactulose.

Renewal only from a gastroenterologist, hepatologist or Practitioner on the recommendation of a gastroenterologist or hepatologist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully Brand or osidised Generic Manufacturer
Diabetes			
Hyperglycaemic Agents			
DIAZOXIDE – Special Authority see SA1320 below – Retail phar Cap 25 mg Cap 100 mg Oral liq 50 mg per ml		100 100 30 ml OP	 Proglicem \$29 Proglicem \$29 Proglycem \$29
⇒SA1320 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals valid plycaemia caused by hyperinsulinism. Renewal from any relevant practitioner. Approvals valid without fur priate and the patient is benefiting from treatment. GLUCAGON HYDROCHLORIDE			
Inj 1 mg syringe kit – Up to 5 kit available on a PSO		1	 Glucagen Hypokit
Insulin - Short-acting Preparations			
NSULIN NEUTRAL ▲ Inj human 100 u per ml	25.26	10 ml OP	 ✓ Actrapid ✓ Humulin R
Inj human 100 u per ml, 3 ml	42.66	5	 Actrapid Penfill Humulin R
Insulin - Intermediate-acting Preparations			
NSULIN ASPART WITH INSULIN ASPART PROTAMINE ▲ Inj 100 iu per ml, 3 ml prefilled pen	52.15	5	✔ NovoMix 30 FlexPen
NSULIN ISOPHANE ▲ Inj human 100 u per ml	17.68	10 ml OP	✓ Humulin NPH✓ Protaphane
Inj human 100 u per ml, 3 ml	29.86	5	 Humulin NPH Protaphane Penfill
NSULIN ISOPHANE WITH INSULIN NEUTRAL Inj human with neutral insulin 100 u per ml	25.26	10 ml OP	✓ Humulin 30/70 ✓ Mixtard 30
▲ Inj human with neutral insulin 100 u per ml, 3 ml	42.66	5	 Humulin 30/70 PenMix 30 PenMix 40 PenMix 50
NSULIN LISPRO WITH INSULIN LISPRO PROTAMINE			
Inj lispro 25% with insulin lispro protamine 75% 100 u per ml 3 ml		5	 Humalog Mix 25
Inj lispro 50% with insulin lispro protamine 50% 100 u per ml 3 ml		5	Humalog Mix 50

	Subsidy (Manufacturer's Pri \$	ce) Sub Per	Fully Brand or sidised Generic Manufacturer
Insulin - Long-acting Preparations			
NSULIN GLARGINE			
Inj 100 u per ml, 10 ml		1	✓ Lantus
▲ Inj 100 u per ml, 3 ml		5	✓ Lantus
Inj 100 u per ml, 3 ml disposable pen		5	 Lantus SoloStar
Insulin - Rapid Acting Preparations			
NSULIN ASPART			
Inj 100 u per ml, 3 ml syringe	51.19	5	NovoRapid FlexPen
Inj 100 u per ml, 3 ml		5	NovoRapid Penfill
Inj 100 u per ml, 10 ml		1	NovoRapid
NSULIN GLULISINE			
Inj 100 u per ml, 10 ml		1	Apidra
Inj 100 u per ml, 3 ml		5	✓ Apidra
Inj 100 u per ml, 3 ml disposable pen	46.07	5	Apidra SoloStar
NSULIN LISPRO			
Inj 100 u per ml, 10 ml		10 ml OP	Humalog
Inj 100 u per ml, 3 ml	59.52	5	Humalog
Alpha Glucosidase Inhibitors			
CARBOSE			
← Tab 50 mg	4.28	90	Glucobay
← Tab 100 mg		90	✓ Glucobay
Oral Hypoglycaemic Agents			
GLIBENCLAMIDE			
★ Tab 5 mg	5.00	100	🗸 Daonil
•		100	• Baoim
	11 50	500	A Clinida
← Tab 80 mg	11.50	500	✓ <u>Glizide</u>
	0.05	400	
 Tab 5 mg 	2.85	100	Minidiab
IETFORMIN HYDROCHLORIDE			
Tab immediate-release 500 mg		1,000	Metchek
Tab immediate-release 850 mg		500	 Metformin Mylan
Mattermin Mulan to be Sale Supply on 1 March 2016	(10.10)		Apotex
Metformin Mylan to be Sole Supply on 1 March 2016 Apotex Tab immediate-release 850 mg to be delisted 1 March 20)16)		
· •			
IOGLITAZONE • Tab 15 mg	1 09	28	✓ Pizaccord
	1.08 3.47	28 90	Vexazone
Vexazone to be Sole Supply on 1 March 2016	5.77		
 Tab 30 mg 	1.57	28	Pizaccord
	5.06	90	✓ Vexazone
Vexazone to be Sole Supply on 1 March 2016			
 Tab 45 mg 		28	Pizaccord
	7.10	90	Vexazone
Vexazone to be Sole Supply on 1 March 2016			

	Subsidy (Manufacturer's F \$		Sub: Per	Fully sidised	Brand or Generic Manufacturer
(Pizaccord Tab 15 mg to be delisted 1 March 2016) (Pizaccord Tab 30 mg to be delisted 1 March 2016) (Pizaccord Tab 45 mg to be delisted 1 March 2016)					
Diabetes Management					
Ketone Testing					
BLOOD KETONE DIAGNOSTIC TEST METER – Up to 1 meter a Meter funded for the purposes of blood ketone diagnostics on at risk of future episodes or patient is on an insulin pump. Only Meter	ly. Patient has	had one	will be	subsidi	
(Freestyle Optium Meter to be delisted 1 May 2016)					
KETONE BLOOD BETA-KETONE ELECTRODES a) Maximum of 20 strip per prescription b) Up to 10 strip available on a PSO					
Test strip – Not on a BSO	15.50	10 stri	р ОР	✔ F	reestyle Optium Ketone
SODIUM NITROPRUSSIDE – Maximum of 50 strip per prescriptic * Test strip – Not on a BSO		50 stri	р ОР	🗸 A	ccu-Chek Ketur-Test
	14.14			🖌 К	etostix
Blood Glucose Testing					
 BLOOD GLUCOSE DIAGNOSTIC TEST METER – Subsidy by en a) Maximum of 1 pack per prescription b) Up to 1 pack available on a PSO c) A diagnostic blood glucose test meter is subsidised for a par 1) is receiving insulin or sulphonylurea therapy; or 2) is pregnant with diabetes; or 3) is on home TPN at risk of hypoglycaemia or hyperglycaem 4) has a genetic or an acquired disorder of glucose homeosta Only one CareSens meter per patient. No further prescription meter. For the avoidance of doubt patients who have previousl a CareSens meter. The prescription must be endorsed accorr where there exists a record of prior dispensing of insulin or sul Meter with 50 lancets, a lancing device and 10 diagnostic test 	tient who: hia; or hisis excluding ty his will be subsi ly received a fu dingly. Pharma	dised for nded me	r patien eter, oth	ts who Ier than	already have a CareSens CareSens, are eligible for
strips		10	P	/ C	areSens II

✔ CareSens N ✓ CareSens N POP

Note: Only 1 meter available per PSO

26

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Sub	sidised	Generic	
\$	Per	~	Manufacturer	

BLOOD GLUCOSE DIAGNOSTIC TEST STRIP - Up to 50 test available on a PSO

The number of test strips available on a prescription is restricted to 50 unless:

- Prescribed for a patient on insulin or a sulphonylurea and endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of insulin or sulphonylurea; or
- Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or
- 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly; or
- 4) Prescribed for a patient on home TPN at risk of hypoglycaemia or hyperglycaemia and endorsed accordingly; or
- Prescribed for a patient with a genetic or an acquired disorder of glucose homeostasis excluding type 1 or type 2 diabetes and metabolic syndrome and endorsed accordingly.

Blood glucose test strips - Note differing brand requirements

✓ Ca	50 test OP	v
V Ca		28.75
F		

✓ CareSens
 ✓ CareSens N

Accu-Chek

- Performa
- ✓ Freestyle Optium

a) Accu-Chek Performa brand: Special Authority see SA1294 below - Retail pharmacy

b) Freestyle Optium brand: Special Authority see SA1291 below - Retail pharmacy

c) Note: Accu-Chek Performa and Freestyle Optium are not available on a PSO

SA1294 Special Authority for Subsidy

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz and can be sent to: PHARMAC

PO Box 10 254 Facsimile: (04) 974 4788

Wellington Email: bgstrips@pharmac.govt.nz

SA1291 Special Authority for Subsidy

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz and can be sent to: PHARMAC

PO Box 10 254 Facsimile: (04) 974 4788

Wellington Email: bgstrips@pharmac.govt.nz

BLOOD GLUCOSE TEST STRIPS (VISUALLY IMPAIRED)

The number of test strips available on a prescription is restricted to 50 unless:

- Prescribed for a patient on insulin or a sulphonylurea and endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of insulin or sulphonylurea; or
- Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or
- 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly; or
- 4) Prescribed for a patient on home TPN at risk of hypoglycaemia or hyperglycaemia and endorsed accordingly; or
- 5) Prescribed for a patient with a genetic or an acquired disorder of glucose homeostasis excluding type 1 or type 2 diabetes and metabolic syndrome and endorsed accordingly.

	Subsidy (Manufacturer's Price) \$	Per	Full Subsidise	
Insulin Syringes and Needles				
Subsidy is available for disposable insulin syringes, ne for the supply of insulin or when prescribed for an insu annotate the prescription as endorsed where there exist	lin patient and the prescription	is en	dorsed ad	
INSULIN PEN NEEDLES - Maximum of 100 dev per pl	rescription			
* 29 g × 12.7 mm		100	~	B-D Micro-Fine
★ 31 g × 5 mm	11.75	100	~	B-D Micro-Fine
* 31 g × 6 mm		100	~	ABM
* 31 g × 8 mm		100	~	B-D Micro-Fine
* 32 g × 4 mm		100	~	B-D Micro-Fine
INSULIN SYRINGES, DISPOSABLE WITH ATTACHED	NEEDLE – Maximum of 100	dev pe	r prescrip	otion
* Syringe 0.3 ml with 29 g \times 12.7 mm needle		100		B-D Ultra Fine
	1.30	10	·	
	(1.99)			B-D Ultra Fine
* Syringe 0.3 ml with 31 g × 8 mm needle	()	100	~	B-D Ultra Fine II
	1.30	10		
	(1.99)			B-D Ultra Fine II
* Syringe 0.5 ml with 29 g × 12.7 mm needle	()	100	~	B-D Ultra Fine
-, , , ,	1.30	10		
	(1.99)			B-D Ultra Fine
* Syringe 0.5 ml with 31 g × 8 mm needle	()	100	~	B-D Ultra Fine II
, , , , , , , , , , , , , , , , , , , ,	1.30	10		
	(1.99)			B-D Ultra Fine II
* Syringe 1 ml with 29 g × 12.7 mm needle	. ,	100	~	B-D Ultra Fine
, , ,	1.30	10		
	(1.99)			B-D Ultra Fine
* Syringe 1 ml with 31 g × 8 mm needle	. ,	100	~	B-D Ultra Fine II
	1.30	10		
	(1.99)			B-D Ultra Fine II

Insulin Pumps

INSULIN PUMP - Special Authority see SA1237 on the next page - Retail pharm	nacy	
a) Maximum of 1 dev per prescription		
b) Only on a prescription		
c) Maximum of 1 insulin pump per patient each four year period.		
Min basal rate 0.025 U/h; black colour4,500.00	1	(
Min basal rate 0.025 U/h; blue colour4,500.00	1	(
Min basal rate 0.025 U/h; green colour4,500.00	1	(
Min basal rate 0.025 U/h; pink colour4,500.00	1	(
Min basal rate 0.025 U/h; silver colour4,500.00	1	(
Min basal rate 0.05 U/h; blue colour4,400.00	1	(
		(
Min basal rate 0.05 U/h; clear colour4,400.00	1	(
		(
Min basal rate 0.05 U/h; pink colour4,400.00	1	(

Min basal rate 0.05 U/h; purple colour4,400.00

Min basal rate 0.05 U/h; smoke colour4.400.00

© Unapproved medicine supplied under Section 29 Sole Subsidised Supply

1

1

Animas Vibe
 Animas Vibe
 Animas Vibe
 Animas Vibe
 Animas Vibe
 Paradigm 522
 Paradigm 722
 Paradigm 722
 Paradigm 722
 Paradigm 522

✓ Paradigm 722

Paradigm 522Paradigm 722

Paradigm 522
Paradigm 722

	Subsidy	Fully	Brand or
(Manu	Ifacturer's Price)	Subsidised	Generic
	\$ Pe	er 🖌	Manufacturer

SA1237 Special Authority for Subsidy

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The IPP Co-ordinator	Phone: (04) 460 4990			
PHARMAC	Facsimile: (04) 974 7806			
PO Box 10 254	Email: ipp@pharmac.govt.nz			
Wellington				

Insulin Pump Consumables

➡SA1240 Special Authority for Subsidy

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

Notes. Application details	may be obtained norm i mAr innAC 3 website mtp.//www.p	nannac.yov	
The IPP Co-ordinator	Phone: (04) 460 4990		
PHARMAC	Facsimile: (04) 974 7806		
PO Box 10 254	Email: ipp@pharmac.govt.nz		
Wellington			
INSULIN PUMP ACCESS	ORIES – Special Authority see SA1240 above – Retail p	harmacy	
a) Maximum of 1 cap	per prescription		
b) Only on a prescripti	on		
c) Maximum of 1 prese	cription per 180 days.		
Battery cap		1	Animas Battery Cap

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
 INSULIN PUMP INFUSION SET (STEEL CANNULA) – Special A a) Maximum of 3 sets per prescription b) Only on a prescription c) Maximum of 13 infusion sets will be funded per year. 10 mm steel needle; 29 G; manual insertion; 60 cm tubing × 	Authority see SA1240) on th	e previous	s page – Retail pharmacy
10 with 10 needles	130.00	1 OP	~	Paradigm Sure-T MMT-884
10 mm steel needle; 29 G; manual insertion; 60 cm tubing × 10 with 10 needles; luer lock	130.00	1 OP	~	Sure-T MMT-883
10 mm steel needle; 29 G; manual insertion; 80 cm tubing × 10 with 10 needles	130.00	1 OP	~	Paradigm Sure-T MMT-886
10 mm steel needle; 29 G; manual insertion; 80 cm tubing × 10 with 10 needles; luer lock	130.00	1 OP	~	Sure-T MMT-885
10 with 10 needles 6 mm steel needle; 29 G; manual insertion; 60 cm tubing ×		1 OP	~	Contact-D
10 with 10 needles	130.00	1 OP	~	Paradigm Sure-T MMT-864
6 mm steel needle; 29 G; manual insertion; 60 cm tubing × 10 with 10 needles; luer lock 6 mm steel needle; 29 G; manual insertion; 80 cm tubing ×	130.00	1 OP	~	Sure-T MMT-863
10 with 10 needles	130.00	1 OP	~	Paradigm Sure-T MMT-866
6 mm steel needle; 29 G; manual insertion; 80 cm tubing × 10 with 10 needles; luer lock	130.00	1 OP	~	Sure-T MMT-865
10 with 10 needles		1 OP	~	Contact-D
10 with 10 needles	130.00	1 OP		Contact-D
10 with 10 needles	130.00	1 OP	~	Paradigm Sure-T MMT-874
8 mm steel needle; 29 G; manual insertion; 60 cm tubing × 10 with 10 needles; luer lock		1 OP	~	Sure-T MMT-873
10 with 10 needles	130.00	1 OP	~	Paradigm Sure-T MMT-876
8 mm steel needle; 29 G; manual insertion; 80 cm tubing \times 10 with 10 needles; luer lock	130.00	1 OP	~	Sure-T MMT-875

30

	Subsidy (Manufacturer's F \$	Price) S Per	Fully Subsidised	Brand or Generic Manufacturer
	•			
SULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE I \1240 on page 29 – Retail pharmacy	INSERTION WITH	INSERTIO	IN DEVICE	 Special Authority se
a) Maximum of 3 sets per prescription				
b) Only on a prescription				
c) Maximum of 13 infusion sets will be funded per year.				
13 mm teflon cannula; angle insertion; insertion device				
110 cm grey line \times 10 with 10 needles		1 OP	🖌 In	iset 30
13 mm teflon cannula; angle insertion; insertion device	;			
60 cm blue line \times 10 with 10 needles		1 OP	🗸 In	set 30
13 mm teflon cannula; angle insertion; insertion device		4.00		
60 cm grey line \times 10 with 10 needles		1 OP	V in	set 30
13 mm teflon cannula; angle insertion; insertion device 60 cm pink line × 10 with 10 needles		1 OP	In	set 30
•				
SULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE I	NSERTION) – S	pecial Autho	ority see SA	A1240 on page 29 – Ret
armacy a) Maximum of 3 sets per prescription				
b) Only on a prescription				
c) Maximum of 13 infusion sets will be funded per year.				
13 mm teflon cannula; angel insertion; 60 cm grey line >	×			
5 with 10 needles		1 OP	🖌 C	omfort Short
13 mm teflon cannula; angle insertion; 120 cm line $ imes$ 10 with	h			
10 needles	130.00	1 OP		aradigm Silhouette
				MMT-382
13 mm teflon cannula; angle insertion; 45 cm line \times 10 with				
10 needles		1 OP		aradigm Silhouette
	L.			MMT-368
13 mm teflon cannula; angle insertion; 60 cm line × 10 with 10 needles		1 OP		aradigm Silhouette
To fleedles		TOF		MMT-381
13 mm teflon cannula; angle insertion; 80 cm line \times 10 with	h			
10 needles		1 OP	🖌 Pa	aradigm Silhouette
				MMT-383
17 mm teflon cannula; angle insertion; 110 cm grey line >	×			
5 with 10 needles	120.00	1 OP	🖌 C	omfort
17 mm teflon cannula; angle insertion; 110 cm line $ imes$ 10 with	h			
10 needles	130.00	1 OP		aradigm Silhouette
				MMT-377
17 mm teflon cannula; angle insertion; 110 cm line \times 10 with				
10 needles; luer lock		1 OP	🗸 Si	ilhouette MMT-371
17 mm teflon cannula; angle insertion; 60 cm grey line >		4.00		f t
5 with 10 needles		1 OP		omfort
17 mm teflon cannula; angle insertion; 60 cm line × 10 with		1 OP		orodiam Cilhouotto
10 needles		1 OP		aradigm Silhouette MMT-378
17 mm teflon cannula; angle insertion; 60 cm line $ imes$ 10 with	h			mm 1-07 0
10 needles; luer lock		1 OP	🖌 Si	ilhouette MMT-373
17 mm teflon cannula; angle insertion; 80 cm line \times 10 with			÷ 01	
10 needles		1 OP	🖌 Pa	aradigm Silhouette
				MMT-384

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	Brand or Generic Manufacturer
INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIG see SA1240 on page 29 – Retail pharmacy a) Maximum of 3 sets per prescription b) Only on a prescription c) Maximum of 13 infusion sets will be funded per year. 6 mm teflon cannula; straight insertion; insertion device		INSERTION DE	VICE) – Special Authority
110 cm grey line × 10 with 10 needles		I OP 🖌 Ir	nset II
45 cm blue tubing × 10 with 10 needles		I OP 🖌 P	aradigm Mio MMT-941
6 mm teflon cannula; straight insertion; insertion device 45 cm pink tubing × 10 with 10 needles		I OP 🖌 P	aradigm Mio MMT-921
6 mm teflon cannula; straight insertion; insertion device 60 cm blue tubing × 10 with 10 needles		I OP 🖌 P	aradigm Mio MMT-943
6 mm teflon cannula; straight insertion; insertion device 60 cm pink tubing × 10 with 10 needles		I OP 🖌 P	aradigm Mio MMT-923
6 mm teflon cannula; straight insertion; insertion device 80 cm blue tubing × 10 with 10 needles		I OP 🖌 P	aradigm Mio MMT-945
6 mm teflon cannula; straight insertion; insertion device 80 cm clear tubing \times 10 with 10 needles		I OP 🖌 P	aradigm Mio MMT-965
6 mm teflon cannula; straight insertion; insertion device 80 cm pink tubing × 10 with 10 needles		I OP 🖌 P	aradigm Mio MMT-925
 6 mm teflon cannula; straight insertionl insertion device 60 cm blue line × 10 with 10 needles 6 mm teflon cannula; straight insertionl insertion device 		I OP 🖌 Ir	nset II
6 mm teflori cannula; straight insertion insertion device 60 cm grey line × 10 with 10 needles		I OP 🖌 Ir	nset II
60 cm pink line \times 10 with 10 needles		I OP 🖌 Ir	nset II
9 mm teflon cannula; straight insertion; insertion device 60 cm blue line × 10 with 10 needles		I OP 🖌 Ir	nset II
9 mm teflon cannula; straight insertion; insertion device 60 cm grey line × 10 with 10 needles		I OP 🖌 Ir	nset II
9 mm teflon cannula; straight insertion; insertion device 60 cm pink line × 10 with 10 needles		I OP 🖌 Ir	nset II
9 mm teflon cannula; straight insertion; insertion device 80 cm clear tubing × 10 with 10 needles		I OP 🖌 P	aradigm Mio MMT-975
9 mm teflon cannula; straight insertionl insertion device 110 cm grey line \times 10 with 10 needles		I OP 🖌 Ir	iset II

32

	Subsidy (Manufacturer's Pr \$	ice) Su Per	Fully bsidised	Brand or Generic Manufacturer
ISULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIGH	HT INSERTION)	- Special A	uthority s	see SA1240 on page 2
etail pharmacy				
a) Maximum of 3 sets per prescription				
 b) Only on a prescription c) Maximum of 13 infusion sets will be funded per year. 				
6 mm teflon cannula; straight insertion; 110 cm tubing \times				
10 with 10 needles		1 OP	🖌 Pa	aradigm Quick-Set MMT-398
6 mm teflon cannula; straight insertion; 110 cm tubing $ imes$				
10 with 10 needles; luer lock	130.00	1 OP	🖌 Q	uick-Set MMT-391
6 mm teflon cannula; straight insertion; 60 cm tubing $ imes$				
10 with 10 needles	130.00	1 OP	🖌 Pa	aradigm Quick-Set
				MMT-399
6 mm teflon cannula; straight insertion; 60 cm tubing $ imes$				
10 with 10 needles; luer lock		1 OP	🖌 Q	uick-Set MMT-393
6 mm teflon cannula; straight insertion; 80 cm tubing $ imes$				
10 with 10 needles	130.00	1 OP	🖌 Pa	aradigm Quick-Set
				MMT-387
9 mm teflon cannula; straight insertion; 106 cm tubing $ imes$				
10 with 10 needles	130.00	1 OP	🖌 Pa	aradigm Quick-Set
				MMT-396
9 mm teflon cannula; straight insertion; 110 cm tubing $ imes$				
10 with 10 needles; luer lock	130.00	1 OP	🖌 Q	uick-Set MMT-390
9 mm teflon cannula; straight insertion; 60 cm tubing $ imes$				
10 with 10 needles	130.00	1 OP	🖌 Pa	aradigm Quick-Set
				MMT-397
9 mm teflon cannula; straight insertion; 60 cm tubing $ imes$				
10 with 10 needles; luer lock		1 OP	🖌 Q	uick-Set MMT-392
9 mm teflon cannula; straight insertion; 80 cm tubing \times				
10 with 10 needles		1 OP	🖌 Pa	aradigm Quick-Set MMT-386
SULIN PUMP RESERVOIR – Special Authority see SA1240 o	n page 29 – Reta	il pharmacv		
a) Maximum of 3 sets per prescription		. ,		
b) Only on a prescription				
c) Maximum of 13 packs of reservoir sets will be funded per y				
10 \times luer lock conversion cartridges 1.8 ml for Paradigm				
pumps		1 OP	🗸 A	DR Cartridge 1.8
10 \times luer lock conversion cartridges 3.0 ml for Paradigm				
pumps		1 OP		DR Cartridge 3.0
Cartridge 200 U, luer lock \times 10		1 OP		nimas Cartridge
Cartridge for 5 and 7 series pump; 1.8 ml \times 10		1 OP	V Pa	aradigm
				1.8 Reservoir
Cartridge for 7 series pump; 3.0 ml \times 10		1 OP	🖌 Pa	aradigm
				3.0 Reservoir
Syringe and cartridge for 50X pump, 3.0 ml \times 10		1 OP	🖌 50	0X 3.0 Reservoir

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Digestives Including Enzymes				
PANCREATIC ENZYME Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease		100	v c	reon 10000
Cap EC 25,000 BP u lipase, 18,000 BP u amylase, 1,000 BP u protease		100		reon 25000
u protease	94.40	100	🗸 P	anzytrat
URSODEOXYCHOLIC ACID – Special Authority see SA1383 bel Cap 250 mg – For ursodeoxycholic acid oral liquid formula- tion refer, page 213		y 100	✓ <u>U</u>	rsosan

SA1383 Special Authority for Subsidy

Initial application — (Alagille syndrome or progressive familial intrahepatic cholestasis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either:

- 1 Patient has been diagnosed with Alagille syndrome; or
- 2 Patient has progressive familial intrahepatic cholestasis.

Initial application — (Chronic severe drug induced cholestatic liver injury) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic severe drug induced cholestatic liver injury; and
- 2 Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
- 3 Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

Initial application — (Cirrhosis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and
- 2 Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis).

Initial application — (Pregnancy) from any relevant practitioner. Approvals valid for 6 months where the patient diagnosed with cholestasis of pregnancy.

Initial application — (Haematological Transplant) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and
- 2 Treatment for up to 13 weeks.

Initial application — (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by Total Parenteral Nutrition (TPN); and
- 2 Liver function has not improved with modifying the TPN composition.

continued...

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

Renewal — (Chronic severe drug induced cholestatic liver injury) from any relevant practitioner. Approvals valid for 6 months where the patient continues to benefit from treatment.

Renewal — (Pregnancy/Cirrhosis) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months where the paediatric patient continues to require TPN and who is benefiting from treatment, defined as a sustained improvement in bilirubin levels.

Note: Ursodeoxycholic acid is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 100 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centre. Treatment failure – doubling of serum bilirubin levels, absence of a significant decrease in ALP or ALT and AST, development of varices, ascites or encephalopathy, marked worsening of pruritus or fatigue, histological progression by two stages, or to cirrhosis, need for transplantation.

Laxatives

Bulk-forming Agents

ISPAGHULA (PSYLLIUM) HUSK – Only on a prescription * Powder for oral soln	5.51	500 g OP	✓ Konsyl-D
MUCILAGINOUS LAXATIVES WITH STIMULANTS			
* Dry	6.02	500 g OP	
	(17.32)		Normacol Plus
	2.41	200 g OP	Newsell
	(8.72)		Normacol Plus
Faecal Softeners			
DOCUSATE SODIUM - Only on a prescription			
* Tab 50 mg		100	✓ <u>Coloxyl</u>
* Tab 120 mg		100	✓ <u>Coloxyl</u>
* Enema conc 18%	5.40	100 ml OP	 Coloxyl
DOCUSATE SODIUM WITH SENNOSIDES			
* Tab 50 mg with sennosides 8 mg	4.40	200	Laxsol
POLOXAMER – Only on a prescription Not funded for use in the ear.			
* Oral drops 10%	3.78	30 ml OP	✓ Coloxyl
Osmotic Laxatives			
GLYCEROL			
* Suppos 3.6 g – Only on a prescription	6.50	20	✓ <u>PSM</u>
LACTULOSE – Only on a prescription			
* Oral liq 10 g per 15 ml		500 ml	✓ Laevolac
MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM SA1473 on the next page – Retail pharmacy Powder for oral soln 13.125 g with potassium chlor 46.6 mg, sodium bicarbonate 178.5 mg and sodium ch	BICARBONATE AN	ID SODIUM CH	
ride 350.7 mg - Maximum of 90 sach per prescription		30	✓ Lax-Sachets

	Subsidy (Manufacturer's Price \$) S Per	Fully ubsidised	Brand or Generic Manufacturer
SA1473 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approva Both:	Is valid for 6 months for app	lications	meeting t	he following criteria:
 The patient has problematic constipation despite where lactulose is not contraindicated; and The patient would otherwise require a per rectal per section 	·	oral pha	armacothe	erapies including lactulose
Renewal from any relevant practitioner. Approvals valid	•	atient is	compliant	and is continuing to gain
benefit from treatment.			oompiian	and to continuing to gain
SODIUM ACID PHOSPHATE - Only on a prescription				
Enema 16% with sodium phosphate 8%	2.50	1	🖌 Fl	leet Phosphate Enema
SODIUM CITRATE WITH SODIUM LAURYL SULPHOAC	ETATE - Only on a prescrip	tion		
Enema 90 mg with sodium lauryl sulphoacetate 9 mg	per ml,			
5 ml		50	✓ <u>M</u>	icolette
Stimulant Laxatives				
BISACODYL – Only on a prescription				
* Tab 5 mg	5.99	200	🖌 <u>L</u>	ax-Tab
* Suppos 10 mg	3.78	10	🖌 Li	ax-Suppositories
	2.27	6		
	(3.00)		D	ulcolax
Lax-Suppositories to be Sole Supply on 1 April 20 (Dulcolax Suppos 10 mg to be delisted 1 April 2016)	16			
SENNA – Only on a prescription				
* Tab, standardised		100		
	(6.84)		S	enokot
	0.43	20	c	enokot
	(1.72)		3	enokol
Metabolic Disorder Agents				
Gaucher's Disease				
MIGLUCERASE - Special Authority see SA0473 below -	 Retail pharmacy 			
Inj 40 iu per ml, 200 iu vial		1	🖌 C	erezyme
Inj 40 iu per ml, 400 iu vial	2,144.00	1	🖌 C	erezyme
SA0473 Special Authority for Subsidy				
Special Authority approved by the Gaucher's Treatment Pa				
Notes: Subject to a budgetary cap. Applications will be co				lability.
Application details may be obtained from PHARMAC's we		ovt.nz or	:	
	e: (04) 460 4990			
	nile: (04) 916 7571			
Wellington Email:	gaucherpanel@pharmac.	jovt.nz		

36

	Subsidy (Manufacturer's	Price) Sub	Fully Brand or sidised Generic
	\$	Per	Manufacturer
Mouth and Throat			
Agents Used in Mouth Ulceration			
BENZYDAMINE HYDROCHLORIDE			
Soln 0.15% – Higher subsidy of up to \$17.01 per 500 ml with			
Endorsement	9.00	500 ml	
	(17.01)		Difflam
	3.60	200 ml	D.(()
Additional cubaids by and second for a matient sub-	(8.50)		Difflam
Additional subsidy by endorsement for a patient who has o tion is endorsed accordingly.	rai mucositis as	a result of treat	ment for cancer, and the prescr
CHLORHEXIDINE GLUCONATE			
Mouthwash 0.2%	2.57	200 ml OP	healthE
CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE			
₭ Adhesive gel 8.7% with cetalkonium chloride 0.01%	2.06	15 g OP	
	(6.00)		Bonjela
SODIUM CARBOXYMETHYLCELLULOSE			
With pectin and gelatin paste	17.20	56 g OP	 Stomahesive
	4.55	15 g OP	
	(7.90)		Orabase
	1.52	5 g OP	Orehees
With pectin and gelatin powder	(3.60)	29 a OB	Orabase
		28 g OP	Stomahesive
RIAMCINOLONE ACETONIDE	(10.00)		etemanoono
Paste 0.1%	5 33	5 g OP	Kenalog in Orabase
		5 y 01	
Oropharyngeal Anti-infectives			
MPHOTERICIN B Lozenges 10 mg	E 96	20	✓ Fungilin
• •		20	• Funginin
	4 70	10 × 00	
Oral gel 20 mg per g	4.79	40 g OP	Decozol
	0.55	04	
Oral liq 100,000 u per ml	2.55	24 ml OP	✓ Nilstat
m-Nystatin to be Sole Supply on 1 May 2016 Nilstat Oral lig 100,000 u per ml to be delisted 1 May 2016)			✓ m-Nystatin
Other Oral Agents			
for folioio mouthuroch, pilocomine and limitel an adher sub-state fo	armula refer Ote	ndard Course 1-	n nora 016
For folinic mouthwash, pilocarpine oral liquid or saliva substitute for	ormula refer Sta	ndard Formula	e, page 216
IYDROGEN PEROXIDE			
HYDROGEN PEROXIDE ★ Soln 3% (10 vol) – Maximum of 200 ml per prescription		ndard Formulae 100 ml	e, page 216 Pharmacy Health
IYDROGEN PEROXIDE	1.40		

	Subsidy (Manufacturer's F \$	Price) Sub Per	Fully Brand or sidised Generic ✔ Manufacturer
Vitamins			
Vitamin A			
ITAMIN A WITH VITAMINS D AND C Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops	4.50	10 ml OP	Vitadol C
Vitamin B			
YDROXOCOBALAMIN Inj 1 mg per ml, 1 ml ampoule – Up to 6 inj available on a PS	02.31	3	✓ <u>Neo-B12</u>
YRIDOXINE HYDROCHLORIDE a) No more than 100 mg per dose b) Only on a prescription			
Tab 25 mg – No patient co-payment payable	2.15	90	Vitamin B6 25
Tab 50 mg HIAMINE HYDROCHLORIDE – Only on a prescription	11.55	500	✓ <u>Apo-Pyridoxine</u>
Tab 50 mg	5.62	100	 Apo-Thiamine
ITAMIN B COMPLEX • Tab, strong, BPC	4.30	500	✓ <u>Bplex</u>
Vitamin C			
SCORBIC ACID a) No more than 100 mg per dose b) Only on a prescription			
F Tab 100 mg	7.00	500	✓ <u>Cvite</u>
Vitamin D			
LFACALCIDOL			
Cap 0.25 mcg		100	One-Alpha
Cap 1 mcg		100	One-Alpha
Oral drops 2 mcg per ml		20 ml OP	One-Alpha
ALCITRIOL			
- Cap 0.25 mcg		30	✓ Airflow
A	10.10	100	 Calcitriol-AFT
Cap 0.5 mcg		30	✓ Airflow
	18.73	100	 Calcitriol-AFT
HOLECALCIFEROL · Tab 1.25 mg (50,000 iu) – Maximum of 12 tab per prescriptio	n7.76	12	✓ Cal-d-Forte
Multivitamin Preparations			
ULTIVITAMIN RENAL – Special Authority see SA1546 on the n	ext page – Reta	il pharmacy	
сар		30	 Clinicians Renal Vit

Subsidy Fully Brand or Subsidied Subsidied Generic Manufacturer's Price) Subsidied Generic Manufacturer ■>SA1546 Special Authority for Subsidy Manufacturer Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications me the following criteria: The patient has chronic kidney disease and is receiving either peritoneal dialysis or haemodialysis; or 2 1 The patient has chronic kidney disease and is receiving either peritoneal dialysis or haemodialysis; or 2 2 The patient has chronic kidney disease and is receiving either peritoneal dialysis or haemodialysis; or 2 4 The patient has chronic kidney disease area (BSA). MULTIVITAMINS – Special Authority see SA1036 below – Retail pharmacy * Powder
Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications me the following criteria: Either: 1 1 The patient has chronic kidney disease and is receiving either peritoneal dialysis or haemodialysis; or 2 The patient has chronic kidney disease grade 5, defined as patient with an estimated glomerular filtration rate 15 ml/min/1.73 m ² body surface area (BSA). MULTIVITAMINS – Special Authority see SA1036 below – Retail pharmacy * Powder
2 The patient has chronic kidney disease grade 5, defined as patient with an estimated glomerular filtration rate 15 ml/min/1.73 m ² body surface area (BSA). MULTIVITAMINS – Special Authority see SA1036 below – Retail pharmacy * Powder
 ★ Powder
Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where the patient inborn errors of metabolism. Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where patient has had a prevaproval for multivitamins. VITAMINS * Tab (BPC cap strength) 7.60 * Tab (BPC cap strength) 9.00 ✓ Mvite * Cap (fat soluble vitamins A, D, E, K) – Special Authority see SA1002 below – Retail pharmacy 23.40 60 ✓ Vitabdeck Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications methe following criteria: 1 Patient has cystic fibrosis with pancreatic insufficiency; or 2 Patient is an infant or child with liver disease or short gut syndrome. Minerals Calcium 6.21 30 ✓ Calsource * Tab eff 1.75 g (10 g elemental) 5.38 250 ✓ Arrow-Calcium CALCIUM GLUCONATE 34.24 10 ✓ Hospira Fluoride 10%, 10 ml ampoule 34.24 10 ✓ Hospira
 ★ Tab (BPC cap strength)
SA1002 below – Retail pharmacy 23.40 60 ✓ Vitabdeck Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications me the following criteria: Either: 1 Patient has cystic fibrosis with pancreatic insufficiency; or 2 Patient has cystic fibrosis with pancreatic insufficiency; or 2 Patient has cystic fibrosis with pancreatic insufficiency; or Calcium Calcium Calcium Calcium CALCIUM CARBONATE
Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications me the following criteria: Either: 1 Patient has cystic fibrosis with pancreatic insufficiency; or 2 Patient is an infant or child with liver disease or short gut syndrome. Minerals CALCIUM CARBONATE * Tab eff 1.75 g (1 g elemental) * Tab 1.25 g (500 mg elemental) CALCIUM GLUCONATE * Inj 10%, 10 ml ampoule * Inj 10%, 10 ml ampoule
* Tab eff 1.75 g (1 g elemental) 6.21 30 ✓ Calsource * Tab 1.25 g (500 mg elemental) 5.38 250 ✓ Arrow-Calcium CALCIUM GLUCONATE * inj 10%, 10 ml ampoule 34.24 10 ✓ Hospira Fluoride
Fluoride
* Tab 1.1 mg (0.5 mg elemental)
lodine
POTASSIUM IODATE * Tab 253 mcg (150 mcg elemental iodine)
Iron
FERROUS FUMARATE * Tab 200 mg (65 mg elemental) EFERROUS FUMARATE WITH FOLIC ACID * Tab 310 mg (100 mg elemental) with folic acid 350 mcg 4.75 60

	Subsidy (Manufacturer's Pri \$	ice) Sub Per	Fully Brand or osidised Generic ✔ Manufacturer
FERROUS SULPHATE			
* Tab long-acting 325 mg (105 mg elemental)		30	✓ Ferrograd
*‡ Oral liq 30 mg (6 mg elemental) per 1 ml	10.28	500 ml	Ferodan
FERROUS SULPHATE WITH FOLIC ACID			
* Tab long-acting 325 mg (105 mg elemental) with folic acid			
350 mcg		30	
	(4.29)		Ferrograd F
IRON POLYMALTOSE		_	/-
* Inj 50 mg per ml, 2 ml ampoule		5	✓ <u>Ferrum H</u>
Magnesium			
For magnesium hydroxide mixture refer Standard Formulae, page	216		
MAGNESIUM SULPHATE			
* Inj 2 mmol per ml, 5 ml ampoule	12.65	10	✓ <u>DBL</u>
Zinc			
ZINC SULPHATE			
* Cap 137.4 mg (50 mg elemental)	11.00	100	✓ Zincaps

Por

Subsidy (Manufacturer's Price) Fully Brand or Subsidised Generic Manufacturer

Antianaemics

Hypoplastic and Haemolytic

SA1469 Special Authority for Subsidy

Initial application — (chronic renal failure) from any specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient in chronic renal failure; and
- 2 Haemoglobin ≤ 100g/L; and
- 3 Any of the following:
 - 3.1 Both:
 - 3.1.1 Patient does not have diabetes mellitus; and
 - 3.1.2 Glomerular filtration rate \leq 30ml/min; or
 - 3.2 Both:
 - 3.2.1 Patient has diabetes mellitus; and
 - 3.2.2 Glomerular filtration rate \leq 45ml/min; or
 - 3.3 Patient is on haemodialysis or peritoneal dialysis.

Note: Erythropoietin alfa is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy.

Initial application — (myelodysplasia) from any specialist. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a confirmed diagnosis of myelodysplasia (MDS)*; and
- 2 Has had symptomatic anaemia with haemoglobin <100g/L and is red cell transfusion-dependent; and
- 3 Patient has very low, low or intermediate risk MDS based on the WHO classification based prognostic scoring system for myelodysplastic syndrome (WPSS); and
- 4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
- 5 Patient has a serum erythropoietin level of <500 IU/L; and
- 6 The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

Note: Indication marked with * is an Unapproved Indication

Renewal — (chronic renal failure) from any specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Erythropoietin alfa is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy.

Renewal — (myelodysplasia) from any specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient's transfusion requirement continues to be reduced with erythropoietin treatment; and
- 2 Transformation to acute myeloid leukaemia has not occurred; and
- 3 The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

Note: Indication marked with * is an Unapproved Indication

	Subsidy (Manufacturer's Price \$	e) Subs Per	Fully sidised	Brand or Generic Manufacturer		
EPOETIN ALFA [ERYTHROPOIETIN ALFA] – Special Authority see SA1469 on the previous page – Retail pharmacy						
Wastage claimable – see rule 3.3.2 on page 13						
Inj 1,000 iu in 0.5 ml, syringe		6	✓ <u>E</u>			
Inj 2,000 iu in 0.5 ml, syringe		6	✓ <u>E</u>			
Inj 3,000 iu in 0.3 ml, syringe		6	✓ <u>E</u>	prex		
Inj 4,000 iu in 0.4 ml, syringe		6	✓ <u>E</u>			
Inj 5,000 iu in 0.5 ml, syringe		6	✓ <u>E</u>			
Inj 6,000 iu in 0.6 ml, syringe		6	✓ <u>E</u>	prex		
Inj 8,000 iu in 0.8 ml, syringe		6	✓ E			
Inj 10,000 iu in 1 ml, syringe		6	✓ <u>E</u>			
Inj 40,000 iu in 1 ml, syringe		1	✓ E	prex		
Megaloblastic						
FOLIC ACID						
* Tab 0.8 mg		1,000	🖌 A	po-Folic Acid		
* Tab 5 mg		500	VĀ	po-Folic Acid		
Oral liq 50 mcg per ml		25 ml OP	🖌 В	iomed		
Antifibrinolytics, Haemostatics and Local Sclero						
ELTROMBOPAG – Special Authority see SA1418 below – Retail Wastage claimable – see rule 3.3.2 on page 13	pharmacy					

Tab 25 mg	1,771.00	28	Revolade
Tab 50 mg		28	Revolade

➡SA1418 Special Authority for Subsidy

Initial application — (idiopathic thrombocytopenic purpura - post-splenectomy) only from a haematologist. Approvals valid for 6 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has had a splenectomy; and
- 2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Any of the following:
 - 3.1 Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding; or
 - 3.2 Patient has a platelet count of ≤ 20,000 platelets per microlitre and has evidence of active bleeding; or
 - 3.3 Patient has a platelet count of \leq 10,000 platelets per microlitre.

Initial application — (idiopathic thrombocytopenic purpura - preparation for splenectomy) only from a haematologist. Approvals valid for 6 weeks where the patient requires eltrombopag treatment as preparation for splenectomy.

Renewal — (idiopathic thrombocytopenic purpura - post-splenectomy) only from a haematologist. Approvals valid for 12 months where the patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required.

Note: Response to treatment is defined as a platelet count of >30,000 platelets per microlitre.

EPTACOG ALFA [RECOMBINANT FACTOR VIIA] - [Xpharm]

For patients with haemophilia, whose funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

Inj 1 mg syringe1,163.75	1	NovoSeven RT
Inj 2 mg syringe2,327.50	1	NovoSeven RT
Inj 5 mg syringe	1	NovoSeven RT
Inj 8 mg syringe	1	NovoSeven RT

	Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic
	\$	Per	~	Manufacturer
ACTOR EIGHT INHIBITOR BYPASSING FRACTION - [Xpharm]]			
For patients with haemophilia, whose funded treatment is mar	aged by the Haemo	philia T	Treaters Gro	oup in conjunction with
National Haemophilia Management Group.				
Inj 500 U	1,450.00	1	🖌 F	EIBA NF
Inj 1,000 U	2,900.00	1	🖌 F	EIBA NF
Inj 2,500 U	7,250.00	1	🖌 F	EIBA NF
IOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] - [Xpharn	nl			
For patients with haemophilia, whose treatment is managed by		eaters	Group in co	niunction with the Natio
Haemophilia Management Group.			0.100.00	
Inj 250 iu prefilled syringe	210.00	1	✓ X	vntha
Inj 500 iu prefilled syringe		1		yntha
Inj 1,000 iu prefilled syringe		1		vntha
Inj 2,000 iu prefilled syringe		1		yntha
Inj 3,000 iu prefilled syringe	,	1		yntha
, , , , , ,			• ^	ynna
ONACOG ALFA [RECOMBINANT FACTOR IX] – [Xpharm]				
For patients with haemophilia, whose funded treatment is mar	laged by the Haemo	philia	Ireaters Gro	oup in conjunction with
National Haemophilia Management Group.				
Inj 250 iu vial		1		eneFIX
Inj 500 iu vial		1	• =	eneFIX
Inj 1,000 iu vial	,	1		eneFIX
Inj 2,000 iu vial		1		eneFIX
Inj 3,000 iu vial	3,720.00	1	🖌 В	eneFIX
CTOCOG ALEA [RECOMBINIANT EACTOR VIII] - [Ynharm]				
	the Heemonhilie Tre	oatoro	Group in co	niunction with the Natio
For patients with haemophilia, whose treatment is managed by	the Haemophilia Tre	eaters	Group in co	njunction with the Natio
For patients with haemophilia, whose treatment is managed by Haemophilia Management Group.			·	
For patients with haemophilia, whose treatment is managed by	237.50	eaters (• к	ogenate FS
For patients with haemophilia, whose treatment is managed by Haemophilia Management Group. Inj 250 iu vial	237.50 287.50	1	✓ K ✓ A	ogenate FS dvate
For patients with haemophilia, whose treatment is managed by Haemophilia Management Group.	237.50 287.50 475.00		✓ K ✓ A ✓ K	ogenate FS dvate ogenate FS
For patients with haemophilia, whose treatment is managed by Haemophilia Management Group. Inj 250 iu vial	237.50 287.50 475.00 575.00	1 1	✓ K ✓ A ✓ K ✓ A	ogenate FS dvate ogenate FS dvate
For patients with haemophilia, whose treatment is managed by Haemophilia Management Group. Inj 250 iu vial	237.50 287.50 475.00 575.00 950.00	1	✓ K ✓ A ✓ K ✓ A	ogenate FS dvate ogenate FS dvate ogenate FS
For patients with haemophilia, whose treatment is managed by Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial	237.50 287.50 475.00 575.00 950.00 1,150.00	1 1 1	 K A K A K A 	ogenate FS dvate ogenate FS dvate ogenate FS dvate
For patients with haemophilia, whose treatment is managed by Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial	237.50 287.50 475.00 575.00 950.00 1,150.00 1,725.00	1 1 1	 K K K K K A K A 	ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate dvate
For patients with haemophilia, whose treatment is managed by Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial	237.50 287.50 475.00 575.00 950.00 1,150.00 1,725.00 1,900.00	1 1 1		ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate dvate ogenate FS
For patients with haemophilia, whose treatment is managed by Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial Inj 2,000 iu vial	237.50 287.50 475.00 575.00 1,150.00 1,725.00 1,900.00 2,300.00	1 1 1 1 1	 KA <	ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate ogenate FS dvate
For patients with haemophilia, whose treatment is managed by Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial	237.50 287.50 475.00 575.00 1,150.00 1,150.00 1,725.00 1,900.00 2,300.00 2,850.00	1 1 1	<pre></pre>	ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate ogenate FS dvate ogenate FS
For patients with haemophilia, whose treatment is managed by Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial Inj 2,000 iu vial	237.50 287.50 475.00 575.00 1,150.00 1,725.00 1,900.00 2,300.00	1 1 1 1 1	<pre></pre>	ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate ogenate FS dvate
For patients with haemophilia, whose treatment is managed by Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial Inj 3,000 iu vial	237.50 287.50 475.00 575.00 1,150.00 1,150.00 1,725.00 1,900.00 2,300.00 2,850.00	1 1 1 1 1	<pre></pre>	ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate ogenate FS dvate ogenate FS
For patients with haemophilia, whose treatment is managed by Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial Inj 2,000 iu vial Inj 3,000 iu vial DDIUM TETRADECYL SULPHATE	237.50 287.50 287.50 575.00 1,150.00 1,150.00 1,725.00 1,900.00 2,300.00 2,300.00 3,450.00	1 1 1 1 1	<pre></pre>	ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate ogenate FS dvate ogenate FS
For patients with haemophilia, whose treatment is managed by Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial Inj 2,000 iu vial Inj 3,000 iu vial DDIUM TETRADECYL SULPHATE	237.50 287.50 287.50 575.00 1,150.00 1,150.00 1,1725.00 1,250.00 2,300.00 2,300.00 3,450.00 3,450.00	1 1 1 1 1		ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate
For patients with haemophilia, whose treatment is managed by Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial Inj 2,000 iu vial Inj 3,000 iu vial ODIUM TETRADECYL SULPHATE	237.50 287.50 287.50 575.00 1,150.00 1,150.00 1,725.00 1,900.00 2,300.00 2,300.00 3,450.00	1 1 1 1 1		ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate ogenate FS dvate ogenate FS
For patients with haemophilia, whose treatment is managed by Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial Inj 2,000 iu vial Inj 3,000 iu vial ODIUM TETRADECYL SULPHATE Finj 3% 2 ml RANEXAMIC ACID	237.50 287.50 287.50 575.00 1,150.00 1,150.00 1,1725.00 1,1725.00 2,300.00 2,300.00 2,300.00 3,450.00 3,450.00 (73.00)	1 1 1 1 1 5	У А К А К А К А К А К А К А К А К А К А	ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate ogenate FS dvate ogenate FS dvate
For patients with haemophilia, whose treatment is managed by Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial Inj 2,000 iu vial Inj 3,000 iu vial ODIUM TETRADECYL SULPHATE	237.50 287.50 287.50 575.00 1,150.00 1,150.00 1,1725.00 1,1725.00 2,300.00 2,300.00 2,300.00 3,450.00 3,450.00 (73.00)	1 1 1 1 1	У А К А К А К А К А К А К А К А К А К А	ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate ogenate FS dvate ogenate FS dvate ogenate FS dvate
For patients with haemophilia, whose treatment is managed by Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial Inj 2,000 iu vial Inj 3,000 iu vial ODIUM TETRADECYL SULPHATE : Inj 3% 2 ml RANEXAMIC ACID Tab 500 mg	237.50 287.50 287.50 575.00 1,150.00 1,150.00 1,1725.00 1,1725.00 2,300.00 2,300.00 2,300.00 3,450.00 3,450.00 (73.00)	1 1 1 1 1 5	У А К А К А К А К А К А К А К А К А К А	ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate ogenate FS dvate ogenate FS dvate
For patients with haemophilia, whose treatment is managed by Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial Inj 2,000 iu vial Inj 3,000 iu vial ODIUM TETRADECYL SULPHATE : Inj 3% 2 ml RANEXAMIC ACID Tab 500 mg Vitamin K	237.50 287.50 287.50 575.00 1,150.00 1,150.00 1,1725.00 1,1725.00 2,300.00 2,300.00 2,300.00 3,450.00 3,450.00 (73.00)	1 1 1 1 1 5	У А К А К А К А К А К А К А К А К А К А	ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate ogenate FS dvate ogenate FS dvate
Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial Inj 2,000 iu vial Inj 3,000 iu vial ODIUM TETRADECYL SULPHATE i Inj 3% 2 ml RANEXAMIC ACID Tab 500 mg Vitamin K HYTOMENADIONE	237.50 287.50 475.00 575.00 950.00 1,150.00 1,725.00 1,900.00 2,300.00 2,300.00 3,450.00 3,450.00 28.50 (73.00)	1 1 1 1 1 5	У А К У А К У А А К У А А К У А А У А А Г У <u>С</u>	ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate ogenate FS dvate ogenate FS dvate bro-vein <u>yklokapron</u>
For patients with haemophilia, whose treatment is managed by Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial Inj 2,000 iu vial Inj 3,000 iu vial DDIUM TETRADECYL SULPHATE Inj 3% 2 ml RANEXAMIC ACID Tab 500 mg /itamin K	237.50 287.50 287.50 575.00 575.00 1,150.00 1,150.00 1,725.00 2,300.00 2,300.00 3,450.00 3,450.00 28.50 (73.00) 	1 1 1 1 1 5	✓ К ✓ А ✓ А ✓ А ✓ А ✓ А ✓ А ✓ А ✓ С ✓ К	ogenate FS dvate ogenate FS dvate ogenate FS dvate dvate ogenate FS dvate ogenate FS dvate

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Antithrombotic Agents				
Antiplatelet Agents				
ASPIRIN * Tab 100 mg	10.50	990	✓ <u>E</u>	thics Aspirin EC
CLOPIDOGREL * Tab 75 mg – For clopidogrel oral liquid formulation refer, page 213		84	✓ <u>A</u>	rrow - Clopid
DIPYRIDAMOLE				
 * Tab 25 mg – For dipyridamole oral liquid formulation refer, page 213 * Tab long-acting 150 mg 		84 60		ersantin ytazen SR
PRASUGREL - Special Authority see SA1201 below - Retail pha	armacy			
Tab 5 mg Tab 10 mg ■>SA1201 Special Authority for Subsidy		28 28	• -	ffient ffient

Initial application — (coronary angioplasty and bare metal stent) from any relevant practitioner. Approvals valid for 6 months where the patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic*.

Initial application — (drug eluting stent) from any relevant practitioner. Approvals valid for 12 months where the patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*.

Initial application — (stent thromobosis) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has experienced cardiac stent thromosis whilst on clopidogrel.

Renewal — (coronary angioplasty and bare metal stent) from any relevant practitioner. Approvals valid for 6 months where the patient has undergone coronary angioplasty or had a bare metal cardiac stent inserted in the previous 4 weeks and is clopidogrelallergic*.

Renewal — (drug eluting stent) from any relevant practitioner. Approvals valid for 12 months where had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*.

Note: * Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.

TICAGRELOR – Special Authority see SA1382 below – Retail pharmacy

* Tab 90 mg90.00 56 🖌 Brilinta

SA1382 Special Authority for Subsidy

Initial application — (acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and
- 2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned.

Renewal — (subsequent acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and
- 2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Heparin and Antagonist Preparations				
DALTEPARIN SODIUM – Special Authority see SA1270 below – Inj 2,500 iu per 0.2 ml prefilled syringe		10	🖌 Fr	agmin
Inj 5,000 iu per 0.2 ml prefilled syringe Inj 7,500 iu per 0.75 ml graduated syringe	60.03	10 10	🖌 Fr	agmin agmin
Inj 10,000 iu per 1 ml graduated syringe Inj 12,500 iu per 0.5 ml prefilled syringe		10 10	🖌 Fr	agmin agmin
Inj 15,000 iu per 0.6 ml prefilled syringe Inj 18,000 iu per 0.72 ml prefilled syringe		10 10		agmin agmin

SA1270 Special Authority for Subsidy

Initial application — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Initial application — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic level of oral anti-coagulant treatment; or
- 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
- 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
- 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
- 5 To be used in association with cardioversion of atrial fibrillation.

Renewal — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, Acute Coronary Syndrome, cardioversion, or prior to oral anti-coagulation).

ENOXAPARIN SODIUM – Special Authority see SA1174 on the next page – Retail pharmacy

Inj 20 mg		10	Clexane
Inj 40 mg		10	Clexane
Inj 60 mg		10	Clexane
Inj 80 mg		10	Clexane
Inj 100 mg		10	Clexane
Inj 120 mg		10	Clexane
Inj 150 mg	177.60	10	 Clexane

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

➡SA1174 Special Authority for Subsidy

Initial application — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patients pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Initial application — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

- Any of the following:
 - 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic level of oral anti-coagulant treatment; or
 - 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
 - 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
 - 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
 - 5 To be used in association with cardioversion of atrial fibrillation.

Renewal — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, ACS, cardioversion, or prior to oral anti-coagulation).

HEPARIN SODIUM

lnj 1,000 iu per ml, 5 ml	10	Hospira	
61.04	50	✓ Pfizer	
66.80		✓ Hospira	
Inj 1,000 iu per ml, 35 ml vial	1	✓ Hospira	
lnj 5,000 iu per ml, 1 ml	5	✓ Hospira	
lnj 5,000 iu per ml, 5 ml	50	✓ Pfizer	
lnj 25,000 iu per ml, 0.2 ml	5	✓ Hospira	
HEPARINISED SALINE			
Inj 10 iu per ml, 5 ml	50	 Pfizer 	
PROTAMINE SULPHATE			
* Inj 10 mg per ml, 5 ml	10		
(119.23)	10	Artex	
Oral Anticoagulants			
DABIGATRAN			
Cap 75 mg – No more than 2 cap per day	60	Pradaxa	
	60	✓ Pradaxa	
Cap 110 mg	••		
Cap 150 mg148.00	60	Pradaxa	
RIVAROXABAN - Special Authority see SA1066 on the next page - Retail pharman	су		
Tab 10 mg153.00	15	✓ Xarelto	

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Sub	osidised	Generic	
\$	Per	~	Manufacturer	

►SA1066 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 weeks for applications meeting the following criteria: Either:

- 1 For the prophylaxis of venous thromboembolism following a total hip replacement; or
- 2 For the prophylaxis of venous thromboembolism following a total knee replacement.

Note: Rivaroxaban is only currently indicated and subsidised for up to 5 weeks therapy for prophylaxis of venous thromboembolism following a total hip replacement and up to 2 weeks therapy for prophylaxis of venous thromboembolism following a total knee replacement.

Renewal from any relevant practitioner. Approvals valid for 5 weeks where prophylaxis for venous thromboembolism is required for patients following a subsequent total hip or knee replacement.

WARFARIN SODIUM

Note: Marevan and Coumadin are not interchangeable.

*	Tab 1 mg3.46	50	Coumadin
	6.86	100	Marevan
*	Tab 2 mg4.31	50	Coumadin
*	Tab 3 mg9.70	100	Marevan
*	Tab 5 mg5.93	50	Coumadin
	11.75	100	Marevan

Blood Colony-stimulating Factors

FILGRASTIM - Special Authority see SA1259 below - Retail pharma	acy		
Inj 300 mcg per 0.5 ml prefilled syringe	540.00	5	 Zarzio
Inj 480 mcg per 0.5 ml prefilled syringe	864.00	5	🗸 Zarzio

SA1259 Special Authority for Subsidy

Initial application only from a relevant specialist, vocationally registered general practitioner or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk \geq 20%*); or
- 2 Peripheral blood stem cell mobilisation in patients undergoing haematological transplantation; or
- 3 Peripheral blood stem cell mobilisation or bone marrow donation from healthy donors for transplantation; or
- 4 Treatment of severe chronic neutropenia (ANC < 0.5×10^9 /L); or
- 5 Treatment of drug-induced prolonged neutropenia (ANC < 0.5×10^9 /L).

Note: *Febrile neutropenia risk $\geq 20\%$ after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

PEGFILGRASTIM - Special Authority see SA1384 below - Retail pharmacy

Inj 6 mg per 0.6 ml syringe1,080.00 1

J.00 I

Neulastim

SA1384 Special Authority for Subsidy

Initial application only from a relevant specialist, vocationally registered general practitioner or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where used for prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk $\geq 20\%^*$).

Note: *Febrile neutropenia risk \geq 20% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

	Subsidy (Manufacturer's Pric \$	e) Su Per	Fully bsidised	Brand or Generic Manufacturer
Fluids and Electrolytes			-	
Intravenous Administration				
GLUCOSE [DEXTROSE]				
* Inj 50%, 10 ml ampoule - Up to 5 inj available on a PSO		5		iomed
* Inj 50%, 90 ml bottle – Up to 5 inj available on a PSO	14.50	1	✓ <u>B</u>	iomed
POTASSIUM CHLORIDE	FF 00	50		
* Inj 75 mg per ml, 10 ml		50	V A	straZeneca
SODIUM BICARBONATE Inj 8.4%, 50 ml	10.05	1		iomed
a) Up to 5 inj available on a PSO		I	V D	lomea
b) Not in combination				
Inj 8.4%, 100 ml	20.50	1	🖌 Bi	iomed
a) Up to 5 inj available on a PSO				
b) Not in combination				
SODIUM CHLORIDE Not funded for use as a nasal drop. Only funded for nebulise	r use when in coniu	nction with	an antibi	otic intended for nebulise
USE.			anando	
Inf 0.9% – Up to 2000 ml available on a PSO	3.06	500 ml	🖌 Ba	
	4.06	1,000 ml	_ 🖌 Ва	
Only if prescribed on a prescription for renal dialysis, mat for emergency use. (500 ml and 1,000 ml packs)	ernity or post-natal	care in the	home o	t the patient, or on a PSC
Inj 23.4%, 20 ml ampoule		5	🖌 Bi	iomed
For Sodium chloride oral liquid formulation refer Standard				
Inj 0.9%, 5 ml – Up to 5 inj available on a PSO		50		ultichem
$ \mathbf{n} = 0.00/10$ m/L $ \mathbf{n} $ to E initiation of BCO	15.50	50	V Pi	
Inj 0.9%, 10 ml – Up to 5 inj available on a PSO	11.50 15.50	50	V M	ultichem fizer
Inj 0.9%, 20 ml		6		harmacia
	8.41	20		ultichem
	11.79	30	🖌 Pi	harmacia
TOTAL PARENTERAL NUTRITION (TPN) - Retail pharmacy-Sp			4	
Infusion	CBS	1 OP	V TI	PN
WATER				had in the Discussion disc
 On a prescription or Practitioner's Supply Order only wh Schedule requiring a solvent or diluent; or 	en on the same for	m as an inj	ection lis	ted in the Pharmaceutica
2) On a bulk supply order; or				
3) When used in the extemporaneous compounding of eye	drops.			
Purified for inj, 5 ml – Up to 5 inj available on a PSO		50	· · ·	ultichem
Purified for inj, 10 ml – Up to 5 inj available on a PSO		50		ultichem
Purified for inj, 20 ml – Up to 5 inj available on a PSO		20	V M	ultichem
Oral Administration				
CALCIUM POLYSTYRENE SULPHONATE				
Powder		300 g OP	🖌 Ca	alcium Resonium
COMPOUND ELECTROLYTES				
Powder for oral soln – Up to 10 sach available on a PSO	1.80	10	🖌 <u>E</u>	nerlyte

(Subsidy Manufacturer's \$	Price) Sub Per	Fully sidised	Brand or Generic Manufacturer
DEXTROSE WITH ELECTROLYTES				
Soln with electrolytes	6.55	1,000 ml OP		edialyte - Bubblegum
PHOSPHORUS				
Tab eff 500 mg (16 mmol)	82.50	100	🖌 P	hosphate-Sandoz
POTASSIUM CHLORIDE				
* Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq)	5.26 (11.85)	60	C	hlorvescent
Tab long-acting 600 mg (8 mmol)	```	200		pan-K
SODIUM BICARBONATE				
Cap 840 mg	8.52	100	🗸 S	odibic
SODIUM POLYSTYRENE SULPHONATE				
Powder	84.65	454 g OP	🖌 R	esonium-A

	0.1.11		F 1	
	Subsidy (Manufacturar's Price	na) 61	Fully ubsidised	Brand or Generic
	(Manufacturer's Prices)	Per Si		Manufacturer
	÷	1.01		
Alpha Adrenoceptor Blockers				
DOXAZOSIN				
* Tab 2 mg	6.75	500	🗸 A	po-Doxazosin
* Tab 4 mg		500		po-Doxazosin
PHENOXYBENZAMINE HYDROCHLORIDE				•
* Cap 10 mg	65.00	30	V B	NM S29
	05.00	50	• •	
PRAZOSIN	E E 2	100		no Brozooin
* Tab 1 mg * Tab 2 mg		100 100		po-Prazosin po-Prazosin
* Tab 5 mg		100		po-Prazosin
0		100	• 1	0011020011
TERAZOSIN * Tab 1 mg	0.50	28		rrow
* Tab 2 mg		28	-	rrow
* Tab 5 mg		28	✓ Â	
5		20	• <u>-</u>	
Agents Affecting the Renin-Angiotensin System				
ACE Inhibitors				
CAPTOPRIL *1 Oral lig 5 mg per ml	04.00	95 ml OP		apoten
Oral liquid restricted to children under 12 years of age.		95 III OF	•	apolen
CILAZAPRIL * Tab 0.5 mg	2.00	90	🗸 Z	opril
* Tab 0.5 mg		90 90	✓ Z	
* Tab 5 mg		90	✓ z	
ENALAPRIL MALEATE		00	• =	
ENALAPRIL MALEALE * Tab 5 mg	0.96	100	V F	thics Enalapril
* Tab 5 mg		100		thics Enalapril
 * Tab 20 mg – For enalapril maleate oral liquid formulation re- 		100	• =	
fer, page 213		100	🖌 E	thics Enalapril
LISINOPRIL				
* Tab 5 mg	1.80	90	V F	thics Lisinopril
* 100 0 mg	(3.58)	00		rrow-Lisinopril
Ethics Lisinopril to be Sole Supply on 1 April 2016	(0.00)			
* Tab 10 mg	2.05	90	🖌 E	thics Lisinopril
-	(4.08)		A	rrow-Lisinopril
Ethics Lisinopril to be Sole Supply on 1 April 2016				
* Tab 20 mg		90		thics Lisinopril
Ethica Licinacuil to be Cale Currely on 1 April 2010	(4.88)		A	rrow-Lisinopril
Ethics Lisinopril to be Sole Supply on 1 April 2016 (Arrow-Lisinopril Tab 5 mg to be delisted 1 April 2016)				
(Arrow-Lisinopril Tab 10 mg to be delisted 1 April 2010)				
(Arrow-Lisinopril Tab 20 mg to be delisted 1 April 2016)				
PERINDOPRIL				
* Tab 2 mg	3 75	30	~ ^	po-Perindopril
* Tab 4 mg		30 30		po-Perindopril

_					
		Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
ວບ	IINAPRIL				
*	Tab 5 mg	4.31	90	V Į	Arrow-Quinapril 5
*	Tab 10 mg	3.15	90	~ A	Arrow-Quinapril 10
*	Tab 20 mg		90	V <u>I</u>	Arrow-Quinapril 20
TR/	ANDOLAPRIL				
	Higher subsidy by endorsement is available for patients who we prior to 1 June 1998. The prescription must be endorsed accor- are "certified condition" or an appropriate description of the cardiac failure" or "CCF". For the purposes of this endorsem- infarction with an ejection fraction of less than 40%. Patients we full subsidy by endorsement. Cap 1 mg – Higher subsidy of \$18.67 per 28 cap with En-	prdingly. We recomme patient such as "co ment, congestive hea	end th ongest art fail	hat the word tive heart fa lure include	ds used to indicate eligibility ailure", "CHF", "congestive es patients post myocardial
ጥ	dorsement	3.06	28		
		(18.67)	20	C	Gopten
*	Cap 2 mg - Higher subsidy of \$27.00 per 28 cap with En-	<u> </u>			
-	dorsement	4.43	28		
		(27.00)		Ċ	Gopten
A	CE Inhibitors with Diuretics				
CIL	AZAPRIL WITH HYDROCHLOROTHIAZIDE				
*	Tab 5 mg with hydrochlorothiazide 12.5 mg	10.72	100	✓ <u>A</u>	
					Cilazapril/Hydrochlorothia
EN/	ALAPRIL MALEATE WITH HYDROCHLOROTHIAZIDE				
*	Tab 20 mg with hydrochlorothiazide 12.5 mg		30		
		(8.70)		C	Co-Renitec
(Co	p-Renitec Tab 20 mg with hydrochlorothiazide 12.5 mg to be del	listed 1 April 2016)			
QU	IINAPRIL WITH HYDROCHLOROTHIAZIDE				
*	Tab 10 mg with hydrochlorothiazide 12.5 mg		30		Accuretic 10
*	Tab 20 mg with hydrochlorothiazide 12.5 mg	4.78	30	<u> </u>	Accuretic 20
A	ngiotensin II Antagonists				
CA'	NDESARTAN CILEXETIL – Special Authority see SA1223 belo	ow – Retail pharmac	N		
*	Tab 4 mg		,y 90	~ (Candestar
*	Tab 8 mg		90		Candestar
*	Tab 16 mg		90		Candestar
*	Tab 32 mg		90	V	Candestar
	SA1223 Special Authority for Subsidy			_	
	cherical stationary for caperaly				

Initial application — (ACE inhibitor intolerance) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

1 Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor); or

2 Patient has a history of angioedema.

Initial application — (Unsatisfactory response to ACE inhibitor) from any relevant practitioner. Approvals valid without further renewal unless notified where patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor.

CARDIOVASCULAR SYSTEM

	Subsidy (Manufacturer's Price \$) Per	Fully Brand or Subsidised Generic ✔ Manufacturer	
LOSARTAN POTASSIUM				
* Tab 12.5 mg		84	Losartan Actavis	
* Tab 25 mg		84	✓ Losartan Actavis	
* Tab 50 mg		84	✓ Losartan Actavis	
		84		
* Tab 100 mg	2.00	64	 Losartan Actavis 	
Angiotensin II Antagonists with Diuretics				
OSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE				
Tab 50 mg with hydrochlorothiazide 12.5 mg	2.18	30	Arrow-Losartan & Hudrooblorethio	
Autombuthatice			<u>Hydrochlorothiaz</u>	lae
Antiarrhythmics				
For lignocaine hydrochloride refer to NERVOUS SYSTEM, Anae	esthetics, Local, page	125		
AMIODARONE HYDROCHLORIDE				
Tab 100 mg – Retail pharmacy-Specialist		30	Aratac	
			Cordarone-X	
▲ Tab 200 mg – Retail pharmacy-Specialist		30	Aratac	
			✓ Cordarone-X	
Inj 50 mg per ml, 3 ml ampoule - Up to 6 inj available on	а			
PSO	22.80	6	✓ Cordarone-X	
ATROPINE SULPHATE				
 Inj 600 mcg per ml, 1 ml ampoule – Up to 5 inj available on 	0			
PSO		50	✓ AstraZeneca	
DIGOXIN				
	0.07	040		
* Tab 62.5 mcg – Up to 30 tab available on a PSO		240	Lanoxin PG	
₭ Tab 250 mcg – Up to 30 tab available on a PSO		240	Lanoxin	
≰‡ Oral liq 50 mcg per ml	16.60	60 ml	Lanoxin	
DISOPYRAMIDE PHOSPHATE				
▲ Cap 100 mg	15.00	100		
	()	100	Buthmodon	
0	(23.87)	400	Rythmodan	
▲ Cap 150 mg		100	 Rythmodan 	
LECAINIDE ACETATE – Retail pharmacy-Specialist				
Tab 50 mg		60	Tambocor	
▲ Tab 100 mg - For flecainide acetate oral liquid formulation				
refer, page 213		60	Tambocor	
▲ Cap long-acting 100 mg		30	✓ Tambocor CR	
		30	✓ Tambocor CR	
Cap long-acting 200 mg				
Inj 10 mg per ml, 15 ml ampoule	52.45	5	Tambocor	
Tambocor Tab 100 mg to be delisted 1 April 2016)				
IEXILETINE HYDROCHLORIDE				
▲ Cap 150 mg		100	Mexiletine	
			Hydrochloride	
			USP S29	
	000.00	100		
▲ Cap 250 mg		100	 Mexiletine 	
			Hydrochloride USP S29	
PROPAFENONE HYDROCHLORIDE – Retail pharmacy-Specie	alist			
▲ Tab 150 mg		50	Rytmonorm	
			,	

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Antihypotensives				
MIDODRINE – Special Authority see SA1474 below – Retail phan	,	100		utron
Tab 2.5 mg Tab 5 mg		100 100		utron

SA1474 Special Authority for Subsidy

Beta Adrenoceptor Blockers

Initial application from any relevant practitioner. Approvals valid for 2 years where patient has disabling orthostatic hypotension not due to drugs.

Note: Treatment should be started with small doses and titrated upwards as necessary. Hypertension should be avoided, and the usual target is a standing systolic blood pressure of 90 mm Hg.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

ATENOLOL			
* Tab 50 mg	4.61	500	Mylan Atenolol
5	7.67	500	Mylan Atenolol
	21.25	300 ml OP	Atenolol AFT
Restricted to children under 1	2 years of age.		
BISOPROLOL FUMARATE			
Tab 2.5 mg		30	Bosvate
Tab 5 mg		30	Bosvate
Tab 10 mg	6.40	30	Bosvate
CARVEDILOL			
		60	Dicarz
•		60	✓ Dicarz
* Tab 25 mg – For carvedilol oral			· <u></u>
-		60	Dicarz
	0.00	00	• <u>Diouiz</u>
CELIPROLOL	24.42	100	40.11
* Tab 200 mg		180	Celol
LABETALOL			
* Tab 50 mg		100	Hybloc
* Tab 100 mg - For labetalol oral	liquid formulation refer, page		
213		100	Hybloc
* Tab 200 mg		100	✓ Hybloc
* Inj 5 mg per ml, 20 ml ampoule		5	-
	(88.60)		Trandate
METOPROLOL SUCCINATE			
	0.96	30	Metoprolol - AFT CR
o o o		30	✓ Metoprolol - AFT CR
		30	✓ Metoprolol - AFT CR
		30	Metoprolol - AFT CR
METOPROLOL TARTRATE			
	whents and limited former dations		
* Tab 50 mg - For metoprolol ta	•	100	
		100	✓ Lopresor
5		60	✓ Lopresor
0 0 0		28 5	 Slow-Lopresor Lopresor
* Inj 1 mg per ml, 5 ml vial		Э	✓ Lopresor

	Subsidy (Manufacturer's Price \$) Per	Fully Subsidised	Generic
NADOLOL				
* Tab 40 mg		100	~	Apo-Nadolol
* Tab 80 mg	24.70	100	~	Apo-Nadolol
PINDOLOL				
* Tab 5 mg	9.72	100	~	Apo-Pindolol
* Tab 10 mg		100	~	Apo-Pindolol
* Tab 15 mg	23.46	100	~	Apo-Pindolol
PROPRANOLOL				
* Tab 10 mg	3.65	100	~	Аро-
				Propranolol S29
* Tab 40 mg	4 65	100	~	Аро-
		100	·	Propranolol S29
* Cap long-acting 160 mg		100	~	Cardinol LA
* Oral lig 4 mg per ml - Special Authority see SA1327 below -				
Retail pharmacy	CBS	500 m	 ✓ 	Roxane S29
Salary Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid Either:	for 2 years for applic	ations	meeting t	he following criteria:
1. For the treatment of a shild under 12 years with an basis			l :	

- 1 For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only); or
- 2 For the treatment of a child under 12 years with cardiac arrthymias or congenital cardiac abnormalities.

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only); or
 - 2 For the treatment of a child under 12 years with cardiac arrthymias or congenital cardiac abnormalities.

SOTALOL

✤ Tab	80 mg - For sotalol oral liquid formulation refer, page 213	27.50	500	🖌 Mylan
✤ Tab	160 mg	10.50	100	🖌 Mylan
米 Inj 1	0 mg per ml, 4 ml ampoule	65.39	5	 Sotacor
TIMOLO	L			
∗ Tab	10 mg	10.55	100	Apo-Timol

Calcium Channel Blockers

Dihydropyridine Calcium Channel Blockers

AMLODIPINE		
* Tab 2.5 mg2.21	100	Apo-Amlodipine
* Tab 5 mg – For amlodipine oral liquid formulation refer, page		
213	250	Apo-Amlodipine
* Tab 10 mg7.21	250	✓ Apo-Amlodipine
FELODIPINE		
* Tab long-acting 2.5 mg1.45	30	Plendil ER
* Tab long-acting 5 mg1.55	30	Plendil ER
* Tab long-acting 10 mg2.30	30	Plendil ER

	Subsidy		Fully Brand or
	(Manufacturer's Price)		Subsidised Generic
	\$	Per	 Manufacturer
SRADIPINE			
Cap long-acting 2.5 mg	7.50	30	Dynacirc-SRO
Cap long-acting 5 mg	7.85	30	Dynacirc-SRO
IFEDIPINE			
	17 70	60	Adalat 10
5 5 5 5			
Tab long-acting 20 mg		100	✓ Nyefax Retard
* Tab long-acting 30 mg		30	Adefin XL
 Tab long-acting 60 mg 	5.75	30	✓ Adefin XL
Other Calcium Channel Blockers			
NILTIAZEM HYDROCHLORIDE			
★ Tab 30 mg	4.60	100	Dilzem
 Tab 60 mg – For diltiazem hydrochloride oral liquid formula 			
tion refer, page 213		100	V Dilzem
			Cardizem CD
Cap long-acting 120 mg		30	
	31.83	500	Apo-Diltiazem CD
Cap long-acting 180 mg		30	Cardizem CD
	47.67	500	Apo-Diltiazem CD
 Cap long-acting 240 mg 		30	Cardizem CD
	63.58	500	Apo-Diltiazem CD
PERHEXILINE MALEATE			
₭ Tab 100 mg	62.90	100	✓ Pexsig
	02.00		e i energ
ERAPAMIL HYDROCHLORIDE			. .
₭ Tab 40 mg		100	 Isoptin
 Tab 80 mg – For verapamil hydrochloride oral liquid formula 	-		
tion refer, page 213	11.74	100	Isoptin
Tab long-acting 120 mg		250	 Verpamil SR
 Tab long-acting 240 mg 		250	Verpamil SR
Inj 2.5 mg per ml, 2 ml ampoule – Up to 5 inj available on a	9		•
PSO		5	✓ Isoptin
Centrally-Acting Agents		-	
CLONIDINE			
 Patch 2.5 mg, 100 mcg per day – Only on a prescription 	12.80	4	✓ Catapres-TTS-1
		4 4	✓ <u>Catapres-TTS-1</u> ✓ <u>Catapres-TTS-2</u>
Patch 5 mg, 200 mcg per day – Only on a prescription			
 Patch 7.5 mg, 300 mcg per day – Only on a prescription 	22.00	4	Catapres-TTS-3
LONIDINE HYDROCHLORIDE			
 Tab 25 mcg 		112	Clonidine BNM
€ Tab 150 mcg		100	✓ Catapres
Inj 150 mcg per ml, 1 ml ampoule		5	✓ Catapres
		-	
IETHYLDOPA	44.05		
* Tab 125 mg		100	Prodopa
₭ Tab 250 mg		100	ProdopaProdopa
* Tab 500 mg		100	

	Subsidy (Manufacturer's I \$	Price) Sub Per	Fully Brand or osidised Generic Manufacturer
Diuretics	Ŷ	101	
Loop Diuretics			
BUMETANIDE			
₭ Tab 1 mg		100	 Burinex
 Inj 500 mcg per ml, 4 ml vial 	7.95	5	 Burinex
UROSEMIDE [FRUSEMIDE]	8.00	1 000	
Tab 40 mg – Up to 30 tab available on a PSO Tab 500 mg		1,000 50	 ✓ <u>Diurin 40</u> ✓ Urex Forte
tab 500 mg ∉1 Oral liq 10 mg per ml		30 ml OP	✓ Lasix
Inj 10 mg per ml, 25 ml ampoule		6	✓ Lasix
Inj 10 mg per ml, 2 ml ampoule - Up to 5 inj available on a	a		
PSO	1.30	5	 Frusemide-Claris
Potassium Sparing Diuretics			
MILORIDE HYDROCHLORIDE			
 Tab 5 mg 		100	Apo-Amiloride
Oral liq 1 mg per ml		25 ml OP	Biomed
ETOLAZONE – Special Authority see SA1349 below – Retail	pharmacy		
Tab 5 mg	CBS	1	Metolazone S29
		50	Zaroxolyn S29
SA1349 Special Authority for Subsidy itial application from any relevant practitioner. Approvals vali tent of patients with refractory heart failure who are intolerant o ation therapy. PIRONOLACTONE Tab 25 mg Tab 100 mg Oral liq 5 mg per ml	r have not respor 		
Potassium Sparing Combination Diuretics			
MILORIDE HYDROCHLORIDE WITH FUROSEMIDE K Tab 5 mg with furosemide 40 mg	8 63	28	🖌 Frumil
MILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZ		20	
Tab 5 mg with hydrochlorothiazide 50 mg		50	 Moduretic
Thiazide and Related Diuretics			
ENDROFLUMETHIAZIDE [BENDROFLUAZIDE]			
Tab 2.5 mg – Up to 150 tab available on a PSO	5.48	500	✓ <u>Arrow-</u> Bondrofluozido
No. I so that the POO (Bendrofluazide

	fully subsidised
56	[HP4] refer page 4

CHLORTALIDONE [CHLORTHALIDONE]

CHLOROTHIAZIDE

*

‡

* Tab 25 mg8.00

500

25 ml OP

50

✓ Arrow-

Biomed

Hygroton

Bendrofluazide

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
INDAPAMIDE	0.05	90		ana Taha
* Tab 2.5 mg Lipid-Modifying Agents	2.25	90	<u>v</u> <u>u</u>	<u>apa-Tabs</u>
Fibrates				
BEZAFIBRATE				
# Tab 200 mg		90	🖌 В	ezalip
* Tab long-acting 400 mg		30		ezalip Retard
GEMFIBROZIL				
* Tab 600 mg		60	V L	ipazil
Other Lipid-Modifying Agents				
ACIPIMOX				
* Cap 250 mg		30	v 0	lbetam
NICOTINIC ACID				
* Tab 50 mg		100	🖌 A	po-Nicotinic Acid
* Tab 500 mg		100		po-Nicotinic Acid
Resins				
CHOLESTYRAMINE				
Powder for oral liq 4 g	19 25	50		
	(52.68)	00	Q	uestran-Lite
COLESTIPOL HYDROCHLORIDE	()			
Grans for oral liq 5 g		30	🗸 C	olestid
HMG CoA Reductase Inhibitors (Statins)				
Prescribing Guidelines				
Treatment with HMG CoA Reductase Inhibitors (statins) is red	commended for patients	with d	yslipidaem	ia and an absolute 5 ye
cardiovascular risk of 15% or greater.				
ATORVASTATIN – See prescribing guideline above * Tab 10 mg	2 52	90	V 7	arator
* Tab 20 mg		90	• =	arator
* Tab 40 mg		90	• =	arator
* Tab 80 mg		90	🗸 Z	arator
PRAVASTATIN - See prescribing guideline above				
* Tab 20 mg	3.45	30	V C	holvastin
* Tab 40 mg		30	✓ C	holvastin
SIMVASTATIN – See prescribing guideline above				
1 Tob 10 mg	0.05	00		were Cimero 10mm

* Tab 80 mg	7.91	90	 Arrow-Simva 80mg
Selective Cholesterol Absorption Inhibitors			
EZETIMIBE – Special Authority see SA1045 on the next page – Re Tab 10 mg	, ,	30	✓ Ezemibe

Tab 10 mg0.95

Tab 20 mg1.61

*

*

*

✓ Arrow-Simva 10mg

✓ Arrow-Simva 20mg

✓ Arrow-Simva 40mg

90

90

90

CARDIOVASCULAR SYSTEM

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

➡SA1045 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 Any of the following:
 - 3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than 10 $\times\,$ normal) when treated with one statin; or
 - 3.2 The patient is intolerant to both simvastatin and atorvastatin; or
 - 3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Notes: A patient who has failed to reduce their LDL cholesterol to < 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy.

If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

EZETIMIBE WITH SIMVASTATIN - Special Authority see SA1046 below - Retail pharmacy

Tab 10 mg with simvastatin 10 mg		30	Zimybe
Tab 10 mg with simvastatin 20 mg	6.15	30	 Zimybe
Tab 10 mg with simvastatin 40 mg	7.15	30	 Zimybe
Tab 10 mg with simvastatin 80 mg	8.15	30	Zimybe

➡SA1046 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Notes: A patient who has failed to reduce their LDL cholesterol to ≤ 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy.

If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Nitrates

GLYCERYL TRINITRATE

GL	CERYLTRINITRATE		
*	Tab 600 mcg – Up to 100 tab available on a PSO8.00	100 OP	Lycinate
*	Oral pump spray, 400 mcg per dose – Up to 250 dose avail-		
	able on a PSO	250 dose OP	Nitrolingual Pump
			Spray
*	Oral spray, 400 mcg per dose – Up to 250 dose available on		
	a PSO	250 dose OP	🖌 Glytrin
*	Patch 25 mg, 5 mg per day	30	Nitroderm TTS
	Patch 50 mg, 10 mg per day	30	Nitroderm TTS

		Subsidy (Manufacturer's Price)		Fully Subsidised	
		(Manulacturer 3 Trice) \$	Per		Manufacturer
ISO	SORBIDE MONONITRATE				
*	Tab 20 mg	17.10	100	~	Ismo 20
*	Tab long-acting 40 mg	7.50	30		Ismo 40 Retard
*	Tab long-acting 60 mg	3.94	90	~	Duride
Sy	mpathomimetics				
ADF	RENALINE				
	Inj 1 in 1,000, 1 ml ampoule - Up to 5 inj available on a PSO.	4.98 5.25	5		Aspen Adrenaline Hospira
	Inj 1 in 10,000, 10 ml ampoule - Up to 5 inj available on a				
	PSO		5	~	Hospira
		49.00	10	~	Aspen Adrenaline
ISO	PRENALINE				
	Inj 200 mcg per ml, 1 ml ampoule		25		
		(164.20)			Isuprel
Va	sodilators	. ,			
۸M	/L NITRITE				
*	Liq 98% in 0.3 ml cap		12		
		(73.40)			Baxter
НУГ	DRALAZINE HYDROCHLORIDE				
	Tab 25 mg - Special Authority see SA1321 below - Retail				
	pharmacy	CBS	1	~	Hydralazine
	F		56		Onelink S29
*	Inj 20 mg ampoule		5	-	Apresoline
Initi the	SA1321 Special Authority for Subsidy al application from any relevant practitioner. Approvals valid	without further rene	ewal u	nless notif	ied for applications meeting
Eith	following criteria: er: 1 For the treatment of refractory hypertension; or 2 For the treatment of heart failure in combination with a nitr	rate, in patients who	are int		have not responded to ACE
Eith	er: 1 For the treatment of refractory hypertension; or	rate, in patients who	are inf		have not responded to ACE
	er: 1 For the treatment of refractory hypertension; or 2 For the treatment of heart failure in combination with a nitr	nacy	are int 100	tolerant or	have not responded to ACE
MIN	 er: 1 For the treatment of refractory hypertension; or 2 For the treatment of heart failure in combination with a nitr inhibitors and/or angiotensin receptor blockers. OXIDIL – Special Authority see SA1271 below – Retail pharm 	nacy 70.00 without further rene	100	tolerant or	Loniten
MIN ▲ Initi refra	er: 1 For the treatment of refractory hypertension; or 2 For the treatment of heart failure in combination with a nitr inhibitors and/or angiotensin receptor blockers. OXIDIL – Special Authority see SA1271 below – Retail pharm Tab 10 mg SA1271 Special Authority for Subsidy al application only from a relevant specialist. Approvals valid actory hypertension which has failed to respond to extensive m	nacy 70.00 without further rene iultiple therapies.	100	tolerant or v	Loniten
MIN MIN Initi refra NIC	er: 1 For the treatment of refractory hypertension; or 2 For the treatment of heart failure in combination with a nitr inhibitors and/or angiotensin receptor blockers. OXIDIL – Special Authority see SA1271 below – Retail pharm Tab 10 mg SA1271 Special Authority for Subsidy al application only from a relevant specialist. Approvals valid actory hypertension which has failed to respond to extensive m ORANDIL Tab 10 mg	nacy 70.00 without further rene nultiple therapies. 27.95	100 wal un	tolerant or v Iless notifi	Loniten ed where patient has severe
MIN	er: 1 For the treatment of refractory hypertension; or 2 For the treatment of heart failure in combination with a nitr inhibitors and/or angiotensin receptor blockers. OXIDIL – Special Authority see SA1271 below – Retail pharm Tab 10 mg SA1271 Special Authority for Subsidy al application only from a relevant specialist. Approvals valid actory hypertension which has failed to respond to extensive m ORANDIL Tab 10 mg 	nacy 70.00 without further rene nultiple therapies. 27.95	100 wal un 60	tolerant or v Iless notifi	Loniten ed where patient has severe Ikorel
MIN MIN Initi refra NIC A PAP	er: 1 For the treatment of refractory hypertension; or 2 For the treatment of heart failure in combination with a nitr inhibitors and/or angiotensin receptor blockers. OXIDIL – Special Authority see SA1271 below – Retail pharm Tab 10 mg SA1271 Special Authority for Subsidy al application only from a relevant specialist. Approvals valid actory hypertension which has failed to respond to extensive m ORANDIL Tab 10 mg 	nacy 	100 wal un 60 60	tolerant or v uless notifie	Loniten ed where patient has severe Ikorel Ikorel
MIN MIN Initi refra NIC A PAP *	er: 1 For the treatment of refractory hypertension; or 2 For the treatment of heart failure in combination with a nitr inhibitors and/or angiotensin receptor blockers. OXIDIL – Special Authority see SA1271 below – Retail pharm Tab 10 mg SA1271 Special Authority for Subsidy al application only from a relevant specialist. Approvals valid actory hypertension which has failed to respond to extensive m ORANDIL Tab 10 mg Tab 20 mg AVERINE HYDROCHLORIDE Inj 12 mg per ml, 10 ml ampoule	nacy 	100 wal un 60	tolerant or v uless notifie	Loniten ed where patient has severe Ikorel
MIN MIN Initi refra NIC A PAP *	er: 1 For the treatment of refractory hypertension; or 2 For the treatment of heart failure in combination with a nitr inhibitors and/or angiotensin receptor blockers. OXIDIL – Special Authority see SA1271 below – Retail pharm Tab 10 mg SA1271 Special Authority for Subsidy al application only from a relevant specialist. Approvals valid actory hypertension which has failed to respond to extensive m ORANDIL Tab 10 mg MVERINE HYDROCHLORIDE Inj 12 mg per ml, 10 ml ampoule ITOXIFYLLINE [OXPENTIFYLLINE]	nacy 	100 wal un 60 60 5	tolerant or v uless notifie	Loniten ed where patient has severe Ikorel Ikorel
MIN Initi refra NIC PAP *	er: 1 For the treatment of refractory hypertension; or 2 For the treatment of heart failure in combination with a nitr inhibitors and/or angiotensin receptor blockers. OXIDIL – Special Authority see SA1271 below – Retail pharm Tab 10 mg SA1271 Special Authority for Subsidy al application only from a relevant specialist. Approvals valid actory hypertension which has failed to respond to extensive m ORANDIL Tab 10 mg Tab 20 mg AVERINE HYDROCHLORIDE Inj 12 mg per ml, 10 ml ampoule	nacy 	100 wal un 60 60	tolerant or v aless notific	Loniten ed where patient has severe Ikorel Ikorel

	Subsidy (Manufacturer's Price) \$	Per	Full Subsidise	,
Endothelin Receptor Antagonists				
► SA0967 Special Authority for Subsidy Special Authority approved by the Pulmonary Arterial Hypertensis Notes: Application details may be obtained from PHARMAC's we The Coordinator, PAH Panel PHARMAC, PO Box 10-254, WELLINGTON Tel: (04) 916 7561, Fax: (04) 974 4858, Email: PAH@pharmac.e	bsite http://www.phar	mac.(govt.nz or	:
AMBRISENTAN – Special Authority see SA0967 above – Retail Tab 5 mg Tab 10 mg	4,585.00	30 30	-	Volibris Volibris
BOSENTAN – Special Authority see SA0967 above – Retail pha Tab 62.5 mg	rmacy	56 60	V	Mylan-Bosentan pms-Bosentan
Mylan-Bosentan to be Sole Supply on 1 April 2016	(4,585.00)			Tracleer
Tab 125 mg		56 60	~	Mylan-Bosentan pms-Bosentan Tracleer
Mylan-Bosentan to be Sole Supply on 1 April 2016 (pms-Bosentan Tab 62.5 mg to be delisted 1 April 2016) (Tracleer Tab 62.5 mg to be delisted 1 April 2016) (pms-Bosentan Tab 125 mg to be delisted 1 April 2016)	(,,,			

(Tracleer Tab 125 mg to be delisted 1 April 2016)

Phosphodiesterase Type 5 Inhibitors

➡SA1293 Special Authority for Subsidy

Initial application — (Raynaud's Phenomenon* - for Pulmonary Arterial Hypertension see note below) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following:

- 1 Patient has Raynaud's Phenomenon*; and
- 2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
- 3 Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of sympathomimetic drugs); and
- 4 Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated).

Notes: Sildenafil is also funded for patients with Pulmonary Arterial Hypertension who are approved by the Pulmonary Arterial Hypertension Panel (an application must be made using form <u>SA1293-PAH</u>).

Application d	details may be	obtained from:
---------------	----------------	----------------

The Coordinator, PAH Panel

PHARMAC, PO Box 10 254, Wellington

Phone: (04) 916 7561 Facsimile: (04) 974 4858 Email: PAH@pharmac.govt.nz

Indications marked with * are Unapproved Indications.

SILDENAFIL - Special Authority see SA1293 above - Retail pharmacy

Tab 25 mg	0.75	4	Vedafil
Tab 50 mg	0.75	4	Vedafil
Tab 100 mg – For sildenafil oral liquid formulation refer, page			
213	2.75	4	Vedafil

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	Brand or Generic Manufacturer
Prostacyclin Analogues			
► SA0969 Special Authority for Subsidy Special Authority approved by the Pulmonary Arterial Hypertensic Notes: Application details may be obtained from PHARMAC's we The Coordinator, PAH Panel PHARMAC, PO Box 10-254, WELLINGTON Tel: (04) 916 7561, Fax: (04) 974 4858, Email: PAH@pharmac.g	bsite <u>http://www.pharr</u>	mac.govt.nz or:	
ILOPROST – Special Authority see SA0969 above – Retail phan Nebuliser soln 10 mcg per ml, 2 ml	,	30 🗸 V	/entavis

()	Subsidy Manufacturer's Pri \$	ice) Su Per	Fully Ibsidised	Brand or Generic Manufacturer
Antiacne Preparations				
For systemic antibacterials, refer to INFECTIONS, Antibacterials, pa	ge 91			
ADAPALENE				
a) Maximum of 30 g per prescription				
 b) Only on a prescription 				
Crm 0.1%	22.89	30 g OP	🗸 D	ifferin
Gel 0.1%	22.89	30 g OP	🖌 D	ifferin
SOTRETINOIN - Special Authority see SA1475 below - Retail pha	irmacy			
Cap 10 mg	12.47	100	🖌 İs	otane 10
	14.96	120	v 0	ratane
Cap 20 mg	19.27	100	🖌 İs	otane 20
	23.12	120	v 0	ratane

➡SA1475 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 2 Applicant has an up to date knowledge of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and
- 3 Either:
 - 3.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
 - 3.2 Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either:

- 1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
- 2 Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

TRETINOIN

Crm 0.5 mg per g	 Maximum of 50 g 	g per prescription.	13.90	50 g OP	ReTrieve
------------------	-------------------------------------	---------------------	-------	---------	----------

	Subsidy (Manufacturer's F \$	Price) S Per	Fully Brand or Subsidised Generic Manufacturer
Antibacterials Topical			
or systemic antibacterials, refer to INFECTIONS, Antibacterials	, page 91		
USIDIC ACID			
Crm 2%	2.52	15 g OP	✓ DP Fusidic Acid
 a) Maximum of 15 g per prescription b) Only on a prescription c) Not in combination 			<u>Cream</u>
Oint 2%	3.45	15 g OP	Foban
 a) Maximum of 15 g per prescription b) Only on a prescription c) Not in combination 			
YDROGEN PEROXIDE	0.50	45 00	
• Crm 1%	8.56	15 g OP	 Crystaderm
UPIROCIN	0.00	15 - 00	
Oint 2%	6.60 (9.26)	15 g OP	Bactroban
a) Only on a prescriptionb) Not in combination	(0.20)		Buotroburi
ILVER SULPHADIAZINE			
Crm 1%a) Up to 250 g available on a PSO b) Not in combination	12.30	50 g OP	 Flamazine
Antifungals Topical			
or systemic antifungals, refer to INFECTIONS, Antifungals, pag	e 97		
MOROLFINE a) Only on a prescription b) Not in combination Nail soln 5%		5 ml OP	✓ <u>MycoNail</u>
ICLOPIROX OLAMINE a) Only on a prescription b) Not in combination			
Nail-soln 8%	6.50	7 ml OP	✓ <u>Apo-Ciclopirox</u>
LOTRIMAZOLE	0.52	20 g OP	Clomazol
a) Only on a prescription b) Not in combination		20 9 01	
: Soln 1%	4.36	20 ml OP	
a) Only on a prescription	(7.55)		Canesten
b) Not in combination			

	Subsidy (Manufacturer's F	Price) Su	Fully Brand or bsidised Generic
	(Manulacialer 3 1 \$	Per	Manufacturer
CONAZOLE NITRATE			
Crm 1%	1.00	20 g OP	
	(7.48)	•	Pevaryl
 a) Only on a prescription 			
b) Not in combination			
Foaming soln 1%, 10 ml sachets		3	
	(17.23)		Pevaryl
a) Only on a prescription			
b) Not in combination			
MICONAZOLE NITRATE			
* Crm 2%	0.55	15 g OP	Multichem
a) Only on a prescription			
b) Not in combination	4.00	00 ml OD	
₭ Lotn 2%		30 ml OP	Delsterin
a) Only on a prescription	(10.03)		Daktarin
b) Not in combination			
► Tinct 2%	4.36	30 ml OP	
	(12.10)	00 111 01	Daktarin
a) Only on a prescription	(12.10)		Danann
b) Not in combination			
VYSTATIN			
Crm 100,000 u per g	1 00	15 g OP	
	(7.90)	10 9 01	Mycostatin
a) Only on a prescription	()		,
b) Not in combination			
Antipruritic Preparations			
CALAMINE			
a) Only on a prescription			
b) Not in combination			
Crm, aqueous, BP		100 g	Pharmacy Health
Lotn, BP	12.94	2,000 ml	✓ <u>PSM</u>
ROTAMITON			
a) Only on a prescription			
b) Not in combination			
Crm 10%	3.37	20 g OP	Itch-Soothe
IENTHOL – Only in combination			
1) Only in combination with a dermatological base or pr	oprietary Topical C	orticosteriod -	- Plain, refer dermatological ba
page 212			
2) With or without other dermatological galenicals.			
Crystals	6.50	25 g	🖌 PSM
-	6.92		✓ MidWest
	29.60	100 g	✓ MidWest

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully Brand or sidised Generic ✔ Manufacturer
Corticosteroids Topical			
For systemic corticosteroids, refer to CORTICOSTEROIDS AND	RELATED AGE	NTS, page 79	
Corticosteroids - Plain			
BETAMETHASONE DIPROPIONATE			
Crm 0.05%	2.96	15 g OP	 Diprosone
	8.97	50 g OP	 Diprosone
Crm 0.05% in propylene glycol base		30 g OP	Diprosone OV
Oint 0.05%		15 g OP	 Diprosone
.	8.97	50 g OP	✓ Diprosone
Oint 0.05% in propylene glycol base	4.33	30 g OP	Diprosone OV
BETAMETHASONE VALERATE			
* Crm 0.1%	3.15	50 g OP	Beta Cream
* Oint 0.1%	3.15	50 g OP	Beta Ointment
₭ Lotn 0.1%	10.05	50 ml OP	 Betnovate
CLOBETASOL PROPIONATE			
* Crm 0.05%	3.20	30 g OP	Clobetasol BNM
* Oint 0.05%	3.20	30 g OP	Clobetasol BNM
CLOBETASONE BUTYRATE		Ū	
Crm 0.05%	5 38	30 g OP	
	(7.09)	00 g 01	Eumovate
	16.13	100 g OP	
	(22.00)		Eumovate
DIFLUCORTOLONE VALERATE	()		
Crm 0.1%	9.07	50 g OP	
CIIII 0.176	(15.86)	50 y OF	Nerisone
Fatty oint 0.1%		50 g OP	Nelisone
	(15.86)	00 9 01	Nerisone
IVEROCORTISONE	(10.00)		
	0.75	100 -	
Crm 1% – Only on a prescription	3.75 14.00	100 g 500 g	Pharmacy Health
* Powder – Only in combination		25 g	 Pharmacy Health ABM
Up to 5% in a dermatological base (not proprietary To			
galenicals. Refer, page 212		ou – main) wit	in or without other definationogic
HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN			
	L.		
Lotn 1% with paraffin liquid 15.9% and lanolin 0.6% – On	•	250 ml	DB Lote HC
on a prescription	10.57	250 mi	✓ DP Lotn HC
HYDROCORTISONE BUTYRATE			
Lipocream 0.1%		30 g OP	 Locoid Lipocream
.	6.85	100 g OP	 Locoid Lipocream
Oint 0.1%		100 g OP	✓ Locoid
Milky emul 0.1%	6.85	100 ml OP	Locoid Crelo
METHYLPREDNISOLONE ACEPONATE			
Crm 0.1%	4.95	15 g OP	 Advantan Advantan

	Subsidy		Fully Brand or
	(Manufacturer's I	Price) Sub	sidised Generic
	\$	Per	 Manufacturer
MOMETASONE FUROATE			
Crm 0.1%	1.51	15 g OP	Elocon Alcohol Free
	2.90	50 g OP	 Elocon Alcohol Free
Oint 0.1%	1.51	15 g OP	✓ Elocon
	2.90	50 g OP	Elocon
Lotn 0.1%	7.35	30 ml OP	Elocon
TRIAMCINOLONE ACETONIDE			
Crm 0.02%	6.30	100 g OP	✓ <u>Aristocort</u>
Oint 0.02%	6.35	100 g OP	✓ Aristocort
Corticosteroids - Combination			
BETAMETHASONE VALERATE WITH CLIOQUINOL – Only on a		15 ~ OD	
Crm 0.1% with clioquinol 3%		15 g OP	Betnovate-C
	(4.90)		Dell'IOvale-C
BETAMETHASONE VALERATE WITH FUSIDIC ACID			
Crm 0.1% with fusidic acid 2%		15 g OP	– · ·
	(10.45)		Fucicort
a) Maximum of 15 g per prescription			
b) Only on a prescription			
HYDROCORTISONE WITH MICONAZOLE - Only on a prescrip		45 00	
* Crm 1% with miconazole nitrate 2%		15 g OP	Micreme H
HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN - O			
Crm 1% with natamycin 1% and neomycin sulphate 0.5%		15 g OP	 Pimafucort
Oint 1% with natamycin 1% and neomycin sulphate 0.5%	2.79	15 g OP	Pimafucort
TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCI	N AND NYSTAT	IN	
Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg			
and gramicidin 250 mcg per g - Only on a prescription .		15 g OP	
	(6.60)		Viaderm KC
Disinfecting and Cleansing Agents			
CHLORHEXIDINE GLUCONATE – Subsidy by endorsement			
a) No more than 500 ml per month			
b) Only if prescribed for a dialysis patient and the prescription	n is endorsed ac	cordinalv.	
* Handrub 1% with ethanol 70%		500 ml	✓ healthE
* Soln 4% wash	3.98	500 ml	✓ healthE
TRICLOSAN – Subsidy by endorsement			
a) Maximum of 500 ml per prescription			
b)	registent Ctorbul		(MDCA) prior to cleating surger
 a) Only if prescribed for a patient identified with Methicillin- is beautial and the prescription is andered accordingly. 		ococcus aureu	s (IVIHSA) prior to elective surge
in hospital and the prescription is endorsed accordingly; b) Only if prescribed for a patient with recurrent Staphyloco		ation and the pr	accription is andoread according
Soln 1%	4.50 5.90	500 ml OP	 Pharmacy Health healthE
	5.90		

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully Brand or sidised Generic Manufacturer
Barrier Creams and Emollients	Ŷ		• Manaladaror
Barrier Creams			
DIMETHICONE			4 .
₭ Crm 5% pump bottle	4.73	500 ml OP	 <u>healthE</u> Dimethicone 5%
€ Crm 10% pump bottle	4.90	500 ml OP	✓ <u>healthE</u> Dimethicone 10%
INC AND CASTOR OIL			
Oint BP	3.83	500 g	 Multichem
Emollients			
QUEOUS CREAM			
- Crm		500 g	✓ AFT
	1.99		AFT SLS-free
ETOMACROGOL			
Crm BP	2.74	500 g	✓ healthE
ETOMACROGOL WITH GLYCEROL			
Crm 90% with glycerol 10%	4.50	500 ml OP	 Pharmacy Health Sorbolene with Glycerin
	6.50	1,000 ml OP	 Pharmacy Health Sorbolene with Glycerin
MULSIFYING OINTMENT			
Oint BP	2.73	500 g	✓ AFT
IL IN WATER EMULSION		Ū	
	2.25	500 g	 O/W Fatty Emulsion Cream
	2.63		healthE Fatty Cream
REA			
€ Crm 10%	1.65	100 g OP	healthE Urea Cream
OOL FAT WITH MINERAL OIL - Only on a prescription		U U	
Lotn hydrous 3% with mineral oil	5.60	1,000 ml	
-	(11.95)	-	DP Lotion
	1.40	250 ml OP	
	(4.53)		DP Lotion
	5.60	1,000 ml	
	(20.53)		Alpha-Keri Lotion
	(23.91)	050 ml 05	BK Lotion
	1.40	250 ml OP	BK Lotion
	(7.73)		DR LUUUI

	Subsidy (Manufacturer's Prie \$	ce) Per	Fully Subsidised	
Other Dermatological Bases				
PARAFFIN				
White soft – Only in combination	20.20	2,500 g	~	IPW
	3.58	500 g		
	(7.78)			IPW
	(8.69)			PSM
Only in combination with a dermatological galenical or as	a diluent for a prop	rietary To	pical Cort	ticosteroid – Plain.
Minor Skin Infections				
POVIDONE IODINE				
Oint 10%	3.27	25 g OP	 ✓ 	Betadine
 a) Maximum of 100 g per prescription b) Only on a prescription 				
Antiseptic soln 10%	6.20	500 ml	~	Betadine
· · · · · · · · · · · · · · · · · · ·			V	Riodine
	1.28	100 ml		
	(4.20)		I	Riodine
	(8.25)			Betadine
	0.19	15 ml		
	(4.45)			Betadine
Skin preparation, povidone iodine 10% with 30% alcohol		500 ml	~	Betadine Skin Prep
	1.63	100 ml		
	(3.65)		I	Betadine Skin Prep
Skin preparation, povidone iodine 10% with 70% alcohol		500 ml		o :
	(18.63)	100	(Orion
	1.63	100 ml		Orien
	(6.04)			Orion

Parasiticidal Preparations

IVERMECTIN – Special Authority see SA1225 below – Retail pharmacy

- Tab 3 mg Up to 100 tab available on a PSO......17.20 4 V Stromectol
- 1) PSO for institutional use only. Must be endorsed with the name of the institution for which the PSO is required and a valid Special Authority for patient of that institution.
- 2) Ivermectin available on BSO provided the BSO includes a valid Special Authority for a patient of the institution.
- For the purposes of subsidy of ivermectin, institution means age related residential care facilities, disability care facilities or penal institutions.

SA1225 Special Authority for Subsidy

Initial application — (Scables) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Both:

68

1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist; and

2 Either:

- 2.1 Both:
 - 2.1.1 The patient is in the community; and
 - 2.1.2 Any of the following:
 - 2.1.2.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or

continued...

Subsidy		Fully	Brand or	
(Manufacturer's Price)	S	Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- 2.1.2.2 The community patient is physically or mentally unable to comply with the application instructions of topical therapy; or
- 2.1.2.3 The patient has previously tried and failed to clear infestation using topical therapy; or
- 2.2 All of the following:
 - 2.2.1 The Patient is a resident in an institution; and
 - 2.2.2 All residents of the institution with scabies or at risk of carriage are to be treated for scabies concurrently; and
 - 2.2.3 Any of the following:
 - 2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation.

Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation.

Initial application — (Other parasitic infections) only from an infectious disease specialist, clinical microbiologist or dermatologist. Approvals valid for 1 month for applications meeting the following criteria: Any of the following:

- 1 Filaricides: or
- 2 Cutaneous larva migrans (creeping eruption); or
- 3 Strongyloidiasis.

Renewal — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria: Both:

- 1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 The patient is in the community; and
 - 2.1.2 Any of the following:
 - 2.1.2.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.1.2.2 The community patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.1.2.3 The patient has previously tried and failed to clear infestation using topical therapy; or
 - 2.2 All of the following:
 - 2.2.1 The Patient is a resident in an institution; and
 - 2.2.2 All residents of the institution with scabies or at risk of carriage are to be treated for scabies concurrently; and
 - 2.2.3 Any of the following:
 - 2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation.

Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation.

Renewal — (Other parasitic infections) only from an infectious disease specialist, clinical microbiologist or dermatologist. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 Filaricides; or
- 2 Cutaneous larva migrans (creeping eruption); or
- 3 Strongyloidiasis.

	Subsidy (Manufacturer's Price \$	e) Sul Per		Brand or Generic Manufacturer
MALATHION WITH PERMETHRIN AND PIPERONYL BUTOXIDE Spray 0.25% with permethrin 0.5% and piperonyl butoxide 2%		90 g OP	🖌 Pa	ra Plus
PERMETHRIN Crm 5% Lotn 5%		30 g OP 30 ml OP	✓ <u>Ly</u> ✓ <u>A-</u>	<u>derm</u> Scabies
Psoriasis and Eczema Preparations				
ACITRETIN – Special Authority see SA1476 below – Retail pharr Cap 10 mg Cap 25 mg	17.86	60 60		vatretin vatretin

SA1476 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice: and
- 2 Applicant has an up to date knowledge of the safety issues around acitretin and is competent to prescribe acitretin; and
- 3 Either:
 - 3.1 Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment: or
 - 3.2 Patient is male.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Fither:

- 1 Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two vears after the completion of the treatment: or
- 2 Patient is male.

BETAMETHASONE DIPROPIONATE WITH CAI CIPOTRIOL

Gel 500 mcg with calcipotriol 50 mcg per g	30 g OP	Daivobet
Oint 500 mcg with calcipotriol 50 mcg per g26.12	30 g OP	Daivobet
CALCIPOTRIOL		
Crm 50 mcg per g16.00	30 g OP	Daivonex
45.00	100 g OP	Daivonex
Oint 50 mcg per g45.00	100 g OP	Daivonex
Soln 50 mcg per ml16.00	30 ml OP	Daivonex
COAL TAR		
Soln – Only in combination	200 ml	Midwest

- Midwest 1) Up to 10% only in combination with a dermatological base or proprietary Topical Corticosteriod - Plain, refer dermatological base, page 212
- 2) With or without other dermatological galenicals.

COAL TAR WITH ALLANTOIN, MENTHOL, PHENOL AND SULPHUR

Soln 5% with sulphur 0.5%, menthol 0.75%, phenol 0.5% and			
allantoin crm 2.5%	6.59	75 g OP	
	(8.00)	-	Egopsoryl TA
	3.43	30 g OP	
	(4.35)	•	Egopsoryl TA

	Subsidy (Manufacturer's I \$	Price) Sub Per	Fully Brand or sidised Generic Manufacturer
COAL TAR WITH SALICYLIC ACID AND SULPHUR	Ŷ		
Soln 12% with salicylic acid 2% and sulphur 4% oint	7.95	40 g OP	Coco-Scalp
SALICYLIC ACID		•	·
 Powder – Only in combination 1) Only in combination with a dermatological base or prodermatological base, page 212 2) With or without other dermatological galenicals. 		250 g Corticosteroid	✓ PSM - Plain or collodion flexible, refer
SULPHUR			
Precipitated – Only in combination		100 g	✓ Midwest
 Only in combination with a dermatological base or propage 212 With or without other dermatological galenicals. 			
TAR WITH TRIETHANOLAMINE LAURYL SULPHATE AND FLU		nly on a prescr	iption
Soln 2.3% with triethanolamine lauryl sulphate and fluores cein sodium		500 ml	Pinetarsol
	0.00	000 111	
Scalp Preparations			
BETAMETHASONE VALERATE			
* Scalp app 0.1%	7.75	100 ml OP	Beta Scalp
CLOBETASOL PROPIONATE			4-
* Scalp app 0.05%	6.96	30 ml OP	V Dermol
HYDROCORTISONE BUTYRATE Scalp lotn 0.1%		100 ml OP	✓ Locoid
KETOCONAZOLE			
Shampoo 2% a) Maximum of 100 ml per prescription b) Only on a prescription	2.99	100 ml OP	✓ <u>Sebizole</u>
Sunscreens			
SUNSCREENS, PROPRIETARY – Subsidy by endorsement Only if prescribed for a patient with severe photosensitivity endorsed accordingly.	v secondary to a	defined clinical	condition and the prescription is
Crm		100 g OP	
Lotn,	(5.89) 3.30	100 g OP	Hamilton Sunscreen Marine Blue Lotion
	5.10	200 g OP	SPF 50+ ✓ Marine Blue Lotion SPF 50+
Lotn	4.13	125 ml OP	
	(6.94)		Aquasun 30+
Wart Preparations			
For salicylic acid preparations refer to PSORIASIS AND ECZEM	A PREPARATION	NS, page 70	
IMIQUIMOD			
Crm 5%, 250 mg sachet	17.98	12	✓ <u>Apo-Imiquimod</u> <u>Cream 5%</u>

	Subsidy (Manufacturer's P \$	rice) Subs Per	Fully sidised	Brand or Generic Manufacturer
PODOPHYLLOTOXIN Soln 0.5% a) Maximum of 3.5 ml per prescription b) Only on a prescription Other Skin Preparations	33.60	3.5 ml OP	✔ C	ondyline
Antineoplastics				
FLUOROURACIL SODIUM Crm 5%	8.95	20 g OP	✓ <u>E</u>	fudix

	Subsidy (Manufacturer's Price \$) Per	Fully Subsidised	
Contraceptives - Non-hormonal				
Condoms				
CONDOMS				
* 49 mm – Up to 144 dev available on a PSO.		144		MarquisTantiliza Shield 49
* 52 mm – Up to 144 dev available on a PSO		144		Marquis Selecta Marquis Sensolite
			~	Marquis Supalite
# 52 mm extra strength – Up to 144 dev availa	ble on a PSO13.36	144	~	Marquis Protecta
* 53 mm – Up to 144 dev available on a PSO	1.11	12	~	Gold Knight Shield Blue
	13.36	144	~	Marquis Black Marquis Titillata Shield Blue
* 53 mm (chocolate) – Up to 144 dev available	on a PSO 1.11	12		Gold Knight
	13.36	144		Gold Knight
* 53 mm (strawberry) – Up to 144 dev availabl		12		Gold Knight
· · · · · · · · · · · · · · · · · · ·	13.36	144		Gold Knight
* 54 mm, shaped – Up to 144 dev available or		12		j
· · · · · · · · · · · · · · · · · · ·	(1.24)			Lifestyles Flared
	13.36	144		
	(14.84)			Lifestyles Flared
* 55 mm – Up to 144 dev available on a PSO	()	144		Marguis Conforma
 56 mm – Up to 144 dev available on a PSO 		12	~	Gold Knight
·	13.36	144		Durex Extra Safe Gold Knight
* 56 mm, shaped – Up to 144 dev available on	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	12		Durex Confidence
	13.36	144		Durex Confidence
60 mm – Up to 144 dev available on a PSO. (Marquis Sensolite 52 mm to be delisted 1 May 20 (Marquis Supalite 52 mm to be delisted 1 May 20 (Marquis Titillata 53 mm to be delisted 1 May 201		144	-	Shield XL
Contraceptive Devices				
DIAPHRAGM – Up to 1 dev available on a PSO				
One of each size is permitted on a PSO.				
* 65 mm		1	~	Ortho All-flex
卷 70 mm		1		Ortho All-flex
卷 75 mm		1		Ortho All-flex
₭ 80 mm		1	\checkmark	Ortho All-flex
NTRA-UTERINE DEVICE a) Up to 40 dev available on a PSO				
b) Only on a PSO				
# IUD 29.1 mm length × 23.2 mm width		1	~	Choice TT380 Short
# IUD 33.6 mm length × 29.9 mm width		1	~	Choice TT380 Standard

73

GENITO-URINARY SYSTEM

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

Contraceptives - Hormonal

Combined Oral Contraceptives

➡SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 Either:

- 1.1 Patient is on a Social Welfare benefit; or
- 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 Patient is on a Social Welfare benefit; or
- 2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

ETHINYLOESTRADIOL WITH DESOGESTREL

*	Tab 20 mcg with desogestrel 150 mcg and 7 inert tab	6.62 (19.80)	84	Mercilon 28
	a) Higher subsidy of \$13.80 per 84 tab with Special Authority	see SA0500 abov	e	
	 b) Up to 84 tab available on a PSO 			
*	Tab 30 mcg with desogestrel 150 mcg and 7 inert tab	6.62	84	
		(19.80)		Marvelon 28
	a) Higher subsidy of \$13.80 per 84 tab with Special Authority	see SA0500 abov	e	
	b) Up to 84 tab available on a PSO			
ETI	HINYLOESTRADIOL WITH LEVONORGESTREL			
*	Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tab – Up			
	to 84 tab available on a PSO	2.65	84 🖌	🖊 Ava 20 ED
*	Tab 50 mcg with levonorgestrel 125 mcg and 7 inert tab – Up			
	to 84 tab available on a PSO	9.45	84 🖌	 Microgynon 50 ED
*	Tab 30 mcg with levonorgestrel 150 mcg	6.62	63	
		(16.50)		Microgynon 30
	a) Higher subsidy of \$15.00 per 63 tab with Special Authority	see SA0500 abov	e	
	b) Up to 63 tab available on a PSO			
*	Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tab – Up			
	to 84 tab available on a PSO	2.30	84 🖌	Ava 30 ED

GENITO-URINARY SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
ETHINYLOESTRADIOL WITH NORETHISTERONE				
* Tab 35 mcg with norethisterone 1 mg – Up to 63 tab available on a PSO	6.62	63	~	Brevinor 1/21
Tab 35 mcg with norethisterone 1 mg and 7 inert tab – Up to 84 tab available on a PSO	6.62	84	~	Brevinor 1/28
 Tab 35 mcg with norethisterone 500 mcg – Up to 63 tab avail- able on a PSO 	6.62	63	~	Brevinor 21
* Tab 35 mcg with norethisterone 500 mcg and 7 inert tab – Up to 84 tab available on a PSO	6.62	84	~	Norimin

Progestogen-only Contraceptives

➡SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 Either:

- 1.1 Patient is on a Social Welfare benefit; or
- 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 Patient is on a Social Welfare benefit; or
- 2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

LEVONORGESTREL

* Tab 30 mcg	6.62	84	
ů –	(16.50)		Microlut
 a) Higher subsidy of \$13.80 per 84 tab with Special Auth b) Up to 84 tab available on a PSO 	ority see SA0500 at	ove	
* Subdermal implant (2 × 75 mg rods)		1	✓ Jadelle
MEDROXYPROGESTERONE ACETATE * Inj 150 mg per ml, 1 ml syringe – Up to 5 inj available on a F	PSO7.00	1	✓ <u>Depo-Provera</u>
NORETHISTERONE * Tab 350 mcg – Up to 84 tab available on a PSO	6.25	84	✓ <u>Noriday 28</u>

	Subsidy (Manufacturer's Pric \$	ce) Sub Per	Fully sidised	Brand or Generic Manufacturer
Emergency Contraceptives				
LEVONORGESTREL * Tab 1.5 mg a) Maximum of 2 tab per prescription b) Up to 5 tab available on a PSO	3.50	1	✔ <u>Po</u>	ostinor-1
Antiandrogen Oral Contraceptives				
Prescribers may code prescriptions "contraceptive" (code "O") whe prescription charge will be as per other contraceptives, as follows: • \$5.00 prescription charge (patient co-payment) will apply. • prescription may be written for up to six months supply. Prescriptions coded in any other way are subject to the non contr of supply. ie. Prescriptions may be written for up to three months s CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL * Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs – Up	aceptive prescripti			
to 168 tab available on a PSO	5.36	168	🖌 <u>G</u> i	inet
Gynaecological Anti-infectives				
ACETIC ACID WITH HYDROXYQUINOLINE AND RICINOLEIC A Jelly with glacial acetic acid 0.94%, hydroxyquinoline sul- phate 0.025%, glycerol 5% and ricinoleic acid 0.75% with	CID			
applicator	8.43 (24.00)	100 g OP	Ad	ci-Jel
CLOTRIMAZOLE * Vaginal crm 1% with applicators * Vaginal crm 2% with applicators MICONAZOLE NITRATE		35 g OP 20 g OP		lomazol Iomazol
* Vaginal crm 2% with applicator	3.95	40 g OP	✓ <u>M</u>	icreme
NYSTATIN Vaginal crm 100,000 u per 5 g with applicator(s)	4.71	75 g OP	🗸 Ni	ilstat
Myometrial and Vaginal Hormone Preparations		-		
ERGOMETRINE MALEATE Inj 500 mcg per ml, 1 ml ampoule – Up to 5 inj available on a	04.70	F		BI Excomptoine
PSO OESTRIOL		5		BL Ergometrine
 Crm 1 mg per g with applicator Pessaries 500 mcg 		15 g OP 15		vestin vestin
OXYTOCIN – Up to 5 inj available on a PSO Inj 5 iu per ml, 1 ml ampoule Inj 10 iu per ml, 1 ml ampoule		5 5		xytocin BNM xytocin BNM
OXYTOCIN WITH ERGOMETRINE MALEATE – Up to 5 inj availa Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml		5	✓ <u>S</u> ı	yntometrine

76

	Subsidy (Manufacturer's Pi \$	rice) Subs Per	Fully Brand of idised Generic ✔ Manufa	C
Pregnancy Tests - hCG Urine				
PREGNANCY TESTS - HCG URINE a) Up to 200 test available on a PSO b) Only on a PSO Cassette		40 test OP	✓ <u>EasyChe</u>	<u>ck</u>
Urinary Agents				
For urinary tract Infections refer to INFECTIONS, Antibacterials, p	age 111			
5-Alpha Reductase Inhibitors				
FINASTERIDE – Special Authority see SA0928 below – Retail pr * Tab 5 mg 	2.08	30	✓ <u>Finpro</u>	
Initial application from any relevant practitioner. Approvals valic the following criteria: Both:	I without further i	renewal unless	notified for ap	plications meeting
 Patient has symptomatic benign prostatic hyperplasia; an Either: 	d			
2.1 The patient is intolerant of non-selective alpha blo 2.2 Symptoms are not adequately controlled with non			ed; or	
Note: Patients with enlarged prostates are the appropriate candid				
Alpha-1A Adrenoreceptor Blockers				
TAMSULOSIN HYDROCHLORIDE – Special Authority see SA10 * Cap 400 mcg		l pharmacy 100	✓ <u>Tamsulos</u>	sin-Rex
SA1032 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid the following criteria: Both:	I without further r	renewal unless	notified for ap	plications meeting
 Patient has symptomatic benign prostatic hyperplasia; an The patient is intolerant of non-selective alpha blockers of 		aindicated.		
Other Urinary Agents				
OXYBUTYNIN * Tab 5 mg * Oral liq 5 mg per 5 ml POTASSIUM CITRATE		500 473 ml	✓ <u>Apo-Oxyl</u> ✓ <u>Apo-Oxyl</u>	
Oral liq 3 mmol per ml – Special Authority see SA1083 below – Retail pharmacy		200 ml OP	 Biomed 	
SA1083 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid Both:	for 12 months for	applications m	eeting the follo	wing criteria:
1 The patient has recurrent calcium oxalate urolithiasis; and	d			

2 The patient has had more than two renal calculi in the two years prior to the application.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from the treatment.

77

GENITO-URINARY SYSTEM

	Subsidy (Manufacturer's Pric \$	ce) Per	Fully Subsidised	Generic
SODIUM CITRO-TARTRATE				
* Grans eff 4 g sachets	2.93	28	~	Ural
SOLIFENACIN SUCCINATE - Special Authority see SA0998 belo	ow – Retail pharm	acy		
Tab 5 mg		30	~	Vesicare
Tab 10 mg		30	~	Vesicare
SA0998 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals vali overactive bladder and a documented intolerance of, or is non-res			unless not	ified where the patient has
TOLTERODINE - Special Authority see SA1272 below - Retail p	harmacy			
Tab 1 mg	14.56	56	~	Arrow-Tolterodine
Tab 2 mg	14.56	56	~	Arrow-Tolterodine
► SA1272 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid tive bladder and a documented intolerance of, or is non-responsiv		ewal unl	ess notifie	d where patient has overac-
Detection of Substances in Urine				
ORTHO-TOLIDINE				
* Compound diagnostic sticks	7.50 (8.25)	50 test C		Hemastix
TETRABROMOPHENOL				
* Blue diagnostic strips	7.02 1 (13.92)	100 test (Albustix

	<u> </u>		
	Subsidy (Manufacturer's I	Price) Sub	Fully Brand or bsidised Generic
	\$	Per	✓ Manufacturer
Calcium Homeostasis			
CALCITONIN			
* Inj 100 iu per ml, 1 ml ampoule		5	✓ Miacalcic
ZOLEDRONIC ACID			
Inj 4 mg per 5 ml, vial – Special Authority see SA1512 belo	W		
- Retail pharmacy	550.00	1	Zometa
SA1512 Special Authority for Subsidy Initial application only from an oncologist, haematologist or unless notified for applications meeting the following criteria:	palliative care spe	ecialist. Appro	vals valid without further renew
Any of the following:			
 Patient has hypercalcaemia of malignancy; or Both: 			
2.1 Patient has bone metastases or involvement; ar2.2 Patient has severe bone pain resistant to standard		nents; or	
3 Both:			
3.1 Patient has bone metastases or involvement; ar3.2 Patient is at risk of skeletal-related events pat surgery to bone).		, spinal cord c	compression, radiation to bone
Corticosteroids and Related Agents for System			
BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHA	ASONE ACETATE		
BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHA	ASONE ACETATE	5	Celestone
BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHA	ASONE ACETATE		Celestone Chronodose
BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHA * Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml	ASONE ACETATE		
BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHA * Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml DEXAMETHASONE * Tab 0.5 mg – Retail pharmacy-Specialist	ASONE ACETATE 19.20 (36.96)		
BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHA * Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml DEXAMETHASONE * Tab 0.5 mg – Retail pharmacy-Specialist a) Up to 60 tab available on a PSO	ASONE ACETATE 19.20 (36.96)	5	Chronodose
 BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHA Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml DEXAMETHASONE Tab 0.5 mg – Retail pharmacy-Specialist a) Up to 60 tab available on a PSO b) Dexmethsone to be Sole Supply on 1 April 2016 	ASONE ACETATE 19.20 (36.96) 0.88	5 30	Chronodose
 BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHA Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml DEXAMETHASONE Tab 0.5 mg – Retail pharmacy-Specialist a) Up to 60 tab available on a PSO b) Dexmethsone to be Sole Supply on 1 April 2016 	ASONE ACETATE 19.20 (36.96) 0.88	5	Chronodose
 BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHA Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml DEXAMETHASONE Tab 0.5 mg – Retail pharmacy-Specialist	ASONE ACETATE 19.20 (36.96) 0.88 5.87 1.84	5 30 100 30	Chronodose Chronodose Dexmethsone Douglas Dexmethsone
 BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHA Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml DEXAMETHASONE Tab 0.5 mg – Retail pharmacy-Specialist a) Up to 60 tab available on a PSO b) Dexmethsone to be Sole Supply on 1 April 2016 Tab 1 mg – Retail pharmacy-Specialist Up to 30 tab available on a PSO Tab 4 mg – Retail pharmacy-Specialist 	ASONE ACETATE 19.20 (36.96) 0.88 5.87	5 30 100	Chronodose ✓ Dexmethsone ✓ Douglas
 BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHA inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml DEXAMETHASONE Tab 0.5 mg - Retail pharmacy-Specialist	ASONE ACETATE 19.20 (36.96) 0.88 5.87 1.84	5 30 100 30	Chronodose Chronodose Dexmethsone Douglas Dexmethsone
 BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHA inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml DEXAMETHASONE Tab 0.5 mg - Retail pharmacy-Specialist	ASONE ACETATE 	5 30 100 30	Chronodose Chronodose Dexmethsone Douglas Dexmethsone
 BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHA inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml DEXAMETHASONE Tab 0.5 mg – Retail pharmacy-Specialist	ASONE ACETATE 19.20 (36.96) 0.88 5.87 1.84 6.13 45.00	5 30 100 30 100	Chronodose Chronodose Dexmethsone Douglas Dexmethsone Douglas
 BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHA inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml DEXAMETHASONE Tab 0.5 mg – Retail pharmacy-Specialist	ASONE ACETATE 19.20 (36.96) 0.88 5.87 1.84 6.13 45.00 ogist; or	5 30 100 30 100	Chronodose Chronodose Dexmethsone Douglas Dexmethsone Douglas
 BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHA inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml DEXAMETHASONE Tab 0.5 mg – Retail pharmacy-Specialist	ASONE ACETATE 19.20 (36.96) 0.88 5.87 1.84 6.13 45.00 ogist; or	5 30 100 30 100	Chronodose Chronodose Dexmethsone Douglas Dexmethsone Douglas
 BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHA inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml DEXAMETHASONE Tab 0.5 mg – Retail pharmacy-Specialist	ASONE ACETATE 19.20 (36.96) 0.88 5.87 1.84 6.13 45.00 ogist; or	5 30 100 30 100	Chronodose Chronodose Dexmethsone Douglas Dexmethsone Douglas
 BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHA inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml DEXAMETHASONE Tab 0.5 mg - Retail pharmacy-Specialist	ASONE ACETATE 19.20 (36.96) 0.88 5.87 1.84 6.13 45.00 ogist; or	5 30 100 30 100	Chronodose Chronodose Dexmethsone Douglas Dexmethsone Douglas
 BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHA inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml DEXAMETHASONE Tab 0.5 mg - Retail pharmacy-Specialist	ASONE ACETATE 	5 30 100 30 100	Chronodose Chronodose Dexmethsone Douglas Dexmethsone Douglas
 BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHA inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml DEXAMETHASONE Tab 0.5 mg - Retail pharmacy-Specialist	ASONE ACETATE 	5 30 100 30 100	Chronodose Chronodose Dexmethsone Douglas Dexmethsone Douglas
 BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHA * Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml DEXAMETHASONE * Tab 0.5 mg – Retail pharmacy-Specialist	ASONE ACETATE 	5 30 100 30 100 25 ml OP	Chronodose Chronodose Dexmethsone Douglas Douglas Biomed
 BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHA * Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml DEXAMETHASONE * Tab 0.5 mg – Retail pharmacy-Specialist	ASONE ACETATE 	5 30 100 30 100 25 ml OP	Chronodose Chronodose Dexmethsone Douglas Douglas Biomed Max Health

	Subsidy (Manufacturer's F	Price) Sul	Fully Brand or osidised Generic
	(Inianulaciulei 5 i \$	Per	Manufacturer
IYDROCORTISONE			
⊱ Tab 5 mg		100	✓ Douglas
 Tab 20 mg – For hydrocortisone oral liquid formulation refer 			· <u></u>
page 213		100	✓ Douglas
k Inj 100 mg vial		1	✓ <u>Solu-Cortef</u>
a) Up to 5 inj available on a PSO			
b) Only on a PSO			
METHYLPREDNISOLONE – Retail pharmacy-Specialist	~~~~	100	/
K Tab 4 mg		100	Medrol
K Tab 100 mg		20	✓ Medrol
IETHYLPREDNISOLONE (AS SODIUM SUCCINATE) - Retail	pharmacy-Specia	alist	
Inj 40 mg vial		1	Solu-Medrol
Inj 125 mg vial		1	✓ Solu-Medrol
Inj 500 mg vial	9.00	1	✓ Solu-Medrol
Inj 1 g vial		1	✓ Solu-Medrol
IETHYLPREDNISOLONE ACETATE			
	40.00	F	A Dono-Madral
Inj 40 mg per ml, 1 ml vial		5	Depo-Medrol
METHYLPREDNISOLONE ACETATE WITH LIDOCAINE [LIGNO			
Inj 40 mg per ml with lidocaine [lignocaine] 1 ml vial	9.25	1	Depo-Medrol with
			Lidocaine
REDNISOLONE			
Oral lig 5 mg per ml – Up to 30 ml available on a PSO	7.50	30 ml OP	Redipred
Restricted to children under 12 years of age.		-	•
REDNISONE			
← Tab 1 mg	2 13	100	✓ Apo-Prednisone
	2.10	100	
			S29 S29
	10.68	500	Apo-Prednisone
₭ Tab 2.5 mg		500	Apo-Prednisone
Tab 5 mg – Up to 30 tab available on a PSO		500	Apo-Prednisone
₭ Tab 20 mg	29.03	500	Apo-Prednisone
ETRACOSACTRIN			
 Inj 250 mcg per ml, 1 ml ampoule 		1	Synacthen
k lnj 1 mg per ml, 1 ml		1	Synacthen Depot
		-	· · · · · · · · · · · · · · · · · · ·
	00.00	-	/ Kanasark A 10
Inj 10 mg per ml, 1 ml ampoule		5	✓ Kenacort-A 10
Inj 40 mg per ml, 1 ml ampoule	51.10	5	Kenacort-A 40
Sex Hormones Non Contraceptive			
Androgen Agonists and Antagonists			
YPROTERONE ACETATE – Retail pharmacy-Specialist			
Tab 50 mg		50	✓ Procur
		50	✓ Procur
Tab 100 mg			
·			
ESTOSTERONE	90.00	60	Androdorm
ESTOSTERONE Transdermal patch, 2.5 mg per day	80.00	60	 Androderm
ESTOSTERONE	80.00	60	✓ Androderm✓ Depo-Testosterone

80

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
TESTOSTERONE ESTERS – Retail pharmacy-Specialist Inj 250 mg per ml, 1 ml	12.98	1	🖌 Si	ustanon Ampoules
TESTOSTERONE UNDECANOATE – Retail pharmacy-Specialis Cap 40 mg Inj 250 mg per ml, 4 ml vial	16.80	60 1		ndriol Testocaps eandron 1000

Hormone Replacement Therapy - Systemic

➡SA1018 Special Authority for Alternate Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 years for applications meeting the following criteria: Any of the following:

- 1 acute or significant liver disease where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written confirmation from such a specialist with the patient's record; or
- 2 oestrogen induced hypertension requiring antihypertensive therapy documented evidence must be kept on file that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens; or
- 3 hypertriglyceridaemia documented evidence must be kept on file that triglyceride levels increased to at least $2 \times$ normal triglyceride levels post oral oestrogens; or
- 4 Somatropin co-therapy patient is being prescribed somatropin with subsidy provided under a valid approval issued under Special Authority.

Note: Prescriptions with a valid Special Authority (CHEM) number will be reimbursed at the level of the lowest priced TDDS product within the specified dose group.

Renewal from any relevant practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment, or the patient remains on subsidised somatropin co-therapy.

Prescribing Guideline

HRT should be taken at the lowest dose for the shortest period of time necessary to control symptoms. Patients should be reviewed 6 monthly in line with the updated NZGG "Evidence-based Best Practice Guideline on Hormone Replacement Therapy March 2004".

	Subsidy (Manufacturer's Pr \$	ice) Su Per	Fully Brand or ubsidised Generic ✔ Manufacturer
Oestrogens			
DESTRADIOL – See prescribing guideline on the previous page	•		
₭ Tab 1 mg		28 OP	
-	(11.10)		Estrofem
K Tab 2 mg	4.12	28 OP	
	(11.10)		Estrofem
 TDDS 25 mcg per day 		8	
	(10.86)		Estradot
 a) Higher subsidy of \$10.86 per 8 patch with Special Auth b) No more than 2 patch per week c) Only on a prescription 	ority see SA1018	on the previo	bus page
TDDS 3.9 mg (releases 50 mcg of oestradiol per day)	4.12	4	
	(13.18)		Climara 50
 a) Higher subsidy of \$13.18 per 4 patch with Special Auth b) No more than 1 patch per week c) Only on a prescription 	ority see SA1018	on the previo	ous page
✤ TDDS 50 mcg per day	4.12	8	
	(13.18)		Estradot 50 mcg
 a) Higher subsidy of \$13.18 per 8 patch with Special Auth b) No more than 2 patch per week c) Only on a prescription 		·	ous page
 TDDS 7.8 mg (releases 100 mcg of oestradiol per day) 		4	
a) Llinkar aukaidu af ¢10 14 mar 4 matak with Omasial Auth	(16.14)		Climara 100
 a) Higher subsidy of \$16.14 per 4 patch with Special Auth b) No more than 1 patch per week c) Only on a prescription 	ority see SA1018	on the previo	bus page
FTDDS 100 mcg per day	7.05	8	
51 5	(16.14)		Estradot
a) Higher subsidy of \$16.14 per 8 patch with Special Auth b) No more than 2 patch per week c) Only on a prescription		on the previo	bus page
DESTRADIOL VALERATE – See prescribing guideline on the pr			
€ Tab 1 mg		84	Progynova
Tab 2 mg	12.36	84	Progynova
ESTROGENS – See prescribing guideline on the previous page	le		
Conjugated, equine tab 300 mcg	3.01	28	
	(11.48)		Premarin
Conjugated, equine tab 625 mcg		28	
	(11.48)		Premarin
Progestogens			
IEDROXYPROGESTERONE ACETATE - See prescribing guid			_
₭ Tab 2.5 mg		30	✓ Provera
₭ Tab 5 mg		100	✓ Provera
₭ Tab 10 mg	6.85	30	Provera

	Subsidy (Manufacturer's Price \$	e) Per	Fully Brand or Subsidised Generic Manufacturer
Progestogen and Oestrogen Combined Prepara	tions		
DESTRADIOL WITH NORETHISTERONE – See prescribing gui			
* Tab 1 mg with 0.5 mg norethisterone acetate		28 OP	
* Tab 2 mg with 1 mg norethisterone acetate	(18.10)	28 OP	Kliovance
	(18.10)	20 UF	Kliogest
* Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg	()		· ····g····
oestradiol tab (12) and 1 mg oestradiol tab (6)		28 OP	
	(18.10)		Trisequens
DESTROGENS WITH MEDROXYPROGESTERONE – See pres		page 8	81
* Tab 625 mcg conjugated equine with 2.5 mg medroxyproges-		~~~~	
terone acetate tab (28)	5.40 (22.96)	28 OP	, Premia
	(22.30)		2.5 Continuous
* Tab 625 mcg conjugated equine with 5 mg medroxyproges-			
terone acetate tab (28)	5.40	28 OP	
	(22.96)		Premia 5 Continuous
Other Oestrogen Preparations			
ETHINYLOESTRADIOL			
* Tab 10 mcg	17.60	100	✓ NZ Medical and
			Scientific
DESTRIOL	7.00	~~	
* Tab 2 mg	7.00	30	 Ovestin
Other Progestogen Preparations			
EVONORGESTREL			
 Levonorgestrel - releasing intrauterine system 20 mcg/24 hr – 			
Special Authority see SA0782 below – Retail pharmacy.		1	 Mirena
►SA0782 Special Authority for Subsidy			

Initial application — (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and
- 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and
- 3 Either:
 - 3.1 serum ferritin level < 16 mcg/l (within the last 12 months); or
 - 3.2 haemoglobin level < 120 g/l.

Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria.

Initial application — (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and
- 2 Patient demonstrated clinical improvement of heavy menstrual bleeding; and
- 3 Applicant to state date of the previous insertion.

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🖌	Manufacturer	

continued...

Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria. Renewal only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or
 - 1.2 Previous insertion was removed or expelled within 3 months of insertion; and
- 2 Applicant to state date of the previous insertion.

MEDROXYPROGESTERONE ACETATE * Tab 100 mg – Retail pharmacy-Specialist	6.50	100	
NORETHISTERONE			
* Tab 5 mg – Up to 30 tab available on a PSO18	8.29	100	
PROGESTERONE			
Cap 100 mg - Special Authority see SA1392 below - Retail			

30 ✓ Utrogestan

►SA1392 Special Authority for Subsidy

Initial application only from an obstetrician or gynaecologist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 For the prevention of pre-term labour*; and
- 2 Fither:
 - 2.1 The patient has a short cervix on ultrasound (defined as < 25 mm at 16 to 28 weeks); or
 - 2.2 The patient has a history of pre-term birth at less than 28 weeks.

Note: Indications marked with * are Unapproved Indications (refer to Interpretations and Definitions).

Thyroid and Antithyroid Agents

CARRIMAZOLE

* Tab 5 mg		0	Neo-Mercazole
LEVOTHYROXINE			
* Tab 25 mcg		0 🖌	Synthroid
‡ Safety cap for extemporaneously compounded of	ral liquid preparations.		•
* Tab 50 mcg	4.05 9	0 🖌	 Synthroid
-	64.28 1,0	00 🖌	Eltroxin
‡ Safety cap for extemporaneously compounded of	ral liquid preparations.		
* Tab 100 mcg		0 🖌	 Synthroid
	66.78 1,0	00 🖌	Eltroxin
‡ Safety cap for extemporaneously compounded c	ral liquid preparations.		
LEVOTHYROXINE (MERCURY PHARMA)			
* Tab 50 mcg		8 🖌	Mercury Pharma
‡ Safety cap for extemporaneously compounded of	ral liquid preparations.		•
* Tab 100 mcg		B 🖌	 Mercury Pharma
‡ Safety cap for extemporaneously compounded of	ral liquid preparations.		-
	a dha an a dha an a' Dadadh a baann		

PROPYLTHIOURACIL - Special Authority see SA1199 on the next page - Retail pharmacy Propylthiouracil is not recommended for patients under the age of 18 years unless the patient is pregnant and other treatments are contraindicated. 100 ✓ PTU S29

84

Provera

Primolut N

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

➡SA1199 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 The patient has hyperthyroidism; and
- 2 The patient is intolerant of carbimazole or carbimazole is contraindicated.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from the treatment.

Trophic Hormones			

Growth Hormones

SO	MATROPIN (OMNITROPE) - Special Authority see SA	1451 below – Retail phar	rmacy	
*	Inj 5 mg cartridge		1	 Omnitrope
*	Inj 10 mg cartridge	219.00	1	 Omnitrope
	Inj 15 mg cartridge		1	 Omnitrope
	SA1451 Special Authority for Subsidy			

SA1451 | Special Authority for Subsidy

Initial application — (growth hormone deficiency in children) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria: Fither:

- 1 Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient seguelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or
- 2 All of the following:
 - 2.1 Height velocity < 25th percentile for age adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985): and
 - 2.2 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
 - 2.3 Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and
 - 2.4 If the patient has been treated for a malignancy, they should be disease free for at least one year based upon followup laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and
 - 2.5 Appropriate imaging of the pituitary gland has been obtained.

Renewal — (growth hormone deficiency in children) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 A current bone age is \leq 14 years (female patients) or \leq 16 years (male patients); and
- 2 Height velocity is ≥ 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and
- 3 Height velocity is ≥ 2.0 cm per year, as calculated over 6 months; and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred: and
- 5 No malignancy has developed since starting growth hormone.

Initial application — (Turner syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a post-natal genotype confirming Turner Syndrome; and
- 2 Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and

Subsidy		Fully	Brand or	
(Manufacturer's Price)	S	ubsidised	Generic	
\$	Per	~	Manufacturer	

continued...

3 A current bone age is < 14 years.

Renewal — (Turner syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity ≥ 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke's Turner Syndrome growth velocity charts); and
- 2 Height velocity is \geq 2 cm per year, calculated over six months; and
- 3 A current bone age is \leq 14 years; and
- 4 No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

Initial application — (short stature without growth hormone deficiency) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

- All of the following:
 - 1 The patient's height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and
 - 2 Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies(1985); and
 - 3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
 - 4 The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

Renewal — (short stature without growth hormone deficiency) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 Height velocity is ≥ 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is \geq 2 cm per year as calculated over six months; and
- 3 A current bone age is \leq 14 years (female patients) or \leq 16 years (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred.

Initial application — (short stature due to chronic renal insufficiency) only from a paediatric endocrinologist, endocrinologist or renal physician on the recommendation of a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient's height is more than 2 standard deviations below the mean; and
- 2 Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is \leq to 14 years (female patients) or \leq to 16 years (male patients); and
- 4 The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
- 5 The patient is under the supervision of a specialist with expertise in renal medicine; and
- 6 Either:

86

- 6.1 The patient has a GFR ≤ 30 ml/min/1.73m² as measured by the Schwartz method (Height(cm)/plasma creatinine (umol/l) × 40 = corrected GFR (ml/min/1.73m² in a child who may or may not be receiving dialysis; or
- 6.2 The patient has received a renal transplant and has received < 5mg/ m²/day of prednisone or equivalent for at least 6 months..

(Man	Subsidy	Fully	Brand or
	ufacturer's Price)	Subsidised	Generic
(\$ Pe		Manufacturer

continued...

Renewal — (short stature due to chronic renal insufficiency) only from a paediatric endocrinologist, endocrinologist or renal physician on the recommendation of a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is ≥ 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is ≥ 2 cm per year as calculated over six months; and
- 3 A current bone age is \leq 14 years (female patients) or \leq 16 years (male patients); and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
- 7 The patient has not received renal transplantation since starting growth hormone treatment; and
- 8 If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

Initial application — (Prader-Willi syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and
- 2 The patient's height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 3 Either:
 - 3.1 The patient is under two years of age and height velocity has been assessed over a minimum six month period from the age of 12 months, with at least three supine length measurements over this period demonstrating clear and consistent evidence of linear growth failure (with height velocity < 25th percentile); or</p>
 - 3.2 The patient is aged two years or older; and
- 4 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 5 Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and
- 6 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by ≥ 0.5 standard deviations in the preceding 12 months.

Renewal — (Prader-Willi syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is ≥ 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is ≥ 2 cm per year as calculated over six months; and
- 3 A current bone age is \leq 14 years (female patients) or \leq 16 years (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by ≥ 0.5 standard deviations in the preceding 12 months.

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🖌	Manufacturer	

continued...

Initial application — (adults and adolescents) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
- 2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
- 3 The patient has severe growth hormone deficiency (see notes); and
- 4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
- 5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA[®]).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of $\leq 3 \text{ mcg}$ per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of ≤ 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until the serum IGF-I is within 1 standard deviation of the mean normal value for age and sex; and

Dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

Renewal — (adults and adolescents) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has been treated with somatropin for < 12 months; and
 - 1.2 There has been an improvement in Quality of Life defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA^(B)) score from baseline; and
 - 1.3 Serum IGF-I levels have been increased within ±1SD of the mean of the normal range for age and sex; and
 - 1.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients, or 1 mg per day for female patients; or
- 2 All of the following:
 - 2.1 The patient has been treated with somatropin for more than 12 months; and
 - 2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA® score on treatment (other than due to obvious external factors such as external stressors); and
 - 2.3 Serum IGF-I levels have continued to be maintained within ±1SD of the mean of the normal range for age and sex (other than for obvious external factors); and
 - 2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients.

GnRH Analogues

GOSERELIN ACETATE

Inj 3.6 mg	6.20	1	Zoladex
Inj 10.8 mg	3.76	1	Zoladex

88

	Subsidy		Full	y Brand or
(Manufacturer's Price)		Subsidised	d Generic
	\$	Per	~	Manufacturer
EUPRORELIN				
Inj 3.75 mg prefilled syringe	221.60	1	~	Lucrin Depot PDS
Inj 7.5 mg		1	~	Eligard
Inj 11.25 mg prefilled syringe	591.68	1	~	Lucrin Depot PDS
Inj 22.5 mg		1	~	Eligard
Inj 30 mg	591.68	1	~	Eligard
Inj 30 mg prefilled syringe		1	~	Lucrin Depot PDS
Inj 45 mg	832.05	1	~	Eligard
Vasopressin Agonists				
ESMOPRESSIN ACETATE				
Tab 100 mcg - Special Authority see SA1401 below - Retail				
pharmacy	36.40	30	~	Minirin
Tab 200 mcg – Special Authority see SA1401 below – Retail				
pharmacy	93.60	30	~	Minirin
Nasal drops 100 mcg per ml – Retail pharmacy-Specialist		5 ml O	-	Minirin
Nasal spray 10 mcg per dose – Retail pharmacy-Specialist		ml OF		Desmopressin-
			•	PH&T
Inj 4 mcg per ml, 1 ml – Special Authority see SA1401 below				<u></u>
– Retail pharmacy	67.18	10	~	Minirin
			5	

SA1401 Special Authority for Subsidy

Initial application — (Desmopressin tablets for Nocturnal enuresis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has primary nocturnal enuresis; and
- 2 The nasal forms of desmopressin are contraindicated; and
- 3 An enuresis alarm is contraindicated.

Initial application — (Desmopressin tablets for Diabetes insipidus) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has cranial diabetes insipidus; and
- 2 The nasal forms of desmopressin are contraindicated.

Renewal — (Desmopressin tablets) from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from the treatment.

Initial application — (Desmopressin injection) only from a relevant specialist. Approvals valid for 2 years where the patient cannot use desmopressin nasal spray or nasal drops.

Renewal — (Desmopressin injection) only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Other Endocrine Agents

CABERGOLINE

		Tab 0.5 mg – Maximum of 2 tab per prescription; can be
2 V Dostinex	2	waived by Special Authority see SA1370 on the next page4.75
8 V Dostinex	8	19.00

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

SA1370 Special Authority for Waiver of Rule

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 pathological hyperprolactinemia; or
- 2 acromegaly*.

Renewal — (for patients who have previously been funded under Special Authority form SA1031) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has previously held a valid Special Authority which has expired and the treatment remains appropriate and the patient is benefiting from treatment. Note: Indication marked with * is an Unapproved indication.

CLOMIPHENE CITRATE

Tab 50 mg		10	✓ Serophene
DANAZOL			
Cap 100 mg		100	🖌 Azol
Cap 200 mg		100	🖌 Azol
METYRAPONE			
Cap 250 mg – Retail pharmacy-	Specialist520.00	50	 Metopirone

	Subsidy		Fully	Brand or
	(Manufacturer's P	rice) Su	bsidised	Generic
	\$	Per	~	Manufacturer
Anthelmintics				
ALBENDAZOLE – Special Authority see SA1318 below – Reta		60		akazala coo
Tab 400 mg		60	VE	skazole S29
SA1318 Special Authority for Subsidy nitial application only from an infectious disease specialist of batient has hydatids. Renewal only from an infectious disease specialist or clinical				
remains appropriate and the patient is benefitting from the treat				
MEBENDAZOLE – Only on a prescription	04.10	0.4		
Tab 100 mg Oral lig 100 mg per 5 ml		24 15 ml	VD	e-Worm
	(7.17)	10 111	V	ermox
	(7.17)		v	
PRAZIQUANTEL	69.00	0	. / P	iltricide
Tab 600 mg		8	VD	IIIricide
Antibacterials				
a) For topical antibacterials, refer to DERMATOLOGICALS, pag	e 63			
b) For anti-infective eye preparations, refer to SENSORY ORGA				
· · · · · · · · · · · · · · · · · · ·	-,15			
Cephalosporins and Cephamycins				
CEFACLOR MONOHYDRATE				
Cap 250 mg		100	✓ <u>R</u>	anbaxy-Cefaclor
Grans for oral liq 125 mg per 5 ml – Wastage claimable – se				
rule 3.3.2 on page 13	3.53	100 ml	✓ <u>R</u>	anbaxy-Cefaclor
CEFALEXIN				
Cap 500 mg		20	✓ <u>C</u>	ephalexin ABM
Grans for oral liq 25 mg per ml – Wastage claimable – se				
rule 3.3.2 on page 13		100 ml		efalexin Sandoz
Note: Cefalexin grans for oral liq will not be funded in an Grans for oral liq 50 mg per ml – Wastage claimable – se		4 days treatm	ent per o	aispensing.
rule 3.3.2 on page 13		100 ml	~ ~	efalexin Sandoz
Note: Cefalexin grans for oral liq will not be funded in arr				
CEFAZOLIN – Subsidy by endorsement		. aajo noam	on por	alop ollonig.
Only if prescribed for dialysis or cellulitis in accordance with	a DHB approved r	protocol and th	ne presc	ription is endorsed accord
ingly.	a 2112 approved p			
Inj 500 mg vial	3.99	5	✓ <u>A</u>	<u>FT</u>
Inj 1 g vial	3.38	5	✓ A	FT
CEFTRIAXONE – Subsidy by endorsement				
a) Up to 5 inj available on a PSO				
b) Subsidised only if prescribed for a dialysis or cystic fib	rosis patient, or th	e treatment o	of gonor	rhoea, or the treatment of
pelvic inflammatory disease, or the treatment of suspected	I meningitis in patie	ents who have	e a know	n allergy to penicillin, an
the prescription or PSO is endorsed accordingly.		,		
Inj 500 mg vial		1		eftriaxone-AFT
Inj 1 g vial	5.22	5	<u>v</u> <u>c</u>	eftriaxone-AFT
CEFUROXIME AXETIL – Subsidy by endorsement				
		and according	11.7	
Only if prescribed for prophylaxis of endocarditis and the pr Tab 250 mg		50		innat

	Subsidy (Manufacturer's Price \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer
Macrolides				
 AZITHROMYCIN – Maximum of 5 days treatment per prescription For Endorsement, patient has either: 1) Received a lung transplant and requires treatment or proceeding of the process of t	ophylaxis for bronchi	olitis obl	literans syn	
Indications marked with * are Unapproved Indications	0.00	~~		A _111
Tab 250 mg		30		po-Azithromycin
Tab 500 mg – Up to 8 tab available on a PSO		2	✓ <u>A</u>	po-Azithromycin
Grans for oral liq 200 mg per 5 ml (40 mg per ml) – Wastag- claimable – see rule 3.3.2 on page 13		15 ml	✓ Z	thromax
CLARITHROMYCIN – Maximum of 500 mg per prescription; car Tab 250 mg		al Autho 14		po-Clarithromycin
Grans for oral liq 125 mg per 5 ml – Wastage claimable – se	е			
rule 3.3.2 on page 13	23.12	70 ml	🖌 K	lacid
 Approvals valid for 2 years for applications meeting the following sither: 1 Atypical mycobacterial infection; or 2 Mycobacterium tuberculosis infection where there is drug 		erance to	o standard	pharmaceutical agents.
	0		• • • • • • • • •	pila inaccoulou agoino.
				or paediatrician. Approva
alid for 2 years where the treatment remains appropriate and th				or paediatrician. Approva
alid for 2 years where the treatment remains appropriate and th	e patient is benefiting		reatment.	or paediatrician. Approva
alid for 2 years where the treatment remains appropriate and th RYTHROMYCIN ETHYL SUCCINATE Tab 400 mg a) Up to 20 tab available on a PSO	e patient is benefiting	g from tr 100	reatment.	
alid for 2 years where the treatment remains appropriate and th RYTHROMYCIN ETHYL SUCCINATE Tab 400 mg a) Up to 20 tab available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r	e patient is benefiting 	g from tr 100	reatment.	Mycin
alid for 2 years where the treatment remains appropriate and th RYTHROMYCIN ETHYL SUCCINATE Tab 400 mg a) Up to 20 tab available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r Grans for oral liq 200 mg per 5 ml	e patient is benefiting 	g from tr 100	reatment.	
alid for 2 years where the treatment remains appropriate and th RYTHROMYCIN ETHYL SUCCINATE Tab 400 mg a) Up to 20 tab available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r Grans for oral liq 200 mg per 5 ml a) Up to 300 ml available on a PSO	e patient is benefiting 	9 from tr 100 100 ml	reatment.	Mycin
alid for 2 years where the treatment remains appropriate and th ERYTHROMYCIN ETHYL SUCCINATE Tab 400 mg a) Up to 20 tab available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r Grans for oral liq 200 mg per 5 ml a) Up to 300 ml available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r	e patient is benefiting 	9 from tr 100 100 ml	reatment.	Mycin
alid for 2 years where the treatment remains appropriate and th ERYTHROMYCIN ETHYL SUCCINATE Tab 400 mg a) Up to 20 tab available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r Grans for oral liq 200 mg per 5 ml a) Up to 300 ml available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r c) Wastage claimable – see rule 3.3.2 on page 13	e patient is benefiting 	9 from tr 100 100 ml	reatment. ✓ E	Mycin
alid for 2 years where the treatment remains appropriate and th RYTHROMYCIN ETHYL SUCCINATE Tab 400 mg a) Up to 20 tab available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r Grans for oral liq 200 mg per 5 ml a) Up to 300 ml available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r	e patient is benefiting 	9 from tr 100 100 ml	reatment. ✓ E	-Mycin Mycin
alid for 2 years where the treatment remains appropriate and th ERYTHROMYCIN ETHYL SUCCINATE Tab 400 mg a) Up to 20 tab available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r Grans for oral liq 200 mg per 5 ml a) Up to 300 ml available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r c) Wastage claimable – see rule 3.3.2 on page 13 Grans for oral liq 400 mg per 5 ml	e patient is benefiting 	9 from tr 100 100 ml	reatment. ✓ E	-Mycin -Mycin
alid for 2 years where the treatment remains appropriate and th ERYTHROMYCIN ETHYL SUCCINATE Tab 400 mg a) Up to 20 tab available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r Grans for oral liq 200 mg per 5 ml a) Up to 300 ml available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r c) Wastage claimable – see rule 3.3.2 on page 13 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r c) Wastage claimable – see rule 3.3.2 on page 13 Wastage claimable – see rule 3.3.2 on page 13	e patient is benefiting 	9 from tr 100 100 ml	reatment. ✓ E	-Mycin -Mycin
alid for 2 years where the treatment remains appropriate and th ERYTHROMYCIN ETHYL SUCCINATE Tab 400 mg a) Up to 20 tab available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r Grans for oral liq 200 mg per 5 ml a) Up to 300 ml available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r c) Wastage claimable – see rule 3.3.2 on page 13 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 13 b) Wastage claimable – see rule 3.3.2 on page 13	e patient is benefiting 	9 from tr 100 100 ml	reatment. ✓ E ✓ E	-Mycin Mycin
 a) Up to 20 tab available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r Grans for oral liq 200 mg per 5 ml a) Up to 300 ml available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r c) Wastage claimable – see rule 3.3.2 on page 13 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 13 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 13 ERYTHROMYCIN LACTOBIONATE lnj 1 g 	e patient is benefiting 	g from tr 100 100 ml 100 ml	reatment. ✓ E ✓ E	-Mycin -Mycin -Mycin
alid for 2 years where the treatment remains appropriate and th ERYTHROMYCIN ETHYL SUCCINATE Tab 400 mg a) Up to 20 tab available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r Grans for oral liq 200 mg per 5 ml a) Up to 300 ml available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r c) Wastage claimable – see rule 3.3.2 on page 13 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 13 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 13 ERYTHROMYCIN LACTOBIONATE Inj 1 g ERYTHROMYCIN STEARATE	e patient is benefiting 	g from tr 100 100 ml 100 ml	reatment. ✓ E ✓ E	-Mycin -Mycin -Mycin
alid for 2 years where the treatment remains appropriate and th RYTHROMYCIN ETHYL SUCCINATE Tab 400 mg a) Up to 20 tab available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r Grans for oral liq 200 mg per 5 ml a) Up to 300 ml available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r c) Wastage claimable – see rule 3.3.2 on page 13 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 13 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 13 RYTHROMYCIN LACTOBIONATE Inj 1 g	e patient is benefiting 	g from tr 100 100 ml 100 ml	reatment. ✓ E ✓ E ✓ E	-Mycin -Mycin -Mycin
alid for 2 years where the treatment remains appropriate and th ERYTHROMYCIN ETHYL SUCCINATE Tab 400 mg a) Up to 20 tab available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r Grans for oral liq 200 mg per 5 ml a) Up to 300 ml available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r c) Wastage claimable – see rule 3.3.2 on page 13 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 13 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 13 ERYTHROMYCIN LACTOBIONATE Inj 1 g ERYTHROMYCIN STEARATE Tab 250 mg – Up to 30 tab available on a PSO	e patient is benefiting 	g from tr 100 100 ml 100 ml	reatment. ✓ E ✓ E ✓ E	-Mycin -Mycin -Mycin rythrocin IV
alid for 2 years where the treatment remains appropriate and th ERYTHROMYCIN ETHYL SUCCINATE Tab 400 mg a) Up to 20 tab available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r Grans for oral liq 200 mg per 5 ml a) Up to 300 ml available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r c) Wastage claimable – see rule 3.3.2 on page 13 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 13 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 13 ERYTHROMYCIN LACTOBIONATE Inj 1 g ERYTHROMYCIN STEARATE	e patient is benefiting 	g from tr 100 100 ml 100 ml 1 100	reatment. ✓ E ✓ E ✓ E ✓ E E	-Mycin -Mycin -Mycin rythrocin IV
alid for 2 years where the treatment remains appropriate and th RYTHROMYCIN ETHYL SUCCINATE Tab 400 mg a) Up to 20 tab available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r Grans for oral liq 200 mg per 5 ml a) Up to 300 ml available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r c) Wastage claimable – see rule 3.3.2 on page 13 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 13 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 13 RYTHROMYCIN LACTOBIONATE Inj 1 g RYTHROMYCIN STEARATE Tab 250 mg – Up to 30 tab available on a PSO Tab 500 mg	e patient is benefiting 	g from tr 100 100 ml 100 ml 1 100	reatment. ✓ E ✓ E ✓ E ✓ E E	-Mycin -Mycin -Mycin rythrocin IV RA
alid for 2 years where the treatment remains appropriate and th ERYTHROMYCIN ETHYL SUCCINATE Tab 400 mg a) Up to 20 tab available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r Grans for oral liq 200 mg per 5 ml a) Up to 300 ml available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r c) Wastage claimable – see rule 3.3.2 on page 13 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 13 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 13 ERYTHROMYCIN LACTOBIONATE Inj 1 g Tab 250 mg – Up to 30 tab available on a PSO Tab 500 mg ROXITHROMYCIN	e patient is benefiting 	g from tr 100 100 ml 100 ml 1 100	reatment. ✓ E ✓ E ✓ E E E	-Mycin -Mycin -Mycin rythrocin IV RA
alid for 2 years where the treatment remains appropriate and th ERYTHROMYCIN ETHYL SUCCINATE Tab 400 mg a) Up to 20 tab available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r Grans for oral liq 200 mg per 5 ml a) Up to 300 ml available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r c) Wastage claimable – see rule 3.3.2 on page 13 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 13 Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 13 ERYTHROMYCIN LACTOBIONATE Inj 1 g ERYTHROMYCIN STEARATE Tab 250 mg – Up to 30 tab available on a PSO	e patient is benefiting 	g from tr 100 100 ml 100 ml 1 100 100	reatment. ✓ E ✓ E ✓ E E E	-Mycin -Mycin -Mycin rythrocin IV RA

92

	Subsidy (Manufacturer's P	rice) Su	Fully Brand or bsidised Generic
	\$	Per	✓ Manufacturer
Penicillins			
MOXICILLIN			
Cap 250 mg		500	Apo-Amoxi
a) Up to 30 cap available on a PSO			
b) Up to 10 x the maximum PSO quantity for RFPP – see r	ule 5.2.6 on page	e 17	
Cap 500 mg	20.94	500	Apo-Amoxi
a) Up to 30 cap available on a PSO			
b) Up to 10 x the maximum PSO quantity for RFPP – see r			4 • • •
Grans for oral liq 125 mg per 5 ml	0.88	100 ml	Alphamox
			Amoxicillin Actavis
	2.00		✓ Ranmoxy
a) Up to 200 ml available on a PSO	2.00		 Ospamox
b) Wastage claimable – see rule 3.3.2 on page 13			
Grans for oral liq 250 mg per 5 ml	0.97	100 ml	Alphamox
		100 111	✓ Amoxicillin Actavis
			✓ Ranmoxy
	2.00		✓ Ospamox
a) Up to 300 ml available on a PSO			•
b) Up to 10 x the maximum PSO quantity for RFPP – see r	ule 5.2.6 on page	e 17	
c) Wastage claimable – see rule 3.3.2 on page 13			
Inj 250 mg vial	10.67	10	Ibiamox
Inj 500 mg vial		10	Ibiamox
Inj 1 g vial – Up to 5 inj available on a PSO	17.29	10	Ibiamox
MOXICILLIN WITH CLAVULANIC ACID			
Tab 500 mg with clavulanic acid 125 mg - Up to 30 tab avail-			
able on a PSO		20	 Augmentin
	9.75	100	Curam Duo
Grans for oral liq amoxicillin 125 mg with clavulanic acid			
31.25 mg per 5 ml	1.61	100 ml	Curam
	3.83		 Augmentin
a) Up to 200 ml available on a PSO			
b) Wastage claimable – see rule 3.3.2 on page 13			
Grans for oral liq amoxicillin 250 mg with clavulanic acid	0.10	100 ml	1 Current
62.5 mg per 5 ml		100 ml	Curam
a) Up to 200 ml available on a PSO	4.97		 Augmentin
b) Wastage claimable – see rule 3.3.2 on page 13			
Curam Grans for oral lig amoxicillin 125 mg with clavulanic acid 3	1 25 ma ner 5 m	l to he deliste	ed 1 April 2016)
Curam Grans for oral lig amoxicillin 125 mg with clavulanic acid 6	01		. ,
, 0			r ==/
ENZATHINE BENZYLPENICILLIN			
Inj 900 mg (1.2 million units) in 2.3 ml syringe – Up to 5 inj available on a PSO	215.00	10	
		10	Bicillin LA
ENZYLPENICILLIN SODIUM (PENICILLIN G)			
Inj 600 mg (1 million units) vial – Up to 5 inj available on a			
PSO	10.35	10	Sandoz

	Subsidy (Manufacturer's P	Price) S	Fully Brand or ubsidised Generic
	\$	Per	✓ Manufacturer
LUCLOXACILLIN			
Cap 250 mg – Up to 30 cap available on a PSO		250	Staphlex
Cap 500 mg		500	✓ Staphlex
Grans for oral liq 25 mg per ml	2.29	100 ml	✓ <u>AFT</u>
a) Up to 200 ml available on a PSO			
b) Wastage claimable – see rule 3.3.2 on page 13			
Grans for oral liq 50 mg per ml	3.08	100 ml	✓ <u>AFT</u>
a) Up to 200 ml available on a PSO			
b) Wastage claimable – see rule 3.3.2 on page 13			
Inj 250 mg vial	8.80	10	Flucloxin
Inj 500 mg vial	9.20	10	✓ Flucloxin
Inj 1 g vial – Up to 10 inj available on a PSO		10	✓ Flucloxin
PHENOXYMETHYLPENICILLIN (PENICILLIN V)			
Cap 250 mg – Up to 30 cap available on a PSO	2 00	50	Cilicaine VK
Cap 500 mg		50 50	✓ Cilicaine VK
	4.75	50	
 a) Up to 20 cap available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see r 		17	
, ,		100 ml	
Grans for oral liq 125 mg per 5 ml	1.04	100 111	✓ <u>AFT</u>
a) Up to 200 ml available on a PSO			
b) Wastage claimable – see rule 3.3.2 on page 13	1 74	100 ml	
Grans for oral liq 250 mg per 5 ml	1./4	100 ml	✓ <u>AFT</u>
a) Up to 300 ml available on a PSO		17	
b) Up to 2 x the maximum PSO quantity for RFPP – see r	ule 5.2.6 on page	917	
c) Wastage claimable – see rule 3.3.2 on page 13			
PROCAINE PENICILLIN			
Inj 1.5 g in 3.4 ml syringe – Up to 5 inj available on a PSO		5	Cilicaine
Tetracyclines			
· · · ·			
DOXYCYCLINE			
K Tab 50 mg – Up to 30 tab available on a PSO		30	
	(6.00)		Doxy-50
K Tab 100 mg – Up to 30 tab available on a PSO	6.75	250	✓ Doxine
/INOCYCLINE HYDROCHLORIDE			
🖌 Tab 50 mg – Additional subsidy by Special Authority see	9		
SA1355 below – Retail pharmacy	5.79	60	
	(12.05)		Mino-tabs
₭ Cap 100 mg		100	
	(52.04)		Minomycin
SA1355 Special Authority for Manufacturers Price	. /		,
nitial application from any relevant practitioner. Approvals va	lid without furthe	r renewal un	less notified where the patient
osacea.			
ETRACYCLINE – Special Authority see SA1332 below – Retai			
Cap 500 mg		30	Tetracyclin

SA1332 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 For the eradication of helicobacter pylori following unsuccessful treatment with appropriate first-line therapy; and
- 2 For use only in combination with bismuth as part of a quadruple therapy regimen.

94

Wolff S29

	Subsidy (Manufacturer's Pric \$	e) S Per	Fully Subsidised	Brand or Generic Manufacturer
Other Antibiotics				
For topical antibiotics, refer to DERMATOLOGICALS, page 63				
CIPROFLOXACIN Recommended for patients with any of the following: i) microbiologically confirmed and clinically significant pseu ii) prostatitis; or iii) pyelonephritis; or iv) gonorrhoea.	udomonas infection;	or		
Tab 250 mg – Up to 5 tab available on a PSO		28		<u>Sipflox</u>
Tab 500 mg – Up to 5 tab available on a PSO		28 28		Cipflox Sinflox
Tab 750 mg	3.75	28	<u>v</u> <u>u</u>	<u>Sipflox</u>
CLINDAMYCIN Cap hydrochloride 150 mg – Maximum of 4 cap per prescrip- tion; can be waived by endorsement - Retail pharmacy - Specialist		16	<u>~ c</u>	lindamycin ABM
Inj phosphate 150 mg per ml, 4 ml – Retail pharmacy- Specialist		10		Palacin C
CO-TRIMOXAZOLE				
 * Tab trimethoprim 80 mg and sulphamethoxazole 400 mg – Up to 30 tab available on a PSO 		500	/ T	risul
 * Oral liq trimethoprim 40 mg and sulphamethoxazole 200 mg per 5 ml – Up to 200 ml available on a PSO 		100 ml	🗸 D	Deprim
COLISTIN SULPHOMETHATE – Retail pharmacy-Specialist – S Only if prescribed for dialysis or cystic fibrosis patient and the Inj 150 mg	e prescription is end			Colistin-Link
FUSIDIC ACID				
Tab 250 mg – Retail pharmacy-Specialist		12	🖌 F	ucidin
Prescriptions must be written by, or on the recommendation	on of, an infectious of	lisease p	hysician o	r a clinical microbiologist
GENTAMICIN SULPHATE				
Inj 10 mg per ml, 1 ml – Subsidy by endorsement		5		lospira
Only if prescribed for a dialysis or cystic fibrosis patient or c accordingly.	complicated urinary	tract inted	ction and ti	ne prescription is endorsed
Inj 10 mg per ml, 2 ml – Subsidy by endorsement		25	🗸 A	PP
1 - 3 (- 1				Pharmaceuticals S29
Only if prescribed for a dialysis or cystic fibrosis patient or o accordingly.	complicated urinary	tract infe	ction and t	he prescription is endorsed
Inj 40 mg per ml, 2 ml ampoule – Subsidy by endorsement Only if prescribed for a dialysis or cystic fibrosis patient or o accordingly.		10 tract infec		f <u>fizer</u> he prescription is endorsed
MOXIFLOXACIN – Special Authority see SA1358 on the next pay No patient co-payment payable	ge – Retail pharma	су		
Tab 400 mg		5	🗸 A	velox
		-		

Subsidy	Full	/ Brand or	
(Manufacturer's Price)	Subsidised	I Generic	
\$	Per 🖌	Manufacturer	

SA1358 Special Authority for Subsidy

Initial application — (Tuberculosis) only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria:

Either:

1 Both:

- 1.1 Active tuberculosis*; and
- 1.2 Any of the following:
 - 1.2.1 Documented resistance to one or more first-line medications; or
 - 1.2.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or
 - 1.2.3 Impaired visual acuity (considered to preclude ethambutol use); or
 - 1.2.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or
 - 1.2.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; or
- 2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated.*.

Note: Indications marked with * are Unapproved Indications (refer to Interpretations and Definitions).

Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Mycoplasma genitalium) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium*; and
- 2 Has tried and failed to clear infection using azithromycin; and
- 3 Treatment is only for 7 days.

Initial application — (Penetrating eye injury) only from an ophthalmologist. Approvals valid for 1 month where the patient requires prophylaxis following a penetrating eye injury and treatment is for 5 days only.

Note: Indications marked with * are Unapproved Indications (refer to Interpretations and Definitions).

PAROMOMYCIN - Special Authority see SA1324 below - Retail pharmacy

Cap 250 mg		16	Humatin S29
------------	--	----	-------------

SA1324 Special Authority for Subsidy

Initial application only from an infectious disease specialist or clinical microbiologist. Approvals valid for 1 month where the patient has confirmed cryptosporidium infection.

Renewal only from an infectious disease specialist or clinical microbiologist. Approvals valid for 1 month where the patient has confirmed cryptosporidium infection.

PYRIMETHAMINE - Special Authority see SA1328 below - Retail pharmacy

Tab 25 mg		30	Daraprim S29
	36.95	50	🖌 Daraprim S29

➡SA1328 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 For the treatment of toxoplasmosis in patients with HIV for a period of 3 months; or
- 2 For pregnant patients for the term of the pregnancy; or
- 3 For infants with congenital toxoplasmosis until 12 months of age.

Tab 500 mg		56	Wockhardt S2
------------	--	----	--------------

	Subsidy (Manufacturer's Price \$) Sub Per	Fully osidised	Brand or Generic Manufacturer
Salary Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valie the following criteria: Any of the following:			s notifie	d for applications meeting
 For the treatment of toxoplasmosis in patients with HIV fe For pregnant patients for the term of the pregnancy; or For infants with congenital toxoplasmosis until 12 months 		ins; or		
TOBRAMYCIN Inj 40 mg per ml, 2 ml ampoule – Subsidy by endorsement Only if prescribed for dialysis or cystic fibrosis patient and Solution for inhalation 60 mg per ml, 5 ml – Subsidy by en-	the prescription is e	5 ndorsed ac		BL Tobramycin ^{y.}
dorsement a) Wastage claimable – see rule 3.3.2 on page 13 b) Only if prescribed for a cystic fibrosis patient and the pr TRIMETHOPRIM	2,200.00	56 dose ed accordir	✓ TO gly.	DBI
* Tab 300 mg – Up to 30 tab available on a PSO VANCOMYCIN – Subsidy by endorsement	15.00	50	✓ <u>11</u>	<u>NP</u>
Only if prescribed for a dialysis or cystic fibrosis patient or for following metronidazole failure and the prescription is endors		carditis or f	or treatn	nent of Clostridium difficile
Inj 500 mg	2.64	1	✓ <u>M</u>	ylan
Antifungals				
a) For topical antifungals refer to DERMATOLOGICALS, page 63 b) For topical antifungals refer to GENITO URINARY, page 76				
FLUCONAZOLE	2.40	00		
Cap 50 mg – Retail pharmacy-Specialist Cap 150 mg – Subsidy by endorsement		28 1	✓ <u>0</u>	
a) Maximum of 1 cap per prescription; can be waived by e		•	-	
b) Patient has vaginal candida albicans and the practition	ner considers that a	topical imic	dazole (ι	used intra-vaginally) is not
recommended and the prescription is endorsed according	ly; can be waived by	endorsem	ent - Re	tail pharmacy - Specialist.
Cap 200 mg – Retail pharmacy-Specialist		28	✓ <u>0</u> :	zole
Powder for oral suspension 10 mg per ml – Special Authority	/			
see SA1359 below - Retail pharmacy		35 ml		flucan S29 S29 flucan

➡SA1359 Special Authority for Subsidy

Initial application — (Systemic candidiasis) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 Patient requires prophylaxis for, or treatment of systemic candidiasis; and
- 2 Patient is unable to swallow capsules.

Initial application — (Immunocompromised) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient is immunocompromised; and
- 2 Patient is at moderate to high risk of invasive fungal infection; and
- 3 Patient is unable to swallow capsules.

continued...

97

	Subsidy (Manufacturer's P \$	rice) Sul Per	Fully osidised	Brand or Generic Manufacturer
continued Renewal — (Systemic candidiasis) from any relevant prac ollowing criteria: Both:	titioner. Approvals	valid for 6 w	eeks for	applications meeting th
 Patient requires prophylaxis for, or treatment of system Patient is unable to swallow capsules. 	ic candidiasis; and			
Renewal — (Immunocompromised) from any relevant prac ollowing criteria: All of the following:	titioner. Approvals	valid for 6 m	onths for	r applications meeting th
 Patient remains immunocompromised; and Patient remains at moderate to high risk of invasive fur Patient is unable to swallow capsules. 	ngal infection; and			
TRACONAZOLE Cap 100 mg – Subsidy by endorsement Funded for tinea vesicolor where topical treatment has n or for tinea unguium where terbinafine has not been su diagnosis has been confirmed by mycology and the pre Retail pharmacy - Specialist Specialist must be an infect or dermatologist.	ot been successful ccessful in eradicat scription is endorse	ion or the pat d accordingly	has bee ient is in Can be	tolerant to terbinafine ar waived by endorsement
5	W/			
Oral liq 10 mg per ml – Special Authority see SA1322 belo — Retail pharmacy		150 ml OP	🗸 SI	poranox
Oral liq 10 mg per ml – Special Authority see SA1322 belo – Retail pharmacy	141.80 nical microbiologist, nical microbiologist	clinical immu or clinical im	nologist (munolog	or any relevant practition jist. Approvals valid for
Oral liq 10 mg per ml – Special Authority see SA1322 bek – Retail pharmacy	141.80 nical microbiologist, nical microbiologist nonths where the t	clinical immu or clinical im	nologist (munolog	or any relevant practition jist. Approvals valid for
Oral liq 10 mg per ml – Special Authority see SA1322 bek – Retail pharmacy	141.80 nical microbiologist, nical microbiologist nonths where the tu	clinical immu or clinical im	nologist o munolog ains app	or any relevant practition ist. Approvals valid for ropriate and the patient nk Healthcare \$29
Oral liq 10 mg per ml – Special Authority see SA1322 bek – Retail pharmacy	141.80 nical microbiologist, nical microbiologist nonths where the tr dy CBS	clinical immun or clinical im reatment rema 30	nologist o munolog ains app	or any relevant practition ist. Approvals valid for ropriate and the patient
Oral liq 10 mg per ml – Special Authority see SA1322 bek – Retail pharmacy	141.80 nical microbiologist, nical microbiologist nonths where the tr dy CBS	clinical immun or clinical im reatment rema 30	nologist o munolog ains app	or any relevant practition ist. Approvals valid for ropriate and the patient nk Healthcare \$29
Oral liq 10 mg per ml – Special Authority see SA1322 bek – Retail pharmacy		clinical immun or clinical im reatment rema 30	nologist (munolog ains app ∠ Li ∠ Ni	or any relevant practition jist. Approvals valid for ropriate and the patient nk Healthcare s29 izoral s29
Oral liq 10 mg per ml – Special Authority see SA1322 bek – Retail pharmacy		clinical immun or clinical im reatment rema 30 st 50	nologist (munolog ains app ∠ Li ∠ Ni	or any relevant practition ist. Approvals valid for ropriate and the patient nk Healthcare \$29
Oral liq 10 mg per ml – Special Authority see SA1322 bek – Retail pharmacy		clinical immun or clinical im reatment rema 30	nologist (munolog ains app Li V Ni	or any relevant practition jist. Approvals valid for ropriate and the patient nk Healthcare s29 izoral s29

Either:

98

- 1 Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy; or
- 2 Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive therapy*.

Subsidy (Manufacturer's Price)	Subs	Fully	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

Renewal only from a haematologist or infectious disease specialist. Approvals valid for 6 weeks for applications meeting the following criteria:

Either:

- 1 Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy; or
- 2 Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppression* and requires on going posaconazole treatment.

Note: * Graft versus host disease (GVHD) on significant immunosuppression is defined as acute GVHD, grade II to IV, or extensive chronic GVHD, or if they were being treated with intensive immunosuppressive therapy consisting of either high-dose corticosteroids (\geq 1 mg per kilogram of body weight per day for patients with acute GVHD or \geq 0.8 mg per kilogram every other day for patients with chronic GVHD), antithymocyte globulin, or a combination of two or more immunosuppressive agents or types of treatment.

TERBINAFINE

(Vfend Tab 200 mg to be delisted 1 April 2016)

SA1273 Special Authority for Subsidy

Initial application — (invasive fungal infection) only from a haematologist, infectious disease specialist or clinical microbiologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is immunocompromised; and
- 2 Applicant is part of a multidisciplinary team including an infectious disease specialist; and
- 3 Any of the following:
 - 3.1 Patient has proven or probable invasive aspergillus infection; or
 - 3.2 Patient has possible invasive aspergillus infection; or
 - 3.3 Patient has fluconazole resistant candidiasis; or
 - 3.4 Patient has mould strain such as Fusarium spp. and Scedosporium spp.

Renewal — (invasive fungal infection) only from a haematologist, infectious disease specialist or clinical microbiologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is immunocompromised; and
- 2 Applicant is part of a multidisciplinary team including an infectious disease specialist; and
- 3 Any of the following:
 - 3.1 Patient continues to require treatment for proven or probable invasive aspergillus infection; or
 - 3.2 Patient continues to require treatment for possible invasive aspergillus infection; or
 - 3.3 Patient has fluconazole resistant candidiasis; or
 - 3.4 Patient has mould strain such as Fusarium spp. and Scedosporium spp.

	Subsidy (Manufacturer's Price) Subs	Fully Brand or sidised Generic	
	\$	Per	✓ Manufacturer	
Antimalarials				
PRIMAQUINE PHOSPHATE – Special Authority see SA1326 belo	w – Retail pharma	су		
Tab 7.5 mg	117.00	56	Primacin S29	
 SA1326 Special Authority for Subsidy Initial application only from an infectious disease specialist or clin meeting the following criteria: Both: The patient has vivax or ovale malaria; and 	nical microbiologist	. Approvals	valid for 1 month for	applications
2 Primaquine is to be given for a maximum of 21 days.				
Antiparasitics				
Antiprotozoals				
QUININE SULPHATE * Tab 300 mg ‡ Safety cap for extemporaneously compounded oral liquid		500	🖌 Q 300	
Antitrichomonal Agents				
METRONIDAZOLE Tab 200 mg – Up to 30 tab available on a PSO Tab 400 mg Oral liq benzoate 200 mg per 5 ml Suppos 500 mg		100 100 100 ml 10	 ✓ Trichozole ✓ Trichozole ✓ Flagyl-S ✓ Flagyl 	
ORNIDAZOLE				
Tab 500 mg		10	 Arrow-Ornidaz 	ole
Antituberculotics and Antileprotics Note: There is no co-payment charge for all pharmaceuticals liste immigration status. CLOFAZIMINE – Retail pharmacy-Specialist a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendation dermatologist.	on of, an infectious	disease ph	nysician, clinical micr	
* Cap 50 mg	442.00	100	 Lamprene S29 	
CYCLOSERINE – Retail pharmacy-Specialist a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendation respiratory physician. Cap 250 mg		disease ph 100	nysician, clinical micr	obiologist oi
DAPSONE – Retail pharmacy-Specialist			-	
a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendation dermatologist Tab 25 mg		disease ph 100	nysician, clinical micr	obiologist o
Tab 100 mg		100	✓ Dapsone	

	Subsidy (Manufacturer's Pric \$	e) Si Per	Fully Brand ubsidised Gene V Manu	
ETHAMBUTOL HYDROCHLORIDE – Retail pharmacy-Speci	alist			
a) No patient co-payment payable	detion of on infection.		where the all all all all all all all all all al	
b) Prescriptions must be written by, or on the recomment respiratory physician	dation of, an infectiou	s disease	pnysician, ciini	cal microbiologist or
Tab 100 mg	48.01	56	🗸 Myamb	utol
Tab 400 mg		56	✓ Myamb	
ISONIAZID – Retail pharmacy-Specialist			·,	
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommend	ation of, an internal me	edicine phy	vsician, paediati	ician. clinical micro-
biologist, dermatologist or public health physician			,,.	,.
* Tab 100 mg		100	✓ PSM	
* Tab 100 mg with rifampicin 150 mg		100	 <u>Rifinah</u> 	
 * Tab 150 mg with rifampicin 300 mg 	170.60	100	 <u>Rifinah</u> 	
PARA-AMINO SALICYLIC ACID – Retail pharmacy-Specialisi	:			
a) No patient co-payment payable				
b) Specialist must be an infectious disease specialist, clini				
Grans for oral liq 4 g sachet		30	Paser §	29
PROTIONAMIDE – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Specialist must be an infectious disease specialist, clini	cal microbiologist or re	spiratory s	specialist.	
Tab 250 mg		100	Peteha	S29
PYRAZINAMIDE – Retail pharmacy-Specialist				
 a) No patient co-payment payable 				
b) Prescriptions must be written by, or on the recommen	dation of, an infectiou	s disease	physician, clini	cal microbiologist of
respiratory physician	,			
* Tab 500 mg – For pyrazinamide oral liquid formulation re manual 2		100		
page 213		100	🖌 AFT-Py	razinamide
RIFABUTIN – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommer	idation of, an infectiou	is disease	physician, resp	piratory physician oi
gastroenterologist * Cap 150 mg – For rifabutin oral liquid formulation refer, pa	200			
213		30	🖌 Mycobi	itin
		00	• <u>mycobi</u>	
RIFAMPICIN – Subsidy by endorsement				
 a) No patient co-payment payable b) For confirmed recurrent Staphylococcus aureus infection 	a in combination with a	thar affact	ivo onti stonbulo	access antimicrobia
based on susceptibilities and the prescription is endorse				
Specialist. Specialist must be an internal medicine physical				
health physician.		3,		,.
* Tab 600 mg		30	✓ <u>Rifadin</u>	
* Cap 150 mg		100	 Rifadin 	
* Cap 300 mg		100	 Rifadin 	
* Oral liq 100 mg per 5 ml	12.00	60 ml	 <u>Rifadin</u> 	
(Rifadin Tab 600 mg to be delisted 1 July 2016)				

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	Brand or Generic Manufacturer
Antivirals			
For eye preparations refer to Eye Preparations, Anti-Infective Pre-	eparations, page 205		
Hepatitis B Treatment			
ADEFOVIR DIPIVOXIL – Special Authority see SA0829 below - Tab 10 mg		30 🖌 H	epsera
 SA0829 Special Authority for Subsidy Initial application only from a gastroenterologist or infectious di the following criteria: All of the following: Patient has confirmed Hepatitis B infection (HBsAg+); a Documented resistance to lamivudine, defined as: Patient has raised serum ALT (> 1 × ULN); and 	Ind		
 3 Patient has HBV DNA greater than 100,000 copies per 4 Detection of M204I or M204V mutation; and 5 Either: 5.1 Both: 5.1.1 Patient is cirrhotic; and 5.1.2 adefovir dipivoxil to be used in combination 5.2 Both: 5.2.1 Patient is not cirrhotic; and 5.2.2 adefovir dipivoxil to be used as monother 	on with lamivudine; or	fold over nadir; a	nd
Renewal only from a gastroenterologist or infectious disease s treating physician, treatment remains appropriate and patient is Notes: Lamivudine should be added to adefovir dipivoxil if a pat as: i) raised serum ALT (> 1 × ULN); and ii) HBV DNA greater than 100,000 copies per mL, or viral iii) Detection of N236T or A181T/V mutation.	benefiting from treatme tient develops documer	nt. Ited resistance to	
Adefovir dipivoxil should be stopped 6 months following HBeAg s adefovir dipivoxil. The recommended dose of adefovir dipivoxil is no more than 10 In patients with renal insufficiency adefovir dipivoxil dose should Adefovir dipivoxil should be avoided in pregnant women and chi	mg daily. be reduced in accorda		
ENTECAVIR – Special Authority see SA1361 below – Retail ph Tab 0.5 mg	armacy	30 🖌 B	araclude
► SA1361 Special Authority for Subsidy Initial application only from a gastroenterologist or infectious notified for applications meeting the following criteria: All of the following:	disease specialist. App	provals valid with	out further renewal unless
 Patient has confirmed Hepatitis B infection (HBsAg pos Patient is Hepatitis B nucleoside analogue treatment-na Entecavir dose 0.5 mg/day; and Either: 		onths); and	
4.1 ALT greater than upper limit of normal; or			continued

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- 4.2 Bridging fibrosis (Metavir stage 3 or greater or moderate fibrosis) or cirrhosis on liver histology; and
- 5 Either:
 - 5.1 HBeAg positive; or
 - 5.2 patient has \geq 2,000 IU HBV DNA units per ml and fibrosis (Metavir stage 2 or greater) on liver histology; and
- 6 No continuing alcohol abuse or intravenous drug use; and
- 7 Not co-infected with HCV, HIV or HDV; and
- 8 Neither ALT nor AST greater than 10 times upper limit of normal; and
- 9 No history of hypersensitivity to entecavir; and
- 10 No previous documented lamivudine resistance (either clinical or genotypic).

Notes:

- Entecavir should be continued for 6 months following documentation of complete HBeAg seroconversion (defined as loss
 of HBeAg plus appearance of anti-HBe plus loss of serum HBV DNA) for patients who were HBeAg positive prior to
 commencing this agent. This period of consolidation therapy should be extended to 12 months in patients with advanced
 fibrosis (Metavir Stage F3 or F4).
- Entecavir should be taken on an empty stomach to improve absorption.

LAMIVUDINE - Special Authority see SA1360 below - Retail pharmacy

Tab 100 mg6.00	28	✓ Zeffix
Oral liq 5 mg per ml270.00	240 ml	✓ Zeffix

➡SA1360 Special Authority for Subsidy

Initial application only from a gastroenterologist, infectious disease specialist, paediatrician, general physician or medical practitioner on the recommendation of a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 HBV DNA positive cirrhosis prior to liver transplantation; or
- 2 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or
- 3 Hepatitis B virus naive patient who has received a liver transplant from an anti-HBc (Hepatitis B core antibody) positive donor; or
- 4 Hepatitis B surface antigen (HbsAg) positive patient who is receiving chemotherapy for a malignancy, or high dose steroids (at least 20mg/day for at least 7 days), or who has received such treatment within the previous two months; or
- 5 Hepatitis B surface antigen positive patient who is receiving anti tumour necrosis factor treatment; or
- 6 Hepatitis B core antibody (anti-HBc) positive patient who is receiving rituximab plus high dose steroids (e.g. R-CHOP).

Renewal only from a gastroenterologist, infectious disease specialist, paediatrician, general physician or medical practitioner on the recommendation of a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

Renewal for patients who have maintained continuous treatment and response to lamivudine

- 1 All of the following:
 - 1.1 Have maintained continuous treatment with lamivudine; and
 - 1.2 Most recent test result shows continuing biochemical response (normal ALT); and
 - 1.3 HBV DNA <100,000 copies per ml by quantitative PCR at a reference laboratory; or

Renewal when given in combination with adefovir dipivoxil for patients with cirrhosis and resistance to lamivudine

- 2 All of the following:
 - 2.1 Lamivudine to be used in combination with adefovir dipivoxil; and
 - 2.2 Patient is cirrhotic; and
 - Documented resistance to lamivudine, defined as:
 - 2.3 Patient has raised serum ALT (> 1 $\times\,$ ULN); and

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- 2.4 Patient has HBV DNA greater than 100,000 copies per mL, or viral load = 10 fold over nadir; and 2.5 Detection of M204U mutation; or
- 2.5 Detection of M204I or M204V mutation; or

Renewal when given in combination with adefovir dipivoxil for patients with resistance to adefovir dipivoxil 3 All of the following:

- 3.1 Lamivudine to be used in combination with a defovir dipivoxil; and
- Documented resistance to adefovir, defined as:
- 3.2 Patient has raised serum ALT (> 1 $\times\,$ ULN); and
- 3.3 Patient has HBV DNA greater than 100,000 copies per mL, or viral load = 10 fold over nadir; and
- 3.4 Detection of N236T or A181T/V mutation.

Herpesvirus Treatments

ACICLOVIR

*	Tab dispersible 200 mg	1.78	25	🖌 Lovir
*	Tab dispersible 400 mg	5.98	56	Lovir
*	Tab dispersible 800 mg	6.64	35	✓ Lovir
VA	LACICLOVIR – Special Authority see SA1363 below – Retail	pharmacy		
	Tab 500 mg	6.42	30	Vaclovir
	-	102.72		Valtrex
	Tab 1,000 mg	12.75	30	Vaclovir

SA1363 Special Authority for Subsidy

Initial application — (recurrent genital herpes) from any medical practitioner. Approvals valid for 12 months where the patient has genital herpes with 2 or more breakthrough episodes in any 6 month period while treated with aciclovir 400 mg twice daily.

Renewal — (recurrent genital herpes) from any medical practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (ophthalmic zoster) from any medical practitioner. Approvals valid without further renewal unless notified where the patient has previous history of ophthalmic zoster and the patient is at risk of vision impairment.

Initial application — (CMV prophylaxis) from any medical practitioner. Approvals valid for 3 months where the patient has undergone organ transplantation.

Initial application — (immunocompromised patients) from any medical practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patients is immunocompromised; and
- 2 Patient has herpes zoster; and
- 3 Valaciclovir is to be given for a maximum of 7 days per course.

Valcyte

60

➡SA1404 Special Authority for Subsidy

Initial application — (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months where the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.

Renewal — (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis; and
- 2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin.

Subs	sidy Fu	ly Brand or	
(Manufactur	urer's Price) Subsidise	d Generic	
\$	\$ Per o	 Manufacturer 	

continued...

Initial application — (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 Patient has undergone a solid organ transplant and received valganciclovir under Special Authority more than 2 years ago (27 months); and
- 2 Patient has received anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

Renewal — (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist. Approvals valid for 3 months where the patient has received a further course of anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

Initial application — (Lung transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has undergone a lung transplant; and
- 2 Either:
 - 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
 - 2.2 The recipient is cytomegalovirus positive.

Initial application — (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Renewal — (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Note: for the purpose of this Special Authority "immunocompromised" includes transplant recipients, patients with immunosuppressive diseases (e.g. HIV) or those receiving immunosuppressive treatment for other conditions.

Hepatitis B/ HIV/AIDS Treatment

TENOFOVIR DISOPROXIL FUMARATE – Subsidy by endorsement; can be waived by Special Authority see SA1362 on the next page

Endorsement for treatment of HIV: Prescription is deemed to be endorsed if tenofovir disoproxil fumarate is co-prescribed with another anti-retroviral subsidised under Special Authority SA1364 and the prescription is annotated accordingly by the Pharmacist or endorsed by the prescriber.

Note: Tenofovir disoproxil fumarate prescribed under endorsement for the treatment of HIV is included in the count of up to 4 subsidised antiretrovirals for the purposes of Special Authority SA1364, page 107

Tab 300 mg	531.00	30	Viread
------------	--------	----	--------

Subsidy	Fu	lly Brand or	
(Manufacturer's Price)	Subsidise	d Generic	
\$	Per	 Manufacturer 	

SA1362 Special Authority for Waiver of Rule

Initial application — (Chronic Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following:

- 1 All of the following:
 - 1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
 - 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
 - 1.3 HBV DNA greater than 20,000 IU/mL or increased \geq 10 fold over nadir; and
 - 1.4 Any of the following:
 - 1.4.1 Lamivudine resistance detection of M204I/V mutation; or
 - 1.4.2 Adefovir resistance detection of A181T/V or N236T mutation; or
 - 1.4.3 Entecavir resistance detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or
- 2 Patient is either listed or has undergone liver transplantation for HBV; or
- 3 Patient has decompensated cirrhosis with a Mayo score >20.

Initial application — (Pregnant, Active hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 12 months for applications meeting the following criteria:

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA > 20,000 IU/mL and ALT > ULN.

Renewal — (Confirmed Hepatitis B following funded tenofovir treatment for pregnancy within the previous two years) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
 - 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
 - 1.3 HBV DNA greater than 20,000 IU/mL or increased \geq 10 fold over nadir; and
 - 1.4 Any of the following:
 - 1.4.1 Lamivudine resistance detection of M204I/V mutation; or
 - 1.4.2 Adefovir resistance detection of A181T/V or N236T mutation; or
 - 1.4.3 Entecavir resistance detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or
- 2 Patient is either listed or has undergone liver transplantation for HBV.

Renewal — (Subsequent pregnancy or Breastfeeding, Active hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 Patient is HBsAg positive and pregnant or breastfeeding; and
- 2 HBV DNA > 20,000 IU/mL and ALT > ULN.

Initial application — (Pregnant, prevention of vertical transmission) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA > 20 million IU/mL and ALT normal.

Renewal — (Subsequent pregnancy, prevention of vertical transmission) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 6 months for applications meeting the following criteria: Both:

336

Victrelis

Subsidy		Fully	Brand or	
(Manufacturer's Price	5	Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA > 20 million IU/mL and ALT normal.

Notes:

- Tenofovir disoproxil fumarate should be stopped 6 months following HBeAg seroconversion for patients who were HBeAg
 positive prior to commencing this agent and 6 months following HBsAg seroconversion for patients who were HBeAg
 negative prior to commencing this agent.
- The recommended dose of Tenofovir disoproxil fumarate for the treatment of all three indications is 300 mg once daily.
- In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Tenofovir disoproxil fumarate dose should be reduced in accordance with the approved Medsafe datasheet guidelines.
- Tenofovir disoproxil fumarate is not approved for use in children.

Hepatitis C Treatment

BOCEPREVIR - Special Authority see SA1402 below - Retail pharmacy

Cap 200 mg – Wastage claimable – see rule 3.3.2 on page

SA1402 Special Authority for Subsidy

Initial application — (chronic hepatitis C - genotype 1, first-line) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has not received prior pegylated interferon treatment; and
- 3 Patient has IL-28B genotype CT or TT; and
- 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and
- 5 Patient is hepatitis C protease inhibitor treatment-naive; and
- 6 Maximum of 44 weeks therapy.

Initial application — (chronic hepatitis C - genotype 1, second-line) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria: All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has received pegylated interferon treatment; and
- 3 Any of the following:
 - 3.1 Patient was a responder relapser; or
 - 3.2 Patient was a partial responder; or
 - 3.3 Patient received pegylated interferon prior to 2004; and
- 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and
- 5 Maximum of 44 weeks therapy.

Notes:

- Due to risk of severe sepsis boceprevir should not be initiated if either Platelet count < 100 x10⁹ /l or Albumin <35 g/l
- · The wastage rule applies to boceprevir to allow dispensing to occur more frequently than monthly

Antiretrovirals

➡SA1364 Special Authority for Subsidy

Initial application — (Confirmed HIV) only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

1 Confirmed HIV infection; and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

2 Any of the following:

- 2.1 Symptomatic patient; or
- 2.2 Patient aged 12 months and under; or
- 2.3 Both:
 - 2.3.1 Patient aged 1 to 5 years; and
 - 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts < 1000 cells/mm³; or
 - 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
 - 2.3.2.3 Viral load counts > 100000 copies per ml; or

2.4 Both:

- 2.4.1 Patient aged 6 years and over; and
- 2.4.2 CD4 counts $< 500 \text{ cells/mm}^3$.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Confirmed HIV) only from a named specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Prevention of maternal transmission) only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Some antiretrovirals are unapproved or contraindicated for this indication. Practitioners prescribing these medications should exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of a Pharmaceutical for an indication for which it is not approved or contraindicated.

Initial application — (post-exposure prophylaxis following non-occupational exposure to HIV) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria:

- Both:
 - 1 Treatment course to be initiated within 72 hours post exposure; and
 - 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🖌	Manufacturer	

continued...

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (second or subsequent post-exposure prophylaxis) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria:

- Both:
 - 1 Treatment course to be initiated within 72 hours post exposure; and
 - 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Initial application — (Percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Second or subsequent percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Non-nucleosides Reverse Transcriptase Inhibitors

EFAVIRENZ - Special Authority see SA1364 on page 10	07 – Retail pharmacy		
Tab 50 mg	63.38	30	Stocrin S29
Tab 200 mg		90	✓ <u>Stocrin</u>
Tab 600 mg	63.38	30	✓ <u>Stocrin</u>
Oral liq 30 mg per ml		180 ml OP	✓ Stocrin S29
ETRAVIRINE - Special Authority see SA1364 on page 1	07 – Retail pharmacy		
Tab 200 mg	770.00	60	✓ Intelence
NEVIRAPINE - Special Authority see SA1364 on page 1	07 – Retail pharmacy		
Tab 200 mg	65.00	60	Nevirapine
Oral suspension 10 mg per ml		240 ml	<u>Alphapharm</u> ✔ Viramune Suspension

Nucleosides Reverse Transcriptase Inhibitors

ABACAVIR SULPHATE - Special Authority see SA1364 on	page 107 - Retail ph	narmacy		
Tab 300 mg		60	Ziagen	
Oral liq 20 mg per ml	256.31	240 ml OP	 Ziagen 	
ABACAVIR SULPHATE WITH LAMIVUDINE - Special Auth	ority see SA1364 on	page 107 - Re	tail pharmacy	
Note: abacavir with lamivudine (combination tablets) c	ounts as two anti-rel	troviral medicat	ions for the purpose	s of the anti-

renovital Special Authority.		
Tab 600 mg with lamivudine 300 mg	 30	Kivexa

	Subsidy (Manufacturer's Pr \$	ice) Sub Per	Fully Brand or osidised Generic Manufacturer
DIDANOSINE [DDI] - Special Authority see SA1364 on page 107	/ – Retail pharma	су	
Cap 125 mg		30	Videx EC
Cap 200 mg		30	Videx EC
Cap 250 mg		30	Videx EC
Cap 400 mg		30	Videx EC
EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPR Retail pharmacy Note: Efavirenz with emtricitabine and tenofovir disoproxil fum of the anti-retroviral Special Authority Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil	arate counts as t	hree anti-retro	oviral medications for the purpose
fumarate 300 mg		30	Atripla
EMTRICITABINE – Special Authority see SA1364 on page 107 – Cap 200 mg		30	✓ Emtriva
EMTRICITABINE WITH TENOFOVIR DISOPROXIL FUMARATE Note: Emtricitabine with tenofovir disoproxil fumarate counts retroviral Special Authority	s as two anti-retro	oviral medicat	tions for the purposes of the ant
Tab 200 mg with tenofovir disoproxil fumarate 300 mg	838.20	30	Truvada
AMIVUDINE - Special Authority see SA1364 on page 107 - Rei	tail pharmacy		
Tab 150 mg	52.50	60	Lamivudine
			Alphapharm
Oral liq 10 mg per ml	102.50	240 ml OP	✓ <u>3TC</u>
STAVUDINE [D4T] - Special Authority see SA1364 on page 107	 Retail pharmac 	у	
Cap 40 mg	503.80	60	✓ Zerit
Powder for oral soln 1 mg per ml	100.76	200 ml OP	Zerit S29
ZIDOVUDINE [AZT] - Special Authority see SA1364 on page 107	7 – Retail pharma	CV	
Cap 100 mg	•	100	✓ <u>Retrovir</u>
Oral liq 10 mg per ml		200 ml OP	✓ Retrovir
ZIDOVUDINE [AZT] WITH LAMIVUDINE – Special Authority see Note: zidovudine [AZT] with lamivudine (combination tablets) anti-retroviral Special Authority. Tab 300 mg with lamivudine 150 mg	counts as two ar		. ,
Protease Inhibitors			
TAZANAVIR SULPHATE – Special Authority see SA1364 on pag	ge 107 – Retail pl	harmacy	
Cap 150 mg	568.34	60	✓ Reyataz
Cap 200 mg	757.79	60	✓ Reyataz
DARUNAVIR – Special Authority see SA1364 on page 107 – Reta	ail pharmacy		
Tab 400 mg		60	Prezista
Tab 600 mg		60	✓ Prezista
NDINAVIR – Special Authority see SA1364 on page 107 – Retail	l pharmacy		
Cap 200 mg		360	Crixivan
		180	 Crixivan
Cap 400 mg			
	n nago 107 _ Do	tail nharmaou	
OPINAVIR WITH RITONAVIR – Special Authority see SA1364 o		•	
Cap 400 mg OPINAVIR WITH RITONAVIR – Special Authority see SA1364 o Tab 100 mg with ritonavir 25 mg Tab 200 mg with ritonavir 50 mg		tail pharmacy 60 120	 ✓ Kaletra ✓ Kaletra

	Subsidy (Manufacturer's Price) \$		Ily Brand or ed Generic ✔ Manufacturer
RITONAVIR – Special Authority see SA1364 on page 107 – Re Tab 100 mg Oral liq 80 mg per ml	43.31		 Norvir Norvir
Strand Transfer Inhibitors			
RALTEGRAVIR POTASSIUM – Special Authority see SA1364 o Tab 400 mg			' Isentress
Antiretrovirals - Additional Therapies			
HIV Fusion Inhibitors			
 ENFUVIRTIDE - Special Authority see SA0845 below - Retail Powder for inj 90 mg per ml × 60 ⇒SA0845 Special Authority for Subsidy Initial application only from a named specialist. Approvals value All of the following: 	2,380.00		Fuzeon g the following criteria:
 Confirmed HIV infection; and Enfuvirtide to be given in combination with optimized ba the patient has never previously been exposed to) for tr Either: 		luding at least	1 other antiretroviral drug that
3.1 Patient has evidence of HIV replication, despite3.2 Patient has treatment-limiting toxicity to previou		and	
4 Previous treatment with 3 different antiretroviral regime 5 All of the following:	•		
5.1 Previous treatment with a non-nucleoside rever5.2 Previous treatment with a nucleoside reverse tr5.3 Previous treatment with a protease inhibitor has	anscriptase inhibitor h		nd
Renewal only from a named specialist. Approvals valid for 1 years Both:	ar for applications mee	ting the followi	ng criteria:
1 Evidence of at least a 10 fold reduction in viral load at 1 2 The treatment remains appropriate and the patient is b		nt.	
Immune Modulators			
Guidelines for the use of interferon in the treatment of hepa Physicians considering treatment of patients with hepatitis C sho physician. All subjects undergoing treatment require careful mor Patients should be otherwise fit. Hepatocellular carcinoma should be excluded by ultrasound exa Criteria for Treatment	uld discuss cases with nitoring for side effects		logist or an infectious disease

- a) Diagnosis
 - Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by a supplementary RIBA test; or
 - · PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or
 - Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR for HCV RNA but with a liver biopsy consistent with 2(b) following.

Exclusion Criteria

	Subsidy (Manufacturer's Price) \$	Su Per	Fully bsidised	Brand or Generic Manufacturer
continued				
a) Autoimmune liver disease. (Interferon may exacerbate at	utoimmune liver dise	ase as v	vell as ot	her autoimmune disease
such as thyroid disease).				
b) Pregnancy. c) Neutropenia (<2.0 \times 10 ⁹) and/or thrombocytopenia.				
 d) Continuing alcohol abuse and/or continuing intravenous d 	rua users.			
Dosage				
The current recommended dosage is 3 million units of interferon a	lfa-2a or interferon a	lfa-2b ad	ministere	ed subcutaneously 3 time
a week for 52 weeks (twelve months)				
Exit Criteria				
The patient's response to interferon treatment should be reviewed discontinued in patients who do not show a substantial reduction (
NTERFERON ALFA-2A – PCT – Retail pharmacy-Specialist				ioroi al ino olago.
a) See prescribing guideline on the previous page				
b) Prescriptions must be written by, or on the recommendation	of. an internal medi	cine phys	sician or	ophthalmologist
Inj 3 m iu prefilled syringe		1		oferon-A
NTERFERON ALFA-2B – PCT – Retail pharmacy-Specialist				
a) See prescribing guideline on the previous page				
b) Prescriptions must be written by, or on the recommendation		cine phys	sician or	ophthalmologist
Inj 18 m iu, 1.2 ml multidose pen		1		tron-A
Inj 30 m iu, 1.2 ml multidose pen		1		itron-A
Inj 60 m iu, 1.2 ml multidose pen		1		tron-A
PEGYLATED INTERFERON ALFA-2A – Special Authority see SA	1400 below – Retail	pharmad	;y	
See prescribing guideline on the previous page Inj 135 mcg prefilled syringe	1 449 00	4		eqasys
Inj 180 mcg prefilled syringe		4		egasys egasys
Inj 135 mcg prefilled syringe \times 4 with ribavirin tab 200 mg \times		·	• -	<u>uuju</u>
112	1,799.68	1 OP	🖌 P	egasys RBV
				Combination Pack
Inj 135 mcg prefilled syringe \times 4 with ribavirin tab 200 mg \times				
168	1,975.00	1 OP		egasys RBV
Inj 180 mcg prefilled syringe $ imes$ 4 with ribavirin tab 200 mg $ imes$				Combination Pack
112	1,159,84	1 OP	V P	egasys RBV
				Combination Pack
Inj 180 mcg prefilled syringe \times 4 with ribavirin tab 200 mg \times				
168	1,290.00	1 OP		egasys RBV
				Combination Pack

➡SA1400 Special Authority for Subsidy

Initial application — (chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant) from any specialist. Approvals valid for 18 months for applications meeting the following criteria: Both:

- 1 Any of the following:
 - 1.1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
 - 1.2 Patient has chronic hepatitis C and is co-infected with HIV; or
 - 1.3 Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant; and
- 2 Maximum of 48 weeks therapy.

Notes:

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🖌	Manufacturer	

continued...

- Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
- Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml

Renewal — (Chronic hepatitis C - genotype 1 infection) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

- All of the following:
 - 1 Patient has chronic hepatitis C, genotype 1; and
 - 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
 - 3 Either:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; and
 - 4 Patient is to be treated in combination with boceprevir; and
 - 5 Maximum of 48 weeks therapy.

Initial application — (Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Any of the following:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; or
 - 3.3 Patient received interferon treatment prior to 2004; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

Initial application — (chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and
- 2 Maximum of 6 months therapy.

Initial application — (Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naive; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log10 IU/ml; and
- 5 Either:
 - 5.1 HBeAg positive; or
 - 5.2 serum HBV DNA ≥ 2,000 units/ml and significant fibrosis (≥ Metavir Stage F2 or moderate fibrosis); and
- 6 Compensated liver disease; and
- 7 No continuing alcohol abuse or intravenous drug use; and
- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon; and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	

continued...

11 Maximum of 48 weeks therapy.

Notes:

- Approved dose is 180 mcg once weekly.
- The recommended dose of Pegylated Interferon alfa-2a is 180 mcg once weekly.
- In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon-alfa 2a dose should be reduced to 135 mcg once weekly.
- In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines.
- Pegylated Interferon-alfa 2a is not approved for use in children.

Urinary Tract Infections

HEXAMINE HIPPURATE			
* Tab 1 g	18 /0	100	
* Tau Ty		100	
	(38.10)		Hiprex
NITROFURANTOIN			
* Tab 50 mg - For nitrofurantoin oral liquid formulation refer,			
page 213		100	Nifuran
* Tab 100 mg		100	 Nifuran
NORFLOXACIN			
Tab 400 mg – Subsidy by endorsement		100	Arrow-Norfloxacin
Only if prescribed for a patient with an uncomplicated urina	ary tract infectior	n that is unre	sponsive to a first line agent or with

proven resistance to first line agents and the prescription is endorsed accordingly.

	Subsidy		Fully Brand or
	(Manufacturer's Price) \$) Per	Subsidised Generic Manufacturer
Anticholinesterases	•	-	
NEOSTIGMINE METILSULFATE	~~~~		<pre>/ • • •</pre>
Inj 2.5 mg per ml, 1 ml ampoule		50	AstraZeneca
PYRIDOSTIGMINE BROMIDE			
▲ Tab 60 mg		100	Mestinon
Non-Steroidal Anti-Inflammatory Drugs			
DICLOFENAC SODIUM			
* Tab EC 25 mg	1.30	50	Diclofenac Sandoz
-	2.60	100	
	(4.00)		Apo-Diclo
Diclofenac Sandoz to be Sole Supply on 1 March 2016			
* Tab 50 mg dispersible		20	Voltaren D
* Tab EC 50 mg		50	 Diclofenac Sandoz
	10.00	500	
	(16.00)		Apo-Diclo
Diclofenac Sandoz to be Sole Supply on 1 March 2016	15.00		
* Tab long-acting 75 mg		500	✓ Apo-Diclo SR
And Diele CD to be Cale Supply on 1 March 2016			Diclax SR
Apo-Diclo SR to be Sole Supply on 1 March 2016	26.20	500	✔ Apo-Diclo SR
* Tab long-acting 100 mg	20.20	500	✓ Apo-Dicio Sh ✓ Diclax SR
Apo-Diclo SR to be Sole Supply on 1 March 2016			UCIAX Sh
 * Inj 25 mg per ml, 3 ml ampoule – Up to 5 inj available on a 			
PSO		5	Voltaren
* Suppos 12.5 mg		10	Voltaren
* Suppos 25 mg		10	Voltaren
* Suppos 50 mg - Up to 10 supp available on a PSO	4.22	10	Voltaren
* Suppos 100 mg	7.00	10	Voltaren
(Apo-Diclo Tab EC 25 mg to be delisted 1 March 2016)			
(Apo-Diclo Tab EC 50 mg to be delisted 1 March 2016)			
(Diclax SR Tab long-acting 75 mg to be delisted 1 March 2016)			
(Diclax SR Tab long-acting 100 mg to be delisted 1 March 2016)			
IBUPROFEN			
* Tab 200 mg	9.45	1,000	✓ Ibugesic
* Tab long-acting 800 mg	7.99	30	Brufen SR
* Oral liq 20 mg per ml	1.89	200 ml	Fenpaed
KETOPROFEN			
* Cap long-acting 200 mg		28	Oruvail SR
MEFENAMIC ACID			
* Cap 250 mg		50	
	(9.16)		Ponstan
	0.50	20	
	(5.60)		Ponstan

	Subsidy (Manufacturer's Price \$) Per	Fully Subsidised	Generic
NAPROXEN * Tab 250 mg * Tab 500 mg * Tab long-acting 750 mg * Tab long-acting 1 g SULINDAC * Tab 100 mg * Tab 200 mg TENOXICAM * Tab 20 mg		500 250 90 90 50 50 20		<u>Noflam 250</u> Noflam 500 Naprosyn SR 750 Naprosyn SR 1000 Aclin Aclin Reutenox
* Inj 20 mg vial NSAIDs Other	9.95	1	•	AFT
 MELOXICAM – Special Authority see SA1034 below – Retail p * Tab 7.5 mg >SA1034 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals vathe following criteria: All of the following: The patient has moderate to severe haemophilia with factor; and The patient has haemophilic arthropathy; and Pain and inflammation associated with haemophilic art options, or alternative funded treatment options are co 	alid without further ren less than or equal to hropathy is inadequate	o 5% of	less notifi normal ci	irculating functional clotting
Topical Products for Joint and Muscular Pain CAPSAICIN Crm 0.025% – Special Authority see SA1289 below – Ret pharmacy	6.95	25 g OP 15 g OP		Zostrix Zostrix
► SA1289 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals we osteoarthritis that is not responsive to paracetamol and oral nor				

Antirheumatoid Agents

AURANOFIN		
Tab 3 mg68.99	60	Ridaura s29 S29
HYDROXYCHLOROQUINE		
* Tab 200 mg10.50	100	Plaquenil
LEFLUNOMIDE		
Tab 10 mg55.00	30	Arava
Tab 20 mg	30	Arava
Tab 100 mg54.44	3	🖌 Arava
PENICILLAMINE		
Tab 125 mg61.93	100	D-Penamine
Tab 250 mg	100	D-Penamine

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	
SODIUM AUROTHIOMALATE					
Inj 10 mg in 0.5 ml ampoule	76.87	10	🖌 M	lyocrisin	
Inj 20 mg in 0.5 ml ampoule	113.17	10	🖌 M	lyocrisin	
Inj 50 mg in 0.5 ml ampoule		10	🖌 M	lyocrisin	

Drugs Affecting Bone Metabolism

Alendronate for Osteoporosis

SA1039 Special Authority for Subsidy

Initial application — (Underlying cause – Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score \leq -3.0 (see Note); or
- 5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause Osteoporosis) or raloxifene.

Initial application — (Underlying cause – glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The patient is receiving systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
 - 2.1 The patient has documented BMD \geq 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for zoledronic acid (Underlying cause glucocorticosteroid therapy) or raloxifene.

Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year where the patient is continuing systemic glucocorticosteriod therapy (\geq 5 mg per day prednisone equivalents).

Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - osteoporosis' criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score \leq -3.0 (see Note); or

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
(Included of Free)	Per 🖌	Manufacturer	

continued...

- 5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause Osteoporosis' criteria) or raloxifene.

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) In line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

ALE	NDRONATE SODIUM – Special Authority see SA1039 on the	previous page	e – Retail pharn	nacy	
*	Tab 70 mg		4	 Fosamax 	
ALE	NDRONATE SODIUM WITH CHOLECALCIFEROL – Special	Authority see	SA1039 on the	previous page - Retai	il pharmacy
*	Tab 70 mg with cholecalciferol 5,600 iu		4	Fosamax Plus	

Alendronate for Paget's Disease

SA0949 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Paget's disease; and
- 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or
 - 2.5 Preparation for orthopaedic surgery.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

	ENDRONATE SODIUM – Special Authority see SA0949 above – Retail pharmacy Tab 40 mg133.00	30	✓ Fosamax
0	ther Treatments		
*	DRONATE DISODIUM – See prescribing guideline below Tab 200 mg13.50 scribing Guidelines	100	✓ <u>Arrow-Etidronate</u>

Etidronate for osteoporosis should be prescribed for 14 days (400 mg in the morning) and repeated every three months. It should not be taken at the same time of the day as any calcium supplementation (minimum dose – 500 mg per day of elemental calcium). Etidronate should be taken at least 2 hours before or after any food or fluid, except water.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
PAMIDRONATE DISODIUM				
Inj 3 mg per ml, 10 ml vial	6.80	1	✓ P	amisol
Inj 6 mg per ml, 10 ml vial		1	V Pa	amisol
Inj 9 mg per ml, 10 ml vial		1	✓ P	amisol
RALOXIFENE HYDROCHLORIDE - Special Authority see SA11	38 below – Retail pha	irmac	v	
* Tab 60 mg		28		vista

SA1138 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Notes); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score \leq -3.0 (see Notes); or
- 5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or
- 6 Patient has had a prior Special Authority approval for zoledronic acid (Underlying cause Osteoporosis) or alendronate (Underlying cause - Osteoporosis).

Notes:

- BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for raloxifene funding.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

RISEDRONATE SODIUM

Tab 35 mg4.00	0 4	1	 Risedronate Sandoz
TERIPARATIDE – Special Authority see SA1139 below – Retail pharmacy			
Inj 250 mcg per ml, 2.4 ml	0 1	1	 Forteo

SA1139 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria: All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and
- 3 The patient has had two or more fractures due to minimal trauma; and
- 4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Sub:		ully	Brand or
(Manufactu		sed	Generic
\$	\$ Per	r	Manufacturer

continued...

Notes:

- a) The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- b) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.
- c) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
- d) A maximum of 18 months of treatment (18 cartridges) will be subsidised.

ZOLEDRONIC ACID

SA1187 Special Authority for Subsidy

Initial application — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Paget's disease; and
- 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications; or
 - 2.5 Preparation for orthopaedic surgery; and
- 3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Initial application — (Underlying cause - Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score \leq -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause Osteoporosis) or raloxifene; and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

Initial application — (Underlying cause - glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

Subsidy		Fully Subsidised	Brand or
(Manufacturer's Price) \$	Per		Generic Manufacturer

continued...

- 1 The patient is receiving systemic glucocorticosteroid therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
 - 2.1 The patient has documented BMD \geq 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for alendronate (Underlying cause glucocorticosteroid therapy) or raloxifene; and
- 3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Renewal — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
 - 1.2 The patient's serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
 - 1.3 Symptomatic disease (prescriber determined); and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

The patient must not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is continuing systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents); and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

The patient must not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - osteoporosis' criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score \leq -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause Osteoporosis' criteria) or raloxifene; and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

Notes:

 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic	
(Manuadari strace) \$	Per	Vabbilaisea	Manufacturer	

continued...

- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Hyperuricaemia and Antigout

ALLOPURINOL			
* Tab 100 mg	15.11	1,000	Apo-Allopurinol
* Tab 300 mg - For allopurinol oral liquid formulation refer,			
page 213	15.91	500	Apo-Allopurinol
BENZBROMARONE - Special Authority see SA1537 below - Retail	pharmacy		
Tab 100 mg	45.00	100	Benzbromaron AL
			100 S29

➡SA1537 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has been diagnosed with gout; and
- 2 Any of the following:
 - 2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.3 Both:
 - 2.3.1 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Notes); and
 - 2.3.2 The patient has a rate of creatinine clearance greater than or equal to 20 ml/min; or
 - 2.4 All of the following:
 - 2.4.1 The patient is taking azathioprine and requires urate-lowering therapy; and
 - 2.4.2 Allopurinol is contraindicated; and
 - 2.4.3 Appropriate doses of probenecid are ineffective or probenecid cannot be used due to reduced renal function; and
- 3 The patient is receiving monthly liver function tests.

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefitting from the treatment; and
- 2 There is no evidence of liver toxicity and patient is continuing to receive regular (at least every three months) liver function tests.

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

Notes: Benzbromarone has been associated with potentially fatal hepatotoxicity.

In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

The New Zealand Rheumatology Association has developed information for prescribers which can be accessed from its website at www.rheumatology.org.nz/downloads/Benzbromarone-prescriber-information-NZRA-V2.pdf

COLCHICINE

* Tab 500 mcg1	10.08	100	Colgout
FEBUXOSTAT - Special Authority see SA1538 below - Retail pharmacy	1		-
Tab 80 mg		28	✓ Adenuric
Tab 120 mg	39.50	28	 Adenuric

SA1538 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient has been diagnosed with gout; and
- 2 Any of the following:
 - 2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.3 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note).

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from treatment.

Note: In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. The efficacy and safety of febuxostat have not been fully evaluated in patients with severe renal impairment (creatinine clearance less than 30 ml/minute). No dosage adjustment of febuxostat is necessary in patients with mild or moderate renal impairment. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

гп	OBENECID			
*	Tab 500 mg	55.00	100	Probenecid-AFT
N	uscle Relaxants			
BA	CLOFEN			
*	Tab 10 mg – For baclofen oral liquid formulation refer, page 213 Inj 0.05 mg per ml, 1 ml ampoule – Subsidy by endorsement		100 1	 ✓ Pacifen ✓ Lioresal Intrathecal
	Subsidised only for use in a programmable pump in patients caused intolerable side effects and the prescription is endors	s where oral ar	1 0	ents have been ineffective or have
	Inj 2 mg per ml, 5 ml ampoule – Subsidy by endorsement Subsidised only for use in a programmable pump in patients caused intolerable side effects and the prescription is endors	s where oral ar	1 0	Lioresal Intrathecal ents have been ineffective or have
DA 米 米	NTROLENE Cap 25 mg Cap 50 mg		100 100	✔ Dantrium✔ Dantrium

‡ safety cap *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per		Brand or Generic Manufacturer
ORPHENADRINE CITRATE Tab 100 mg		100	🗸 N	orflex

	Subsidy (Manufacturer's Price)		Fully Subsidised	
	\$	Per	~	Manufacturer
Agents for Parkinsonism and Related Disorders				
Dopamine Agonists and Related Agents				
AMANTADINE HYDROCHLORIDE				
▲ Cap 100 mg		60	V <u>9</u>	Symmetrel
APOMORPHINE HYDROCHLORIDE				
Inj 10 mg per ml, 2 ml ampoule	119.00	5	\checkmark	Apomine
BROMOCRIPTINE MESYLATE				
* Tab 2.5 mg		100	\checkmark	Apo-Bromocriptine
ENTACAPONE				_
▲ Tab 200 mg		100	~	Entapone
EVODOPA WITH BENSERAZIDE				
* Tab dispersible 50 mg with benserazide 12.5 mg		100		Madopar Rapid
 Cap 50 mg with benserazide 12.5 mg Cap 100 mg with benserazide 25 mg 		100 100		Madopar 62.5
 Cap 100 mg with benserazide 25 mg Cap long-acting 100 mg with benserazide 25 mg 		100		Madopar 125 Madopar HBS
 Cap 200 mg with benserazide 50 mg 		100		Madopar 250
EVODOPA WITH CARBIDOPA	20.00	100	•	
 Tab 100 mg with carbidopa 25 mg - For levodopa with car- 				
bidopa oral liquid formulation refer, page 213	20.00	100	~	Kinson
	20100			Sinemet
* Tab long-acting 200 mg with carbidopa 50 mg		100	~	Sinemet CR
* Tab 250 mg with carbidopa 25 mg		100	~	Sinemet
LISURIDE HYDROGEN MALEATE				
▲ Tab 200 mcg	25.00	30	~	Dopergin
PRAMIPEXOLE HYDROCHLORIDE				
▲ Tab 0.25 mg	7.20	100	~	Ramipex
▲ Tab 1 mg	24.39	100	~ [Ramipex_
ROPINIROLE HYDROCHLORIDE				
▲ Tab 0.25 mg	2.36	100		Apo-Ropinirole
▲ Tab 1 mg		100		Apo-Ropinirole
▲ Tab 2 mg		100		Apo-Ropinirole
▲ Tab 5 mg	14.48	100	V	Apo-Ropinirole
	40.00			
* Tab 5 mg		100		Apo-Selegiline
			~	Apo-Selegiline S29 S29
				323 328
	106.00	100		Toomor
▲ Tab 100 mg	126.20	100	V	Tasmar
Anticholinergics				
BENZTROPINE MESYLATE				
Tab 2 mg		60		Benztrop
Inj 1 mg per ml, 2 ml	95.00	5		Cogentin
a) Up to 5 inj available on a PSO				
b) Only on a PSO				

‡ safety cap *Three months or six months, as applicable, dispensed all-at-once ▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. 125

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
PROCYCLIDINE HYDROCHLORIDE	7.40	400	4.14	
Tab 5 mg		100	₩ K	emadrin
Agents for Essential Tremor, Chorea and Related	Disorders			
RILUZOLE – Special Authority see SA1403 below – Retail pharm Wastage claimable – see rule 3.3.2 on page 13 Tab 50 mg		56	✔ R	ilutek
► SA1403 Special Authority for Subsidy Initial application only from a neurologist or respiratory special following criteria: All of the following:				applications meeting the
 The patient has amyotrophic lateral sclerosis with disease The patient has at least 60 percent of predicted forced vit The patient has not undergone a tracheostomy; and The patient has not experienced respiratory failure; and Any of the following: 				initial application; and
5.1 The patient is ambulatory; or5.2 The patient is able to use upper limbs; or5.3 The patient is able to swallow.				
Renewal from any relevant practitioner. Approvals valid for 18 mon All of the following:	nths for applications	meetir	ng the follow	ving criteria:
 The patient has not undergone a tracheostomy; and The patient has not experienced respiratory failure; and Any of the following: 				
3.1 The patient is ambulatory; or3.2 The patient is able to use upper limbs; or3.3 The patient is able to swallow.				
TETRABENAZINE				
Tab 25 mg	118.00	112	✓ <u>M</u>	otetis
Anaesthetics				
Local				
LIDOCAINE [LIGNOCAINE] Gel 2%, 10 ml urethral syringe – Subsidy by endorsement a) Up to 5 each available on a PSO		10	√ P	
b) Subsidised only if prescribed for urethral or cervical adm	inistration and the pl	rescrip	tion is endo	orsed accordingly.
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE Oral (viscous) soln 2%		200 ml	✔ X	vlocaine Viscous
Inj 1%, 5 ml ampoule – Up to 25 inj available on a PSO		25 50		idocaine-Claris
	(35.00)			ylocaine
Inj 2%, 5 ml ampoule – Up to 5 inj available on a PSO		25		idocaine-Claris
Inj 1%, 20 ml ampoule – Up to 5 inj available on a PSO	2.40 12.00	1 5	V L	idocaine-Claris
	(20.00)	5	X	vlocaine
Inj 2%, 20 ml ampoule – Up to 5 inj available on a PSO	(/	1		idocaine-Claris

	Subsidy (Manufacturer's Price \$	e) Sub Per	Fully Brand or osidised Generic Manufacturer	
LIDOCAINE [LIGNOCAINE] WITH CHLORHEXIDINE				
Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes - Subsidy by endorsement a) Up to 5 each available on a PSO		10	✓ Pfizer	
b) Subsidised only if prescribed for urethral or cervical adr	ministration and the	prescription	is endorsed accordin	ngly.
Topical Local Anaesthetics				
►SA0906 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid condition requiring frequent injections or venepuncture. Renewal from any relevant practitioner. Approvals valid for 2 yes benefiting from treatment.	·			
LIDOCAINE [LIGNOCAINE] – Special Authority see SA0906 abo Crm 4% Crm 4% (5 g tubes)		cy 30 g OP 5	✓ LMX4 ✓ LMX4	
LIDOCAINE [LIGNOCAINE] WITH PRILOCAINE – Special Authors Crm 2.5% with prilocaine 2.5% Crm 2.5% with prilocaine 2.5% (5 g tubes)		ove – Retai 30 g OP 5	il pharmacy	
Analgesics				
For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, pa	age 115			
Non-opioid Analgesics				
For aspirin & chloroform application refer Standard Formulae, pag	ge 216			
* Tab EC 300 mg	2.00 (8.50)	100	Aspec 300	
* Tab dispersible 300 mg - Up to 30 tab available on a PSO	(/	100	 Ethics Aspirin 	L
CAPSAICIN – Subsidy by endorsement Subsidised only if prescribed for post-herpetic neuralgia or accordingly.				is endorsed
Crm 0.075%	12.50	45 g OP	Zostrix HP	
NEFOPAM HYDROCHLORIDE Tab 30 mg	23.40	90	🖌 Acupan	

	Subsidy		Fully Brand or
	(Manufacturer's F \$	Price) Sut Per	bsidised Generic Manufacturer
	Ψ	1.61	
PARACETAMOL			
* Tab 500 mg – Up to 30 tab available on a PSO	8.47	1,000	Pharmacare
★‡ Oral liq 120 mg per 5 mla) Up to 200 ml available on a PSO b) Not in combination	4.15	1,000 ml	✓ Paracare
*‡ Oral liq 250 mg per 5 ml	4.35	1,000 ml	 Paracare Double Strength
a) Up to 100 ml available on a PSO b) Not in combination			Strength
* Suppos 125 mg	3 69	10	✓ Gacet
- capped to my	7.38	20	
	(7.49)	20	Panadol
Gacet to be Sole Supply on 1 March 2016	(75)		
* Suppos 250 mg	3 79	10	✓ Gacet
	7.58	20	
	(14.40)	20	Panadol
Gacet to be Sole Supply on 1 March 2016	(14.40)		
 Suppos 500 mg Panadol Suppos 125 mg to be delisted 1 March 2016) 	12.60	50	✓ Paracare
(Panadol Suppos 250 mg to be delisted 1 March 2016)			
Opioid Analgesics			
CODEINE PHOSPHATE – Safety medicine; prescriber may dete	armina dispansing	n frequency	
Tab 15 mg		100	🖌 PSM
Tab 30 mg		100	✓ PSM
Tab 60 mg		100	✓ PSM
•	12.00	100	
	10.04		
Tab long-acting 60 mg	13.64	60	DHC Continus
ENTANYL			
 a) Only on a controlled drug form 			
b) No patient co-payment payable			
c) Safety medicine; prescriber may determine dispensing fre	equency		
Inj 50 mcg per ml, 2 ml ampoule	3.95	10	Boucher and Muir
Inj 50 mcg per ml, 10 ml ampoule	10.45	10	Boucher and Muir
Patch 12.5 mcg per hour	2.92	5	Fentanyl Sandoz
Patch 25 mcg per hour	3.66	5	Fentanyl Sandoz
Patch 50 mcg per hour	6.64	5	Fentanyl Sandoz
Patch 75 mcg per hour	0 18	5	Fentanyl Sandoz
· uten / e meg per neur		0	• I Childhyr Gandoz

		Subsidy (Manufacturer's P \$	rice) Su Per	Fully Brand or Ibsidised Generic Manufacturer
METHADONE HYDRO	CHI OBIDE	¥	1.01	
a) Only on a control				
b) No patient co-pa				
, , ,	; prescriber may determine dispensing	frequency		
	isly compounded methadone will only b		rate of the ch	neanest form available (methador
powder, not metha				
	hydrochloride oral liquid refer Standard	Formulae nade 216	3	
			, 10	✓ Methatabs
	nl		200 ml	✓ Biodone
	nl		200 ml	✓ Biodone Forte
			200 ml	✓ Biodone Extra Forte
	ml			
inj i u mg per mi,	ml		10	V AFI
IORPHINE HYDROC	HLORIDE			
a) Only on a contro	olled drug form			
b) No patient co-pa	ayment payable			
c) Safety medicine	; prescriber may determine dispensing	frequency		
	nl		200 ml	RA-Morph
	nl	14.00	200 ml	✓ RA-Morph
Oral liq 5 mg per r	nl		200 ml	✓ RA-Morph
	ml		200 ml	RA-Morph
				·
a) Only on a contr				
b) No patient co-p	, , ,			
	; prescriber may determine dispensing			4.0
	ease 10 mg		10	Sevredol
	mg		10	Arrow-Morphine LA
Tab immediate-rel	ease 20 mg	5.52	10	Sevredol
0 0	mg		10	Arrow-Morphine LA
	mg		10	Arrow-Morphine LA
Tab long-acting 10	0 mg	6.45	10	Arrow-Morphine LA
) mg		10	✓ <u>m-Eslon</u>
Cap long-acting 3) mg	2.50	10	✓ <u>m-Eslon</u>
Cap long-acting 6) mg	5.40	10	✓ <u>m-Eslon</u>
Cap long-acting 10	00 mg	6.38	10	✓ <u>m-Eslon</u>
Inj 5 mg per ml, 1 r	nl ampoule – Up to 5 inj available on a F	PSO12.48	5	✓ DBL Morphine
				Sulphate
Inj 10 mg per ml.	1 ml ampoule – Up to 5 inj available o	na		.
			5	DBL Morphine
				Sulphate
lni 15 ma per ml.	1 ml ampoule – Up to 5 inj available o	na		<u> </u>
, , ,			5	DBL Morphine
			U U	Sulphate
lni 30 ma ner ml	1 ml ampoule – Up to 5 inj available o	na		ouplied
			5	DBL Morphine
1.00			5	Sulphate
	r.			Jupilate
IORPHINE TARTRAT				
a) Only on a contr				
 b) No patient co-patient 				
	; prescriber may determine dispensing			
Ini 80 ma per ml. 1	.5 ml		5	Hospira
	5 ml		5	✓ Hospira

‡ safety cap *Three months or six months, as applicable, dispensed all-at-once ▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. 129

	Subsidy		Fully Brand	d or
	(Manufacturer's Price \$	e) Per	Subsidised Gene	ric lfacturer
YCODONE HYDROCHLORIDE	•			
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequ	iency			
Tab controlled-release 5 mg		20	OxyCor	ntin
Tab controlled-release 10 mg		20		
		20	Contr	olledRelease ts(BNM)
Tab controlled-release 20 mg	11.50	20		lone olledRelease ts(BNM)
Tab controlled-release 40 mg		20	 Oxycod Contr 	
Tab controlled-release 80 mg	34.00	20		lone olledRelease ts(BNM)
Cap immediate-release 5 mg	1.98	20	OxyNor	m
Cap immediate-release 10 mg	3.91	20	OxyNor	m
Cap immediate-release 20 mg	6.84	20	OxyNor	m
Oral lig 5 mg per 5 ml		250 ml	OxyNor	m
Inj 10 mg per ml, 1 ml ampoule		5	OxyNor	m
	(10.08)		Oxycod	one Orion
OxyNorm to be Sole Supply on 1 May 2016	. ,			
Inj 10 mg per ml, 2 ml ampoule		5	🖌 OxyNor	m
	(19.87)		Oxycod	one Orion
OxyNorm to be Sole Supply on 1 May 2016				
Inj 50 mg per ml, 1 ml ampoule	51.00	5	OxyNor	m
xycodone Orion Inj 10 mg per ml, 1 ml ampoule to be delisted 1 xycodone Orion Inj 10 mg per ml, 2 ml ampoule to be delisted 1	May 2016) May 2016)			
RACETAMOL WITH CODEINE - Safety medicine; prescriber m	ay determine disp	ensing f	frequency	
Tab paracetamol 500 mg with codeine phosphate 8 mg		1,000	✓ Paracet Code	<u>amol +</u> ine (Relieve)
ETHIDINE HYDROCHLORIDE				
 a) Only on a controlled drug form 				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequ	,			
Tab 50 mg		10	✓ PSM	
Tab 100 mg		10	✓ <u>PSM</u>	
Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO		5		ochloride
Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO	5.83	5	✓ <u>DBL Pe</u> Hydro	thidine ochloride
RAMADOL HYDROCHLORIDE				
	2.00	20	✓ Tramal	
Tab sustained-release 100 mg		~~	🖌 Tramal	CD 150
Tab sustained-release 150 mg	3.00	20		
Tab sustained-release 150 mg Tab sustained-release 200 mg	3.00	20 20	✓ <u>Tramal</u>	
Tab sustained-release 150 mg	3.00 4.00			SR 200

				NERVOUS STSTEM		
	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer		
Antidepressants						
Cyclic and Related Agents						
AMITRIPTYLINE - Safety medicine; prescriber may determine of	dispensing frequency					
Tab 10 mg	1.68	100	✓ <u>A</u>	rrow Amitriptyline		
Tab 25 mg		100		rrow-Amitriptyline		
Tab 50 mg	2.82	100	✓ <u>A</u>	rrow-Amitriptyline		
CLOMIPRAMINE HYDROCHLORIDE - Safety medicine; prescr	riber may determine di	spensi	ng frequer	су		
Tab 10 mg		100	✓ <u>A</u>	po-Clomipramine		
Tab 25 mg	8.68	100	✓ <u>A</u>	po-Clomipramine		
DOTHIEPIN HYDROCHLORIDE – Safety medicine; prescriber r	may determine dispen	sing fre	equency			
Tab 75 mg		100	V D	opress		
Cap 25 mg		100		opress		
DOXEPIN HYDROCHLORIDE – Safety medicine; prescriber ma		na froa	uency	•		
Cap 10 mg	• •	100		nten		
Cap 25 mg		100		inten		
Cap 50 mg		100		inten		
MIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber		nsina f	requency			
Tab 10 mg	•	50		ofranil		
	6.58	60		ofranil s29 s29		
	10.96	100		ofranil		
Tab 25 mg		50		ofranil		
-		•••				
MAPROTILINE HYDROCHLORIDE – Safety medicine; prescrib Tab 25 mg	• •	30		udiomil		
Tab 25 mg	12.53	50		udiomil		
	25.06	100		udiomil		
Tab 75 mg		20		udiomil		
	21.01	30	• =	udiomil		
MIANSERIN HYDROCHLORIDE - Safety medicine; prescriber	may datarmina dispan	cina fr	oquonov			
Tab 30 mg – Subsidy by endorsement		30		olvon		
Subsidised for patients who were taking mianserin hydroch						
ingly. Pharmacists may annotate the prescription as endo hydrochloride. Note that supply of mianserin hydrochlorid there will be no stock of mianserin available beyond Nove	orsed where there exis	sts a re	cord of pri	or dispensing of mianseri		
(Tolvon Tab 30 mg to be delisted 1 April 2016)						
NORTRIPTYLINE HYDROCHLORIDE - Safety medicine; presc	riber may determine d	ispens	ina freque	ncv		
Tab 10 mg		100	0 1	lorpress		
Tab 25 mg		180		lorpress		
Monoamine-Oxidase Inhibitors (MAOIs) - Non S			_			
	95.00	100	• / N	ardil		
PHENELZINE SULPHATE * Tab 15 mg	95.00	100	🗸 N	lardil		
		100 50		lardil arnate		

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
Monoamine-Oxidase Type A Inhibitors				
MOCLOBEMIDE * Tab 150 mg * Tab 300 mg		500 100		Apo-Moclobemide Apo-Moclobemide
Selective Serotonin Reuptake Inhibitors				
CITALOPRAM HYDROBROMIDE * Tab 20 mg	1.79	84		Arrow-Citalopram PSM Citalopram
PSM Citalopram to be Sole Supply on 1 April 2016 (Arrow-Citalopram Tab 20 mg to be delisted 1 April 2016)				
ESCITALOPRAM * Tab 10 mg * Tab 20 mg		28 28		<u>Air Flow Products</u> Air Flow Products
FLUOXETINE HYDROCHLORIDE	2.40	20	•	All Flow Floudets
 * Tab dispersible 20 mg, scored – Subsidy by endorsement Subsidised by endorsement 1) When prescribed for a patient who cannot swallow whole 		30 Ind the		Arrow-Fluoxetine
or2) When prescribed in a daily dose that is not a multiple of Note: Tablets should be combined with capsules to facili	20 mg in which case	the p	rescription	
* Cap 20 mg	1.74	90	V	Arrow-Fluoxetine
	4.00	00		Lovomino
* Tab 20 mg SERTRALINE	4.32	90	V	<u>Loxamine</u>
Tab 50 mg	1.21	30	~	Sertraline Actavis S29
	3.64	90	-	Arrow-Sertraline
Tab 100 mg	6.28	90	~	Arrow-Sertraline
Other Antidepressants				
MIRTAZAPINE – Brand switch fee payable (Pharmacode 24934	89) - see page 210 for			
Tab 30 mg Tab 45 mg		30 30		Apo-Mirtazapine Apo-Mirtazapine

					_
	Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic	
	\$	Per	~	Manufacturer	
ENLAFAXINE					
Tab 37.5 mg	5.06	28		rrow-Venlafaxine XR	
Tab 75 mg	6.44	28	• • •	rrow-Venlafaxine XR	
Tab 150 mg	8.86	28		rrow-Venlafaxine XR	
Tab 225 mg	14.34	28	🗸 A	rrow-Venlafaxine XR	
Cap 37.5 mg - Special Authority see SA1061 below - Retail					
pharmacy	5.69	28	🖌 E	fexor XR	
Cap 75 mg – Special Authority see SA1061 below – Retail pharmacy Cap 150 mg – Special Authority see SA1061 below – Retail	11.40	28	🖌 E	fexor XR	
pharmacy	13.98	28	🖌 E	fexor XR	

➡SA1061 Special Authority for Subsidy

Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 The patient has 'treatment-resistant' depression; and
- 2 Either:
 - 2.1 The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks); or
 - 2.2 Both:
 - 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and
 - 2.2.2 The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time.

Renewal from any medical practitioner. Approvals valid for 2 years where the patient has a high risk of relapse (prescriber determined).

Antiepilepsy Drugs

Agents for Control of Status Epilepticus

otril
pira
solid
solid

	Subsidy (Manufacturer's Pric \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer
PHENYTOIN SODIUM				
Inj 50 mg per ml, 2 ml ampoule – Up to 5 inj available		_		
PSO		5	✓ <u>H</u>	lospira_
Inj 50 mg per ml, 5 ml ampoule – Up to 5 inj available PSO		5	✓ H	lospira
Control of Epilepsy				
CARBAMAZEPINE				
₭ Tab 200 mg	14.53	100	🖌 T	egretol
K Tab long-acting 200 mg		100	🖌 T	egretol CR
k Tab 400 mg		100		egretol
K Tab long-acting 400 mg		100		egretol CR
€‡ Oral liq 20 mg per ml		250 ml	🖌 T	egretol
CLOBAZAM - Safety medicine; prescriber may determine d	lispensing frequency			
Tab 10 mg ‡ Safety cap for extemporaneously compounded oral		50	🖌 F	risium
CLONAZEPAM – Safety medicine; prescriber may determin	e dispensina freauency			
Oral drops 2.5 mg per ml		10 ml OF	, r B	livotril
THOSUXIMIDE				
Cap 250 mg	16 45	100	v 7	arontin
0ap 200 mg	32.90	200		arontin
Oral lig 250 mg per 5 ml		200 ml	• -	arontin
1 61			• -	
GABAPENTIN – Special Authority see SA1477 below – Ret Cap 100 mg		100		rrow-Gabapentin
		100		leurontin
				lupentin
Cap 200 mg . For apparentin and liquid formulation	votor		• 1	lupentin
 Cap 300 mg – For gabapentin oral liquid formulation page 213 		100		rrow-Gabapentin
paye 210		100		leurontin
				lupentin
Cap 400 mg	13 75	100		Arrow-Gabapentin
• Oap 400 mg		100		leurontin
				lupentin
			• N	upenun

SA1477 Special Authority for Subsidy

Initial application — (Epilepsy) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Either:

- 1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
- 2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents.

Note: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Initial application — (Neuropathic pain or Chronic Kidney Disease associated pruritus) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria: Either:

1 The patient has been diagnosed with neuropathic pain; or

Subsidy		Fully	Brand or	
(Manufacturer's Price		Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

2 Both:

- 2.1 The patient has Chronic Kidney Disease Stage 5-associated pruritus* where no other cause for pruritus can be identified (e.g. scabies, allergy); and
- 2.2 The patient has persistent pruritus not relieved with a trial of emollient/moisturising creams alone.

Renewal — (Epilepsy) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or guality of life.

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Renewal — (Neuropathic pain or Chronic Kidney Disease associated pruritus) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 The patient has demonstrated a marked improvement in their control of pain or itch (prescriber determined); or
- 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site.

Note: Indications marked with * are Unapproved Indications (see Interpretations and Definitions). Dosage adjustment of gabapentin is recommended for patients with renal impairment.

LACOSAMIDE - Special Authority see SA1125 below - Retail pharmacy

▲ Tab 50 mg		14	Vimpat
▲ Tab 100 mg		14	 Vimpat
0	200.24	56	Vimpat
▲ Tab 150 mg		14	Vimpat
Ũ	300.40	56	 Vimpat
▲ Tab 200 mg		56	 Vimpat

SA1125 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both:

- 1 Patient has partial-onset epilepsy; and
- 2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).

Note: "Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.

Renewal from any relevant practitioner. Approvals valid for 24 months where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment (see Note).

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

	Subsidy (Manufacturer's Price)		Fully Brand or Subsidised Generic
	\$	Per	 Manufacturer
MOTRIGINE			
Tab dispersible 2 mg		30	 Lamictal
Tab dispersible 5 mg	9.64	30	 Lamictal
	15.00	56	Arrow-Lamotrigine
Tab dispersible 25 mg		56	Logem
	20.40		Arrow-Lamotrigine
			Mogine
	29.09		Lamictal
Tab dispersible 50 mg		56	Logem
	34.70		Arrow-Lamotrigine
			✓ Mogine
	47.89		
Tab dispersible 100 mg		56	✓ Logem
	59.90	50	 Arrow-Lamotrigine
	59.90		
	70.40		Mogine
le sine Tele d'an antikle OF annuks her de l'ate del Annil 0040)	79.16		Lamictal
ogine Tab dispersible 25 mg to be delisted 1 April 2016)			
logine Tab dispersible 50 mg to be delisted 1 April 2016)			
ogine Tab dispersible 100 mg to be delisted 1 April 2016)			
VETIRACETAM			
Tab 250 mg		60	Everet
			Levetiracetam-Rex
Tab 500 mg - For levetiracetam oral liquid formulation refer,			
•		60	- Everet
page 213		60	 Everet
T 750	45.00	~~	 Levetiracetam-Rex
Tab 750 mg		60	 Everet
			 Levetiracetam-Rex
Tab 1,000 mg	59.12	60	Everet
evetiracetam-Rex Tab 250 mg to be delisted 1 August 2016)			
evetiracetam-Rex Tab 500 mg to be delisted 1 August 2016)			
evetiracetam-Rex Tab 750 mg to be delisted 1 August 2016)			
IENOBARBITONE			
	016		
For phenobarbitone oral liquid refer Standard Formulae, page		500	
Tab 15 mg		500	✓ <u>PSM</u>
Tab 30 mg		500	✓ <u>PSM</u>
ENYTOIN SODIUM			
Tab 50 mg		200	 Dilantin Infatab
Cap 30 mg		200	 Dilantin
Cap 100 mg		200	✓ Dilantin
t Oral liq 30 mg per 5 ml		500 ml	
		iii	♥ Brandii
RIMIDONE			
Tab 250 mg	17.25	100	Apo-Primidone
DIUM VALPROATE			
Tab 100 mg	13.65	100	 Epilim Crushable
5			
Tab 200 mg EC		100	 Epilim Epilim
Tab 500 mg EC		100	✓ Epilim
	20.48	300 ml	Epilim S/F Liquid
Oral liq 200 mg per 5 ml			
: Oral liq 200 mg per 5 ml Inj 100 mg per ml, 4 ml		1	 Epilim Syrup Epilim IV

	Subsidy (Manufacturer's Price) \$	Per		Brand or Generic Manufacturer	
STIRIPENTOL – Special Authority see SA1330 below – Retail pharmacy					
Cap 250 mg		60	🗸 D	iacomit S29	
Powder for oral liq 250 mg sachet		60	🗸 D	iacomit S29	

SA1330 Special Authority for Subsidy

Initial application only from a paediatric neurologist or Practitioner on the recommendation of a paediatric neurologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient has confirmed diagnosis of Dravet syndrome; and
- 2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.

TOPIRAMATE

▲ Tab 25 mg	60	Arrow-Topiramate
Ĵ		Topiramate Actavis
26.04		Topamax
▲ Tab 50 mg18.81	60	Arrow-Topiramate
ů –		Topiramate Actavis
44.26		Topamax
▲ Tab 100 mg	60	Arrow-Topiramate
		Topiramate Actavis
75.25		Topamax
▲ Tab 200 mg55.19	60	Arrow-Topiramate
•		Topiramate Actavis
129.85		Topamax
Sprinkle cap 15 mg20.84	60	Topamax
Sprinkle cap 25 mg26.04	60	Topamax
VIGABATRIN – Special Authority see SA1072 below – Retail pharmacy		
▲ Tab 500 mg	100	 Sabril

►SA1072 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both:

- 1 Either:
 - 1.1 Patient has infantile spasms; or
 - 1.2 Both:
 - 1.2.1 Patient has epilepsy; and
 - 1.2.2 Either:
 - 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
 - 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and
- 2 Either:
 - 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6monthly basis thereafter); or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

 Sı	Fully ubsidised	Brand or Generic	
\$ Per	~	Manufacturer	

continued...

Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and
- 2 Either:
 - 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Antimigraine Preparations

For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, page 115

Acute Migraine Treatment

ERGOTAMINE TARTRATE WITH CAFFEINE		
Tab 1 mg with caffeine 100 mg31.00	100	 Cafergot
RIZATRIPTAN		
Tab orodispersible 10 mg3.24	12	✓ <u>Rizamelt</u>
8.10	30	✓ <u>Rizamelt</u>
SUMATRIPTAN		
Tab 50 mg29.80	100	Arrow-Sumatriptan
Tab 100 mg54.80	100	Arrow-Sumatriptan
Inj 12 mg per ml, 0.5 ml cartridge – Maximum of 10 inj per		
prescription	2 OP	 Arrow-Sumatriptan
		🖌 Sun Pharma S29
Prophylaxis of Migraine		
For Beta Adrenoceptor Blockers refer to CARDIOVASCULAR SYSTEM, page 53 PIZOTIFEN		
* Tab 500 mcg23.21	100	Sandomigran
Antinausea and Vertigo Agents		
For Antispasmodics refer to ALIMENTARY TRACT, page 22		
APREPITANT – Special Authority see SA0987 below – Retail pharmacy		
Cap 2 \times 80 mg and 1 \times 125 mg	3 OP	Emend Tri-Pack
►>SA0987 Special Authority for Subsidy		
Initial application from any relevant practitioner. Approvals valid for 12 months w	here the natie	ent is undergoing highly emetage

Initial application from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.

Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
BETAHISTINE DIHYDROCHLORIDE				
* Tab 16 mg	4.95	84	~	Vergo 16
CYCLIZINE HYDROCHLORIDE				
Tab 50 mg	0.59	20	~	Nauzene
	0.30	10		
	(0.59)			Nausicalm
Nauzene to be Sole Supply on 1 April 2016 (Nausicalm Tab 50 mg to be delisted 1 April 2016)				
CYCLIZINE LACTATE				
Inj 50 mg per ml, 1 ml		5	~	Nausicalm
DOMPERIDONE				
 Tab 10 mg – For domperidone oral liquid formulation refer, 				
page 213		100	~	Prokinex
GRANISETRON				
* Tab 1 mg	5.98	50	~	Granirex
HYOSCINE HYDROBROMIDE		00	•	
* Inj 400 mcg per ml, 1 ml ampoule	46 50	5		Hospira
		-		•
Datch 1 France Constant Authority and CA1007 holowy Datail	93.00	10	V	Martindale S29
Patch 1.5 mg – Special Authority see SA1387 below – Retail		2		Seenedorm TTS
pharmacy		2	v :	Scopoderm TTS

► SA1387 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either:

- 1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents; or
- 2 Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective.

Renewal from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

.

METOCLOPRAMIDE HYDROCHLORIDE

* Tab 10 mg – For metoclopramide hydrochloride oral liquid		
formulation refer, page 2131.82	100	Metamide
* Inj 5 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO4.50	10	Pfizer
ONDANSETRON		
* Tab 4 mg5.51	50	✓ Onrex
* Tab disp 4 mg1.00	10	Dr Reddy's
		Ondansetron
* Tab 8 mg6.19	50	✓ Onrex
* Tab disp 8 mg1.50	10	Ondansetron
		ODT-DRLA
PROCHLORPERAZINE		
* Tab 3 mg buccal	50	
(15.00)		Buccastem
* Tab 5 mg – Up to 30 tab available on a PSO9.75	500	Antinaus
* Inj 12.5 mg per ml, 1 ml – Up to 5 inj available on a PSO25.81	10	 Stemetil
* Suppos 25 mg23.87	5	 Stemetil
(Stemetil Suppos 25 mg to be delisted 1 July 2016)		

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
PROMETHAZINE THEOCLATE * Tab 25 mg	1.20 (6.24)	10		Avomine
Antipsychotics General				
AMISULPRIDE – Safety medicine; prescriber may determine disp Tab 100 mg Tab 200 mg Tab 400 mg Oral liq 100 mg per ml	6.22 21.92 44.52	30 60 60 60 ml	v v	Solian Solian Solian Solian
ARIPIPRAZOLE – Special Authority see SA1539 below – Retail Safety medicine; prescriber may determine dispensing freque Tab 5 mg – No more than 1 tab per day Tab 10 mg Tab 15 mg Tab 20 mg Tab 30 mg	ency 123.54 123.54 175.28 213.42	30 30 30 30 30		Abilify Abilify Abilify Abilify Abilify

➡SA1539 Special Authority for Subsidy

Initial application — (Schizophrenia or related psychoses) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Patient is suffering from schizophrenia or related psychoses; and
- 2 Either:
 - 2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or
 - 2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response.

Initial application — (Autism spectrum disorder*) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has been diagnosed with an autism spectrum disorder* and has symptoms of severe irritability; and
- 2 An effective dose of risperidone has been trialled and has been discontinued because of unacceptable side effects or inadequate response; and
- 3 The patient is aged less than 18 years.

Renewal — (Schizophrenia or related psychoses) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Autism spectrum disorder*) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Indications marked with * are Unapproved Indications

CHLORPROMAZINE HYDROCHLORIDE - Safety medicine; prescriber may determine dispensing frequency

Tab 10 mg - Up to 30 tab available on a PSO12.36	100	Largactil
Tab 25 mg – Up to 30 tab available on a PSO13.02	100	Largactil
Tab 100 mg - Up to 30 tab available on a PSO	100	Largactil
Inj 25 mg per ml, 2 ml - Up to 5 inj available on a PSO25.66	10	 Largactil

	Subsidy (Manufacturar's Bri	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Full	
	(Manufacturer's Pri	ce) S Per	Subsidise	
OZAPINE – Hospital pharmacy [HP4]				
Safety medicine; prescriber may determine dispensing freq	uency			
Tab 25 mg		50	~	Clozaril
	6.69			Clopine
	11.36	100		Clozaril
	13.37	100		Clopine
Tab 50 mg		50		Clopine
Tab 50 mg	17.33	100		Clopine
Tab 100 mg		50		Clozaril
Tab 100 Hig	17.33	50		
		100		Clopine
	29.45	100		Clozaril
T-1, 000	34.65	50		Clopine
Tab 200 mg		50		Clopine
	69.30	100		Clopine
Suspension 50 mg per ml	17.33	100 ml	~	Clopine
LOPERIDOL – Safety medicine; prescriber may determine	dispensina freauenc	/		
Tab 500 mcg – Up to 30 tab available on a PSO		, 100	~	Serenace
Tab 1.5 mg – Up to 30 tab available on a PSO		100		Serenace
Tab 5 mg – Up to 30 tab available on a PSO		100		Serenace
Oral lig 2 mg per ml – Up to 200 ml available on a PSO		100 ml	· · · ·	Serenace
		100 111		Serenace
Inj 5 mg per ml, 1 ml – Up to 5 inj available on a PSO				
VOMEPROMAZINE MALEATE – Safety medicine; prescribe	er may determine dis	pensing fre	equency	
Tab 25 mg		100	~	Nozinan
Tab 100 mg		100	~	Nozinan
Inj 25 mg per ml, 1 ml	73.68	10	~	Nozinan
THIUM CARBONATE - Safety medicine; prescriber may dete	ormino disponsina fr	auonov		
Tab 250 mg		500		Lithicarb FC
Tab 400 mg		100		Lithicarb FC
5		100		Priadel
Tab long-acting 400 mg				
Cap 250 mg	9.42	100	V	<u>Douglas</u>
ANZAPINE - Safety medicine; prescriber may determine dis	spensing frequency			
Tab 2.5 mg	0.75	28	~	Zypine
Tab 5 mg		28	~	Zypine
Tab orodispersible 5 mg		28		Zypine ODT
Tab 10 mg		28		Zypine
Tab orodispersible 10 mg		28		Zypine ODT
			•	
RICYAZINE – Safety medicine; prescriber may determine di				
Tab 2.5 mg		100		Neulactil
Tab 10 mg		100	~	Neulactil
JETIAPINE - Safety medicine; prescriber may determine dis	pensing frequency			
Tab 25 mg		90	~	Quetapel
Tab 100 mg		90		Quetapel
Tab 200 mg		90 90		Quetapel
		90 90		
Tab 300 mg	12.00	90	~	Quetapel

_... - .

	Subsidy (Manufacturer's Price) \$	Per	Full Subsidise	d Generic
RISPERIDONE – Safety medicine; prescriber may determine dis	pensing frequency			
Tab orodispersible 0.5 mg - Special Authority see SA0927				
below – Retail pharmacy	21.42	28	~	Risperdal Quicklet
Tab 0.5 mg	1.90	60	~	Actavis
Tab 1 mg	2.10	60	~	Actavis
Tab orodispersible 1 mg - Special Authority see SA0927 be-				
low – Retail pharmacy		28	~	Risperdal Quicklet
Tab 2 mg	2.34	60	~	Actavis
Tab orodispersible 2 mg - Special Authority see SA0927 be-				
low – Retail pharmacy		28	~	Risperdal Quicklet
Tab 3 mg		60	~	Actavis
Tab 4 mg	3.50	60	~	Actavis
Oral liq 1 mg per ml	9.75	30 ml	~	Risperon

SA0927 Special Authority for Subsidy

Initial application — (Acute situations) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

Initial application — (Chronic situations) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

Note: Risperdal Quicklets cost significantly more than risperidone tablets and should only be used where necessary.

TRIFLUOPERAZINE HYDROCHLORIDE - Safety medicine; prescriber may determine dispensing frequency

	s, procoribor may dotor	mine alopen	ioning noquorioy
Tab 1 mg		100	 Stelazine
Tab 2 mg	14.64	100	Stelazine
Tab 5 mg		100	 Stelazine
ZIPRASIDONE - Safety medicine; prescriber may determin	e dispensing frequenc	у	
Cap 20 mg	14.56	60	ZeldoxZusdone
Zusdone to be Sole Supply on 1 April 2016			
Cap 40 mg	24.75	60	✓ Zeldox✓ Zusdone
Zusdone to be Sole Supply on 1 April 2016			
Cap 60 mg		60	✓ Zeldox✓ Zusdone
Zusdone to be Sole Supply on 1 April 2016			
Cap 80 mg		60	 ✓ Zeldox ✓ Zusdone

Zusdone to be Sole Supply on 1 April 2016

()	Subsidy /anufacturer's Price) \$	Subs Per	Full <u>y</u> idised	d Generic
Zeldox Cap 20 mg to be delisted 1 April 2016) Zeldox Cap 40 mg to be delisted 1 April 2016) Zeldox Cap 60 mg to be delisted 1 April 2016) Zeldox Cap 80 mg to be delisted 1 April 2016)				
UCLOPENTHIXOL HYDROCHLORIDE – Safety medicine; prescri Tab 10 mg		dispensin 100	•	quency Clopixol
Depot Injections				
 LUPENTHIXOL DECANOATE – Safety medicine; prescriber may of Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO LUPHENAZINE DECANOATE – Safety medicine; prescriber may of Inj 12.5 mg per 0.5 ml, 0.5 ml – Up to 5 inj available on a PSO Inj 25 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO HALOPERIDOL DECANOATE – Safety medicine; prescriber may of Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO HALOPERIDOL DECANOATE – Safety medicine; prescriber may of Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO	13.14 20.90 40.87 determine dispensi 17.60 27.90 154.50 etermine dispensin 28.39	5 5 5 ng frequer 5 5 5		Fluanxol Fluanxol Fluanxol Modecate Modecate Modecate Haldol Haldol Concentrate
DLANZAPINE – Special Authority see SA1428 below – Retail pharr Safety medicine; prescriber may determine dispensing frequenc Inj 210 mg vial Inj 300 mg vial Inj 405 mg vial ■>SA1428 Special Authority for Subsidy	nacy y 280.00 460.00	1 1 1	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Zyprexa Relprevv Zyprexa Relprevv Zyprexa Relprevv

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 The patient has had an initial Special Authority approval for paliperidone depot injection or risperidone depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia; and
 - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: The patient should be monitored for post-injection syndrome for at least two hours after each injection.

PALIPERIDONE - Special Authority see SA1429 on the next page - Retail pharmacy

Safety medicine; prescriber may determine dispensing frequency	
	10105

Inj 50 mg syringe	
	na
Inj 75 mg syringe	na
Inj 100 mg syringe	na
Inj 150 mg syringe	

Subsidy (Manufacturer's Price)	Sı	Fully ubsidised	Brand or Generic	
\$	Per	~	Manufacturer	

➡SA1429 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: Paliperidone depot injection should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialling paliperidone depot injection.

PIPOTHIAZINE PALMITATE - Subsidy by endorsement

a) Safety medicine; prescriber may determine dispensing frequency

b) Subsidised for patients who were taking pipothiazine palmitate prior to 1 August 2014 and the prescription or PSO is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of pipothiazine palmitate.

Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO.		10	Piportil
Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO.		10	 Piportil
RISPERIDONE - Special Authority see SA1427 below - Re			
Safety medicine; prescriber may determine dispensing f	requency		
Inj 25 mg vial		1	Risperdal Consta
Inj 37.5 mg vial	178.71	1	Risperdal Consta
Inj 50 mg vial	217.56	1	Risperdal Consta

➡SA1427 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: Risperidone depot injection should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialing risperidone depot injection.

ZUCLOPENTHIXOL DECANOATE - Safety medicine; prescriber may determine dispensing frequency

Inj 200 mg per ml, 1 ml – Up to 5 inj available o	on a PSO 19.80	0 5	 Clopixol
---	----------------	-----	------------------------------

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Anxiolytics				
LPRAZOLAM – Safety medicine; prescriber may determine	dispensing frequency			
Tab 250 mcg		50	✓ <u>×</u>	anax
‡ Safety cap for extemporaneously compounded oral li				
Tab 500 mcg		50	✓ <u>×</u>	anax
‡ Safety cap for extemporaneously compounded oral li			4.1	
Tab 1 mg		50	✓ <u>×</u>	anax
‡ Safety cap for extemporaneously compounded oral li	quid preparations.			
Tab 5 mg		100		acific Buspirone
Tab 10 mg		100	VP	acific Buspirone
LONAZEPAM - Safety medicine; prescriber may determine	dispensing frequency			
Tab 500 mcg	7.53	100	🖌 P	axam
Tab 2 mg	14.37	100	🖌 P	axam
IAZEPAM – Safety medicine; prescriber may determine disp	ensing frequency			
Tab 2 mg		500	🗸 A	rrow-Diazepam
‡ Safety cap for extemporaneously compounded oral li	quid preparations.			•
Tab 5 mg		500	🗸 A	rrow-Diazepam
‡ Safety cap for extemporaneously compounded oral li	quid preparations.			
ORAZEPAM - Safety medicine; prescriber may determine d	ispensing frequency			
Tab 1 mg		250	✓ A	tivan
‡ Safety cap for extemporaneously compounded oral li	quid preparations.			
Tab 2.5 mg	13.88	100	✓ <u>A</u>	tivan
‡ Safety cap for extemporaneously compounded oral li	quid preparations.			
XAZEPAM - Safety medicine; prescriber may determine dis	pensing frequency			
Tab 10 mg	6.17	100	<u> </u>)x-Pam
‡ Safety cap for extemporaneously compounded oral li	quid preparations.			
Tab 15 mg		100	✓ <u>0</u>	x-Pam
‡ Safety cap for extemporaneously compounded oral li	quid preparations.			
Multiple Sclerosis Treatments				
IMETHYL FUMARATE – Special Authority see SA1559 belo	w – Retail pharmacy			
Wastage claimable – see rule 3.3.2 on page 13				
Cap 120 mg	520.00	14	/ T	ecfidera
Cap 240 mg		56		ecfidera

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccoordinator@pharmac.govt.nz

Wellington

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. 145

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🖌	Manufacturer	

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). Entry Criteria

- a) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- b) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- c) patients must have:
 - a) EDSS score 0 4.0 and:
 - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
 - Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:
 - i) a gadolinium enhancing lesion; or
 - ii) a Diffusion Weighted Imaging positive lesion; or
 - iii) a T2 lesion with associated local swelling; or
 - iv) a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or
 - v) new T2 lesions compared with a previous MR scan; and
- d) A significant relapse must:
 - a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) start at least one month after the onset of a previous relapse;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
 - f) be distinguishable from the effects of general fatigue; and
 - g) not be associated with a fever (T>37.5°C); and
- e) applications must be made by the patient's neurologist or general physician; and
- f) patients must have no previous history of lack of response to dimethyl fumarate; and
- g) patients must have not previously had intolerance to dimethyl fumarate; and
- h) patient must not be co-prescribed beta interferon or glatiramer acetate.

Stopping Criteria

Any of the following:

- a) Confirmed progression of disability that is sustained for six months. Progression of disability is defined as progress by any
 of the following EDDSS points:
 - a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
 - b) 1.0 to 3.0; or
 - c) 1.5 to 3.5; or
 - d) 2.0 to 4.0; or
 - e) 2.5 to 4.5; or
 - f) 3.0 to 4.5; or
 - g) 3.5 to 4.5; or
 - h) 4.0 to 4.5.
- b) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- c) intolerance to dimethyl fumarate; or
- d) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Switching between natalizumab, fingolimod, dimethyl fumarate and teriflunomide is permitted provided the EDSS stopping criteria are not met. Switching to interferon or glatiramer acetate is only permitted provided the EDSS stopping criteria are not met and both fingolimod and natalizumab are either not tolerated or treatment with both agents would be clinically inappropriate. Continued relapses on treatment would be expected to lead to a switch of treatment provided the stopping criteria are not met. If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur.

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
FINGOLIMOD – Special Authority see SA1562 below – Retail pha Wastage claimable – see rule 3.3.2 on page 13	armacy			
Cap 0.5 mg	2,650.00	28	🖌 G	ilenya

SA1562 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccoordinator@pharmac.govt.nz

Wellington

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

Entry Criteria

- a) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- b) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- c) patients must have:
 - a) EDSS score 0 4.0 and:
 - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
 - Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:
 - i) a gadolinium enhancing lesion; or
 - ii) a Diffusion Weighted Imaging positive lesion; or
 - iii) a T2 lesion with associated local swelling; or
 - iv) a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or
 - v) new T2 lesions compared with a previous MR scan; and
- d) A significant relapse must:
 - a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) start at least one month after the onset of a previous relapse;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
 - f) be distinguishable from the effects of general fatigue; and
 - g) not be associated with a fever (T>37.5 $^{\circ}$ C); and
- e) applications must be made by the patient's neurologist or general physician; and
- f) patients must have no previous history of lack of response to fingolimod; and
- g) patients must have not previously had intolerance to fingolimod; and
- h) patient must not be co-prescribed beta interferon or glatiramer acetate.

Stopping Criteria

Any of the following:

- a) Confirmed progression of disability that is sustained for six months. Progression of disability is defined as progress by any of the following EDDSS points:
 - a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	bsidised	Generic	
\$	Per	~	Manufacturer	

- b) 1.0 to 3.0; or
- c) 1.5 to 3.5; or
- d) 2.0 to 4.0; or
- e) 2.5 to 4.5; or
- f) 3.0 to 4.5; or
- g) 3.5 to 4.5; or
- h) 4.0 to 4.5.
- b) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- c) intolerance to fingolimod; or
- d) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Switching between natalizumab, fingolimod, dimethyl fumarate and teriflunomide is permitted provided the EDSS stopping criteria are not met. Switching to interferon or glatiramer acetate is only permitted provided the EDSS stopping criteria are not met and both fingolimod and natalizumab are either not tolerated or treatment with both agents would be clinically inappropriate. Continued relapses on treatment would be expected to lead to a switch of treatment provided the stopping criteria are not met. If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur.

NATALIZUMAB - Special Authority see SA1563 below - Retail pharmacy

Inj 20 mg per ml, 15 ml via		1	🗸 Tysabri
-----------------------------	--	---	-----------

➡SA1563 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccoordinator@pharmac.govt.nz

Wellington

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

Entry Criteria

- a) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- b) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- c) patients must have:
 - a) EDSS score 0 4.0 and:
 - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
 - Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:
 - i) a gadolinium enhancing lesion; or
 - ii) a Diffusion Weighted Imaging positive lesion; or
 - iii) a T2 lesion with associated local swelling; or
 - iv) a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or
 - v) new T2 lesions compared with a previous MR scan; and
- d) A significant relapse must:
 - a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

- b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
- c) last at least one week;
- d) start at least one month after the onset of a previous relapse;
- e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
- f) be distinguishable from the effects of general fatigue; and
- g) not be associated with a fever (T>37.5°C); and
- e) applications must be made by the patient's neurologist or general physician; and
- f) treatment must be initiated and supervised by a neurologist who is registered in the Tysabri Australasian Prescribing Programme operated by the supplier; and
- g) patients must have no previous history of lack of response to natalizumab; and
- h) patients must have not previously had intolerance to natalizumab; and
- i) a) Patient is JC virus negative, or
 - b) Patient is JC virus positive and has given written informed consent acknowledging an understanding of the risk of progressive multifocal leucoencephalopathy (PML) associated with natalizumab
- j) patient must not be co-prescribed beta interferon or glatiramer acetate.

Stopping Criteria

Any of the following:

- Confirmed progression of disability that is sustained for six months. Progression of disability is defined as progress by any
 of the following EDDSS points:
 - a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
 - b) 1.0 to 3.0; or
 - c) 1.5 to 3.5; or
 - d) 2.0 to 4.0; or
 - e) 2.5 to 4.5; or
 - f) 3.0 to 4.5; or
 - g) 3.5 to 4.5; or
 - h) 4.0 to 4.5.
- b) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- c) intolerance to natalizumab; or

d) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Natalizumab can only be dispensed from a pharmacy registered in the Tysabri Australasian Prescribing Programme operated by the supplier.

Switching between natalizumab, fingolimod, dimethyl fumarate and teriflunomide is permitted provided the EDSS stopping criteria are not met. Switching to interferon or glatiramer acetate is only permitted provided the EDSS stopping criteria are not met and both fingolimod and natalizumab are either not tolerated or treatment with both agents would be clinically inappropriate. Continued relapses on treatment would be expected to lead to a switch of treatment provided the stopping criteria are not met. If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur.

TERIFLUNOMIDE - Special Authority see SA1560 on the next page - Retail pharmacy

Wastage claimable – see rule 3.3.2 on page 13

Tab 14 mg1,582.62 28 🖌 Aubagio

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	lbsidised	Generic	
\$	Per	~	Manufacturer	

►SA1560 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The coordinator	Phone: 04 460 4990		
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571		
PHARMAC PO Box 10 254	Email: mstaccoordinator@pharmac.govt.nz		

Wellington

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

Entry Criteria

- a) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- b) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- c) patients must have:
 - a) EDSS score 0 4.0 and:
 - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
 - Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:
 - i) a gadolinium enhancing lesion; or
 - ii) a Diffusion Weighted Imaging positive lesion; or
 - iii) a T2 lesion with associated local swelling; or
 - iv) a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or
 - v) new T2 lesions compared with a previous MR scan; and
- d) A significant relapse must:
 - a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) start at least one month after the onset of a previous relapse;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
 - f) be distinguishable from the effects of general fatigue; and
 - g) not be associated with a fever (T>37.5°C); and
- e) applications must be made by the patient's neurologist or general physician; and
- f) patients must have no previous history of lack of response to teriflunomide; and
- g) patients must have not previously had intolerance to teriflunomide; and
- h) patient must not be co-prescribed beta interferon or glatiramer acetate.

Stopping Criteria

Any of the following:

- a) Confirmed progression of disability that is sustained for six months. Progression of disability is defined as progress by any
 of the following EDDSS points:
 - a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
 - b) 1.0 to 3.0; or
 - c) 1.5 to 3.5; or
 - d) 2.0 to 4.0; or

Subsidy		Fully E	Brand or
(Manufacturer's	Price) Subsid	lised (Generic
\$	Per	~ 1	Manufacturer

- e) 2.5 to 4.5; or
- f) 3.0 to 4.5; or
- a) 3.5 to 4.5; or
- h) 4.0 to 4.5.
- b) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- c) intolerance to teriflunomide; or
- d) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Switching between natalizumab, fingolimod, dimethyl fumarate and teriflunomide is permitted provided the EDSS stopping criteria are not met. Switching to interferon or glatiramer acetate is only permitted provided the EDSS stopping criteria are not met and both fingolimod and natalizumab are either not tolerated or treatment with both agents would be clinically inappropriate. Continued relapses on treatment would be expected to lead to a switch of treatment provided the stopping criteria are not met. If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur.

Other Multiple Sclerosis Treatments

SA1564 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below). Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccoordinator@pharmac.govt.nz

Wellington

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

These agents will NOT be subsidised if dispensed from a community or hospital pharmacy. Regular supplies will be distributed to all approved patients or their clinicians by courier.

Prescribers must send quarterly prescriptions for approved patients to the MSTAC coordinator.

Only prescriptions for 6 million iu of interferon beta-1-alpha per week, or 8 million iu of interferon beta-1-beta every other day, or 20 mg glatiramer acetate daily will be subsidised.

Switching between treatments is permitted within the 12 month approval period without reapproval by MSTAC. The MSTAC coordinator should be notified of the change and a new prescription provided.

Entry Criteria

- a) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- b) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- c) patients must have:
 - a) EDSS score 0 4.0 and:
 - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
 - Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:
 - i) a gadolinium enhancing lesion; or
 - ii) a Diffusion Weighted Imaging positive lesion; or
 - iii) a T2 lesion with associated local swelling; or
 - iv) a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or
 - v) new T2 lesions compared with a previous MR scan; and

d) A significant relapse must:

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

- a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
- b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
- c) last at least one week;
- d) start at least one month after the onset of a previous relapse;
- e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
- f) be distinguishable from the effects of general fatigue; and
- g) not be associated with a fever (T>37.5°C); and
- e) applications must be made by the patient's neurologist; and
- f) patients must have no previous history of lack of response to beta-interferon or glatiramer acetate; and
- g) patients must have either:
 - a) intolerance to both natalizumab and fingolimod; or
 - b) treatment with both natalizumab and fingolimod is considered clinically inappropriate; and
- h) patient will not be co-prescribed natalizumab or fingolimod.

Stopping Criteria

Any of the following:

- a) Confirmed progression of disability that is sustained for six months during a minimum of one year of treatment. Progression of disability is defined as progress by any of the following EDDSS Points:
 - a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
 - b) 1.0 to 3.0; or
 - c) 1.5 to 3.5; or
 - d) 2.0 to 4.0; or
 - e) 2.5 to 4.5; or
 - f) 3.0 to 4.5; or
 - g) 3.5 to 4.5; or
 - h) 4.0 to 4.5.
- b) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- c) intolerance to interferon beta-1-alpha, and/or interferon beta-1-beta and/or glatiramer acetate; or
- d) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Treatment with interferon beta -1-beta, interferon beta-1-alpha and glatiramer acetate, is permitted only if treatment with both natalizumab and fingolimod is not tolerated or treatment with both would be clinically inappropriate. Beta-interferon or glatiramer acetate will not be funded as second line treatments if EDSS progression has occurred on treatment with natalizumab or fingolimod. Patients who have an increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment) and who do not meet the EDSS Stopping Criteria at annual review may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa. Patients may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa for increased relapses only once, after which they will be required to stop funded treatment if they meet any of the Stopping Criteria at annual review (including the criterion relating to increasing relapse rate over 12 months of treatment). If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur. In this setting anti-JCV antibody positive status may be accepted as a clinically inappropriate reason for treatment with natalizumab.

GLATIRAMER ACETATE – Special Authority see SA1564 on	the previous page – [2	Xpharm]	
Inj 20 mg prefilled syringe	1,089.25	28	 Copaxone
INTERFERON BETA-1-ALPHA - Special Authority see SA15	64 on the previous pa	ge – [Xphar	rm]
Inj 6 million iu prefilled syringe		4	Avonex
Injection 6 million iu per 0.5 ml pen injector	1,170.00	4	Avonex Pen
Inj 6 million iu per vial	1,170.00	4	Avonex

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Full Subsidise	d Generic
INTERFERON BETA-1-BETA – Special Authority see SA1564 on Inj 8 million iu per 1 ml		l] 15	v	Betaferon
Sedatives and Hypnotics				
LORMETAZEPAM – Safety medicine; prescriber may determine c Tab 1 mg		30		Noctamid
‡ Safety cap for extemporaneously compounded oral liquid				
MIDAZOLAM – Safety medicine; prescriber may determine disper Inj 1 mg per ml, 5 ml		10		Pfizer Hypnovel
Inj 5 mg per ml, 3 ml	11.90	5		Hypnovel Pfizer
NITRAZEPAM – Safety medicine; prescriber may determine disperation Tab 5 mg ‡ Safety cap for extemporaneously compounded oral liquid		100	-	<u>Nitrados</u>
PHENOBARBITONE SODIUM – Special Authority see SA1386 b		асу		
Inj 200 mg per ml, 1 ml ampoule	46.20	10	~	Martindale S29
 SA1386 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid the following criteria: Both: For the treatment of terminal agitation that is unresponsiv 2 The applicant is part of a multidisciplinary team working in 	re to other agents; an		nless noti	fied for applications meetin
TEMAZEPAM – Safety medicine; prescriber may determine dispe Tab 10 mg ‡ Safety cap for extemporaneously compounded oral liquid	ensing frequency	25	~	Normison
TRIAZOLAM – Safety medicine; prescriber may determine disper Tab 125 mcg	5.10	100		lhuran
‡ Safety cap for extemporaneously compounded oral liquid Tab 250 mcg		100		Hypam Hypam
‡ Safety cap for extemporaneously compounded oral liquid	preparations.			
ZOPICLONE – Safety medicine; prescriber may determine disper Tab 7.5 mg		30		Zopiclone Actavis

8.99

(11.90)

500

✓ Zopiclone Actavis

Apo-Zopiclone

Zopiclone Actavis to be Sole Supply on 1 March 2016 (Apo-Zopiclone Tab 7.5 mg to be delisted 1 March 2016)

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	
Stimulants/ADHD Treatments					
Stimulants/ADHD treatments					
ATOMOXETINE - Special Authority see SA	416 below – Retail pharmacy				
Cap 10 mg		28	/ S	strattera	
Cap 18 mg		28	v s	strattera	
Cap 25 mg		28	v s	strattera	
Con 40 mg	107.03	28	V S	trattera	
Cap 40 mg				liulloiu	
Cap 40 mg Cap 60 mg		28	/ S	strattera	
Cap 40 mg Cap 60 mg Cap 80 mg					

SA1416 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and
- 2 Once-daily dosing; and
- 3 Any of the following:
 - 3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or
 - 3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy; or
 - 3.3 An effective dose of a subsidised formulation of a stimulant has been trialled and has been discontinued because of inadequate clinical response; or
 - 3.4 Treatment with a subsidised formulation of a stimulant is considered inappropriate because the patient has a history of psychoses or has a first-degree relative with schizophrenia; and
- 4 The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: A "subsidised formulation of a stimulant" refers to currently subsidised methylphenidate hydrochloride tablet formulations (immediate-release, sustained-release and extended-release) or dexampletamine sulphate tablets.

DEXAMFETAMINE SULFATE - Special Authority see SA1149 below - Retail pharmacy

a) Only on a controlled drug form

b) Safety medicine; prescriber may determine dispensing frequency

Tab 5 mg17.00	100

SA1149 Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or

continued...

PSM

Subsidy (Manufacturer's Pric	ce)	Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

3.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

METHYLPHENIDATE HYDROCHLORIDE - Special Authority see SA1150 below - Retail pharmacy

a) Only on a controlled drug form

b) Safety medicine; prescriber may determine dispensing frequency

Tab immediate-release 5 mg	30	Rubifen
Tab immediate-release 10 mg	30	Ritalin
		 Rubifen
Tab immediate-release 20 mg7.85	30	 Rubifen
Tab sustained-release 20 mg10.95	30	Rubifen SR
50.00	100	Ritalin SR

SA1150 Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria.

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🖌	Manufacturer	

Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE - Special Authority see SA1151 on the next page - Retail pharmacy

a) Only on a controlled drug form

b) Safety medicine; prescriber may determine dispensing frequency

Tab extended-release 27 mg Tab extended-release 36 mg Tab extended-release 54 mg Cap modified-release 10 mg Cap modified-release 20 mg Cap modified-release 30 mg	58.96 	30 30 30 30 30 30 30	 Concerta Concerta Concerta Concerta Ritalin LA Ritalin LA Ritalin LA
		30 30	 Ritalin LA Ritalin LA

➡SA1151 Special Authority for Subsidy

Initial application only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria: All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder); and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing; and
- 4 Either:
 - 4.1 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or
 - 4.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

Renewal only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:

NERVOUS STSTEM				
	Subsidy (Manufacturer's Price) \$	Su Per	Fully bsidised	Brand or Generic Manufacturer
continued 2.1 Applicant is a paediatrician or psychiatrist; or 2.2 Applicant is a medical practitioner and confirms last 2 years and has recommended treatment fo			trist has	been consulted within the
MODAFINIL – Special Authority see SA1126 below – Retail pha Tab 100 mg		30	✔ M	lodavigil
► SA1126 Special Authority for Subsidy Initial application only from a neurologist or respiratory speci following criteria: All of the following:	alist. Approvals valid	for 24 m	onths fo	r applications meeting the
 The patient has a diagnosis of narcolepsy and has ex almost daily for three months or more; and Either: 	cessive daytime sleep	oiness ass	sociated	with narcolepsy occurring
2.1 The patient has a multiple sleep latency test with more sleep onset rapid eye movement periods;2.2 The patient has at least one of: cataplexy, sleep	or			
 3 Either: 3.1 An effective dose of a subsidised formulation of a tinued because of intolerable side effects; or 3.2 Methylphenidate and dexamphetamine are cont 	21	xampheta	imine ha	s been trialled and discon
Renewal only from a neurologist or respiratory specialist. Appro and the patient is benefiting from treatment.	ovals valid for 24 mont	hs where	the treat	tment remains appropriate
Treatments for Dementia				
DONEPEZIL HYDROCHLORIDE * Tab 5 mg * Tab 10 mg RIVASTIGMINE – Special Authority see SA1488 below – Retail Patch 4.6 mg per 24 hour	10.51 pharmacy	90 90 30	✓	onepezil-Rex onepezil-Rex xelon
Patch 9.5 mg per 24 hour SA1488 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid Both:	90.00	30 lications n		xelon he following criteria:
 The patient has been diagnosed with dementia; and The patient has experienced intolerable nausea and/or 	vomiting from donepe	zil tablets.		

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate; and
- 2 The patient has demonstrated a significant and sustained benefit from treatment.

Treatments for Substance Dependence

BUPRENORPHINE WITH NALOXONE - Special Authority see SA1203 below - Retail pharmacy

a) No patient co-payment payable			
b) Safety medicine; prescriber may determine dispensing frequency			
Tab sublingual 2 mg with naloxone 0.5 mg5	57.40	28	 Suboxone
Tab sublingual 8 mg with naloxone 2 mg16	6.00	28	 Suboxone

NERVOUS SYSTEM

Subsidy (Manufacturer's Price)	S	Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

➡SA1203 Special Authority for Subsidy

Initial application — (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health...

Initial application — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient will not be receiving methadone; and
- 3 Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Renewal — (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient has previously trialled but failed detoxification with buprenorphine with naloxone with relapse back to opioid use and another attempt is planned; and
- 3 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Renewal — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is or has been receiving maintenance therapy with buprenorphine with naloxone (and is not receiving methadone); and
- 2 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health or is a medical practitioner authorised by the service to manage treatment in this patient.

Renewal — (Maintenance treatment where the patient has previously had an initial application for detoxification) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- - 1 Patient received but failed detoxification with buprenorphine with naloxone; and
 - 2 Maintenance therapy with buprenorphine with naloxone is planned (and patient will not be receiving methadone); and
 - 3 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
 - 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

BUPROPION HYDROCHLORIDE

Tab modified-release 150 mg	4.97	30	Zyban
DISULFIRAM Tab 200 mg	24.30	100	✓ Antabuse
NALTREXONE HYDROCHLORIDE – Special Authority see SA14			• Antabaoo
Tab 50 mg	76.00	30	✓ Naltraccord

<u> </u>				
Subsidy		Fully	Brand or	
(Manufacturer's Price)	SL	ubsidised	Generic	
\$	Per	~	Manufacturer	

➡SA1408 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence; and
- 2 Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard.

Renewal from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Compliance with the medication (prescriber determined); and
- 2 Any of the following:
 - 2.1 Patient is still unstable and requires further treatment; or
 - 2.2 Patient achieved significant improvement but requires further treatment; or
 - 2.3 Patient is well controlled but requires maintenance therapy.

NICOTINE

Nicotine will not be funded under the Dispensing Frequency Rule in amounts less than 4 weeks of treatment.

Patch 7 mg – Up to 28 patch available on a PSO	28	✓ Habitrol
Patch 14 mg – Up to 28 patch available on a PSO11.31	28	Habitrol
Patch 21 mg – Up to 28 patch available on a PSO11.95	28	Habitrol
Lozenge 1 mg – Up to 216 loz available on a PSO 12.91	216	Habitrol
Lozenge 2 mg – Up to 216 loz available on a PSO14.14	216	Habitrol
Gum 2 mg (Classic) – Up to 384 piece available on a PSO	384	Habitrol
Gum 2 mg (Fruit) – Up to 384 piece available on a PSO22.26	384	Habitrol
Gum 2 mg (Mint) – Up to 384 piece available on a PSO22.26	384	Habitrol
Gum 4 mg (Classic) – Up to 384 piece available on a PSO25.67	384	Habitrol
Gum 4 mg (Fruit) – Up to 384 piece available on a PSO25.67	384	Habitrol
Gum 4 mg (Mint) – Up to 384 piece available on a PSO25.67	384	Habitrol

VARENICLINE TARTRATE - Special Authority see SA1161 below - Retail pharmacy

a) A maximum of 3 months' varenicline will be subsidised on each Special Authority approval.

b) Varenicline will not be funded under the Dispensing Frequency Rule in amounts less than 2 weeks of treatment.

Champix	28	Tab 1 mg67.74
Champix	56	135.48
Champix	25 OP	Tab 0.5 mg \times 11 and 1 mg \times 1460.48

➡SA1161 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria: All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 Either:
 - 3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
 - 3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
- 4 The patient has not used funded varenicline in the last 12 months; and
- 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	ubsidised	Generic	
\$	Per	~	Manufacturer	

- 6 The patient is not pregnant; and
- 7 The patient will not be prescribed more than 3 months' funded varenicline (see note).

Renewal from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria: All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 The patient has not used funded varenicline in the last 12 months; and
- 4 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 5 The patient is not pregnant; and
- 6 The patient will not be prescribed more than 3 months' funded varenicline (see note).

The patient must not have had an approval in the past 12 months.

Note: a maximum of 3 months' varenicline will be subsidised on each Special Authority approval.

	Subsidy (Manufacturer's		Fully	Brand or Generic
	\$	Per	~	Manufacturer
Chemotherapeutic Agents				
Alkylating Agents				
USULFAN – PCT – Retail pharmacy-Specialist				
Tab 2 mg		100	V M	yleran
ARBOPLATIN – PCT only – Specialist				
Inj 10 mg per ml, 5 ml vial		1	🗸 D	BL Carboplatin
	20.00		🖌 C	arboplatin Ebewe
Inj 10 mg per ml, 15 ml vial	14.05	1	🖌 D	BL Carboplatin
	19.50		V C	arbaccord
	22.50		V C	arboplatin Ebewe
Inj 10 mg per ml, 45 ml vial		1	🖌 D	BL Carboplatin
	48.50		v c	arbaccord
	50.00		/ C	arboplatin Ebewe
Inj 1 mg for ECP		1 mg	🖌 В	axter
ARMUSTINE – PCT only – Specialist		ũ		
Inj 100 mg vial	E33 00	1	/ P	iCNU
Inj 100 mg for ECP		100 mg OP		axter
, ,		100 Hig OF	VD	axter
HLORAMBUCIL – PCT – Retail pharmacy-Specialist				
Tab 2 mg	29.06	25	🖌 Li	eukeran FC
ISPLATIN – PCT only – Specialist				
Inj 1 mg per ml, 50 ml vial		1	V D	BL Cisplatin
	15.00			isplatin Ebewe
Inj 1 mg per ml, 100 ml vial		1		isplatin Ebewe
	22.46			BL Cisplatin
Inj 1 mg for ECP		1 mg		axter
	0.20	9	• -	
YCLOPHOSPHAMIDE				
Tab 50 mg – PCT – Retail pharmacy-Specialist	79.00	50	V E	ndoxan S29
	158.00	100	🖌 Р	rocytox S29
Wastage claimable – see rule 3.3.2 on page 13				
Inj 1 g vial – PCT – Retail pharmacy-Specialist	35.03	1	🖌 E	ndoxan
	127.80	6	🗸 C	ytoxan
Inj 2 g vial – PCT only – Specialist		1		ndoxan
Inj 1 mg for ECP – PCT only – Specialist	0.04	1 mg	🗸 В	axter
OSFAMIDE - PCT only - Specialist				
Inj 1 g	96.00	1	🖌 Н	oloxan
lnj 2 g		1		oloxan
Inj 1 mg for ECP		1 mg	· · ·	axter
DMUSTINE – PCT – Retail pharmacy-Specialist	100 50	00		NU I
Cap 10 mg		20		eeNU
Cap 40 mg		20	VC	eeNU
ELPHALAN				
Tab 2 mg – PCT – Retail pharmacy-Specialist	40.70	25	🗸 A	lkeran
Inj 50 mg – PCT only – Specialist	67.80	1	🗸 A	lkeran
	3,068.83		🖌 M	ylan
				Melphalan S29

(M	Subsidy anufacturer's Price) \$	Per	Full Subsidise	
OXALIPLATIN – PCT only – Specialist				
Inj 5 mg per ml, 10 ml vial	13.32	1	~	Oxaliccord
Inj 50 mg vial		1	~	Oxaliplatin Actavis 50
	55.00		~	Oxaliplatin Ebewe
	200.00		~	Eloxatin
Inj 100 mg vial	25.01	1	~	Oxaliplatin Actavis 100
	110.00		~	Oxaliplatin Ebewe
	400.00			Eloxatin
Inj 5 mg per ml, 20 ml vial	16.00	1	~	Oxaliccord
Inj 1 mg for ECP	0.28	1 mg	~	Baxter
THIOTEPA – PCT only – Specialist				
Inj 15 mg vial	CBS	1	~	Bedford S29
			~	THIO-TEPA S29
			~	Tepadina S29
Inj 100 mg vial	CBS	1	~	Tepadina S29
Antimetabolites				
AZACITIDINE - PCT only - Specialist - Special Authority see SA1				
Inj 100 mg vial		1	-	Vidaza
Inj 1 mg for ECP	6.66	1 mg	~	Baxter

➡SA1467 Special Authority for Subsidy

Initial application only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 Any of the following:
 - 1.1 The patient has International Prognostic Scoring System (IPSS) intermediate-2 or high risk myelodysplastic syndrome; or
 - 1.2 The patient has chronic myelomonocytic leukaemia (10%-29% marrow blasts without myeloproliferative disorder); or
 - 1.3 The patient has acute myeloid leukaemia with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO); and
 - 2 The patient has performance status (WHO/ECOG) grade 0-2; and
 - 3 The patient does not have secondary myelodysplastic syndrome resulting from chemical injury or prior treatment with chemotherapy and/or radiation for other diseases; and
- 4 The patient has an estimated life expectancy of at least 3 months.

Renewal only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

- Both:
 - 1 No evidence of disease progression; and
 - 2 The treatment remains appropriate and patient is benefitting from treatment.

	Subsidy (Manufacturer's Pri	co) Sul	Fully Brand or psidised Generic
	(Iniditulactule) S F II	Per	Manufacturer
CALCIUM FOLINATE			
Tab 15 mg - PCT - Retail pharmacy-Specialist	104.26	10	 DBL Leucovorin Calcium
Inj 3 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist		5	 Hospira
Inj 50 mg – PCT – Retail pharmacy-Specialist		5	 <u>Calcium Folinate</u> <u>Ebewe</u>
Inj 100 mg – PCT only – Specialist		1	 Calcium Folinate Ebewe
Inj 300 mg – PCT only – Specialist	22.51	1	 Calcium Folinate Ebewe
Inj 1 g – PCT only – Specialist	67.51	1	 Calcium Folinate Ebewe
Inj 1 mg for ECP – PCT only – Specialist	0.06	1 mg	✓ Baxter
APECITABINE – Retail pharmacy-Specialist			
Tab 150 mg		60	 <u>Capecitabine</u> Winthrop
Tab 500 mg	120.00	120	✓ <u>Capecitabine</u> Winthrop
LADRIBINE – PCT only – Specialist			-
Inj 1 mg per ml, 10 ml	5,249.72	7	 Leustatin
Inj 10 mg for ECP	749.96	10 mg OP	Baxter
YTARABINE			
Inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist	55.00	5	Pfizer
	80.00		Hospira
Inj 500 mg – PCT – Retail pharmacy-Specialist		1	Pfizer
	95.36	5	Hospira
Inj 100 mg per ml, 10 ml vial - PCT - Retail pharmacy-			
Specialist		1	 Pfizer
	42.65		Hospira
Inj 100 mg per ml, 20 ml vial – PCT – Retail pharmacy-			
Specialist	17.65	1	Pfizer
	34.47		Hospira
Inj 1 mg for ECP – PCT only – Specialist	0.11	10 mg	Baxter
Inj 100 mg intrathecal syringe for ECP – PCT only – Specialist UDARABINE PHOSPHATE	11.00	100 mg OP	 Baxter
Tab 10 mg – PCT – Retail pharmacy-Specialist	412.00	20	Fludara Oral
Inj 50 mg – PCT only – Specialist		5	✓ Fludarabine Ebewe
	1,430.00	Ŭ	✓ Fludara
Inj 50 mg for ECP – PCT only – Specialist		50 mg OP	✓ Baxter
LUOROURACIL			
	10.00	1	Fluorouracil Ebewe
Inj 50 mg per ml, 20 ml vial – PCT only – Specialist		1	 Fluorouracii Ebewe Fluorouracii Ebewe
Inj 50 mg per ml, 50 ml vial – PCT only – Specialist		1	 Fluorouracii Ebewe Fluorouracii Ebewe
Inj 50 mg per ml, 100 ml vial – PCT only – Specialist			
Inj 1 mg for ECP – PCT only – Specialist	0.66	100 mg	Baxter

/λ	Subsidy /anufacturer's Price)	Full	
(1)	\$	Per	V	Manufacturer
MCITABINE HYDROCHLORIDE - PCT only - Specialist				
lnj 1 g	15.89	1	~	Gemcitabine Ebewe
, .	62.50		~	DBL Gemcitabine
	349.20		~	Gemzar
Inj 200 mg	8.36	1	~	Gemcitabine Ebewe
, ,	78.00		~	Gemzar
Inj 1 mg for ECP	0.02	1 mg	V	Baxter
NOTECAN HYDROCHLORIDE – PCT only – Specialist		0		
, i	11 50	1		Irinotecan Actavis
Inj 20 mg per ml, 2 ml vial	11.50	I	v	40
	44.00			
	41.00			Camptosar
				Irinotecan-Rex
Inj 20 mg per ml, 5 ml vial	17.80	1	V	Irinotecan Actavis
				100
	100.00			Camptosar
				Irinotecan-Rex
Inj 1 mg for ECP	0.19	1 mg	~	Baxter
RCAPTOPURINE – PCT – Retail pharmacy-Specialist				
Tab 50 mg	49.41	25	~	Puri-nethol
			·	
THOTREXATE				_ .
Tab 2.5 mg – PCT – Retail pharmacy-Specialist		30		Trexate
Tab 10 mg – PCT – Retail pharmacy-Specialist		50		Trexate
Inj 2.5 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist		5		Hospira
Inj 7.5 mg prefilled syringe	17.19	1	V	Methotrexate
	17.05			<u>Sandoz</u>
Inj 10 mg prefilled syringe	17.25	1	V	Methotrexate
	17.00			Sandoz
Inj 15 mg prefilled syringe	17.38	1	V	Methotrexate
				Sandoz
Inj 20 mg prefilled syringe	17.50	1	V	Methotrexate
	17.00			Sandoz
Inj 25 mg prefilled syringe	17.63	1	V	Methotrexate
L : 00 (11) L				Sandoz
Inj 30 mg prefilled syringe	17.75	1	V	Methotrexate
		_		<u>Sandoz</u>
Inj 25 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist		5		Hospira
Inj 25 mg per ml, 20 ml – PCT – Retail pharmacy-Specialist		1		Hospira
Inj 100 mg per ml, 10 ml – PCT – Retail pharmacy-Specialist		1		Methotrexate Ebewe
Inj 100 mg per ml, 50 ml – PCT – Retail pharmacy-Specialist		1		Methotrexate Ebewe
Inj 1 mg for ECP – PCT only – Specialist		1 mg		Baxter
Inj 5 mg intrathecal syringe for ECP – PCT only – Specialist	4.73 5	mg O	Ρ 🗸	Baxter
IOGUANINE – PCT – Retail pharmacy-Specialist				
Tab 40 mg	126.31	25	~	Lanvis
ther Cytotoxic Agents				
ISACRINE – PCT only – Specialist				
	1 500 00	e		Ameiding coo
Inj 50 mg per ml, 1.5 ml ampoule		6		Amsidine S29
lnj 75 mg	.1,250.00	5	~	AmsaLyo S29

	Subsidy (Manufacturer's Pric \$	e) Per	Full Subsidise	d Generic
ANAGRELIDE HYDROCHLORIDE - PCT - Retail pharmacy-Spe	cialist			
Cap 0.5 mg	CBS	100		Agrylin S29 Teva S29
ARSENIC TRIOXIDE - PCT only - Specialist			·	
Inj 10 mg	4,817.00	10	~	AFT S29
BLEOMYCIN SULPHATE – PCT only – Specialist				
Inj 15,000 iu, vial	150.48	1	~	DBL Bleomycin Sulfate
Inj 1,000 iu for ECP	11.64	1,000 i	u 🖌	Baxter
BORTEZOMIB - PCT only - Specialist - Special Authority see S	A1127 below			
lnj 1 mg	540.70	1	~	Velcade
Inj 3.5 mg	1,892.50	1	~	Velcade
Inj 1 mg for ECP	594.77	1 mg	~	Baxter

➡SA1127 Special Authority for Subsidy

Initial application — (Treatment naive multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria: Both:

- 1 Either:
 - 1.1 The patient has treatment-naive symptomatic multiple myeloma; or
 - 1.2 The patient has treatment-naive symptomatic systemic AL amyloidosis *; and
- 2 Maximum of 9 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Initial application — (Relapsed/refractory multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 The patient has relapsed or refractory multiple myeloma; or
 - 1.2 The patient has relapsed or refractory systemic AL amyloidosis *; and
- 2 The patient has received only one prior front line chemotherapy for multiple myeloma or amyloidosis; and
- 3 The patient has not had prior publicly funded treatment with bortezomib; and
- 4 Maximum of 4 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Renewal — (Relapsed/refractory multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: Both:

- 1 The patient's disease obtained at least a partial response from treatment with bortezomib at the completion of cycle 4; and
- 2 Maximum of 4 further treatment cycles (making a total maximum of 8 consecutive treatment cycles).

Notes: Responding relapsed/refractory multiple myeloma patients should receive no more than 2 additional cycles of treatment beyond the cycle at which a confirmed complete response was first achieved. A line of therapy is considered to comprise either:

- a) a known therapeutic chemotherapy regimen and supportive treatments; or
- b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments.

Refer to datasheet for recommended dosage and number of doses of bortezomib per treatment cycle.

COLASPASE [L-ASPARAGINASE] - PCT only - Specialist

Inj 10,000 iu	 1	Leunase
Inj 10,000 iu for ECP	 10,000 iu OP	 Baxter

	Subsidy		Fully Brand or
	(Manufacturer's	,	osidised Generic
	\$	Per	 Manufacturer
ACARBAZINE – PCT only – Specialist			
Inj 200 mg vial	51.84	1	Hospira
Inj 200 mg for ECP	51.84	200 mg OP	 Baxter
DACTINOMYCIN [ACTINOMYCIN D] – PCT only – Specialist			
Inj 0.5 mg vial		1	Cosmegen
Inj 0.5 mg for ECP		0.5 mg OP	✓ Baxter
		ere nig er	
AUNORUBICIN – PCT only – Specialist	110 70	1	✓ Pfizer
Inj 2 mg per ml, 10 ml Inj 20 mg for ECP		20 mg OP	✓ Prizer ✓ Baxter
	110.72	20 mg OF	
OCETAXEL – PCT only – Specialist			
Inj 20 mg		1	DBL Docetaxel
	48.75		Docetaxel Sandoz
Inj 20 mg per ml, 1 ml		1	✓ Taxotere
Inj 20 mg per ml, 4 ml		1	✓ Taxotere
Inj 80 mg		1	DBL Docetaxel
	195.00		Docetaxel Sandoz
Inj 1 mg for ECP	0.61	1 mg	Baxter
OXORUBICIN HYDROCHLORIDE - PCT only - Specialist			
Inj 2 mg per ml, 5 ml vial		1	Doxorubicin Ebewe
Inj 2 mg per ml, 25 ml vial		1	Doxorubicin Ebewe
	17.00		Arrow-Doxorubicin
Inj 50 mg vial	40.00	1	DBL Doxorubicin
, ,			DBL Doxorubicin
			S29 S29
Inj 2 mg per ml, 50 ml vial	23.00	1	Doxorubicin Ebewe
Inj 2 mg per ml, 100 ml vial		1	✓ Doxorubicin Ebewe
	65.00		✓ Arrow-Doxorubicin
	150.00		✓ Adriamycin
Inj 1 mg for ECP		1 mg	✓ Baxter
		i ng	• Buildi
PIRUBICIN HYDROCHLORIDE – PCT only – Specialist	05.00		. Coinchiein Chause
Inj 2 mg per ml, 5 ml vial		1	Epirubicin Ebewe
Inj 2 mg per ml, 25 ml vial		1	Epirubicin Ebewe
	39.38		DBL Epirubicin Hydrochlorido
Ini 0 mg nor ml E0 ml viol	00 50		Hydrochloride
Inj 2 mg per ml, 50 ml vial		1	Epirubicin Ebewe
	58.20		DBL Epirubicin
	05.00		Hydrochloride
Inj 2 mg per ml, 100 ml vial		1	Epirubicin Ebewe
	94.50		DBL Epirubicin
			Hydrochloride
Inj 1 mg for ECP	0.36	1 mg	 Baxter
TOPOSIDE			
Cap 50 mg – PCT – Retail pharmacy-Specialist	340.73	20	 Vepesid
Cap 100 mg - PCT - Retail pharmacy-Specialist	340.73	10	Vepesid
Inj 20 mg per ml, 5 ml vial - PCT - Retail pharmacy-Special	list7.90	1	Rex Medical
	25.00		 Hospira
	612.20	10	✓ Vepesid
Inj 1 mg for ECP – PCT only – Specialist	0.30	1 mg	✓ Baxter

	Subsidy (Manufacturer's Price \$	e) Per	Fully Subsidised	Generic
ETOPOSIDE PHOSPHATE – PCT only – Specialist Inj 100 mg (of etoposide base) Inj 1 mg (of etoposide base) for ECP		1 1 mg		Etopophos Baxter
HYDROXYUREA – PCT – Retail pharmacy-Specialist Cap 500 mg	31.76	100	~	Hydrea
IDARUBICIN HYDROCHLORIDE Inj 5 mg vial – PCT only – Specialist Inj 10 mg vial – PCT only – Specialist Inj 1 mg for ECP – PCT only – Specialist	250.00	1 1 1 mg	~	Zavedos Zavedos Baxter
LENALIDOMIDE – Retail pharmacy-Specialist – Special Authorit Wastage claimable – see rule 3.3.2 on page 13	y see SA1468 belo	w		
Cap 10 mg Cap 25 mg		21 21	· · ·	Revlimid Revlimid

➡SA1468 Special Authority for Subsidy

Initial application — (Relapsed/refractory disease) only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has relapsed or refractory multiple myeloma with progressive disease; and
- 2 Either:
 - 2.1 Lenalidomide to be used as third line* treatment for multiple myeloma; or
 - 2.2 Both:
 - 2.2.1 Lenalidomide to be used as second line treatment for multiple myeloma; and
 - 2.2.2 The patient has experienced severe (grade \geq 3), dose limiting, peripheral neuropathy with either bortezomib or thalidomide that precludes further treatment with either of these treatments; and
- 3 Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone.

Renewal only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 No evidence of disease progression; and

2 The treatment remains appropriate and patient is benefitting from treatment.

Note: Indication marked with * is an Unapproved Indication (refer to Interpretations and Definitions). A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.

MESNA

Tab 400 mg – PCT – Retail pharmacy-Specialist	227.50	50	 Uromitexan
Tab 600 mg – PCT – Retail pharmacy-Specialist	339.50	50	 Uromitexan
Inj 100 mg per ml, 4 ml ampoule - PCT only - Specialist	148.05	15	 Uromitexan
Inj 100 mg per ml, 10 ml ampoule - PCT only - Specialist	339.90	15	 Uromitexan
Inj 1 mg for ECP – PCT only – Specialist	2.47	100 mg	 Baxter
MITOMYCIN C – PCT only – Specialist			
Inj 5 mg vial	79.75	1	✓ <u>Arrow</u>
Inj 1 mg for ECP	16.43	1 mg	 Baxter
MITOZANTRONE - PCT only - Specialist			
Inj 2 mg per ml, 10 ml vial	97.50	1	 Mitozantrone Ebewe
Inj 1 mg for ECP	5.51	1 mg	 Baxter

	Subsidy (Manufacturer's Price \$) Per	Full Subsidise	d Generic
PACLITAXEL – PCT only – Specialist				
Inj 30 mg		5	~	Paclitaxel Ebewe
Inj 100 mg		1	~	Paclitaxel Ebewe
	91.67		~	Paclitaxel Actavis
Inj 150 mg		1	~	Paclitaxel Ebewe
	137.50		~	Anzatax
			~	Paclitaxel Actavis
lnj 300 mg		1	~	Paclitaxel Ebewe
	275.00		~	Anzatax
			~	Paclitaxel Actavis
Inj 600 mg	73.06	1	~	Paclitaxel Ebewe
Inj 1 mg for ECP		1 mg	~	Baxter
PEGASPARGASE - PCT only - Special Authority see SA1325 b	elow			
Inj 3,750 IU per 5 ml		1	~	Oncaspar S29

SA1325 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has newly diagnosed acute lymphoblastic leukaemia; and
- 2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and
- 3 Treatment is with curative intent.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has relapsed acute lymphoblastic leukaemia; and
- 2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and
- 3 Treatment is with curative intent.

PENTOSTATIN [DEOXYCOFORMYCIN] - PCT only - Specialist

Inj 10 mg	CBS	1	✓ Nipent S29
PROCARBAZINE HYDROCHLORIDE -	PCT – Retail pharmacy-Specialist		
Cap 50 mg		50	Natulan S29
TEMOZOLOMIDE - Special Authority see	e SA1063 below – Retail pharmacy		
Cap 5 mg		5	Temaccord
Cap 20 mg		5	Temaccord
Cap 100 mg		5	Temaccord
Cap 250 mg		5	✓ Temaccord

SA1063 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 10 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Patient has newly diagnosed glioblastoma multiforme; or
 - 1.2 Patient has newly diagnosed anaplastic astrocytoma*; and
- 2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and
- 3 Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m².

continued...

168

Subsidy	0	Fully	Brand or	
(Manufacturer's Price)		Ibsidised	Generic	
\$	Per	~	Manufacturer	

continued...

Notes: Indication marked with a * is an Unapproved Indication. Temozolomide is not subsidised for the treatment of relapsed glioblastoma multiforme. Reapplications will not be approved.

Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.

THALIDOMIDE	- PCT only - Specialist - Special Authority see SA1124 below	/	
Cap 50 mg		28	Thalomid
Cap 100 mg		28	 Thalomid

SA1124 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Fither:

=ither:

1 The patient has multiple myeloma; or

2 The patient has systemic AL amyloidosis*.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where the patient has obtained a response from treatment during the initial approval period. Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.

Tab 100 mg6.214.20

Indication marked with * is an Unapproved Indication.

IRETINOIN		
Cap 10 mg – PCT – Retail pharmacy-Specialist	100	Vesanoid
VINBLASTINE SULPHATE		
Inj 1 mg per ml, 10 ml vial – PCT – Retail pharmacy-Specialist37.29	1	Hospira
186.46	5	Hospira
Inj 1 mg for ECP – PCT only – Specialist4.14	1 mg	✓ Baxter
VINCRISTINE SULPHATE		
Inj 1 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist	5	Hospira
Inj 1 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist	5	✓ Hospira
Inj 1 mg for ECP – PCT only – Specialist	1 mg	Baxter
VINORELBINE – PCT only – Specialist		
Inj 10 mg per ml, 1 ml vial8.00	1	Navelbine
42.00		Vinorelbine Ebewe
Inj 10 mg per ml, 5 ml vial40.00	1	Navelbine
210.00		Vinorelbine Ebewe
Inj 1 mg for ECP0.90	1 mg	Baxter
Protein-tyrosine Kinase Inhibitors		
DASATINIB – Special Authority see SA0976 on the next page – [Xpharm]		
Tab 20 mg	60	Sprycel
Tab 50 mg6,214.20	60	Sprycel
100 00 mg	50	• • • • • • • • • • • • • • • • • • • •

Sprvcel

60

30

Subsidy		Fully	Brand or	
(Manufacturer's Price)	S	ubsidised	Generic	
\$	Per	~	Manufacturer	

SA0976 Special Authority for Subsidy

Special Authority approved by the CML/GIST Co-ordinator

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz, and prescriptions should be sent to:

The CML/GIST Co-ordinator	Phone: (04) 460 4990
PHARMAC	Facsimile: (04) 916 7571
PO Box 10 254	Email: cmlgistcoordinator@pharmac.govt.nz

Wellington

Special Authority criteria for CML - access by application

- a) Funded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase.
- b) Maximum dose of 140 mg/day for accelerated or blast phase, and 100 mg/day for chronic phase CML.
- c) Subsidised for use as monotherapy only.
- d) Initial approvals valid seven months.
- e) Subsequent approval(s) are granted on application and are valid for six months. The first reapplication (after seven months) should provide details of the haematological response. The third reapplication should provide details of the cytogenetic response after 14-18 months from initiating therapy. All other reapplications should provide details of haematological response, and cytogenetic response if such data is available. Applications to be made and subsequent prescriptions can be written by a haematologist or an oncologist.

Note: Dasatinib is indicated for the treatment of adults with chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib.

Guideline on discontinuation of treatment for patients with CML

- a) Prescribers should consider discontinuation of treatment if, after 6 months from initiating therapy, a patient did not obtain a haematological response as defined as any one of the following three levels of response:
 - a) complete haematologic response (as characterised by an absolute neutrophil count (ANC) > 1.5 × 10⁹/L, platelets > 100 × 10⁹/L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
 - b) no evidence of leukaemia (as characterised by an absolute neutrophil count (ANC) > 1.0 × 10⁹/L, platelets > 20 × 10⁹/L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
 - c) return to chronic phase (as characterised by BM and PB blasts < 15%, BM and PB blasts and promyelocytes < 30%, PB basophils < 20% and absence of extramedullary disease other than spleen and liver).</p>
- Prescribers should consider discontinuation of treatment if, after 18 months from initiating therapy, a patient did not obtain a major cytogenetic response defined as 0-35% Ph+ metaphases.

ERLOTINIB - Retail pharmacy-Specialist - Special Author	ority see SA1519 below		
Tab 100 mg		30	Tarceva
Tab 150 mg	1,500.00	30	Tarceva

SA1519 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
 - 1.2 There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and
 - 1.3 Any of the following:
 - 1.3.1 Patient is treatment naive; or
 - 1.3.2 Both:

Subsidy	Fully	Brand or
(Manufacturer's F	Price) Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 1.3.2.1 Patient has documented disease progression following treatment with first line platinum based chemotherapy: and
- 1.3.2.2 Patient has not received prior treatment with gefitinib; or

1.3.3 Both:

- 1.3.3.1 The patient has discontinued gefitinib within 6 weeks of starting treatment due to intolerance; and
- 1.3.3.2 The cancer did not progress while on gefitinib; and
- 1.4 Erlotinib is to be given for a maximum of 3 months: or
- 2 The patient received funded erlotinib prior to 31 December 2013 and radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

GEFITINIB - Retail pharmacy-Specialist

30 Iressa

SA1520 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria: All of the following:

- 1 Patient has locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
- 2 Fither:
 - 2.1 Patient is treatment naive; or
 - 2.2 Both:

2.2.1 The patient has discontinued erlotinib within 6 weeks of starting treatment due to intolerance; and

2.2.2 The cancer did not progress whilst on erlotinib; and

- 3 There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase; and
- 4 Gefitinib is to be given for a maximum of 3 months.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

IMATINIB MESILATE

Note: Imatinib-AFT is not a registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule.

Tab 100 mg - Special Authority see SA1460 below -

	[Xpharm]	2,400.00	60	Glivec
*	Cap 100 mg		60	Imatinib-AFT
*	Cap 400 mg		30	✓ Imatinib-AFT

SA1460 Special Authority for Subsidy

Special Authority approved by the CML/GIST Co-ordinator

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz, and prescriptions should be sent to:

The CML/GIST Co-ordinator	Phone: (04) 460 4990
PHARMAC	Facsimile: (04) 916 7571
PO Box 10 254	Email: cmlgistcoordinator@pharmac.govt.nz
Wellington	

Special Authority criteria for GIST âĂS access by application Funded for patients:

Subsidy (Manufacturer's			
(Manuacture) \$	Per Per	Manufacturer	

continued...

- a) With a diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST).
- b) Maximum dose of 400 mg/day.
- c) Applications to be made and subsequent prescriptions can be written by an oncologist.
- d) Initial and subsequent applications are valid for one year. The re-application criterion is an adequate clinical response to the treatment with imatinib (prescriber determined).

LAPATINIB DITOSYLATE - Special Authority see SA1191 below - Retail pharmacy

► SA1191 Special Authority for Subsidy

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The patient has not previously received trastuzumab treatment for HER 2 positive metastatic breast cancer; and
 - 1.3 Lapatinib not to be given in combination with trastuzumab; and
 - 1.4 Lapatinib to be discontinued at disease progression; or
- 2 All of the following:
 - 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2.2 The patient started trastuzumab for metastatic breast cancer but discontinued trastuzumab within 3 months of starting treatment due to intolerance; and
 - 2.3 The cancer did not progress whilst on trastuzumab; and
 - 2.4 Lapatinib not to be given in combination with trastuzumab; and
 - 2.5 Lapatinib to be discontinued at disease progression.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib; and
- 3 Lapatinib not to be given in combination with trastuzumab; and
- 4 Lapatinib to be discontinued at disease progression.

NILOTINIB - Special Authority see SA1489 below - Retail pharmacy

Wastage claimable – see rule 3.3.2 on page 13		
Cap 150 mg4,680.00	120	🖌 Tasigna
Cap 200 mg6,532.00	120	 Tasigna

SA1489 Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase; and
- 2 Either:
 - 2.1 Patient has documented CML treatment failure* with imatinib; or
 - 2.2 Patient has experienced treatment limiting toxicity with imatinib precluding further treatment with imatinib; and

	Subsidy (Manufacturer's Price) \$		Fully dised	Brand or Generic Manufacturer
ontinued 3 Maximum nilotinib dose of 800 mg/day; and 4 Subsidised for use as monotherapy only.				
Note: *treatment failure as defined by Leukaemia Net Guide Renewal only from a haematologist. Approvals valid for 6 m All of the following:		ting the follo	owing o	criteria:
 Lack of treatment failure while on nilotinib as define Nilotinib treatment remains appropriate and the pati Maximum nilotinib dose of 800 mg/day; and Subsidised for use as monotherapy only. 	,	,		
PAZOPANIB – Special Authority see SA1190 below – Retai Tab 200 mg Tab 400 mg	1,334.70	30 30		otrient

valid for 3 months for applications meeting the following criteria: All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 Both:

2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and

- 2.3.2 The cancer did not progress whilst on sunitinib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
- The patient has intermediate or poor prognosis defined as:
- 5 Any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of \leq 70; or
 - 5.6 \geq 2 sites of organ metastasis; and
- 6 Pazopanib to be used for a maximum of 3 months.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Pazopanib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

SUNITINIB - Special Authority see SA1266 on the next page -	Retail pharmacy		
Cap 12.5 mg	2,315.38	28	Sutent
Cap 25 mg	4,630.77	28	 Sutent
Cap 50 mg	9,261.54	28	 Sutent

Subsidy (Manufacturer's Price)	Ful Subsidise	,	Brand or Generic
\$	Per	/	Manufacturer

SA1266 Special Authority for Subsidy

Initial application — (RCC) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
 - 2.4 Both:
 - 2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
 - 2.4.2 The cancer did not progress whilst on pazopanib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
 - The patient has intermediate or poor prognosis defined as:
- 5 Any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of \leq 70; or
 - 5.6 \geq 2 sites of organ metastasis; and
- 6 Sunitinib to be used for a maximum of 2 cycles.

Initial application — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
- 2 Either:
 - 2.1 The patient's disease has progressed following treatment with imatinib; or
 - 2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

Renewal — (RCC) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Sunitinib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6

Renewal — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both:

The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:

- 1 Any of the following:
 - 1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- 1.2 The patient has had a partial response (a decrease in size of ≥ 10% or decrease in tumour density in Hounsfield Units (HU) of ≥ 15% on CT and no new lesions and no obvious progression of non measurable disease); or
- 1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of \geq 10% and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

in the existing intratamoral nodales.			
Endocrine Therapy			
For GnRH ANALOGUES – refer to HORMONE PREPARATIONS, T	rophic Hormone	es, page 85	
ABIRATERONE ACETATE - Retail pharmacy-Specialist - Special	Authority see S	A1515 belo	W
Wastage claimable – see rule 3.3.2 on page 13	4 076 10	100	A Tutino
Tab 250 mg	4,270.19	120	✓ Zytiga
SA1515 Special Authority for Subsidy nitial application only from a medical oncologist, radiation oncologist	nist urologist or	medical pra	actitioner on the recommendation of
a medical oncologist, radiation oncologist or urologist. Approvals va			
All of the following:			0 0
1 Patient has prostate cancer; and			
2 Patient has metastases; and			
 Patient's disease is castration resistant; and Either: 			
4.1 All of the following:			
4.1.1 Patient is symptomatic; and			
4.1.2 Patient has disease progression (rising serur	n PSA) after se	cond line an	ti-androgen therapy; and
4.1.3 Patient has ECOG performance score of 0-1			
4.1.4 Patient has not had prior treatment with taxa	ne chemotherap	by; or	
4.2 All of the following:4.2.1 Patient's disease has progressed following place	rior chomothora	ny containir	a a taxana: and
4.2.2 Patient has ECOG performance score of 0-2		py containin	iy a laxalle, allu
4.2.3 Patient has not had prior treatment with abira			
Renewal — (abiraterone acetate) only from a medical oncologis ecommendation of a medical oncologist, radiation oncologist or uro ollowing criteria: All of the following:			
1 Significant decrease in serum PSA from baseline; and			
2 No evidence of clinical disease progression; and			
 3 No initiation of taxane chemotherapy with abiraterone; and 4 The treatment remains appropriate and the patient is benefit 	fiting from troats	nont	
	nung nom neau	nont.	
3ICALUTAMIDE Tab 50 mg	4 90	28	Bicalaccord
LUTAMIDE – Retail pharmacy-Specialist		20	
Tab 250 mg		30	Flutamide
			Mylan \$29
	55.00	100	✓ Flutamin
	00.00	100	Fiuldinin

	Subsidy (Manufacturer's Price \$) Per	Fully Subsidised	Brand or Generic Manufacturer
MEGESTROL ACETATE – Retail pharmacy-Specialist	54.00			.
Tab 160 mg		30	V <u>A</u>	po-Megestrol
OCTREOTIDE				
Inj 50 mcg per ml, 1 ml vial		5	🖌 D	BL
Inj 100 mcg per ml, 1 ml vial		5	V 0)BL
Inj 500 mcg per ml, 1 ml vial		5)BL
OCTREOTIDE LAR (SOMATOSTATIN ANALOGUE) - Special Au	thority see SA1016	below	– Retail ph	armacy
Inj LAR 10 mg prefilled syringe	1,772.50	1	🖌 🖌 S	andostatin LAR
Inj LAR 20 mg prefilled syringe		1	🗸 S	andostatin LAR
Inj LAR 30 mg prefilled syringe	2,951.25	1	🗸 S	andostatin LAR

SA1016 Special Authority for Subsidy

Initial application — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

- 1 The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
- 2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
- 3 Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.

Note: Indications marked with * are Unapproved Indications.

Renewal — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 The patient has acromegaly; and
- 2 Any of the following:
 - 2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
 - 2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
 - 2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

Renewal — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 IGF1 levels have decreased since starting octreotide; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with Acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks

Initial application — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following:

- 1 VIPomas and Glucagonomas for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
- 2 Both:
 - 2.1 Gastrinoma; and
 - 2.2 Either:

Subsidy		Fully	Brand or
(Manufacturer's Price)	S	ubsidised	Generic
\$	Per	~	Manufacturer

continued...

- 2.2.1 Patient has failed surgery; or
- 2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or
- 3 Both:
 - 3.1 Insulinomas; and
 - 3.2 Surgery is contraindicated or has failed; or
- 4 For pre-operative control of hypoglycaemia and for maintenance therapy; or
- 5 Both:
 - 5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
 - 5.2 Disabling symptoms not controlled by maximal medical therapy.

Note: The use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will not be funded as a Special Authority item

Renewal — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

TAMOXIFEN CITRATE

*	Tab 10 mg17	.50	100	 Genox
*	Tab 20 mg2	2.63	30	Genox
	- 8	.75	100	Genox

Aromatase Inhibitors

ANASTROZOLE * Tab 1 mg26.55	30	 ✓ Aremed ✓ Arimidex ✓ DP-Anastrozole
EXEMESTANE	00	A Avenue in
* Tab 25 mg14.50	30	Aromasin
* Tab 2.5 mg	30	 Letrole
(4.85)		Letraccord
Letrole to be Sole Supply on 1 April 2016		

(Letraccord Tab 2.5 mg to be delisted 1 April 2016)

Immunosuppressants

Cytotoxic Immunosuppressants

AZATHIOPRINE – Retail pharmacy-Specialist			
* Tab 25 mg	8.28	60	 Azamun
* Tab 50 mg – For azathioprine oral liquid formu	lation refer,		
page 213		100	Azamun
* Inj 50 mg		1	 Imuran
MYCOPHENOLATE MOFETIL			
Tab 500 mg		50	 Cellcept
Cap 250 mg		100	 Cellcept
Powder for oral liq 1 g per 5 ml - Subsidy by endo	orsement 187.25	165 ml OP	✓ Cellcept

Mycophenolate powder for oral liquid is subsidised only for patients unable to swallow tablets and capsules, and when the prescription is endorsed accordingly.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
Fusion Proteins				
ETANERCEPT – Special Authority see SA1478 below – Retail pl	narmacy			
Inj 25 mg	799.96	4	🖌 E	nbrel
Inj 50 mg autoinjector	1,599.96	4	🖌 E	Inbrel
Inj 50 mg prefilled syringe		4	✔ E	Inbrel

➡SA1478 Special Authority for Subsidy

Initial application — (juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for juvenile idiopathic arthritis (JIA); and 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for JIA; or
- 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.2 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
 - 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
 - 2.5 Both:
 - 2.5.1 Either:
 - 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
 - 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
 - 2.5.2 Physician's global assessment indicating severe disease.

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

Subsidy		Fully	Brand or	
(Manufacturer's Price)	S	ubsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
- 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

2.6 Either:

- 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
- 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.7 Either:

- 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
- 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
 - 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
 - 2.4 The most recent PASI assessment is no more than 1 month old at the time of application.

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Sul	bsidised	Generic	
\$	Per	~	Manufacturer	

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. **Initial application — (ankylosing spondylitis)** only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal antiinflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
 - 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application.

Average normal chest expansion corrected for age and gender:

18-24 years - Male: 7.0 cm; Female: 5.5 cm

- 25-34 years Male: 7.5 cm; Female: 5.5 cm
- 35-44 years Male: 6.5 cm; Female: 4.5 cm
- 45-54 years Male: 6.0 cm; Female: 5.0 cm
- 55-64 years Male: 5.5 cm; Female: 4.0 cm
- 65-74 years Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or

Subsidy	Ful	ly Brand or
(Manufacturer's Price)	Subsidise	d Generic
\$	Per	 Manufacturer

continued...

- 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (pyoderma gangrenosum) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporine, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 4 doses.

Note: Indications marked with * are Unapproved Indications (refer to Interpretations and Definitions).

Initial application — (adult-onset Still's disease) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Fither:

- 1 Both:
 - 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for adalimumab for adult-onset Still's disease (AOSD); or
 - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or tocilizumab; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Subsidy	Fully	
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

Renewal — (juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Applicant is a named specialist or rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a named specialist or rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
 - 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
 - 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a dermatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 2.1.2 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-treatment baseline value; or
 - 2.2 Both:
 - 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 2.2.2 Either:

Subsidy	Ful	ly Brand or	
(Manufacturer's Price)	Subsidise	d Generic	
\$	Per	 Manufacturer 	

continued...

- 2.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
- 2.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Note: A treatment course is defined as a minimum of 12 weeks of etanercept treatment

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Following 12 weeks of etanercept treatment, BASDAI has improved by 4 or more points from pre-treatment baseline on a 10 point scale, or by 50%, whichever is less; and
- 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Renewal — (pyoderma gangrenosum) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 4 doses.

Renewal — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

1 Either:

- 1.1 Applicant is a rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 The patient has a sustained improvement in inflammatory markers and functional status.

(N	Subsidy Ianufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Immune Modulators				
ANTITHYMOCYTE GLOBULIN (EQUINE) – PCT only – Specialist Inj 50 mg per ml, 5 ml	2,351.25	5	🗸 A	TGAM
BACILLUS CALMETTE-GUERIN (BCG) VACCINE – PCT only – Sp Subsidised only for bladder cancer. Inj 2-8 × 100 million CFU		1	√ 0	ncoTICE
Inj 40 mg per ml, vial		3	🖌 SI	II-Onco-BCG S29
Monoclonal Antibodies				
ADALIMUMAB – Special Authority see SA1479 below – Retail pharr	nacy			
Inj 10 mg per 0.2 ml prefilled syringe	1,599.96	2	🖌 Н	umira
Inj 20 mg per 0.4 ml prefilled syringe	1,599.96	2	🖌 Н	umira
Inj 40 mg per 0.8 ml prefilled pen		2	🖌 Н	umiraPen
Inj 40 mg per 0.8 ml prefilled syringe	1,599.96	2	🖌 Н	umira

SA1479 Special Authority for Subsidy

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
 - 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

2.6 Either:

- 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
- 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.7 Either:

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	lbsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
- 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (Crohn's disease) only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
 - 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
 - 2.4 The most recent PASI assessment is no more than 1 month old at the time of application.

Subsidy		ully	Brand or	
(Manufacturer's Price)	Subsidi	sed	Generic	
\$	Per	V	Manufacturer	

continued...

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. **Initial application — (ankylosing spondylitis)** only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal antiinflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the following average normal values corrected for age and gender (see Notes); and
 - 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application.

Average normal chest expansion corrected for age and gender:

18-24 years - Male: 7.0 cm; Female: 5.5 cm

- 25-34 years Male: 7.5 cm; Female: 5.5 cm
- 35-44 years Male: 6.5 cm; Female: 4.5 cm
- 45-54 years Male: 6.0 cm; Female: 5.0 cm
- 55-64 years Male: 5.5 cm; Female: 4.0 cm
- 65-74 years Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for juvenile idiopathic arthritis (JIA); and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for juvenile idiopathic arthritis; or
- 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.2 Patient diagnosed with JIA; and
 - 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
 - 2.5 Both:
 - 2.5.1 Either:
 - 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
 - 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
 - 2.5.2 Physician's global assessment indicating severe disease.

Initial application — (fistulising Crohn's disease) only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subsid	dised	Generic	
\$	Per	~	Manufacturer	

continued...

- 1 Patient has confirmed Crohn's disease; and
- 2 Either:
 - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
 - 2.2 Patient has one or more rectovaginal fistula(e); and
- 3 A Baseline Fistula Assessment has been completed and is no more than 1 month old at the time of application; and
- 4 The patient will be assessed for response to treatment after 4 months' adalimumab treatment (see Note).

Note: A maximum of 4 months' adalimumab will be subsidised on an initial Special Authority approval for fistulising Crohn's disease. **Initial application — (pyoderma gangrenosum)** only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 4 doses.

Note: Note: Indications marked with * are Unapproved Indications (refer to (Interpretations and Definitions).

Initial application — (adult-onset Still's disease) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- Either:
 - 1 Both:
 - 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or
 - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
 - 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

Subsidy		Fully	Brand or	
(Manufacturer's Price)	S	ubsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 4 Either:
 - 4.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or
 - 4.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response.

Renewal — (Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Applicant is a gastroenterologist; or
 - 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Either:
 - 2.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
 - 2.1.2 CDAI score is 150 or less; or
 - 2.2 Both:
 - 2.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
 - 2.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Applicant is a dermatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 2.1.2 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
 - 2.2 Both:
 - 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 2.2.2 Either:
 - 2.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

	Subsidy	Full	Brand or	
()	Manufacturer's Price)	Subsidised	Generic	
	\$	Per 🖌	Manufacturer	

continued...

Note: A treatment course is defined as a minimum of 12 weeks adalimumab treatment

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Following 12 weeks of adalimumab treatment, BASDAI has improved by 4 or more points from pre-adalimumab baseline on a 10 point scale, or by 50%, whichever is less; and
- 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Applicant is a named specialist or rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a named specialist or rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Renewal — (fistulising Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Either:
 - 1.1 Applicant is a gastroenterologist; or

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and

2 Either:

- 2.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
- 2.2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

Renewal — (pyoderma gangrenosum) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 4 doses.

Renewal — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

1 Either:

- 1.1 Applicant is a rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 The patient has a sustained improvement in inflammatory markers and functional status.

OMALIZUMAB – Special Authority see SA1490 below – Retail pharmacy

SA1490 Special Authority for Subsidy

Initial application only from a respiratory specialist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient is over the age of 6; and
- 2 Patient has a diagnosis of severe, life threatening asthma; and
- 3 Past or current evidence of atopy, documented by skin prick testing or RAST; and
- 4 Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline; and
- 5 Proven compliance with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1600 micrograms per day or fluticasone propionate 1000 micrograms per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 micrograms bd or eformoterol 12 micrograms bd) for at least 12 months, unless contraindicated or not tolerated; and
- 6 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated; and
- 7 At least four admissions to hospital for a severe asthma exacerbation over the previous 24 months with at least one of those being in the previous 12 months; and
- 8 An Asthma Control Questionnaire (ACQ-5) score of at least 3.0 as assessed in the previous month .

Renewal only from a respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 Hospital admissions have been reduced as a result of treatment; and
- 2 A reduction in the Asthma Control Questionnaire (ACQ-5) score of at least 1.0 from baseline; and
- 3 A reduction in the maintenance oral corticosteroid dose of at least 50% from baseline.

RITUXIMAB - PCT only - Specialist - Special Authority see SA1152 on the next page

Inj 100 mg per 10 ml vial	2	🖌 Mabthera
Inj 500 mg per 50 ml vial2,688.30	1	 Mabthera
Inj 1 mg for ECP5.64	1 mg	 Baxter

Subsidy (Manufacturer's Price)	s	Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

SA1152 Special Authority for Subsidy

Initial application - (Post-transplant) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 2 To be used for a maximum of 8 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Initial application — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria: Either:

1 Both:

- 1.1 The patient has indolent low grade NHL with relapsed disease following prior chemotherapy; and
- 1.2 To be used for a maximum of 6 treatment cycles; or

2 Both:

- 2.1 The patient has indolent, low grade lymphoma requiring first-line systemic chemotherapy; and
- 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia

Initial application — (Aggressive CD20 positive NHL) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 All of the following:
 - 1.1 The patient has treatment naive aggressive CD20 positive NHL; and
 - 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent: and
 - 1.3 To be used for a maximum of 8 treatment cycles; or
- 2 Both:
 - 2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Initial application - (Chronic Lymphocytic Leukaemia) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
- 2 The patient is rituximab treatment naive; and
- 3 Either:
 - 3.1 The patient is chemotherapy treatment naive; or
 - 3.2 Both:
 - 3.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
 - 3.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; and
- 4 The patient has good performance status; and
- 5 The patient has good renal function (creatinine clearance \geq 30 ml/min); and
- 6 The patient does not have chromosome 17p deletion CLL; and
- 7 Rituximab to be administered in combination with fludarabine and cyclophosphamide for a maximum of 6 treatment cycles; and

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

8 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration).

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to <2.

Renewal — (Post-transplant) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 3 To be used for no more than 6 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Renewal — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria: All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.

Renewal — (Aggressive CD20 positive NHL) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

TRASTUZUMAB - PCT only - Specialist - Special Authority see SA1521 below

Inj 150 mg vial	50.00 1	 Herceptin
Inj 440 mg vial	375.00 1	 Herceptin
Inj 1 mg for ECP	9.36 1 mg	Baxter

SA1521 Special Authority for Subsidy

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer; and
 - 1.3 Trastuzumab not to be given in combination with lapatinib; and
 - 1.4 Trastuzumab to be discontinued at disease progression; or
- 2 All of the following:
 - 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- 2.2 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
- 2.3 The cancer did not progress whilst on lapatinib; and
- 2.4 Trastuzumab not to be given in combination with lapatinib; and
- 2.5 Trastuzumab to be discontinued at disease progression.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

- All of the following:
 - 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
 - 3 Trastuzumab not to be given in combination with lapatinib; and
 - 4 Trastuzumab to be discontinued at disease progression.

Initial application — (early breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria: All of the following:

- 1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH + (including FISH or other current technology); and
- 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
- 3 Any of the following:
 - 3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or
 - 3.4 12 months' treatment with neoadjuvant and adjuvant chemotherapy is planned; or
 - 3.5 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

Renewal — (early breast cancer*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The patient received prior adjuvant trastuzumab treatment for early breast cancer; and
- 3 Any of the following:
 - 3.1 All of the following:
 - 3.1.1 The patient has not previously received lapatinib treatment for metastatic breast cancer; and
 - 3.1.2 Trastuzumab not to be given in combination with lapatinib; and
 - 3.1.3 Trastuzumab to be discontinued at disease progression; or
 - 3.2 All of the following:
 - 3.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 3.2.2 The cancer did not progress whilst on lapatinib; and
 - 3.2.3 Trastuzumab not to be given in combination with lapatinib; and
 - 3.2.4 Trastuzumab to be discontinued at disease progression; or
 - 3.3 All of the following:
 - 3.3.1 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
 - 3.3.2 Trastuzumab not to be given in combination with lapatinib; and
 - 3.3.3 Trastuzumab to be discontinued at disease progression.

Note: * For patients with relapsed HER-2 positive disease who have previously received adjuvant trastuzumab for early breast cancer.

	Subsidy (Manufacturer's \$		Fully osidised	Brand or Generic Manufacturer
Other Immunosuppressants				
CICLOSPORIN Cap 25 mg Cap 50 mg Cap 100 mg Oral liq 100 mg per ml		50 50 50 50 ml OP	• ••	
EVEROLIMUS – Special Authority see SA1491 below – Retail pl Wastage claimable – see rule 3.3.2 on page 13 Tab 5 mg Tab 10 mg	4,555.76	30 30	• • •	finitor finitor

➡SA1491 Special Authority for Subsidy

Initial application only from a neurologist or oncologist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 Patient has tuberous sclerosis; and
- 2 Patient has progressively enlarging sub-ependymal giant cell astrocytomas (SEGAs) that require treatment.

Renewal only from a neurologist or oncologist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 Documented evidence of SEGA reduction or stabilisation by MRI within the last 3 months; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Everolimus to be discontinued at progression of SEGAs.

Note: MRI should be performed at minimum once every 12 months, more frequent scanning should be performed with new onset of symptoms such as headaches, visual complaints, nausea or vomiting, or increase in seizure activity.

SIROLIMUS - Special Authority see SA0866 below - Retail pharmacy

Tab 1 mg813.00	100	Rapamune
Tab 2 mg1,626.00	100	Rapamune
Oral liq 1 mg per ml487.80	60 ml OP	Rapamune

➡SA0866 Special Authority for Subsidy

Initial application from any medical practitioner. Approvals valid without further renewal unless notified where the drug is to be used for rescue therapy for an organ transplant recipient.

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR<30 ml/min; or
- Rapidly progressive transplant vasculopathy; or
- Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- Leukoencepthalopathy; or
- Significant malignant disease

TACROLIMUS - Special Authority see SA1540 on the next page - Retail pharmacy

Cap 0.5 mg	100	✓ Tacrolimus Sandoz
Cap 1 mg	100	✓ Tacrolimus Sandoz
Cap 5 mg – For tacrolimus oral liquid formulation refer, page		
213	50	Tacrolimus Sandoz

Subsidy (Manufacturer's Price		Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

➡SA1540 Special Authority for Subsidy

Initial application — (organ transplant) only from a relevant specialist. Approvals valid without further renewal unless notified where the patient is an organ transplant recipient.

Initial application — (steroid-resistant nephrotic syndrome*) only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either:

- 1 The patient is a child with steroid-resistant nephrotic syndrome* (SRNS) where ciclosporin has been trialled in combination with prednisone and discontinued because of unacceptable side effects or inadequate clinical response; or
- 2 All of the following:
 - 2.1 The patient is an adult with SRNS; and
 - 2.2 Ciclosporin has been trialled in combination with prednisone and discontinued because of unacceptable side effects or inadequate clinical response; and
 - 2.3 Cyclophosphamide or mycophenolate have been trialled and discontinued because of unacceptable side effects or inadequate clinical response, or these treatments are contraindicated.

Note: Indications marked with * are Unapproved Indications

Note: Subsidy applies for either primary or rescue therapy.

	Subsidy (Manufacturer's Price) \$	F Subsidi Per	iully Brand or sed Generic Manufacturer
Antiallergy Preparations			
Allergic Emergenices			
ICATIBANT – Special Authority see SA1558 below – Retail pharm Inj 10 mg per ml, 3 ml prefilled syringe	2,668.00		Firazyr nonths for applications meeting
 Supply for anticipated emergency treatment of laryngeal/or angioedema (HAE) for patients with confirmed diagnosis or 2 The patient has undergone product training and has agree Renewal from any relevant practitioner. Approvals valid for 12 mor 	of C1-esterase inhibited upon an action pla	or deficiency n for self-adı	r; and ministration.
benefiting from treatment. Allergy Desensitisation			
 SA1367 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid f Both: RAST or skin test positive; and Patient has had severe generalised reaction to the sensitis 		itions meetin	g the following criteria:
Renewal only from a relevant specialist. Approvals valid for 2 year benefiting from treatment.	ars where the treatm	ent remains	appropriate and the patient is
BEE VENOM ALLERGY TREATMENT – Special Authority see SA Maintenance kit - 6 vials 120 mcg freeze dried venom, 3 dilu- ent 1.8 ml			Venomil S29
Treatment kit - 1 vial 550 mcg freeze dried venom, 1 diluent 9 ml, 3 diluent 1.8 ml	305.00 1	OP •	Albey
WASP VENOM ALLERGY TREATMENT – Special Authority see S Treatment kit (Paper wasp venom) - 1 vial 550 mcg freeze dried polister venom, 1 diluent 9 ml, 1 diluent 1.8 ml Treatment kit (Paper wasp venom) - 6 vials 120 mcg freeze			Albey
dried venom Treatment kit (Yellow jacket venom) - 1 vial 550 mcg freeze dried vespula venom, 1 diluent 9 ml, 1 diluent 1.8 ml Treatment kit (Yellow jacket venom) - 6 vials 120 mcg freeze		OP •	✓ Venomil [™] \$29 ⁰ ✓ Albey
dried venom	305.00 1	OP I	Venomil S29
CETIRIZINE HYDROCHLORIDE			
* Tab 10 mg *: Oral liq 1 mg per ml CHLORPHENIRAMINE MALEATE			 Zetop <u>Histaclear</u>
*‡ Oral liq 2 mg per 5 ml		00 ml	 Histafen

	Subsidy (Manufacturer's I	Price) Sub	Fully Brand or sidised Generic
	\$	Per	Manufacturer
DEXTROCHLORPHENIRAMINE MALEATE			
* Tab 2 mg	2.02	40	
0	(8.40)		Polaramine
	1.01	20	
	(5.99)		Polaramine
₭‡ Oral liq 2 mg per 5 ml		100 ml	
	(10.29)		Polaramine
EXOFENADINE HYDROCHLORIDE	· · ·		
Tab 60 mg	1 21	20	
* Tab 00 Trig		20	Telfast
(Tab 100 mg	(11.53)	30	Tellast
 Tab 120 mg 		30	Talfaat
	(29.81) 4.74	10	Telfast
		10	Telfeet
	(11.53)		Telfast
ORATADINE			
 Tab 10 mg 	1.30	100	Lorafix
Oral liq 1 mg per ml	4.25	200 ml	LoraPaed
PROMETHAZINE HYDROCHLORIDE			
★ Tab 10 mg	1 78	50	✓ Allersoothe
 ► Tab 10 mg ★ Tab 25 mg 		50	✓ Allersoothe
-		100 ml	✓ <u>Allersoothe</u>
€‡ Oral liq 1 mg per 1 ml	2.09	100 111	Allersoottie
Inj 25 mg per ml, 2 ml ampoule – Up to 5 inj available on a	44.00	-	
PSO		5	 Hospira
RIMEPRAZINE TARTRATE			
Oral liq 30 mg per 5 ml	2.79	100 ml OP	
	(8.06)		Vallergan Forte
Inhaled Corticosteroids			
innaleu conticosteroius			
ECLOMETHASONE DIPROPIONATE			
Aerosol inhaler, 50 mcg per dose	9.30	200 dose OP	🖌 Qvar
Aerosol inhaler, 50 mcg per dose CFC-free		200 dose OP	✓ Beclazone 50
Aerosol inhaler, 100 mcg per dose		200 dose OP	V Qvar
Aerosol inhaler, 100 mcg per dose CFC-free		200 dose OP	✓ Beclazone 100
Aerosol inhaler, 250 mcg per dose CFC-free		200 dose OP	Beclazone 250
		200 0000 01	
BUDESONIDE			4 - • • •
Powder for inhalation, 100 mcg per dose	17.00	200 dose OP	✓ Pulmicort
			Turbuhaler
Powder for inhalation, 200 mcg per dose	19.00	200 dose OP	Pulmicort
			Turbuhaler
Powder for inhalation, 400 mcg per dose		200 dose OP	Pulmicort
			Turbuhaler

	Subsidy (Manufacturer's \$	Price) Si Per	Fully ubsidised	Generic
LUTICASONE				
Aerosol inhaler, 50 mcg per dose		120 dose Ol		Floair
Aerosol inhaler, 50 mcg per dose CFC-free		120 dose Ol	· /	Flixotide
Powder for inhalation, 50 mcg per dose		60 dose OF	~	Flixotide Accuhaler
Powder for inhalation, 100 mcg per dose	7.50	60 dose OF	~ ~	Flixotide Accuhaler
Aerosol inhaler, 125 mcg per dose	13.60	120 dose Ol	· 🗸	Floair
Aerosol inhaler, 125 mcg per dose CFC-free		120 dose Ol	· /	Flixotide
Aerosol inhaler, 250 mcg per dose		120 dose Ol		Floair
Aerosol inhaler, 250 mcg per dose CFC-free		120 dose Ol		Flixotide
Powder for inhalation, 250 mcg per dose	13.60	60 dose OF		Flixotide Accuhaler
nhaled Long-acting Beta-adrenoceptor Agonist	S			
FORMOTEROL FUMARATE				
Powder for inhalation, 6 mcg per dose, breath activated	10.32	60 dose OF	•	
	(16.90)			Oxis Turbuhaler
Powder for inhalation, 12 mcg per dose, and monodose de-				
vice	20.64	60 dose		
	(35.80)			Foradil
IDACATEROL				
Powder for inhalation 150 mcg	61.00	30 dose OF		Onbrez Breezhaler
Powder for inhalation 300 mcg	61.00	30 dose OF		Onbrez Breezhaler
ALMETEROL				
Aerosol inhaler CFC-free, 25 mcg per dose		120 dose Ol	• •	Serevent
Aerosol inhaler 25 mcg per dose		120 dose Ol	· /	Meterol
Powder for inhalation, 50 mcg per dose, breath activated		60 dose OF		Serevent Accuhaler
nhaled Corticosteroids with Long-Acting Beta-/	Adrenocept	or Agonist	s	
UDESONIDE WITH EFORMOTEROL – Special Authority see \$	SA1179 below -	- Retail pharm	acy	
Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg		120 dose Ol	• · 🗸 '	Vannair
Powder for inhalation 100 mcg with eformoterol fumarate)			
6 mcg		120 dose Ol	· 🗸	Symbicort
				Turbuhaler 100/6
Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg	31.25	120 dose Ol	· / ·	Vannair
Powder for inhalation 200 mcg with eformoterol fumarate				
6 mcg	60.00	120 dose Ol	• 🗸	Symbicort
				Turbuhaler 200/6
Powder for inhalation 400 mcg with eformoterol fumarate)			
12 mcg – No more than 2 dose per day	60.00	60 dose OF	· • • •	Symbicort

SA1179 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 All of the following:
 - 1.1 Patient is a child under the age of 12; and
 - 1.2 Has been treated with inhaled corticosteroids of at least 400 mcg per day beclomethasone or budesonide, or 200 mcg per day fluticasone; and

continued...

199

	Subsidy (Manufacturer's \$	Price) Per	Fully Subsidised	Brand or Generic Manufacturer
continued 1.3 The prescriber considers that the patient would re product; or	eceive addition	al clinical be	nefit from s	witching to a combinatior
 2 All of the following: 2.1 Patient is over the age of 12; and 2.2 Has been treated with inhaled corticosteroids of 		non nor dou	boolomoth	aaana ay hudaaanida .a
2.2 Has been neared with image concosteroids of 500 mcg per day fluticasone; and2.3 The prescriber considers that the patient would reproduct.				
Renewal from any relevant practitioner. Approvals valid for 2 ye benefiting from treatment.	ears where the	treatment re	mains appi	ropriate and the patient is
FLUTICASONE WITH SALMETEROL Aerosol inhaler 50 mcg with salmeterol 25 mcg		120 dose (exAir eretide
Aerosol inhaler 125 mcg with salmeterol 25 mcg	49.69	120 dose (DP VR	exAir eretide
Powder for inhalation 100 mcg with salmeterol 50 mcg – No more than 2 dose per day Powder for inhalation 250 mcg with salmeterol 50 mcg – No		60 dose C	P 🗸 S	eretide Accuhaler
more than 2 dose per day		60 dose C	P 🖌 S	eretide Accuhaler
Beta-Adrenoceptor Agonists				
SALBUTAMOL				
Oral liq 400 mcg per ml Infusion 1 mg per ml, 5 ml		150 ml 10	_	entolin entolin
Inj 500 mcg per ml, 1 ml – Up to 5 inj available on a PSO		5		entolin
Inhaled Beta-Adrenoceptor Agonists				
SALBUTAMOL				
Aerosol inhaler, 100 mcg per dose CFC free – Up to 1000 dose available on a PSO		200 dose (🖌 Sa	espigen alAir alamol
	(6.00)			entolin
Nebuliser soln, 1 mg per ml, 2.5 ml ampoule – Up to 30 neb available on a PSO	3.19	20	✓ <u>A</u>	sthalin
Nebuliser soln, 2 mg per ml, 2.5 ml ampoule – Up to 30 neb available on a PSO		20	✓ <u>A</u>	sthalin
TERBUTALINE SULPHATE Powder for inhalation, 250 mcg per dose, breath activated	22.00	200 dose (DP 🖌 B	ricanyl Turbuhaler

	Subsidy (Manufacturer's F \$	Price) Subs Per	Fully idised	Brand or Generic Manufacturer
Anticholinergic Agents				
IPRATROPIUM BROMIDE Aerosol inhaler, 20 mcg per dose CFC-free Nebuliser soln, 250 mcg per ml, 1 ml – Up to 40 neb available		200 dose OP	🗸 At	trovent
on a PSO Nebuliser soln, 250 mcg per ml, 2 ml – Up to 40 neb available	3.26	20	✓ <u>U</u>	nivent
on a PSO Inhaled Beta-Adrenoceptor Agonists with Antich		20	✓ <u>U</u>	nivent
SALBUTAMOL WITH IPRATROPIUM BROMIDE		genta		
Aerosol inhaler, 100 mcg with ipratropium bromide, 20 mcg per dose CFC-free Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per		200 dose OP	🖌 Di	uolin HFA
vial, 2.5 ml ampoule – Up to 20 neb available on a PSO Long-Acting Muscarinic Antagonists	3.59	20	✓ <u>D</u>	uolin

➡SA1485 Special Authority for Subsidy

Initial application only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and
- 2 In addition to standard treatment, the patient has trialled a short acting bronchodilator dose of at least 40 µg ipratropium q.i.d for one month; and
- 3 Either:
 - The patient's breathlessness according to the Medical Research Council (UK) dyspnoea scale is:
 - 3.1 Grade 4 (stops for breath after walking about 100 meters or after a few minutes on the level); or
 - 3.2 Grade 5 (too breathless to leave the house, or breathless when dressing or undressing); and
- 4 All of the following:

Applicant must state recent measurement of:

- 4.1 Actual FEV₁ (litres); and
- 4.2 Predicted FEV₁ (litres); and
- 4.3 Actual FEV₁ as a % of predicted (must be below 60%); and
- 5 Either:
 - 5.1 Patient is not a smoker (for reporting purposes only); or
 - 5.2 Patient is a smoker and has been offered smoking cessation counselling; and
- 6 The patient has been offered annual influenza immunisation.

Renewal only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient is compliant with the medication; and
- 2 Patient has experienced improved COPD symptom control (prescriber determined); and
- 3 All of the following:
 - Applicant must state recent measurement of:
 - 3.1 Actual FEV₁ (litres); and
 - 3.2 Predicted FEV1 (litres); and
 - 3.3 Actual FEV₁ as a % of predicted.

	Subsidy (Manufacturer's Pri \$	ce) Sub Per	Fully sidised	Brand or Generic Manufacturer
GLYCOPYRRONIUM – Special Authority see SA1485 on the prev Glycopyrronium treatment will not be subsidised if patient is a Powder for inhalation 50 mcg per dose	lso receiving treat			d tiotropium. eebri Breezhaler
TIOTROPIUM BROMIDE – Special Authority see SA1485 on the Tiotropium treatment will not be subsidised if patient is also re Powder for inhalation, 18 mcg per dose	eceiving treatment		ed glyc	opyrronium. piriva
Leukotriene Receptor Antagonists				
MONTELUKAST – Special Authority see SA1421 below – Retail Prescribing Guideline: Clinical evidence indicates that the effer in short treatment courses.	. ,	telukast is str	ongest	when montelukast is used
Tab 4 mg		28	🗸 Si	ingulair
Tab 5 mg		28	🖌 Si	ingulair
Tab 10 mg		28	🗸 Si	ingulair
►SA1421 Special Authority for Subsidy Initial application — (Pre-school wheeze) from any relevant pr	actitioner. Approv	als valid for 1	vear fo	or applications meeting the

- Both:
 - To be used for the treatment of intermittent severe wheezing (possibly viral) in children under 5 years; and
 The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical
 - 2 The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention.

Renewal — (Pre-school wheeze) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (exercise-induced asthma) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

following criteria:

- 1 Patient has been trialled with maximal asthma therapy, including inhaled corticosteroids and long-acting beta-adrenoceptor agonists; and
- 2 Patient continues to receive optimal inhaled corticosteroid therapy; and
- 3 Patient continues to experience frequent episodes of exercise-induced bronchoconstriction.

Initial application — (aspirin desensitisation) only from a clinical immunologist or allergist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient is undergoing aspirin desensitisation therapy under the supervision of a Clinical Immunologist or Allergist; and
- 2 Patient has moderate to severe aspirin-exacerbated respiratory disease or Samter's triad; and
- 3 Nasal polyposis, confirmed radiologically or surgically; and
- 4 Documented aspirin or NSAID allergy confirmed by aspirin challenge or a clinical history of severe reaction to aspirin or NSAID where challenge would be considered dangerous.

Mast Cell Stabilisers

NEDOCROMIL

Aerosol inhaler, 2 mg per dose CFC-free	112 dose OP	 Tilade
SODIUM CROMOGLYCATE		
Powder for inhalation, 20 mg per dose		 ✓ Intal Spincaps ✓ Intal Forte CFC Free
	112 0000 01	

	Subsidy		Fully	Brand or
	(Manufacturer's	Price) Sub Per	sidised	Generic
	\$	Per	~	Manufacturer
Methylxanthines				
AMINOPHYLLINE				
* Inj 25 mg per ml, 10 ml ampoule - Up to 5 inj available on a	l			
PSO	118.25	5	✓ DI	3L Aminophylline
THEOPHYLLINE				
* Tab long-acting 250 mg *1 Oral lig 80 mg per 15 ml		100 500 ml		Jelin-SR
	10.00	500 111		
Mucolytics				
DORNASE ALFA - Special Authority see SA0611 below - Retail				
Nebuliser soln, 2.5 mg per 2.5 ml ampoule		6	🖌 Pi	ılmozyme
► SA0611 Special Authority for Subsidy				
Special Authority approved by the Cystic Fibrosis Advisory Panel Notes: Application details may be obtained from PHARMAC's we	bsite http://www	v.pharmac.govt	nz or:	
	4) 460 4990			
	(04) 916 7571			
	Panel@pharma	<u> </u>		
Prescriptions for patients approved for treatment must be written and expertise in treating cystic fibrosis.	by respiratory p	physicians or pa	ediatrici	ans who have experience
SODIUM CHLORIDE				
Not funded for use as a nasal drop.				
Soln 7%	23.50	90 ml OP	🖌 Bi	omed
Nasal Preparations				
Allergy Prophylactics				
BECLOMETHASONE DIPROPIONATE				
Metered aqueous nasal spray, 50 mcg per dose		200 dose OP		
Metered aqueous nasal spray, 100 mcg per dose	(4.85) 2.46	200 dose OP	AI	anase
	(5.75)	200 0000 0.	Al	anase
BUDESONIDE				
Metered aqueous nasal spray, 50 mcg per dose		200 dose OP	_	
Matarad aquaque pasal spray 100 mag par doso	(4.85)	200 dose OP	Βι	itacort Aqueous
Metered aqueous nasal spray, 100 mcg per dose	2.61 (5.75)	200 dose OP	Bi	itacort Aqueous
FLUTICASONE PROPIONATE	()		2.	
Metered aqueous nasal spray, 50 mcg per dose	2.18	120 dose OP	✓ <u>FI</u>	ixonase Hayfever
				& Allergy
	0.05	45 - 105		· · · · · ·
Aqueous nasal spray, 0.03%	3.95	15 ml OP	✓ <u>U</u>	nivent

	Subsidy (Manufacturer's Price) \$	Su Per	Fully bsidised	Brand or Generic Manufacturer
Respiratory Devices				
MASK FOR SPACER DEVICE a) Up to 20 dev available on a PSO b) Only on a PSO c) Only for children aged six years and under Small	2.20	1	√ <u>e</u> -	chamber Mask
PEAK FLOW METER a) Up to 10 dev available on a PSO b) Only on a PSO				
Low range	9.54	1		ini-Wright AFS Low Range
Normal range	9.54	1		ini-Wright Standard
SPACER DEVICE				
a) Up to 20 dev available on a PSO b) Only on a PSO				
220 ml (single patient)	2.95	1	🖌 <u>e</u> -	chamber Turbo
510 ml (single patient)	5.12	1	•••	chamber La Grande
800 ml	8.50	1	🖌 Vo	olumatic
Respiratory Stimulants				
CAFFEINE CITRATE Oral liq 20 mg per ml (10 mg base per ml)		5 ml OP	🗸 Bi	iomed

	<u> </u>			
	Subsidy	Duine) Cub	Fully Brand or	
	(Manufacturer's \$	Price) Sub Per	osidised Generic Manufacturer	
	φ	Fei		
Ear Preparations				
ACETIC ACID WITH 1, 2- PROPANEDIOL DIACETATE AND BEN	ZETHONIUM			
For Vosol ear drops with hydrocortisone powder refer Standa		ap 216		
Ear drops 2% with 1, 2-Propanediol diacetate 3% and		90 210		
benzethonium chloride 0.02%		35 ml OP	Vosol	
	0.07		• 10001	
FLUMETASONE PIVALATE			.	
Ear drops 0.02% with clioquinol 1%	4.46	7.5 ml OP	 Locacorten-Viafo 	orm
			ED's	
			 Locorten-Vioforr 	n
TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCI	N AND NYSTAT	IN		
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate				
2.5 mg and gramicidin 250 mcg per g		7.5 ml OP	Kenacomb	
Ear/Eye Preparations				
DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN				
Ear/Eye drops 500 mcg with framycetin sulphate 5 mg and				
gramicidin 50 mcg per ml		8 ml OP		
	(9.27)		Sofradex	
FRAMYCETIN SULPHATE				
Ear/Eye drops 0.5%	4.13	8 ml OP		
	(8.65)		Soframycin	
Euo Droporationa			-	
Eye Preparations				
Eye preparations are only funded for use in the eye, unless explic	itly stated otherv	vise.		
Anti-Infective Preparations				
ACICLOVIR				
* Eye oint 3%		4.5 g OP	Zovirax	
CHLORAMPHENICOL				
Eye oint 1%		4 g OP	Chlorsig	
Eye drops 0.5%		10 ml OP	Chlorafast	
Funded for use in the ear*. Indications marked with * are l				
CIPROFLOXACIN				
Eye Drops 0.3%	12 43	5 ml OP	Ciloxan	
For treatment of bacterial keratitis or severe bacterial conju				
FUSIDIC ACID	4 50			
Eye drops 1%	4.50	5 g OP	 Fucithalmic 	
GANCICLOVIR				
Eye gel 0.15%		5 g OP	Virgan S29	
GENTAMICIN SULPHATE		-	-	
Eye drops 0.3%	11 /0	5 ml OP	 Genoptic 	
		5111 01		
PROPAMIDINE ISETHIONATE				
* Eye drops 0.1%		10 ml OP		
	(7.99)		Brolene	

	Subsidy (Manufacturer's I \$	Price) Sub Per	Fully Brand or osidised Generic ✔ Manufacturer
TOBRAMYCIN Eye oint 0.3% Eye drops 0.3%		3.5 g OP 5 ml OP	✓ <u>Tobrex</u> ✓ <u>Tobrex</u>
Corticosteroids and Other Anti-Inflammatory Pr	reparations		
DEXAMETHASONE * Eye oint 0.1% * Eye drops 0.1% DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYI * Eye oint 0.1% with neomycin sulphate 0.35% and polymyxi	4.50 MYXIN B SULPH	3.5 g OP 5 ml OP ATE	✓ <u>Maxidex</u> ✓ <u>Maxidex</u>
 Eye one of the with hearingen existing of existing and polymytal b sulphate 6,000 u per g Eye drops 0.1% with neomycin sulphate 0.35% and polymy xin b sulphate 6,000 u per ml 	5.39 -	3.5 g OP 5 ml OP	 ✓ <u>Maxitrol</u> ✓ Maxitrol
DICLOFENAC SODIUM * Eye drops 0.1%		5 ml OP	✓ <u>Voltaren Ophtha</u>
FLUOROMETHOLONE * Eye drops 0.1%		5 ml OP	✓ <u>FML</u>
LEVOCABASTINE Eye drops 0.5 mg per ml	8.71 (10.34)	4 ml OP	Livostin
LODOXAMIDE Eye drops 0.1%	8.71	10 ml OP	✓ Lomide
PREDNISOLONE ACETATE * Eye drops 0.12% * Eye drops 1%		5 ml OP 5 ml OP	Pred MildPred Forte
PREDNISOLONE SODIUM PHOSPHATE – Special Authority se Eye drops 0.5%, single dose (preservative free)		r – Retail pharr 20 dose	nacy Minims Prednisolone

➡SA1547 Special Authority for Subsidy

Initial application only from an ophthalmologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient has severe inflammation; and
- 2 Patient has a confirmed allergic reaction to preservative in eye drops.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

SODIUM CROMOGLYCATE

Eye drops 2%0.85	5 ml OP	✓ <u>Rexacrom</u>
Glaucoma Preparations - Beta Blockers		
BETAXOLOL * Eye drops 0.25%	5 ml OP 5 ml OP	 ✓ <u>Betoptic S</u> ✓ <u>Betoptic</u>
LEVOBUNOLOL * Eye drops 0.5%7.00	5 ml OP	✔ Betagan

	Subsidy		Fully Brand or
	(Manufacturer's F \$	Price) Sub Per	osidised Generic ✓ Manufacturer
	ψ		
TIMOLOL			4
* Eye drops 0.25%		5 ml OP	Arrow-Timolol
* Eye drops 0.25%, gel forming		2.5 ml OP	Timoptol XE
* Eye drops 0.5%		5 ml OP	Arrow-Timolol
* Eye drops 0.5%, gel forming		2.5 ml OP	Timoptol XE
Glaucoma Preparations - Carbonic Anhydrase I	nhibitors		
ACETAZOLAMIDE			
* Tab 250 mg - For acetazolamide oral liquid formulation refer			
page 213		100	Diamox
1 0			·
BRINZOLAMIDE	0.77		Azont
* Eye Drops 1%	9.77	5 ml OP	 Azopt
DORZOLAMIDE HYDROCHLORIDE			
* Eye drops 2%	9.77	5 ml OP	
	(17.44)		Trusopt
DORZOLAMIDE WITH TIMOLOL			
* Eye drops 2% with timolol 0.5%	3.45	5 ml OP	Arrow-Dortim
,	(15.50)		Cosopt
Arrow-Dortim to be Sole Supply on 1 March 2016	()		
(Cosopt Eye drops 2% with timolol 0.5% to be delisted 1 March 2	016)		
Glaucoma Preparations - Prostaglandin Analog	ues		
BIMATOPROST	10 50		
* Eye drops 0.03%		3 ml OP	Lumigan
LATANOPROST			
* Eye drops 0.005%	1.50	2.5 ml OP	✓ <u>Hysite</u>
TRAVOPROST			
* Eye drops 0.004%		2.5 ml OP	✓ Travatan
Glaucoma Preparations - Other			
BRIMONIDINE TARTRATE			
* Eye drops 0.2%	4.32	5 ml OP	Arrow-Brimonidine
BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE			
* Eye drops 0.2% with timolol maleate 0.5%		5 ml OP	Combigan
PILOCARPINE HYDROCHLORIDE			•
* Eye drops 1%	4 26	15 ml OP	Isopto Carpine
* Eye drops 1%		15 ml OP	✓ Isopto Carpine
		15 ml OP	
* Eye drops 4%		15 III OP	Isopto Carpine
Subsidised for oral use pursuant to the Standard Formulae Eye drops 2% single dose – Special Authority see SA0895			
		20 dose	Minime Dilocarnine
on the next page – Retail pharmacy		20 0058	Minims Pilocarpine

SENSORY ORGANS

Subsidy facturer's Price) Subs	Fully	Brand or Generic
\$ Per	~	Manufacturer

➡SA0895 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 Patient has to use an unpreserved solution due to an allergy to the preservative; or
- 2 Patient wears soft contact lenses.

Note: Minims for a general practice are considered to be "tools of trade" and are not approved as special authority items. **Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Mydriatics and Cycloplegics

	SULPHATE	
AINUTINE	SULFIAIE	

* Eye drops 1%	15 ml OP	✓ <u>Atropt</u>
CYCLOPENTOLATE HYDROCHLORIDE * Eye drops 1%8.76	15 ml OP	✓ Cyclogyl
TROPICAMIDE * Eye drops 0.5% * Eye drops 1%		 ✓ <u>Mydriacyl</u> ✓ <u>Mydriacyl</u>

Preparations for Tear Deficiency

For acetylcysteine eye drops refer Standard Formulae, page 216

HYPROMELLOSE * Eye drops 0.5%	2.00	15 ml OP	
	(3.92)		Methopt
HYPROMELLOSE WITH DEXTRAN * Eye drops 0.3% with dextran 0.1%	2.30	15 ml OP	Poly-Tears
POLYVINYL ALCOHOL * Eye drops 1.4%		15 ml OP 15 ml OP	✔ Vistil✔ Vistil Forte
* Eye drops 3%	3.75	15 mi OP	Visui Porte

Preservative Free Ocular Lubricants

SA1388 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Both:

1 Confirmed diagnosis by slit lamp of severe secretory dry eye; and

- 2 Either:
 - 2.1 Patient is using eye drops more than four times daily on a regular basis; or
 - 2.2 Patient has had a confirmed allergic reaction to preservative in eye drop.

Renewal from any relevant practitioner. Approvals valid for 24 months where the patient continues to require lubricating eye drops and has benefited from treatment.

Hylo-Fresh has a 6 month expiry after opening. The Pharmacy Procedures Manual restriction allowing one bottle per month is not relevant and therefore only the prescribed dosage to the nearest OP may be claimed.

SENSORY ORGANS

	Subsidy (Manufacturer's Pr \$	rice) Subs Per	Fully sidised	Brand or Generic Manufacturer
Other Eye Preparations				
NAPHAZOLINE HYDROCHLORIDE * Eye drops 0.1%	4.15	15 ml OP	✓ <u>Na</u>	aphcon Forte
OLOPATADINE Eye drops 0.1%	17.00	5 ml OP	🖌 Pa	atanol
PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN * Eye oint with soft white paraffin	3.63	3.5 g OP	🖌 Re	efresh Night Time
PARAFFIN LIQUID WITH WOOL FAT * Eye oint 3% with wool fat 3%	3.63	3.5 g OP	✓ Po	oly-Visc
RETINOL PALMITATE Eye oint 138 mcg per g	3.80	5 g OP	🖌 Vi	itA-POS

(N	Subsidy anufacturer's Price \$) Per	Fully Subsidised	Brand or Generic Manufacturer
arious				
ay only be claimed once per patient.				
IARMACY SERVICES				
Brand switch fee	4.33	1 fee	🗸 В	
The Pharmacode for BSF Apo-Mirtazapine is 2493489 - see a SF Apo-Mirtazapine Brand switch fee to be delisted 1 May 2016)	Ilso page 132			Apo-Mirtazapine
gents Used in the Treatment of Poisonings				
Intidotes				
ETYLCYSTEINE – Retail pharmacy-Specialist				
Inj 200 mg per ml, 10 ml ampoule	78.34	10		BL Acetylcysteine
ALOXONE HYDROCHLORIDE a) Up to 5 inj available on a PSO				
b) Only on a PSO				
Inj 400 mcg per ml, 1 ml ampoule	48.84	5	🖌 Н	lospira
emoval and Elimination				
IARCOAL				
Oral liq 50 g per 250 mla) Up to 250 ml available on a PSO b) Only on a PSO	43.50 25	50 ml O	P 🗸 C	Carbosorb-X
EFERASIROX – Special Authority see SA1492 below – Retail pha	macy			
Wastage claimable – see rule 3.3.2 on page 13	macy			
Tab 125 mg dispersible		28		xjade
Tab 250 mg dispersible		28		xjade
Tab 500 mg dispersible	1,105.00	28	VE	xjade
SA1492 Special Authority for Subsidy tial application only from a haematologist. Approvals valid for 2 y of the following:	ears for application	ons me	eting the fo	llowing criteria:
1 The patient has been diagnosed with chronic iron overload o	ue to congenital	inherite	ed anaemia	; and
 2 Deferasirox is to be given at a daily dose not exceeding 40 n 3 Any of the following: 	ng/kg/day; and			
3.1 Treatment with maximum tolerated doses of deferipr				
nation therapy have proven ineffective as measured				liac MRI T2*; or
3.2 Treatment with deferiprone has resulted in severe pe3.3 Treatment with deferiprone has resulted in arthritis; or	•	or diari	noea; or	
3.4 Treatment with deferiprone is contraindicated due to count (ANC) of < 0.5 cells per µL) or recurrent episo	a history of agran			
$0.5 - 1.0$ cells per μ L).		المعالم م		
enewal only from a haematologist. Approvals valid for 2 years for a	oplications meeti	na the t	tollowing cr	iteria:

- 1 For the first renewal following 2 years of therapy, the treatment has been tolerated and has resulted in clinical improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels; or
- 2 For subsequent renewals, the treatment has been tolerated and has resulted in clinical stability or continued improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels.

VARIOUS

	Subsidy (Manufacturer's P	rice)	Fully Subsidised	Brand or Generic
	`\$		~	Manufacturer
DEFERIPRONE – Special Authority see SA1480 belo	w – Retail pharmacy			
Tab 500 mm	533 17	100	🖌 Fo	erriprox
Tab 500 mg		100		

➡SA1480 Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; or
- 2 The patient has been diagnosed with chronic iron overload due to acquired red cell aplasia.

DESFERRIOXAMINE MESILATE

* Inj 500 mg vial	51.52	10	Desferal
, .	(109.89)		Hospira
Desferal to be Sole Supply on 1 May 2016			
(Hospira Inj 500 mg vial to be delisted 1 May 2016)			
SODIUM CALCIUM EDETATE			
* Inj 200 mg per ml, 5 ml	53.31	6	
	(156.71)		Calcium Disodium Versenate

INTRODUCTION

The following extemporaneously compounded products are eligible for subsidy:

- The "Standard Formulae".
- Oral liquid mixtures for patients unable to swallow subsidised solid dose oral formulations.
- The preparation of syringe drivers when prescribed by a general practitioner.
- Dermatological preparations
 - a) One or more subsidised dermatological galenical(s) in a subsidised dermatological base.
 - b) Dilution of proprietary Topical Corticosteroid-Plain preparations with a dermatological base (Retail pharmacyspecialist).
 - c) Menthol crystals only in the following bases:

Aqueous cream

Urea cream 10%

Wool fat with mineral oil lotion

Hydrocortisone 1% with wool fat and mineral oil lotion

Glycerol, paraffin and cetyl alcohol lotion.

Glossary

Dermatological base: The products listed in the Barrier creams and Emollients section and the Topical Corticosteroids-Plain section of the Pharmaceutical Schedule are classified as dermatological bases for the purposes of extemporaneous compounding and are the bases to which the dermatological galenicals can be added. Also the dermatological bases in the Barrier Creams and Emollients section of the Pharmaceutical Schedule can be used for diluting proprietary Topical Corticosteroid-Plain preparations. The following products are dermatological bases:

- Aqueous cream
- Cetomacrogol cream BP
- Collodion flexible
- Emulsifying ointment BP
- Hydrocortisone with wool fat and mineral oil lotion
- Oil in water emulsion
- Urea cream 10%
- White soft paraffin
- Wool fat with mineral oil lotion
- Zinc and castor oil ointment BP
- Proprietary Topical Corticosteroid-Plain preparations

Dermatological galenical: Dermatological galenicals will only be subsidised when added to a dermatological base. More than one dermatological galenical can be added to a dermatological base.

The following are dermatological galenicals:

- Coal tar solution up to 10%
- Hydrocortisone powder up to 5%
- Menthol crystals
- Salicylic acid powder
- Sulphur precipitated powder

Standard formulae: Standard formulae are a list of fomulae for ECPs that are subsidised. Their ingredients are listed under the appropriate therapeutic heading in Section B of the Pharmaceutical Schedule and also in Section C.

Explanatory notes

Oral liquid mixtures

Oral liquid mixtures are subsidised for patients unable to swallow subsidised solid oral dose forms where no suitable alternative proprietary formulation is subsidised. Suitable alternatives include dispersible and sublingual formulations, oral liquid formulations or rectal formulations. Before extemporaneously compounding an oral liquid mixture, other alternatives such as dispersing the solid dose form (if appropriate) or crushing the solid dose form in jam, honey or soft foods such as yoghurt should be explored.

The Emixt website **www.pharminfotech.co.nz** has evidence-based formulations which are intended to standardise compounded oral liquids within New Zealand.

Pharmaceuticals with standardised formula for compounding in Ora products

Acetazolamide 25 mg/ml	Flecainide 20 mg/ml	Rifabutin 20 mg/ml
Allopurinol 20 mg/ml	Gabapentin 100 mg/ml	Sildenafil 2 mg/ml
Amlodipine 1 mg/ml	Hydrocortisone 1 mg/ml	Sotalol 5 mg/ml
Azathioprine 50 mg/ml	Labetolol 10 mg/ml	Sulphasalazine 100 mg/ml
Baclofen 10 mg/ml	Levetiracetam 100 mg/ml	Tacrolimus 1 mg/ml
Carvedilol 1 mg/ml	Levodopa with carbidopa (5 mg lev-	Terbinafine 25 mg/ml
Clopidogrel 5 mg/ml	odopa + 1.25 mg carbidopa)/ml	Tramadol 10 mg/ml
Diltiazem hydrochloride 12 mg/ml	Metoclopramide 1 mg/ml	Ursodeoxycholic acid 50 mg/ml
Dipyridamole 10 mg/ml	Metoprolol tartrate 10 mg/ml	Valganciclovir 60 mg/ml*
Domperidone 1 mg/ml	Nitrofurantoin 10 mg/ml	Verapamil hydrochloride 50 mg/ml
Enalapril 1 mg/ml	Pyrazinamide 100 mg/ml	

*Note this is a DCS formulation

PHARMAC endorses the recommendations of the Emixt website and encourages New Zealand pharmacists to use these formulations when compounding is appropriate. The Emixt website also provides stability and expiry data for compounded products. For the majority of products compounded with Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet or Ora-Sweet SF a four week expiry is appropriate.

Please note that no oral liquid mixture will be eligible for Subsidy unless all the requirements of Section B and C of the Schedule applicable to that pharmaceutical are met.

Some community pharmacies may not have appropriate equipment to compound all of the listed products, please use appropriate clinical judgement.

Subsidy for extemporaneously compounded oral liquid mixtures is based on:

Solid dose form	qs
Preservative	qs
Suspending agent	qs
Water	to 100%

or

Solid dose form

qs

Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and/or Ora-Sweet SF to 100% Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients such as flavouring and colouring agents, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

The majority of extemporaneously compounded oral liquid mixtures should contain a preservative and suspending agent.

- Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and Ora-Sweet SF when used correctly are an appropriate preservative and suspending agent.
- Methylcellulose 3% is considered a suitable suspending agent and compound hydroxybenzoate solution or methyl hydroxybenzoate 10% solution are considered to be suitable preservatives. Usually 1 ml of these preservative solutions is added to 100 ml of oral liquid mixture.

Some solid oral dose forms are not appropriate for compounding into oral liquid mixtures and should therefore not be used/considered for extemporaneously compounded oral liquid mixtures. This includes long-acting solid dose formulations, enteric coated tablets or capsules, sugar coated tablets, hard gelatin capsules and chemotherapeutic agents.

The following practices will not be subsidised:

- Where a Standard Formula exists in the Pharmaceutical Schedule for a solid dose form, compounding the solid dose form in Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and/or Ora-Sweet SF.
- Mixing one or more proprietary oral liquids (eg an antihistamine with pholcodine linctus).
- Extemporaneously compounding an oral liquid with more than one solid dose chemical.
- Mixing more than one extemporaneously compounded oral liquid mixture.
- · Mixing one or more extemporaneously compounded oral liquid mixtures with one or more proprietary oral liquids.
- The addition of a chemical/powder/agent/solution to a proprietary oral liquid or extemporaneously compounded oral mixture.

Standard formulae

A list of standard formulae is contained in this section. All ingredients associated with a standard formula will be subsidised and an appropriate compounding fee paid.

Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.


Dermatological Preparations

Proprietary topical corticosteroid preparations may be diluted with a dermatological base (see page 212) from the Barrier Creams and Emollients section of the Pharmaceutical Schedule (Retail pharmacy-Specialist). Dilution of proprietary topical corticosteroid preparations should only be prescribed for withdrawing patients off higher strength proprietary topical corticosteroid products where there is no suitable proprietary product of a lower strength available or an extemporaneously compounded product with up to 5% hydrocortisone is not appropriate. (In general proprietary topical corticosteroid preparations should not be diluted because dilution effects can be unpredictable and may not be linear, and usually there is no stability data available for diluted products).

One or more dermatological galenicals may be added to a dermatological base (including proprietary topical corticosteroid preparations). Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

The addition of dermatological galenicals to diluted proprietary Topical Corticosteroids-Plain will not be subsidised.

The flow diagram on the next page may assist you in deciding whether or not a dermatological ECP is subsidised.



EXTEMPORANEOUSLY COMPOUNDED PRODUCTS AND GALENICALS

to 100 ml

Standard Formulae

ACETYLCYSTEINE EYE DROPS Acetylcysteine inj 200 mg per ml, 10 ml Suitable eye drop base	qs qs
ASPIRIN AND CHLOROFORM APPLICAT Aspirin Soluble tabs 300 mg Chloroform	•
CODEINE LINCTUS PAEDIATRIC (3 mg pr Codeine phosphate Glycerol Preservative Water	er 5 ml) 60 mg 40 ml qs to 100 ml
CODEINE LINCTUS DIABETIC (15 mg per Codeine phosphate Glycerol Preservative Water	⁵ ml) 300 mg 40 ml qs to 100 ml
FOLINIC MOUTHWASH Calcium folinate 15 mg tab Preservative Water (Preservative should be used if quantity sup more than 5 days. Maximum 500 ml per pro-	
MAGNESIUM HYDROXIDE 8% MIXTURE Magnesium hydroxide paste 29% Methyl hydroxybenzoate Water	275 g 1.5 g to 1,000 ml
METHADONE MIXTURE Methadone powder Glycerol Water	qs qs to 100 ml
METHYL HYDROXYBENZOATE 10% SOL Methyl hydroxybenzoate Propylene glycol (Use 1 ml of the 10% solution per 100 ml o mixture)	10 g to 100 ml
OMEPRAZOLE SUSPENSION Omeprazole capules or powder Sodium bicarbonate powder BP	qs 8.4 g

PHENOBARBITONE ORAL LIQUID Phenobarbitone Sodium Glycerol BP Water	1 g 70 ml to 100 ml
PHENOBARBITONE SODIUM PAEDIATRIC	CORAL
Phenobarbitone Sodium	400 mg
Glycerol BP	4 ml
Water	to 40 ml
PILOCARPINE ORAL LIQUID	
Pilocarpine 4% eye drops	qs
Preservative	qs
Water	to 500 ml
(Preservative should be used if quantity sup	oplied is for
more than 5 days.)	
SALIVA SUBSTITUTE FORMULA	
Methylcellulose	5 g
Preservative	qs
Water	to 500 ml
(Preservative should be used if quantity sup	
more than 5 days. Maximum 500 ml per pre	escription.)
SODIUM CHLORIDE ORAL LIQUID	
Sodium chloride inj 23.4%, 20 ml	qs
Water	qs
(Only funded if prescribed for treatment of h	nyponatraemia)
VANCOMYCIN ORAL SOLUTION (50 mg p	or ml)
Vancomycin 500 mg injection	10 vials
Glycerol BP	40 ml
Water	to 100 ml
(Only funded if prescribed for treatment of C	
difficile following metronidazole failure)	
VOSOL EAR DROPS	
WITH HYDROCORTISONE POWDER 1%	
Hydrocortisone powder	1%
Vosol Ear Drops	to 35 ml

Water

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy		Fully Brand or
	(Manufacturer's Pr		bsidised Generic
	\$	Per	 Manufacturer
xtemporaneously Compounded Preparations a	and Galenical	S	
ENZOIN			
Tincture compound BP	24.42	500 ml	
	(39.90)		Pharmacy Health
	2.44	50 ml	
	(5.10)		Pharmacy Health
ILOROFORM – Only in combination			
Only in aspirin and chloroform application.			
Chloroform BP		500 ml	🖌 PSM
DEINE PHOSPHATE - Safety medicine; prescriber may deter	rmine disnensina	frequency	
Powder – Only in combination		25 g	
	(90.09)	20 g	Douglas
	12.62	5 g	
	(25.46)	~ 9	Douglas
a) Only in extemporaneously compounded codeine linctus	· · · ·	ne linctus pa	0
b) ‡ Safety cap for extemporaneously compounded oral lic			
DLLODION FLEXIBLE			
Collodion flexible	19.30	100 ml	✔ PSM
		100 111	
MPOUND HYDROXYBENZOATE – Only in combination			
Only in extemporaneously compounded oral mixtures.			
Soln		100 ml	✓ Midwest
	34.18		David Craig
YCERIN WITH SODIUM SACCHARIN – Only in combination			
Only in combination with Ora-Plus.			
Suspension		473 ml	Ora-Sweet SF
YCERIN WITH SUCROSE - Only in combination			
Only in combination with Ora-Plus.			
Suspension		473 ml	Ora-Sweet
YCEROL			
	0.71	500 ml	A healthE Chroniel BD
Liquid – Only in combination		500 ml	healthE Glycerol BP
Only in extemporaneously compounded oral liquid prepara	allons.		
	00.04		(
Paste 29%		500 g	✓ PSM
THADONE HYDROCHLORIDE			
 a) Only on a controlled drug form 			
 b) No patient co-payment payable 			
c) Safety medicine; prescriber may determine dispensing free	quency		
d) Extemporaneously compounded methadone will only be re	eimbursed at the	rate of the ch	neapest form available (methad
powder, not methadone tablets).			
Powder		1 g	🖌 AFT
‡ Safety cap for extemporaneously compounded oral liquid	d preparations.		
THYL HYDROXYBENZOATE			
Powder	8.00	25 g	🖌 PSM
	8.98	5	✓ Midwest
THYLCELLULOSE			
	26.05	100 ~	MidWast
Powder		100 g	✓ MidWest
Suspension – Only in combination	32.50	473 ml	Ora-Plus

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy		Fully Brand or
	(Manufacturer's P	Price) Sul Per	osidised Generic
	\$	Per	 Manufacturer
METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCH/	ARIN – Only in c	ombination	
Suspension	•	473 ml	 Ora-Blend SF
METHYLCELLULOSE WITH GLYCERIN AND SUCROSE - Only	y in combination		
Suspension	32.50	473 ml	Ora-Blend
PHENOBARBITONE SODIUM			
Powder – Only in combination		10 g	✓ MidWest
	325.00	100 g	✓ MidWest
a) Only in children up to 12 years		-	
b) ‡ Safety cap for extemporaneously compounded oral lic	quid preparations		
PROPYLENE GLYCOL			
Only in extemporaneously compounded methyl hydroxybenze	pate 10% solution	n.	
Liq	10.50	500 ml	🖌 PSM
	11.25		Midwest
SODIUM BICARBONATE			
Powder BP – Only in combination	8.95	500 g	✓ Midwest
	9.80	-	
	(29.50)		David Craig
Only in extemporaneously compounded omeprazole and I	ansoprazole sus	pension.	
SYRUP (PHARMACEUTICAL GRADE) – Only in combination			
Only in extemporaneously compounded oral liquid preparatio			
Liq	21.75	2,000 ml	Midwest
WATER			
Tap – Only in combination	0.00	1 ml	Tap water
· •			•

EXPLANATORY NOTES

The list of special foods to which Subsidies apply is contained in this section. The list of available products, guidelines for use, subsidies and charges is reviewed as required. Applications for new listings and changes to subsidies and access criteria will be considered by the special foods sub-committee of PTAC which meets as and when required. In all cases, subsidies are available by Special Authority only. This means that, unless a patient has a valid Special Authority number for their special food requirements, they must pay the full cost of the products themselves.

Eligibility for Special Authority

Special Authorities will be approved for patients meeting conditions specified under the *Conditions and Guidelines* for each product. In some cases there are also limits to how products can be prescribed (for example quantity, use or duration). Only those brands, presentations and flavours of special foods listed in this section are subsidised.

Who can apply for Special Authority?

 Initial Applications:
 Only from a dietitian, relevant specialist or a vocationally registered general practitioner.

 Reapplications:
 Only from a dietitian, relevant specialist or a vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or a vocationally registered general practitioners.

 Very specialist or a vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or a vocationally registered general practitioner. Other general practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

All applications must be made on an official form available from the PHARMAC website www.pharmac.govt.nz. All applications must include specific details as requested on the form relating to the application. Applications must be forwarded to:

Ministry of Health Sector Services Private Bag 3015 WHANGANUI 4540 Freefax 0800 100 131

Subsidies and manufacturer's surcharges

The Subsidies for some special foods are based on the lowest priced product within each group. Where this is so, or where special foods are otherwise not fully subsidised, a manufacturer's surcharge may be payable by the patient. The manufacturer's surcharge is the difference between the price of the product and the subsidy attached to it and may be subject to mark-ups applied at a pharmacy level. As a result the manufacturer's surcharge may vary. Fully subsidised alternatives are available in most cases (as indicated by a tick in the left hand column). Patients should only have to pay a co-payment on these products.

Where are special foods available from?

Distribution arrangements for special foods vary from region to region. Special foods are available from hospital pharmacies providing an outpatient dispensing service as well as retail pharmacies in the Northern, Midland and Central (including Nelson and Blenheim) regions.

Definitions

 Failure to thrive
 An inability to gain or maintain weight resulting in physiological impairment.

 Growth deficiency
 Where the weight of the child is less than the fifth or possibly third percentile for their age, with evidence of malnutrition

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	~	Manufacturer

Nutrient Modules

Carbohydrate

SA1522 Special Authority for Subsidy

Initial application — (Cystic fibrosis or kidney disease) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Either:

- 1 cystic fibrosis; or
- 2 chronic kidney disease.

Initial application - (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following:

- 1 cancer in children: or
- 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 3 faltering growth in an infant/child; or
- 4 bronchopulmonary dysplasia; or
- 5 premature and post premature infant; or
- 6 inborn errors of metabolism; or
- 7 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula. Renewal - (Cystic fibrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal - (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE SUPPLEMENT	- Special Authority see SA1522 above -	Hospital	l pharmacy [l	HP3]	
Powder	52	9 Z	100 a OP	1	Polvcal

Powder5.29	400 g OP	🖌 Polyc
------------	----------	---------

Carbohydrate And Fat

SA1376 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both:

- 1 Infant or child aged four years or under; and
- 2 cvstic fibrosis.

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	ubsidised	Generic	
\$	Per	~	Manufacturer	

continued...

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 infant or child aged four years or under; and
- 2 Any of the following:
 - 2.1 cancer in children; or
 - 2.2 faltering growth; or
 - 2.3 bronchopulmonary dysplasia; or
 - 2.4 premature and post premature infants.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

```
CARBOHYDRATE AND FAT SUPPLEMENT – Special Authority see SA1376 on the previous page – Hospital pharmacy [HP3]
```

Fat

SA1523 Special Authority for Subsidy

Initial application — (Inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has inborn errors of metabolism.

Initial application — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following:

- 1 faltering growth in an infant/child; or
 - 2 bronchopulmonary dysplasia: or
 - 3 fat malabsorption; or
 - 4 lymphangiectasia: or
 - 5 short bowel syndrome; or
- 6 infants with necrotising enterocolitis; or
- 7 biliarv atresia: or
- 8 for use in a ketogenic diet; or
- 9 chyle leak; or
- 10 ascites; or
- 11 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Subsidy	Fu	lly	Brand or
(Manufacturer's Price)	Subsidis	ed	Generic
\$	Per	~	Manufacturer

continued...

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula. **Renewal — (Inborn errors of metabolism)** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT SUPPLEMENT - Special Authority see SA1523 on the previous page - Hospital pharmacy [HP3]

Emulsion (neutral)	200 ml OP	Calogen
30.75	500 ml OP	Calogen
Emulsion (strawberry)12.30	200 ml OP	Calogen
Oil	500 ml OP	MCT oil (Nutricia)
Oil, 250 ml114.92	4 OP	Liquigen

Protein

SA1524 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 protein losing enteropathy; or
- 2 high protein needs; or
- 3 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula. **Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PROTEIN SUPPLEM			
Powder		225 g OP	Protifar
	8.95	227 g OP	✓ Resource
Powder (vanilla)		275 g OP	Beneprotein Promod

	Subsidy (Manufacturer's Price \$	e) Subs Per	Fully sidised	Brand or Generic Manufacturer
Oral Supplements/Complete Diet (Nasogastric/	Gastrostomy Tu	be Feed)		
Respiratory Products				
►SA1094 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or voo where the patient has CORD and hypercapnia, defined as a CO Renewal only from a dietitian, relevant specialist, vocationally register mendation of a dietitian, relevant specialist or vocationally register meeting the following criteria: Both:	2 value exceeding 55 egistered general pra	5 mmHg. ctitioner or g	jeneral	practitioner on the recom-
 The treatment remains appropriate and the patient is be General Practitioners must include the name of the die tioner and date contacted. 			tionally	registered general practi-
CORD ORAL FEED 1.5KCAL/ML – Special Authority see SA10 Liquid		pharmacy [H 37 ml OP		ulmocare
Diabetic Products				
→SA1095 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or voo where the patient is a type I or and II diabetic who is suffering w Renewal only from a dietitian, relevant specialist, vocationally register mendation of a dietitian, relevant specialist or vocationally register meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is be	eight loss and malnu egistered general pra ered general practitio	trition that re ctitioner or g ner. Approva	quires i jeneral	nutritional support. practitioner on the recom-
 General Practitioners must include the name of the die tioner and date contacted. 			tionally	registered general practi-
DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see Liquid		spital pharm 000 ml OP	✓ Di ✓ Gi	P3] iason RTH lucerna Select RTH
DIABETIC ORAL FEED 1KCAL/ML – Special Authority see SA Liquid (strawberry) Liquid (vanilla)	1.50 2 1.50 2 1.88 2	al pharmacy 00 ml OP 00 ml OP 50 ml OP 37 ml OP	✓ Di ✓ Di ✓ Gi	

Fat Modified Products

SA1525 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

(2.10)

Any of the following:

- 1 Patient has metabolic disorders of fat metabolism; or
- 2 Patient has a chyle leak; or

continued...

Sustagen Diabetic

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

3 Modified as a modular feed, made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule, for adults.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula. **Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT MODIFIED FEED - Special Authority see SA1525 on the previous page - Hospital pharmacy [HP3]

Powder	 	 60.48	400 g OP	Monogen	I.

Paediatric Products For Children Awaiting Liver Transplant

➡SA1098 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) who requires a liver transplant.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA1098 above – Hospital pharmacy [HP3]

Paediatric Products For Children With Chronic Renal Failure

SA1099 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) with acute or chronic kidney disease.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL FEED 1KCAL/ML - Special Authority see SA1099 above - Hospital pharmacy [HP3]

Liquid	 	 400 g OP	Kindergen

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

Paediatric Products

➡SA1379 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Child is aged one to ten years; and
- 2 Any of the following:
 - 2.1 the child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
 - 2.2 any condition causing malabsorption; or
 - 2.3 faltering growth in an infant/child; or
 - 2.4 increased nutritional requirements; or
 - 2.5 the child is being transitioned from TPN or tube feeding to oral feeding.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PAEDIATRIC ENTERAL FEED 1.5KCAL/ML – Special Authority see SA1379 a Liquid	bove – Hospital pharmacy [HP3] 500 ml OP Vutrini Energy RTH
PAEDIATRIC ENTERAL FEED 1KCAL/ML – Special Authority see SA1379 about Liquid	ove – Hospital pharmacy [HP3] 500 ml OP ✓ Nutrini RTH ✓ Pediasure RTH
PAEDIATRIC ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority s Liquid	see SA1379 above – Hospital pharmacy [HP3] 500 ml OP ✓ Nutrini Energy Multi Fibre
PAEDIATRIC ORAL FEED – Special Authority see SA1379 above – Hospital pl Powder (vanilla)	harmacy [HP3] 850 g OP ✓ Pediasure
PAEDIATRIC ORAL FEED 1.5KCAL/ML – Special Authority see SA1379 above Liquid (strawberry)1.60 Liquid (vanilla)1.60	e – Hospital pharmacy [HP3] 200 ml OP 🖌 Fortini 200 ml OP 🖌 Fortini
PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see SA1379 above – Liquid (chocolate)	- Hospital pharmacy [HP3] 200 ml OP ✓ Pediasure 200 ml OP ✓ Pediasure 200 ml OP ✓ Pediasure 250 ml OP ✓ Pediasure
PAEDIATRIC ORAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see 3 Liquid (chocolate)	SA1379 above – Hospital pharmacy [HP3] 200 ml OP 200 ml OP 200 ml OP 200 ml OP 200 ml OP 200 ml OP Fortini Multi Fibre

	Subsidy (Manufacturer's Price) \$	Sub Per	Fully sidised	Brand or Generic Manufacturer
Renal Products				
⇒SA1101 Special Authority for Subsidy nitial application only from a dietitian, relevant specialist or where the patient has acute or chronic kidney disease. Renewal only from a dietitian, relevant specialist, vocationally nendation of a dietitian, relevant specialist or vocationally regimeeting the following criteria:	y registered general prac	titioner or g	general	practitioner on the recon
Both: 1 The treatment remains appropriate and the patient is 2 General Practitioners must include the name of the			tionally	registered general pract
 The treatment remains appropriate and the patient is General Practitioners must include the name of the tioner and date contacted. RENAL ENTERAL FEED 1.8 KCAL/ML – Special Authority s 	dietitian, relevant specia ee SA1101 above - Hos	ist or voca	nacy [HF	P3]
 The treatment remains appropriate and the patient is General Practitioners must include the name of the tioner and date contacted. 	dietitian, relevant specia ee SA1101 above – Hos 6.08 50 SA1101 above – Hospital	ist or voca bital pharm 0 ml OP	nacy [HF N [HP3] N	
 The treatment remains appropriate and the patient is General Practitioners must include the name of the tioner and date contacted. RENAL ENTERAL FEED 1.8 KCAL/ML – Special Authority s Liquid RENAL ORAL FEED 1.8 KCAL/ML – Special Authority see S 	dietitian, relevant specia ee SA1101 above – Hos 6.08 50 SA1101 above – Hospital 2.67 22 .1101 above – Hospital pl 2.88 23 (3.31)	ist or voca bital pharm 0 ml OP pharmacy 0 ml OP	nacy [HF No [HP3] No HP3] No No No No No No No No No No	P3] epro HP RTH epro HP (strawberry)

SA1377 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 malabsorption; or
- 2 short bowel syndrome; or
- 3 enterocutaneous fistulas; or
- 4 eosinophilic oesophagitis; or
- 5 inflammatory bowel disease; or
- 6 patients with multiple food allergies requiring enteral feeding.

Notes: Each of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation.

Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL E	LEMENTAL F	EED 1KCAL/ML	- Special Authority	see SA1377	above - Ho	spital pharmacy	[HP3]
Powder				7.50	76 g OP	🖌 Alitraq	

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	Brand or Generic Manufacturer
ENTERAL/ORAL SEMI-ELEMENTAL FEED 1.5KCAL/ML – Spermacy [HP3] Liquid	,	I377 on the previ 0 mI OP ✔ V	
ORAL ELEMENTAL FEED 0.8KCAL/ML – Special Authority see Liquid (grapefruit), 250 ml carton Liquid (pineapple & orange), 250 ml carton Liquid (summer fruits), 250 ml carton		8 OP VE 8 OP VE	al pharmacy [HP3] lemental 028 Extra lemental 028 Extra lemental 028 Extra
ORAL ELEMENTAL FEED 1KCAL/ML – Special Authority see S/ Powder (unflavoured)			pharmacy [HP3] ivonex TEN
SEMI-ELEMENTAL ENTERAL FEED 1KCAL/ML – Special Autho Liquid	•		– Hospital pharmacy [HP3] eptisorb
Paediatric Products For Children With Low Ener	gy Requirement	s	

►SA1196 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Child aged one to eight years; and
- 2 The child has a low energy requirement but normal protein and micronutrient requirements.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications methods being the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PAEDIATRIC ENTERAL FEED WITH FIBRE 0.76 KCAL/ML – Special Authority see SA1196 above – Hospital pharmacy [HP3]

Liquid	4.00	500 ml OP	Nutrini Low Energy	
			Multi Fibre	

Standard Supplements

SA1554 Special Authority for Subsidy

Initial application — (Children - indications other than exclusive enteral nutrition for Crohn's disease) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 Any of the following:
 - 2.1 The patient has a condition causing malabsorption; or
 - 2.2 The patient has failure to thrive; or
 - 2.3 The patient has increased nutritional requirements; and
- 3 Nutrition goal has been set (eg reach a specific weight or BMI).

Renewal — (Children - indications other than exclusive enteral nutrition for Crohn's disease) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

Subsidy (Manufacturer's Price)	S	Fully ubsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

- 1 The patient is under 18 years of age; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and
- 3 A nutrition goal has been set (eg reach a specific weight or BMI).

Initial application — (Children - exclusive enteral nutrition for Crohn's disease) only from a gastroenterologist or dietitian on the recommendation of a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 The patient is under 18 years of age; and
- 2 It is to be used as exclusive enteral nutrition for the treatment of Crohn's disease; and
- 3 Dietitians must include the name of the gastroenterologist recommending treatment and the date the gastroenterologist was contacted.

Renewal — (Children - exclusive enteral nutrition for Crohn's disease) only from a gastroenterologist, dietitian on the recommendation of a gastroenterologist or vocationally registered general practitioner on the recommendation of a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 It is to be used as exclusive enteral nutrition for the treatment of Crohn's disease; and
- 3 General Practitioners and dietitians must include the name of the gastroenterologist recommending treatment and the date the gastroenterologist was contacted.

Initial application — (Adults) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

1 Any of the following:

Patient is Malnourished

- 1.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or
- 1.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
- 1.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months; and
- 2 Any of the following:
 - Patient has not responded to first-line dietary measures over a 4 week period by:
 - 2.1 Increasing their food intake frequency (eg snacks between meals); or
 - 2.2 Using high-energy foods (e.g. milkshakes, full fat milk, butter, cream, cheese, sugar etc); or
 - 2.3 Using over the counter supplements (e.g. Complan); and
- 3 A nutrition goal has been set (e.g. to reach a specific weight or BMI).

Renewal — (Adults) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 A nutrition goal has been set (eg reach a specific weight or BMI); and
- 2 Any of the following:

Patient is Malnourished

- 2.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or
- 2.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
- 2.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months.

Initial application — (Short-term medical condition) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following:

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	ubsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- 1 Is being fed via a nasogastric tube or a nasogastric tube is to be inserted for feeding; or
- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Is undergoing a bone marrow transplant; or
- 4 Tempomandibular surgery or glossectomy; or
- 5 Both:
 - 5.1 Pregnant; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is in early pregnancy (<13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or</p>
 - 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or
 - 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met.

Renewal — (Short-term medical condition) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a nasogastric tube; or
- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Has undergone a bone marrow transplant; or
- 4 Tempomandibular surgery or glossectomy; or
- 5 Both:
 - 5.1 Pregnant; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is in early pregnancy (<13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or</p>
 - 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or
 - 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met.

Initial application — (Long-term medical condition) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following:

- 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube refer to specific medical condition criteria); or
- 2 Cystic Fibrosis; or
- 3 Liver disease; or
- 4 Chronic Renal failure; or
- 5 Inflammatory bowel disease; or
- 6 Chronic obstructive pulmonary disease with hypercapnia; or
- 7 Short bowel syndrome; or
- 8 Bowel fistula; or
- 9 Severe chronic neurological conditions; or

SPECIAL FOODS

 Subsidy (Manufacturer's Price)	Subsid	Fully lised	Brand or Generic
\$	Per	~	Manufacturer

continued...

10 Epidermolysis bullosa; or

11 AIDS (CD4 count < 200 cells/mm³); or

12 Chronic pancreatitis.

Renewal — (Chronic disease OR tube feeding for patients who have previously been funded under Special Authority forms SA0702 or SA0583) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube refer to specific medical condition criteria); or
- 2 Cystic Fibrosis; or
- 3 Liver disease; or
- 4 Chronic Renal failure; or
- 5 Inflammatory bowel disease; or
- 6 Chronic obstructive pulmonary disease with hypercapnia; or
- 7 Short bowel syndrome; or
- 8 Bowel fistula; or
- 9 Severe chronic neurological conditions.

ENTERAL FEED 1.5KCAL/ML – Special Authority see SA1554 on page 227 – Hospital pharmacy [HP3]

Liquid	7.00	1,000 ml OP	Nutrison Energy
ENTERAL FEED 1KCAL/ML - Special Autho	rity see SA1554 on page 227 – Ho	spital pharmacy	[HP3]
Liquid		250 ml OP	✓ Isosource Standard
			 Osmolite
	2.65	500 ml OP	Osmolite RTH
	5.29	1,000 ml OP	 Isosource Standard RTH
			 Nutrison Standard RTH
			 Osmolite RTH
ENTERAL FEED WITH FIBRE 1 KCAL/ML -	Special Authority see SA1554 on	page 227 – Hosp	ital pharmacy [HP3]
Liquid		237 ml OP	V Jevity
	2.65	500 ml OP	Jevity RTH
	5.29	1,000 ml OP	Jevity RTH
			 Nutrison Multi Fibre
ENTERAL FEED WITH FIBRE 1.5KCAL/ML	 Special Authority see SA1554 or 	n page 227 – Hos	pital pharmacy [HP3]
Liquid		250 ml OP	Ensure Plus HN
	7.00	1,000 ml OP	Ensure Plus RTH
			Jevity HiCal RTH

 Nutrison Energy Multi Fibre

	Subsidy (Manufacturer's P \$	rice) Sub Per	Fully sidised	Brand or Generic Manufacturer
ORAL FEED (POWDER) – Special Authority see SA1554 on pag Note: Higher subsidy for Sustagen Hospital Formula will onl number and an appropriately endorsed prescription.	ly be reimbursed			n a valid Special Authority
Powder (chocolate) – Higher subsidy of up to \$14.90 per 840 g with Endorsement		850 g OP 840 g OP	S	nsure ustagen Hospital Formula
Additional subsidy by endorsement is available for patient scription must be endorsed accordingly. Powder (vanilla) – Higher subsidy of up to \$14.90 per 840 g		sorption, fat in		
with Endorsement	3.67 13.00 9.54 (14.90)	350 g OP 850 g OP 840 g OP	🖌 E	ortisip nsure ustagen Hospital
Additional subsidy by endorsement is available for patient scription must be endorsed accordingly.	, , , , , , , , , , , , , , , , , , ,	sorption, fat in		Formula
Additional subsidy by endorsement is available for patients b molysis bullosa, or as exclusive enteral nutrition in children un prescription must be endorsed accordingly. Liquid (banana) – Higher subsidy of \$1.26 per 200 ml with Endorsement	ider the age of 18		treatme	
Liquid (chocolate) – Higher subsidy of up to \$1.33 per 237 ml with Endorsement	()	237 ml OP		
	(1.33) 0.72 (1.26) (1.26)	200 ml OP	E	nsure Plus nsure Plus ortisip
Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 ml with Endorsement	, , , , , , , , , , , , , , , , , , ,	200 ml OP		nsure Plus
Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml with Endorsement		200 ml OP		nsure Plus ortisip
Liquid (vanilla) – Higher subsidy of up to \$1.33 per 237 ml with Endorsement		237 ml OP 200 ml OP	E	nsure Plus
	(1.26) (1.26)		_	nsure Plus ortisip

SPECIAL FOODS

	Subsidy (Manufacturer's F \$		Fully dised	Brand or Generic Manufacturer
ORAL FEED WITH FIBRE 1.5 KCAL/ML – Special Authority see Additional subsidy by endorsement is available for patients be molysis bullosa. The prescription must be endorsed according Liquid (chocolate) – Higher subsidy of \$1.26 per 200 ml with	ing bolus fed thr			
Endorsement	0.72 (1.26)	200 ml OP	F	ortisip Multi Fibre
Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml with Endorsement		200 ml OP	F	ortisip Multi Fibre
Liquid (vanilla) – Higher subsidy of \$1.26 per 200 ml with Endorsement	0.72 (1.26)	200 ml OP	F	ortisip Multi Fibre

High Calorie Products

➡SA1195 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 Cystic fibrosis; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements.

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Any of the following:
 - 1.1 any condition causing malabsorption; or
 - 1.2 faltering growth in an infant/child; or
 - 1.3 increased nutritional requirements; or
 - 1.4 fluid restricted; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements or is fluid restricted.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Subsidy Fully Brand or (Manufacturer's Price) Subsidised Generic Por Manufacturer \$ ENTERAL FEED 2 KCAL/ML - Special Authority see SA1195 on the previous page - Hospital pharmacy [HP3] 500 ml OP Nutrison Concentrated 11 00 1.000 ml OP Two Cal HN RTH ORAL FEED 2 KCAL/ML - Special Authority see SA1195 on the previous page - Hospital pharmacy [HP3] Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epidermolvsis bullosa. The prescription must be endorsed accordingly. Liquid (vanilla) - Higher subsidy of \$1.90 per 200 ml with 200 ml OP Two Cal HN (1.90)Food Thickeners SA1106 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient has motor neurone disease with swallowing disorder. Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FOOD THICKENER - Special Authority see SA1106 above - Hospital pharmacy [HP3]

Powder	300 g OP	Nutilis
7.25	380 g OP	 Feed Thickener

Gluten Free Foods

The funding of gluten free foods is no longer being actively managed by PHARMAC from 1 April 2011. This means that we are no longer considering the listing of new products, or making subsidy, or other changes to the existing listings. As a result we anticipate that the range of funded items will reduce over time. Management of Coeliac disease with a gluten free diet is necessary for good outcomes. A range of gluten free options are available through retail outlets.

➡SA1107 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either:

- 1 Gluten enteropathy has been diagnosed by biopsy; or
- 2 Patient suffers from dermatitis herpetiformis.

GLUTEN FREE BAKING MIX - Special Authority see SA1107 above - Hospital pharmacy [HP3]

Powder	2.81	1,000 g OP
	(5.15)	-

Healtheries Simple Baking Mix

Karicare Aptamil

SPECIAL FOODS

SPECIAL FOODS

	Subsidy		Fully Brand or
	(Manufacturer's \$	Price) Subsid Per	lised Generic ✔ Manufacturer
GLUTEN FREE BREAD MIX – Special Authority see SA1107 of	on the previous pa	ige – Hospital pha	rmacy [HP3]
Powder	3.93	1,000 g OP	
	(7.32)		NZB Low Gluten Bread Mix
	4.77		
	(8.71)		Bakels Gluten Free Health Bread Mix
	3.51		
	(10.87)		Horleys Bread Mix
GLUTEN FREE FLOUR - Special Authority see SA1107 on the	e previous page -	Hospital pharmad	v [HP3]
Powder		2,000 g OP	y [in o]
	(18.10)	2,000 g 01	Horleys Flour
	(/		,
GLUTEN FREE PASTA – Special Authority see SA1107 on the			y [HP3]
Buckwheat Spirals		250 g OP	Oraraa
Corn and Vegetable Shells	(3.11)	250 g OP	Orgran
Corriand vegetable Shells	(2.92)	250 y OF	Orgran
Corn and Vegetable Spirals	()	250 g OP	Orgian
	(2.92)	250 g OI	Orgran
Rice and Corn Lasagne Sheets	()	200 g OP	orgian
	(3.82)	200 9 01	Orgran
Rice and Corn Macaroni	()	250 g OP	orgran
	(2.92)	200 9 0.	Orgran
Rice and Corn Penne	()	250 g OP	2.3
	(2.92)		Orgran
Rice and Maize Pasta Spirals		250 g OP	2.3
•	(2.92)	0	Orgran
Rice and Millet Spirals		250 g OP	5
	(3.11)	Ū.	Orgran
Rice and corn spaghetti noodles	· · ·	375 g OP	5
	(2.92)	-	Orgran
Vegetable and Rice Spirals		250 g OP	-
-	(2.92)	-	Orgran
Italian long style spaghetti	2.00	220 g OP	
	(3.11)		Orgran

Foods And Supplements For Inborn Errors Of Metabolism

SA1108 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Dietary management of homocystinuria; or
- 2 Dietary management of maple syrup urine disease; or
- 3 Dietary management of phenylketonuria (PKU); or
- 4 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Supplements For Homocystinuria

	ubsidy cturer's Price) \$	Fu Subsidis Per	
Supplements For MSUD			
MINOACID FORMULA WITHOUT VALINE, LEUCINE AND ISOLEUCINE	E – Special A	uthority see	SA1108 on the previous pa
- Hospital pharmacy [HP3]	F.4 F.00		
Powder		J -	MSUD Maxamaid
437	.22	V	' MSUD Maxamum
Supplements For PKU			
MINOACID FORMULA WITHOUT PHENYLALANINE - Special Authority	see SA1108	on the previo	us page – Hospital pharma
HP3]			
Tabs	.00 75	OP 🖌	' Phlexy 10
Powder (unflavoured) 29 g sachets	.12	30 🖌	' PKU Anamix Junior
Powder (unflavoured) 36 g sachets	.00	30 🖌	' PKU Anamix Junior
Infant formula174	.72 400	g OP 🖌 🖌	' PKU Anamix Infant
Powder (orange)221	.00 500	g OP 🗸	' XP Maxamaid
320	.00	· · ·	' XP Maxamum
Powder (unflavoured)221	.00 500	g OP 🖌 🖌	' XP Maxamaid
320	.00	V	' XP Maxamum
Liquid (berry)13	.10 125	ml OP 🖌	PKU Anamix Junior
			LQ
Liquid (orange)13	.10 125	ml OP 🖌	PKU Anamix Junior
Liquid (unflavoured)13	.10 125	ml OP 🖌	' PKU Anamix Junior
			LQ
Liquid (forest berries), 250 ml carton540	.00 18	OP 🖌	' Easiphen Liquid
Liquid (juicy berries) 62.5 ml			PKU Lophlex LQ 10
Liquid (juicy citrus) 62.5 ml			PKU Lophlex LQ 10
Liquid (juicy orange) 62.5 ml			PKU Lophlex LQ 10
Liquid (juicy berries) 125 ml			PKU Lophlex LQ 20
Liquid (juicy citrus) 125 ml			PKU Lophlex LQ 20
Liquid (juicy orange) 125 ml			PKU Lophlex LQ 20
		• •	· · · · · · · · · · · · · · · · · · ·

Foods

LOW PROTEIN BAKING MIX – Special Authority see SA1108 or Powder			oharmacy [HP3] Loprofin Mix
LOW PROTEIN PASTA - Special Authority see SA1108 on the p	revious page – H	lospital pharma	acy [HP3]
Animal shapes	11.91	500 g OP	Loprofin
Lasagne	5.95	250 g OP	 Loprofin
Low protein rice pasta	11.91	500 g OP	 Loprofin
Macaroni	5.95	250 g OP	 Loprofin
Penne	11.91	500 g OP	 Loprofin
Spaghetti	11.91	500 g OP	 Loprofin
Spirals	11.91	500 g OP	 Loprofin

Infant Formulae

For Premature Infants

PRETERM POST-DISCHARGE INFANT FORMULA	- Special Authority see SA1	198 on the next	page – Hospital pharmacy [HP3]
Powder		400 g OP	S-26 Gold Premgro

SPECIAL FOODS

Subsidy	Fully	Brand or
(Manufacturer's	Price) Subsidised	Generic
\$	Per 🗸	Manufacturer

➡SA1198 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The infant was born before 33 weeks gestation or weighed less than 1.5 kg at birth; and
- 2 Either:
 - 2.1 The infant has faltering growth (downward crossing of percentiles); or
 - 2.2 The infant is not maintaining, or is considered unlikely to maintain, adequate growth on standard infant formula.

For Williams Syndrome

SA1110 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is an infant suffering from Williams Syndrome and associated hypercalcaemia.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

LOW CALCIUM INFANT FORMULA – Special Authority see SA1110 above – Hospital pharmacy [HP3]

Powder	 	4	400 g OP	~	Locasol

Gastrointestinal and Other Malabsorptive Problems

Powder	6.00	48.5 g OP	Vivonex Pediatric
	53.00	400 g OP	Neocate LCP
Powder (unflavoured)	53.00	400 g OP	Elecare
		0	Elecare LCP
			Neocate Advance
			Neocate Gold
Powder (vanilla)	53.00	400 g OP	Elecare
· · ·		5	Neocate Advance

➡SA1219 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
- 2 History of anaphylaxis to cows milk protein formula or dairy products; or
- 3 Eosinophilic oesophagitis.
- Note: A reasonable trial is defined as a 2-4 week trial.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

Subsidy		Fully	Brand or	
(Manufacturer's Price)	5	Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- 1 An assessment as to whether the infant can be transitioned to a cows milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

HP3]
tamil Gold+ Pepti unior
oti Junior Gold Aricare Aptamil
ar

(Pepti Junior Gold Karicare Aptamil Powder to be delisted 1 June 2016)

SA1557 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Both:
 - 1.1 Cows milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
 - 1.2 Either:
 - 1.2.1 Soy milk formula has been reasonably trialled without resolution of symptoms; or
 - 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
- 2 Severe malabsorption; or
- 3 Short bowel syndrome; or
- 4 Intractable diarrhoea; or
- 5 Biliary atresia; or
- 6 Cholestatic liver diseases causing malsorption; or
- 7 Cystic fibrosis; or
- 8 Proven fat malabsorption; or
- 9 Severe intestinal motility disorders causing significant malabsorption; or
- 10 Intestinal failure; or
- 11 All of the following:
 - 11.1 For step down from Amino Acid Formula; and
 - 11.2 The infant is currently receiving funded amino acid formula; and
 - 11.3 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula; and
 - 11.4 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

Note: A reasonable trial is defined as a 2-4 week trial, or signs of an immediate IgE mediated allergic reaction.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 An assessment as to whether the infant can be transitioned to a cows milk protein or soy infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per ✓	Manufacturer

Ketogenic Diet

SA1197 Special Authority for Subsidy

Initial application only from a metabolic physician or paediatric neurologist. Approvals valid for 3 months where the patient has intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet.

Renewal only from a metabolic physician or paediatric neurologist. Approvals valid for 2 years where the patient is on a ketogenic diet and the patient is benefiting from the diet.

HIGH FAT LOW CARBOHYDRATE FORMULA - Special Authority see SA1197 above - Retail pharmacy

Powder (unflavoured)	300 g OP	 KetoCal 4:1 Ketocal 3:1
Powder (vanilla)35.50	300 g OP	✓ KetoCal 4:1

Pharmaceuticals and quantities that may be obtained on a Practitioner's Supply Order

ADRENALINE ✓ Inj 1 in 1,000, 1 ml ampoule5 ✓ Inj 1 in 10,000, 10 ml ampoule5
AMINOPHYLLINE ✓ Inj 25 mg per ml, 10 ml ampoule5
AMIODARONE HYDROCHLORIDE ✓ Inj 50 mg per ml, 3 ml ampoule6
AMOXICILLIN ✓ Cap 250 mg
AMOXICILLIN WITH CLAVULANIC ACID ✓ Tab 500 mg with clavulanic acid 125 mg
ASPIRIN V Tab dispersible 300 mg
ATROPINE SULPHATE Inj 600 mcg per ml, 1 ml ampoule5
AZITHROMYCIN V Tab 500 mg – See note on page 928
BENDROFLUMETHIAZIDE [BENDROFLUAZIDE] V Tab 2.5 mg – See note on page 56
BENZATHINE BENZYLPENICILLIN Inj 900 mg (1.2 million units) in 2.3 ml syringe
BENZTROPINE MESYLATE ✔ Inj 1 mg per ml, 2 ml
BENZYLPENICILLIN SODIUM (PENICILLIN G) Inj 600 mg (1 million units) vial
BLOOD GLUCOSE DIAGNOSTIC TEST METER ✓ Meter with 50 lancets, a lancing device and 10 diagnostic test strips – Subsidy by endorsement – See note on page 261
BLOOD GLUCOSE DIAGNOSTIC TEST STRIP Blood glucose test strips – See note on page 27
BLOOD KETONE DIAGNOSTIC TEST METER Meter – See note on page 261

CEFTRIAXONE	
✓ Inj 500 mg vial – Subsidy by endorsement –	
See note on page 91	5
✓ Inj 1 g vial – Subsidy by endorsement – See	
note on page 91	5
1.03	
CHARCOAL	
✓ Oral liq 50 g per 250 ml	250 ml
CHLORPROMAZINE HYDROCHLORIDE	
✓ Tab 10 mg	
✓ Tab 25 mg	
✓ Tab 100 mg	
✓ Inj 25 mg per ml, 2 ml	5
CIPROFLOXACIN	
✓ Tab 250 mg – See note on page 95	5
✓ Tab 500 mg – See note on page 95	
V Tab 500 mg - See note on page 95	
CO-TRIMOXAZOLE	
✓ Tab trimethoprim 80 mg and	
sulphamethoxazole 400 mg	30
✓ Oral lig trimethoprim 40 mg and	
sulphamethoxazole 200 mg per	
5 ml	200 ml
0 111	
COMPOUND ELECTROLYTES	
✓ Powder for oral soln	10
CONDOMS	
✔ 49 mm	
✓ 52 mm	
✓ 52 mm extra strength	
✓ 53 mm	
✓ 53 mm (chocolate)	
✓ 53 mm (strawberry)	
54 mm, shaped	
✓ 55 mm	
✓ 56 mm	
✓ 56 mm, shaped	
✔ 60 mm	
CYPROTERONE ACETATE	WITH
ETHINYLOESTRADIOL	VVIIII
✓ Tab 2 mg with ethinyloestradiol 35 mcg and	
7 inert tabs	
1 IIICII IAUS	160
DEXAMETHASONE	168
DEXAMETHASONE Tab 0.5 mg – Retail pharmacy-Specialist	
✓ Tab 0.5 mg – Retail pharmacy-Specialist	60
	60 30

continued...

(continued)

page 795
DIAPHRAGM ✓ 65 mm – See note on page 731 ✓ 70 mm – See note on page 731 ✓ 75 mm – See note on page 731 ✓ 80 mm – See note on page 731
DIAZEPAM ✓ Inj 5 mg per ml, 2 ml ampoule – Subsidy by endorsement – See note on page 1335 ✓ Rectal tubes 5 mg5 ✓ Rectal tubes 10 mg5
DICLOFENAC SODIUM ✓ Inj 25 mg per ml, 3 ml ampoule
DIGOXIN ✓ Tab 62.5 mcg
DOXYCYCLINE Tab 50 mg
ERGOMETRINE MALEATE ✓ Inj 500 mcg per ml, 1 ml ampoule
ERYTHROMYCIN ETHYL SUCCINATE Tab 400 mg
ERYTHROMYCIN STEARATE Tab 250 mg
ETHINYLOESTRADIOL WITH DESOGESTREL Tab 20 mcg with desogestrel 150 mcg and 7 inert tab
ETHINYLOESTRADIOL WITH LEVONORGESTREL Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tab
 ✓ Tab 50 mcg with levonorgestrel 125 mcg and 7 inert tab

ETHINYLOESTRADIOL WITH NORETHISTERONE Tab 35 mcg with norethisterone 1 mg63
Tab 35 mcg with norethisterone 1 mg and 7 inert tab84
 ✓ Tab 35 mcg with norethisterone 500 mcg63 ✓ Tab 35 mcg with norethisterone 500 mcg and 7 inert tab
FLUCLOXACILLIN ✔ Cap 250 mg
FLUPENTHIXOL DECANOATE ✓ Inj 20 mg per ml, 1 ml
FLUPHENAZINE DECANOATE ✔ Inj 12.5 mg per 0.5 ml, 0.5 ml5 ✔ Inj 25 mg per ml, 1 ml5 ✔ Inj 100 mg per ml, 1 ml5
FUROSEMIDE [FRUSEMIDE] ✔ Tab 40 mg
GLUCAGON HYDROCHLORIDE ✔ Inj 1 mg syringe kit5
GLUCOSE [DEXTROSE] ✔ Inj 50%, 10 ml ampoule5 ✔ Inj 50%, 90 ml bottle5
GLYCERYL TRINITRATE ✓ Tab 600 mcg
GLYCOPYRRONIUM BROMIDE ✔ Inj 200 mcg per ml, 1 ml ampoule10
HALOPERIDOL ✓ Tab 500 mcg
HALOPERIDOL DECANOATE ✔ Inj 50 mg per ml, 1 ml5 ✔ Inj 100 mg per ml, 1 ml5
HYDROCORTISONE ✔ Inj 100 mg vial5
continued

(continued) HYDROXOCOBALAMIN ✔ Inj 1 mg per ml, 1 ml ampoule6
HYOSCINE N-BUTYLBROMIDE ✔ Inj 20 mg, 1 ml5
INTRA-UTERINE DEVICE ✓ IUD 29.1 mm length × 23.2 mm width
IPRATROPIUM BROMIDE ✓ Nebuliser soln, 250 mcg per ml, 1 ml40 ✓ Nebuliser soln, 250 mcg per ml, 2 ml40
IVERMECTIN V Tab 3 mg – See note on page 68 100
KETONE BLOOD BETA-KETONE ELECTRODES ✔ Test strip
LEVONORGESTREL Tab 30 mcg84 ✔ Tab 1.5 mg5
LIDOCAINE [LIGNOCAINE] ✓ Gel 2%, 10 ml urethral syringe – Subsidy by endorsement – See note on page 1265
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE ✓ Inj 1%, 5 ml ampoule
LIDOCAINE [LIGNOCAINE] WITH CHLORHEXIDINE ✓ Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes – Subsidy by endorsement – See note on page 127
LOPERAMIDE HYDROCHLORIDE ✓ Tab 2 mg
MASK FOR SPACER DEVICE ✓ Small – See note on page 204
MEDROXYPROGESTERONE ACETATE ✓ Inj 150 mg per ml, 1 ml syringe5
METOCLOPRAMIDE HYDROCHLORIDE Inj 5 mg per ml, 2 ml ampoule
METRONIDAZOLE ✔ Tab 200 mg

MORPHINE SULPHATE Inj 5 mg per ml, 1 ml ampoule – Only on a controlled drug form 5 Inj 10 mg per ml, 1 ml ampoule – Only on a controlled drug form 5 Inj 15 mg per ml, 1 ml ampoule – Only on a controlled drug form 5 Inj 30 mg per ml, 1 ml ampoule – Only on a controlled drug form 5
 ✓ Inj 400 mcg per ml, 1 ml ampoule
✓ Tab 350 mcg
OXYTOCIN WITH ERGOMETRINE MALEATE ✓ Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml
PEAK FLOW METER ↓ ✓ Low range 10 ✓ Normal range 10 PETHIDINE HYDROCHLORIDE ↓ ✓ Inj 50 mg per ml, 1 ml – Only on a controlled drug form 5 ✓ Inj 50 mg per ml, 2 ml – Only on a controlled drug form 5
PHENOXYMETHYLPENICILLIN (PENICILLIN V) Cap 250 mg

(continued)

 ✓ Cap 500 mg
PHENYTOIN SODIUM ✓ Inj 50 mg per ml, 2 ml ampoule5 ✓ Inj 50 mg per ml, 5 ml ampoule5
PHYTOMENADIONE ✓ Inj 2 mg per 0.2 ml
 PIPOTHIAZINE PALMITATE ✓ Inj 50 mg per ml, 1 ml – Subsidy by endorsement – See note on page 1445 ✓ Inj 50 mg per ml, 2 ml – Subsidy by endorsement – See note on page 1445
PREDNISOLONE ✔ Oral liq 5 mg per ml – See note on page 80
PREDNISONE V Tab 5 mg
PREGNANCY TESTS - HCG URINE Cassette
PROCAINE PENICILLIN ✔ Inj 1.5 g in 3.4 ml syringe5
PROCHLORPERAZINE ✓ Tab 5 mg
PROMETHAZINE HYDROCHLORIDE V Inj 25 mg per ml, 2 ml ampoule
SALBUTAMOL V Inj 500 mcg per ml, 1 ml

 Aerosol inhaler, 100 mcg per dose CFC free
SALBUTAMOL WITH IPRATROPIUM BROMIDE Vebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml ampoule20
SILVER SULPHADIAZINE ✓ Crm 1%250 g
SODIUM BICARBONATE ✓ Inj 8.4%, 50 ml
SODIUM CHLORIDE ✓ Inf 0.9% – See note on page 48
SPACER DEVICE ✓ 220 ml (single patient) ✓ 510 ml (single patient) 20 ✓ 800 ml 20
TRIMETHOPRIM V Tab 300 mg
VERAPAMIL HYDROCHLORIDE VInj 2.5 mg per ml, 2 ml ampoule
WATER ✓ Purified for inj, 5 ml – See note on page 48
ZUCLOPENTHIXOL DECANOATE ✓ Inj 200 mg per ml, 1 ml

Rural Areas for Practitioner's Supply Orders

NORTH ISLAND

Northland DHB Dargaville Hikurangi Kaeo Kaikohe Kaitaia Kawakawa Kerikeri Mangonui Maungaturoto Moerewa Naunauru Paihia Rawene Ruakaka Russell Tutukaka Waipu Whangaroa

Waitemata DHB

Helensville Huapai Kumeu Snells Beach Waimauku Warkworth Wellsford

Auckland DHB

Great Barrier Island Oneroa Ostend

Counties Manukau DHB Tuakau

Waiuku

Waikato DHB

Coromandel Huntly Kawhia Matamata Morrinsville Ngatea Otorohanga Paeroa Pauanui Beach Putaruru Raglan Tairua Taumarunui Te Aroha Te Kauwhata Te Kuiti Tokoroa Waihi Whangamata Whitianga

Bay of Plenty DHB

Edgecumbe Katikati Kawerau Murupara Opotiki Taneatua Te Kaha Waihi Beach Whakatane

Lakes DHB

Mangakino Turangi

Tairawhiti DHB

Ruatoria Te Araroa Te Karaka Te Puia Springs Tikitiki Tokomaru Bay Tolaga Bay

Taranaki DHB

Eltham Inglewood Manaia Oakura Okato Opunake Patea Stratford Waverley

Hawkes Bay DHB

Chatham Islands Waipawa Waipukurau Wairoa Whanganui DHB Bulls Marton Ohakune Raetihi Taihape Waiouru

MidCentral DHB

Dannevirke Foxton Levin Otaki Pahiatua Shannon Woodville

Wairarapa DHB

Carteron Featherston Greytown Martinborough

SOUTH ISLAND

Nelson/Marlborough DHB

Havelock Mapua Motueka Murchison Picton Takaka Wakefield

West Coast DHB

Dobson Greymouth Hokitika Karamea Reefton South Westland Westport Whataroa

Canterbury DHB

Akaroa Amberley Amuri Cheviot Darfield Diamond Harbour Hanmer Springs Kaikoura Leeston Lincoln Methven Oxford Rakaia Rolleston Rotherham Templeton Waikari

South Canterbury DHB

Fairlie Geraldine Pleasant Point Temuka Twizel Waimate

Southern DHB

Alexandra Balclutha Cromwell Gore Kurow I awrence Lumsden Mataura Milton Oamaru Oban Otautau Outram Owaka Palmerston Queenstown Ranfurly Riverton Roxburah Tapanui Te Anau Tokonui Tuatapere Wanaka Winton

SECTION F: PART I

A Community Pharmaceutical identified with a * within the other sections of the Pharmaceutical Schedule:

- a) is exempt from any requirement to dispense in Monthly Lots;
- b) will only be subsidised if it is dispensed in a 90 Day Lot unless it is under the Dispensing Frequency Rule.

A Community Pharmaceutical that is an oral contraceptive and that is identified with a * within the other sections of the Pharmaceutical Schedule:

- a) is exempt from any requirement to dispense in Monthly Lots;
- b) will only be subsidised if it is dispensed in a 180 Day Lot unless it is is under the Dispensing Frequency Rule.

SECTION F: PART II: CERTIFIED EXEMPTIONS AND ACCESS EXEMPTIONS TO MONTHLY DISPENSING

A Community Pharmaceutical, other than a Community Pharmaceutical identified with a * within the other sections of the Pharmaceutical Schedule, may be dispensed in a 90 Day Lot if:

a) the Community Pharmaceutical is identified with a ▲ within the other sections of the Pharmaceutical Schedule and the prescriber/pharmacist has endorsed/annotated the Prescription item(s) on the Prescription to which the exemption applies "certified exemption".

In endorsing/annotating the Prescription items for a certified exemption, the prescriber/pharmacist is certifying that:

- i) the patient wished to have the medicine dispensed in a quantity greater than a Monthly Lot; and
- ii) the patient has been stabilised on the same medicine for a reasonable period of time; and
- iii) the prescriber/pharmacist has reason to believe the patient will continue on the medicine and is compliant.
- b) a patient, who has difficulty getting to and from a pharmacy, signs the back of the Prescription to qualify for an Access Exemption. In signing the Prescription, the patient or his or her nominated representative must also certify which of the following criteria they meet:
 - i) have limited physical mobility;
 - ii) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;
 - iii) are relocating to another area;
 - iv) are travelling extensively and will be out of town when the repeat prescriptions are due.

SECTION F: PART III: FLEXIBLE AND VARIABLE DISPENSING PERIODS FOR PHARMACY

A Community Pharmaceutical, other than a Community Pharmaceutical identified with a ***** within the other sections of the Pharmaceutical Schedule, may be dispensed in variable dispensing periods under the following conditions:

- a) for stock management where the original pack(s) result in dispensing greater than 30 days supply,
- b) to synchronise a patients medication where multiple medicines result in uneven supply periods, note if dispensing a medicine other than a Pharmaceutical identified with a * please refer to Section F; Part II
- Note the total quantity and dispensing period can not exceed the total quantity and period prescribed on the prescription.

The following Community Pharmaceuticals are identified with a ▲ within the other sections of the Pharmaceutical Schedule and may be dispensed in a 90 Day Lot if endorsed as a certified exemption in accordance with paragraph (a) in Section F Part II above.

ALIMENTARY TRACT AND METABOLISM

INSULIN ASPART

INSULIN ASPART WITH INSULIN ASPART PROTAMINE

INSULIN GLARGINE

INSULIN GLULISINE

INSULIN ISOPHANE

INSULIN ISOPHANE WITH INSULIN NEUTRAL

INSULIN LISPRO

INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE

Cordarone-X

Cordarone-X

Tambocor

Tambocor

INSULIN NEUTRAL

Tab 100 mg

Tab 200 mg

Tab 100 mg

MINOXIDIL

NICORANDIL

CARDIOVASCULAR SYSTEM AMIODARONE HYDROCHLORIDE

FLECAINIDE ACETATE Tab 50 mg

DISOPYRAMIDE PHOSPHATE

MEXILETINE HYDROCHLORIDE

PROPAFENONE HYDROCHLORIDE

Cap long-acting 100 mg Tambocor CR

Cap long-acting 200 mg Tambocor CR

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

DESMOPRESSIN ACETATE Nasal drops 100 mcg Minirin per ml Nasal spray 10 mcg per Desmopressin-PH&T dose

MUSCULOSKELETAL SYSTEM

PYRIDOSTIGMINE BROMIDE

NERVOUS SYSTEM

AMANTADINE HYDROCHLORIDE

APOMORPHINE HYDROCHLORIDE

ENTACAPONE

GABAPENTIN

LACOSAMIDE

LAMOTRIGINE

LISURIDE HYDROGEN MALEATE

PRAMIPEXOLE HYDROCHLORIDE

ROPINIROLE HYDROCHLORIDE

TOLCAPONE

TOPIRAMATE

VIGABATRIN

SECTION G: SAFETY CAP MEDICINES

Pharmacists are required, under the Code of Ethics of the Pharmacy Council of New Zealand, to endeavour to use safety caps when dispensing any of the medicines listed in Section G in an oral liquid formulation pursuant to a prescription or Practitioner's Supply Order. This includes all proprietary and extemporaneously compounded oral liquid preparations of those pharmaceuticals listed in Section G of the Pharmaceutical Schedule. These medicines will be identified throughout Section B of the Pharmaceutical Schedule with the symbol '‡'.

Exemptions

Oral liquid preparations of the pharmaceuticals listed in Section G of the Pharmaceutical Schedule will be dispensed in a container with a safety cap unless:

- the practitioner has endorsed the Prescription or Practitioner's Supply Order, stating that, the Pharmaceutical is not to be dispensed in a container with a safety cap; or
- the Contractor has annotated the Prescription or Practitioner's Supply Order stating that, because of infirmity of the particular person, the Pharmaceutical to be used by that person should not be dispensed in a container with a safety cap; or
- the Pharmaceutical is packaged in an Original Pack so designed that on the professional judgement of the Contractor, transfer to a container with a safety cap would be inadvisable or a retrograde procedure.

Reimbursment

Pharmacists will be reimbursed according to their agreement. Where an additional fee is paid on safety caps it will be paid on all dispensings of oral liquid preparations for those pharmaceuticals listed in Section G of the Pharmaceutical Schedule unless the practitioner has endorsed or the contractor has annotated the Prescription or Practitioner's Supply Order that a safety cap has not been supplied.

Safety Caps (NZS 5825:1991)

20 mm	.Clic-Loc, United Closures & Plastics PLC, England
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
24 mm	.Clic-Loc, United Closures & Plastics PLC, England
	Clic-Loc, ACI Closures under license to Owens-Illinois
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
28 mm	.Clic-Loc, United Closures & Plastics PLC, England
	Clic-Loc, ACI Closures under license to Owens-Illinois
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
	PDL Squeezlok
	PDL FG
	. 52. 4

ALIMENTARY TRACT AND METABOLISM

FERROUS SULPHATE Oral lig 30 mg (6 mg el- Ferodan emental) per 1 ml

CARDIOVASCULAR SYSTEM

AMILORIDE HYDROCHLORIDE Oral liq 1 mg per ml Biomed

CAPTOPRIL Oral lig 5 mg per ml Capoten

CHI OROTHIAZIDE Oral lig 50 mg per ml Biomed

DIGOXIN Oral liq 50 mcg per ml Lanoxin

FUROSEMIDE [FRUSEMIDE] Oral lig 10 mg per ml Lasix

SPIBONOI ACTONE Oral liq 5 mg per ml Biomed

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

LEVOTHYROXINE

Tab 25 mcg	Synthroid
Tab 50 mcg	Eltroxin
-	Synthroid
Tab 100 mcg	Eltroxin
-	Synthroid

(Extemporaneously compounded oral liquid preparations)

LEVOTHYROXINE (MERCURY PHARMA)

Tab 50 mcg Mercury Pharma Tab 100 mcg Mercurv Pharma (Extemporaneously compounded oral liquid preparations)

INFECTIONS - AGENTS FOR SYSTEMIC USE

QUININE SULPHATE Tab 300 mg Q 300 (Extemporaneously compounded oral liquid preparations)

NERVOUS SYSTEM

ALPRAZOLAM Tab 250 mcg Xanax Xanax Tab 500 mcg Tab 1 mg Xanax (Extemporaneously compounded oral liquid preparations)

Tegretol

CARBAMAZEPINE

Oral lig 20 mg per ml

CLOBAZAM Frisium Tab 10 mg (Extemporaneously compounded oral liquid preparations)

CLONAZEPAM Oral drops 2.5 mg per Rivotril ml

DIAZEPAM

Tab 2 mg Arrow-Diazepam Arrow-Diazepam Tab 5 mg (Extemporaneously compounded oral liquid preparations)

ETHOSUXIMIDE Oral lig 250 mg per 5 ml Zarontin

LORAZEPAM Tab 1 mg Ativan Ativan Tab 2.5 mg (Extemporaneously compounded oral liquid preparations)

I ORMETAZEPAM

Tab 1 mg Noctamid (Extemporaneously compounded oral liquid preparations)

METHADONE HYDROCHLORIDE

Oral liq 2 mg per ml Biodone **Biodone Forte** Oral lig 5 mg per ml **Biodone Extra Forte** Oral lig 10 mg per ml

MORPHINE HYDROCHLORIDE

Oral lig 1 mg per ml Oral lig 2 mg per ml Oral lig 5 mg per ml Oral lig 10 mg per ml

RA-Morph **RA-Morph RA-Morph RA-Morph**

NITRA7FPAM

Nitrados Tab 5 mg (Extemporaneously compounded oral liquid preparations)

OXA7FPAM

Tab 10 mg Ox-Pam Tab 15 mg Ox-Pam (Extemporaneously compounded oral liquid preparations)

OXYCODONE HYDROCHLORIDE Oral lig 5 mg per 5 ml OxvNorm

PARACETAMOL Oral lig 120 mg per 5 ml Paracare Oral lig 250 mg per 5 ml Paracare Double Strength

PHENYTOIN SODIUM Oral lig 30 mg per 5 ml

Dilantin

SAFETY CAP MEDICINES

SODIUM VALPROATE Oral liq 200 mg per 5 ml

Epilim S/F Liquid Epilim Syrup

TEMAZEPAM Tab 10 mg Normison (Extemporaneously compounded oral liquid preparations)

TRIAZOLAM Tab 125 mcg Hypam Tab 250 mcg Hypam (Extemporaneously compounded oral liquid preparations)

RESPIRATORY SYSTEM AND ALLERGIES

CETIRIZINE HYDROCHLORIDE Oral liq 1 mg per ml Histaclear

CHLORPHENIRAMINE MALEATE Oral liq 2 mg per 5 ml Histafen

DEXTROCHLORPHENIRAMINE MALEATE Oral liq 2 mg per 5 ml Polaramine

PROMETHAZINE HYDROCHLORIDE Oral liq 1 mg per 1 ml Allersoothe SALBUTAMOL Oral liq 400 mcg per ml Ventolin

THEOPHYLLINE Oral liq 80 mg per 15 ml Nuelin

TRIMEPRAZINE TARTRATE Oral liq 30 mg per 5 ml Vallergan Forte

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

CODEINE PHOSPHATE Powder Douglas (Extemporaneously compounded oral liquid preparations)

METHADONE HYDROCHLORIDE Powder AFT (Extemporaneously compounded oral liquid preparations)

PHENOBARBITONE SODIUM Powder MidWest (Extemporaneously compounded oral liquid preparations)

	Subsidy (Manufacturer's Price \$	e) Su Per	Fully ubsidised	Brand or Generic Manufacturer
Vaccinations				
ADULT DIPHTHERIA AND TETANUS VACCINE – [Xpharm] Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid in 0.5 ml Any of the following: 1) For vaccination of patients aged 45 and 65 years old; or	0.00	5 1		<u>DT Booster</u> DT Booster
 For vaccination of previously unimmunised or partially im For revaccination following immunosuppression; or For boosting of patients with tetanus-prone wounds; or 	·		f on interr	ad madiaina abvaisian ar
 For use in testing for primary immunodeficiency disease paediatrician. Note: Please refer to the Immunisation Handbook for apprendicts 				
 BACILLUS CALMETTE-GUERIN VACCINE – [Xpharm] For infants at increased risk of tuberculosis. Increased risk is 1) living in a house or family with a person with current or pa 2) having one or more household members or carers who wito 40 per 100,000 for 6 months or longer; or 3) during their first 5 years will be living 3 months or longer i Note a list of countries with high rates of TB are available www.bcgatlas.org/index.php. Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), 	defined as: ast history of TB; or ithin the last 5 years n a country with a ra	lived in a ate of TB :	country w	ith a rate of TB > or equal to 40 per 100,000
Danish strain 1331, live attenuated, vial with diluent	0.00	1 10		CG Vaccine CG Vaccine
DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE – [Xpharm Funded for any of the following criteria:	-			
 A single vaccine for pregnant woman between gestationa A course of up to four vaccines is funded for children from immunisation; or 			ars inclusiv	ve to complete full primary
 An additional four doses (as appropriate) are funded for transplantation or chemotherapy; pre or post splenector severely immunosuppressive regimens. 				
Notes: Tdap is not registered for patients aged less than 10 y schedule for catch up programmes. Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg per-	ears. Please refer to	o the Imm	unisation	Handbook for appropriate
tussis toxoid, 8 mcg pertussis filamentous haemagluttinin and 2.5 mcg pertactin in 0.5 ml syringe		10 1		postrix postrix

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
 DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE – Funded for any of the following: A single dose for children up to the age of 7 who have con A course of four vaccines is funded for catch up programming immunisation; or An additional four doses (as appropriate) are funded for or post splenectomy; pre- or post solid organ transplant, or Five doses will be funded for children requiring solid organ Note: Please refer to the Immunisation Handbook for appropring 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagluttinin, 8 mcg pertactin and 80 D-antigen units and an antigenetic sector of the s	[Xpharm] mpleted primary imm mes for children (to th (re-)immunisation for renal dialysis and oth n transplantation. iate schedule for catc	unisatione age patient her sev h up pr	of 10 years s post HS0 rerely immu	s) to complete full primary CT, or chemotherapy; pre- unosuppressive regimens; S.
poliomyelitis virus in 0.5ml syringe	0.00	1 10		<u>fanrix IPV</u> fanrix IPV
 Funded for patients meeting any of the following criteria: 1) Up to four doses for children up to and under the age of 1 2) An additional four doses (as appropriate) are funded for (are patients post haematopoietic stem cell transplantatio organ transplant, renal dialysis and other severely immun 3) Up to five doses for children up to and under the age of 1 Note: A course of up-to four vaccines is funded for catch up to complete full primary immunisation. Please refer to the Im programmes. Inj 30IU diphtheriatoxoid with 40IU tetanustoxoid, 25mcg per- tussistoxoid, 25mcg pertussisfilamentoushaemagluttinin, 8 mcgpertactin, 80 D-AgUpoliovirus, 10mcghepatitisB- surfaceantigen in 0.5ml syringe 	re-)immunisation for of n, or chemotherapy; osuppressive regimer 0 receiving solid orga programmes for chilo munisation Handbool	childrei pre or ns; or n trans Iren (u	n up to and post splen plantation. p to and u ne appropri	ectomy; pre- or post solid nder the age of 10 years)
 HAEMOPHILUS INFLUENZAE TYPE B VACCINE – [Xpharm] One dose for patients meeting any of the following: 1) For primary vaccination in children; or 2) An additional dose (as appropriate) is funded for (re-)imm tion, or chemotherapy; pre or post splenectomy; pre- or p dialysis and other severely immunosuppressive regimens 3) For use in testing for primary immunodeficiency disease paediatrician. 	oost solid organ trans ; or s, on the recommend	plant,	pre- or pos	st cochlear implants, renal
Inj 10 mcg vial with diluent syringe HEPATITIS A VACCINE – [Xpharm] Funded for patients meeting any of the following criteria: 1) Two vaccinations for use in transplant patients; or 2) Two vaccinations for use in children with chronic liver dise 3) One dose of vaccine for close contacts of known hepatitis	ease; or	1	✓ <u>A</u> (ct-HIB

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
HEPATITIS B RECOMBINANT VACCINE – [Xpharm] Inj 5 mcg per 0.5 ml vial Funded for patients meeting any of the following criteria:	0.00	1	<u>✓ H</u>	<u>BvaxPRO</u>
 for household or sexual contacts of known acute hepatitis for children born to mothers who are hepatitis B surface a for children up to and under the age of 18 years inclusive require additional vaccination; or for HIV positive patients; or for hepatitis C positive patients; or for patients following non-consensual sexual intercourse; for transplant patients; or for transplant patients; or for transplant patients; or for labeled stick injury. 	ntigen (HBsAg) posit who are considered r	ive; o	r	red a positive serology and
9) following needle stick injury. Inj 10 mcg per 1 ml vial	0.00	1	✔ н	BvaxPRO
 Funded for patients meeting any of the following criteria: 1) for household or sexual contacts of known acute hepatitis 2) for children born to mothers who are hepatitis B surface a 3) for children up to and under the age of 18 years inclusive require additional vaccination; or 4) for HIV positive patients; or 5) for hepatitis C positive patients; or 6) for patients following non-consensual sexual intercourse; 7) for patients following immunosuppression; or 8) for transplant patients; or 9) following needle stick injury. 	Intigen (HBsAg) posit who are considered r or	ive; o not to	r have achiev	
 Inj 40 mcg per 1 ml vial Funded for any of the following criteria: 1) for dialysis patients; or 2) for liver or kidney transplant patient. 	0.00	1	✓ <u>H</u>	<u>BvaxPRO</u>
HUMAN PAPILLOMAVIRUS (6, 11, 16 AND 18) VACCINE [HPV] Maximum of three doses for patient meeting any of the followi 1) Females aged under 20 years old; or 2) Patients aged under 26 years old with confirmed HIV infe 3) For use in transplant (including stem cell) patients; or 4) An additional dose for patients under 26 years of age pos	ng criteria: ction; or			
Inj 120 mcg in 0.5 ml syringe		10 1		ardasil ardasil

Subsidy (Manufacturer's Price)		
\$	Per 🖌	Manufacturer

INFLUENZA VACCINE - [Xpharm]

- A) is available each year for patients who meet the following criteria, as set by PHARMAC:
 - a) all people 65 years of age and over; or
 - b) people under 65 years of age who:
 - i) have any of the following cardiovascular diseases:
 - a) ischaemic heart disease, or
 - b) congestive heart failure, or
 - c) rheumatic heart disease, or
 - d) congenital heart disease, or
 - e) cerebo-vascular disease; or
 - ii) have either of the following chronic respiratory diseases:
 - a) asthma, if on a regular preventative therapy, or
 - b) other chronic respiratory disease with impaired lung function; or
 - iii) have diabetes; or
 - iv) have chronic renal disease; or
 - v) have any cancer, excluding basal and squamous skin cancers if not invasive; or
 - vi) have any of the following other conditions:
 - a) autoimmune disease, or
 - b) immune suppression or immune deficiency, or
 - c) HIV, or
 - d) transplant recipients, or
 - e) neuromuscular and CNS diseases/disorders, or
 - f) haemoglobinopathies, or
 - g) are children on long term aspirin, or
 - h) have a cochlear implant, or
 - i) errors of metabolism at risk of major metabolic decompensation, or
 - j) pre and post splenectomy, or
 - k) down syndrome, or
 - vii) are pregnant; or
 - c) children aged four years and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness;

Unless meeting the criteria set out above, the following conditions are excluded from funding:

- a) asthma not requiring regular preventative therapy,
- b) hypertension and/or dyslipidaemia without evidence of end-organ disease.
- B) Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.
- C) Individual DHBs may fund patients over and above the above criteria. The claiming process for these additional patients should be determined between the DHB and Contractor, or
- D) Stock of the seasonal influenza vaccine is typically available from February until late July with suppliers being required to ensure supply until at least 30 June. Exact start and end dates for each season will be notified each year.

NATIONAL IMMUNISATION SCHEDULE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
 MEASLES, MUMPS AND RUBELLA VACCINE – [Xpharm] A maximum of two doses for any patient meeting the following 1) For primary vaccination in children; or 2) For revaccination following immunosuppression; or 3) For any individual susceptible to measles, mumps or rube 4) A maximum of three doses for children who have had the 	ella; or ir first dose prior to 1			
Note: Please refer to the Immunisation Handbook for appropr Inj 1000 TCID50 measles, 12500 TCID50 mumps and	late schedule for cate	cn up p	programme	S.
1000 TCID50 rubella vial with diluent 0.5 ml vial	0.00	10 1		<u>-M-R II</u> -M-R II
 anatomic asplenia, HIV, complement deficiency (acquired 2) One dose for close contacts of meningococcal cases; or 3) A maximum of two doses for bone marrow transplant pati 4) A maximum of two doses for patients following immunosu Note: children under seven years of age require two doses 8 and then five yearly. *Immunosuppression due to steroid or other immunosuppressive Inj 4 mcg of each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial 	ents; or ippression*. weeks apart, a boos therapy must be for a	ter dos	e three yea	trs after the primary series
 MENINGOCOCCAL C CONGUGATED VACCINE – [Xpharm] Any of the following: Up to three doses and a booster every five years for patie anatomic asplenia, HIV, complement deficiency (acquired One dose for close contacts of meningococcal cases; or A maximum of two doses for bone marrow transplant patie A maximum of two doses for patients following immunosu Note: children under seven years of age require two doses 8 and then five yearly. 	l or inherited), or pre ents; or uppression*. weeks apart, a boos	or pos ter dos	t solid orga e three yea	n transplant; or ars after the primary series
Inj 10 mcg in 0.5 ml syringe		1 10	N	eisvac-C eisvac-C

NATIONAL IMMUNISATION SCHEDULE

	Subsidy (Manufacturer's Price)	Si	Fully ubsidised	Brand or Generic
	\$	Per	~	Manufacturer
PNEUMOCOCCAL (PCV13) VACCINE – [Xpharm]				
Any of the following:				
1) A primary course of four doses for previously unvaccinat	ed individuals up to th	e age of	59 mont	hs inclusive; or
 Up to three doses as appropriate to complete the primary who have received one to three doses of PCV10; or 	course of immunisation	on for ind	lividuals u	Inder the age of 59 months
 One dose is funded for high risk children (over the age of four doses of PCV10; or 	17 months and up to	the age	of 18) wh	o have previously received
 Up to an additional four doses (as appropriate) are fur haematopoietic stem cell transplantation, or chemother solid organ transplant, renal dialysis, complement deficie odeficiency; or 	apy; pre- or post sple	nectomy	; functio	nal asplenia, pre- or post-
 For use in testing for primary immunodeficiency diseas paediatrician. 	es, on the recommen	dation o	f an inter	nal medicine physician or
Note: please refer to the Immunisation Handbook for the app	ropriate schedule for	catch up	program	mes
Inj 30.8 mcg in 0.5 ml syringe	0.00	10 1		revenar 13 revenar 13
PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE - [X	(pharm]			
Either of the following:				
1) Up to three doses for patients pre- or post-splenectomy of	or with functional aspl	enia; or		
Up to two doses are funded for high risk children to the a				
Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each				
23 pneumococcal serotype)	0.00	1	✓ P	neumovax 23
POLIOMYELITIS VACCINE – [Xpharm]				
Up to three doses for patients meeting either of the following:				
 For partially vaccinated or previously unvaccinated indivi 	duals; or			
For revaccination following immunosuppression.				
Note: Please refer to the Immunisation Handbook for approp				
Inj 80D antigen units in 0.5 ml syringe	0.00	1	✓ IP	POL
ROTAVIRUS LIVE REASSORTANT ORAL VACCINE - [Xpharm]				
Maximum of three doses for patients meeting the following:				
1) first dose to be administered in infants aged under 15 we				
2) no vaccination being administered to children aged 8 mc				
Oral susp G1, G2, G3, G4, P1(8)11.5 million CCID50 units per 2 ml, tube		10		otaTeg
	0.00	10	• <u>n</u>	ulaiey

NATIONAL IMMUNISATION SCHEDULE

Subsidy	Fully	Brand or
facturer's Price)	Subsidised	Generic
\$ Per	 ✓ 	

VARICELLA VACCINE [CHICKEN POX VACCINE] - [Xpharm]

Maximum of two doses for any of the following:

- For non-immune patients:
 a) with chronic liver d
 - a) with chronic liver disease who may in future be candidates for transplantation; or
 - b) with deteriorating renal function before transplantation; or
 - c) prior to solid organ transplant; or
 - d) prior to any elective immunosuppression*.
- 3) For patients at least 2 years after bone marrow transplantation, on advice of their specialist.
- 4) For patients at least 6 months after completion of chemotherapy, on advice of their specialist.
- 5) For HIV positive non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist.
- 6) For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella.
- For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.
- 8) For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.

* immunosuppression due to steroid or other immunosuppressiv	e therapy must be	for a treatm	nent period o	of greater than 28 days
Inj 2000 PFU vial with diluent	0.00	1	🖌 <u>Varilr</u>	ix

- Symbols -	
3TC	110
- A -	
A-Scabies	70
Abacavir sulphate	109
Abacavir sulphate with	
lamivudine	109
Abilify	
Abiraterone acetate	175
Acarbose	
Accu-Chek Ketur-Test	26
Accu-Chek Performa	27
Accuretic 10	
Accuretic 20	51
Acetazolamide	207
Acetic acid with 1, 2- propanediol	
diacetate and	
benzethonium	205
Acetic acid with hydroxyquinoline	
and ricinoleic acid	
Acetylcysteine	
Aci-Jel	76
Aciclovir	
Infection	
Sensory	
Acidex	
Acipimox	
Acitretin	
Aclasta	
Aclin	
Act-HIB	
Actavis	
Actinomycin D	166
Actrapid	24
Actrapid Penfill	
Acupan	
Adalat 10	
Adalimumab Adapalene	
Adefin XL	
Adefovir dipivoxil	
Adenuric	
ADR Cartridge 1.8	
ADR Cartridge 3.0	
Adrenaline	
Adriamycin	
ADT Booster	
Adult diphtheria and tetanus	0
vaccine	249
Advantan	
Advate	
Afinitor	

AFT SLS-free AFT-Pyrazinamide10	
Agents Affecting the	
Renin-Angiotensin System	50
Agents for Parkinsonism and Related Disorders12	25
Agents Used in the Treatment of	
Poisonings2	10
Agrylin10	65
Air Flow Products1	
Alanase20	03
Albendazole	91
Albey19	97
Albustix	78
Alendronate sodium1	18
Alendronate sodium with	
cholecalciferol1	18
Alfacalcidol	
Alginic acid	20
Alitrag2	26
Alkeran10	61
Allersoothe19	98
Allopurinol12	22
Alpha Adrenoceptor Blockers	50
Alpha-Keri Lotion	67
Alphamox	93
Alprazolam14	45
Alu-Tab	20
Aluminium hydroxide	
Amantadine hydrochloride12	25
Ambrisentan	
Amiloride hydrochloride	56
Amiloride hydrochloride with	
furosemide	56
Amiloride hydrochloride with	
hydrochlorothiazide	56
Aminophylline 20	03
Amiodarone hydrochloride	52
Amisulpride14	40
Amitriptyline1	31
Amlodipine	54
Amorolfine	
Amoxicillin	93
Amoxicillin Actavis	93
Amoxicillin with clavulanic	
acid	93
Amphotericin B	37
Amsacrine10	
AmsaLyo10	64
Amsidine10	64
Amyl nitrite	
Anaesthetics12	26

Anagrelide hydrochloride	165
Analgesics	
Anastrozole	
Andriol Testocaps	81
Androderm	80
Animas Battery Cap	29
Animas Cartridge	33
Animas Vibe	28
Antabuse	158
Antacids and Antiflatulants	20
Anten	
Anthelmintics	91
Antiacne Preparations	62
Antiallergy Preparations	197
Antianaemics	41
Antiandrogen Oral	
Contraceptives	.76
Antiarrhythmics	
Antibacterials	
Antibacterials Topical	63
Anticholinergic Agents	201
Anticholinesterases	115
Antidepressants	131
Antidiarrhoeals	20
Antiepilepsy Drugs	133
Antifibrinolytics, Haemostatics	100
and Local Sclerosants	42
Antifungals	97
Antifungals Topical	
Antihistamines	107
Antihypotensives	
Antimalarials	100
Antimigraine Preparations	138
Antinaus	
Antinausea and Vertigo	109
Agents	120
Antiparasitics	100
Antipruritic Preparations	64
Antipsychotics	140
Antiretrovirals	140
Antiretrovirals - Additional	107
Therapies	
Antirheumatoid Agents	110
Antispasmodics and Other	110
Agents Altering Gut	
Motility	00
	.22
Antithrombotic Agents	44
Antithymocyte globulin	101
(equine)	104
Antitrichomonal Agents	100
Antituberculotics and	
Antileprotics	100

Antiulcerants22
Antivirals102
Anxiolytics145
Anzatax168
Apidra25
Apidra SoloStar25
Apo-Allopurinol122
Apo-Amiloride56
Apo-Amlodipine54
Apo-Amoxi93
Apo-Azithromycin92
Apo-Bromocriptine
Apo-Ciclopirox
Apo-
Cilazapril/Hydrochlorothiazide51
Apo-Clarithromycin
Alimentary
Infection
Apo-Clomipramine
Apo-Diclo115
Apo-Diclo SR115
Apo-Diltiazem CD55
Apo-Doxazosin50
Apo-Folic Acid42
Apo-Imiquimod Cream 5%71
Apo-Megestrol176
Apo-Mirtazapine132
Apo-Moclobemide132
Apo-Nadolol54
Apo-Nicotinic Acid57
Apo-Oxybutynin77
Apo-Perindopril50
Apo-Pindolol54
Apo-Prazosin50
Apo-Prednisone80
Apo-Prednisone S2980
Apo-Primidone136
Apo-Propranolol54
Apo-Pyridoxine
Apo-Ropinirole125
Apo-Selegiline125
Apo-Selegiline S29125
Apo-Thiamine
Apo-Timol54
Apo-Zopiclone153
Apomine
Apomorphine hydrochloride
Aprepitant
Apresoline
Aptamil Gold+ Pepti Junior
Aquasun 30+71
Aqueous cream67
Aratac
/ watao

Arava	116
Aremed	
Arimidex	
Aripiprazole	140
Aristocort	66
Aromasin	177
Arrow - Clopid	
Arrow Amitriptyline	401
Arrow-Amitriptyline	101
Arrow-Bendrofluazide	131
Arrow-Brimonidine	207
Arrow-Calcium	
Arrow-Citalopram	
Arrow-Diazepam	145
Arrow-Dortim	207
Arrow-Doxorubicin	166
Arrow-Etidronate	
Arrow-Fluoxetine	132
Arrow-Gabapentin	134
Arrow-Lamotrigine	136
Arrow-Lisinopril	50
Arrow-Losartan &	
Hydrochlorothiazide	52
Arrow-Meloxicam	
Arrow-Morphine LA	129
Arrow-Norfloxacin	11/
Arrow-Ornidazole	100
Arrow-Quinapril 10	100
Arrow-Quinapril 20	 51
Arrow-Quinapril 20	5I
Arrow-Quinapril 5	51
Arrow-Roxithromycin	92
Arrow-Sertraline	132
Arrow-Simva 10mg	57
Arrow-Simva 20mg	57
Arrow-Simva 40mg	57
Arrow-Simva 80mg	57
Arrow-Sumatriptan	138
Arrow-Timolol	207
Arrow-Tolterodine	78
Arrow-Topiramate	137
Arrow-Tramadol	130
Arrow-Venlafaxine XR	133
Arsenic trioxide	165
Asacol	
Asamax	
Ascorbic acid	
Aspec 300	107
Aspec 300	127
Aspen Aurenaline	59
Aspirin Blood	
Blood	44
Nervous	
Asthalin	200
Atazanavir sulphate	110

Atenolol53
Atenolol AFT53
ATGAM
Ativan145
Atomoxetine154
Atorvastatin
Atripla110
Atronine sulphate
Cardiovascular
Sensory
Atropt
Atrovent201
Aubagio149
Augmentin
Auranofin116
Avelox
Avenus
Avonex
Avonex Pen
Azacitidine
Azamun
Azathioprine177
Azithromycin92
Azol90
Azopt207
AZT110
- B -
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine

Benzathine benzylpenicillin	93
Benzbromaron AL 100	.122
Benzbromarone	
Benzoin	.217
Benztrop	.125
Benztropine mesylate	.125
Benzydamine hydrochloride	
Benzylpenicillin sodium (penicillin	
G)	93
Beta Adrenoceptor Blockers	
Beta Cream	
Beta Ointment	
Beta Scalp	
Beta-Adrenoceptor Agonists	
Betadine	68
Betadine Skin Prep	68
Betaferon	
Betagan	.206
Betahistine dihydrochloride	.139
Betamethasone dipropionate	65
Betamethasone dipropionate	
with calcipotriol	70
Betamethasone sodium	
phosphate with	
betamethasone acetate	79
Betamethasone valerate65	5. 71
Betamethasone valerate with	-,
	66
clioquinol	66
clioquinol Betamethasone valerate with	
clioquinol Betamethasone valerate with fusidic acid	66
clioquinol Betamethasone valerate with fusidic acid Betaxolol	66 .206
clioquinol Betamethasone valerate with fusidic acid Betaxolol Betnovate	66 .206 65
clioquinol Betamethasone valerate with fusidic acid Betaxolol Betnovate Betnovate-C	66 .206 65 66
clioquinol Betamethasone valerate with fusidic acid Betaxolol Betnovate Betnovate-C Betoptic	66 .206 65 66 .206
clioquinol Betamethasone valerate with fusidic acid Betaxolol Betnovate Betnovate-C Betoptic Betoptic S	66 65 66 .206 .206
clioquinol Betamethasone valerate with fusidic acid Betaxolol Betnovate Betnovate-C Betoptic Betoptic S Bezafibrate	66 65 66 .206 .206 57
clioquinol Betamethasone valerate with fusidic acid Betaxolol Betnovate Betnovate-C Betoptic Betoptic S Bezafibrate Bezalip	66 65 66 .206 57 57
clioquinol Betamethasone valerate with fusidic acid Betaxolol Betnovate Betnovate Betoptic Betoptic S Bezalip Bezalip Retard	66 65 66 .206 .206 57 57 57
clioquinol Betamethasone valerate with fusidic acid Betaxolol Betnovate Betnovate .C Betoptic Betoptic S Bezalip Bezalip Bezalip Retard Bicalaccord	66 65 66 .206 57 57 57 57 57
clioquinol Betamethasone valerate with fusidic acid Betaxolol Betnovate Betnovate .C Betoptic Betoptic S Bezalip Bezalip Bezalip Retard Bicalaccord Bicalutamide	66 65 66 .206 .206 57 57 57 57 57 57 57
clioquinol Betamethasone valerate with fusidic acid Betaxolol Betnovate Betnovate C Betoptic Betoptic S Bezafibrate Bezalip Retard Bicalaccord Bicalutamide Bicillin LA	66 65 66 .206 .206 57 57 57 57 75 93
clioquinol Betamethasone valerate with fusidic acid Betaxolol Betnovate Betnovate-C Betoptic Betoptic S Bezafibrate Bezalip Retard Bicalaccord Bicalutamide Bicillin LA BiCNU	66 206 65 206 206 57 57 57 57 57 57 93 161
clioquinol Betamethasone valerate with fusidic acid Betaxolol Betnovate Betnovate .C. Betoptic Betoptic S Bezafibrate Bezalip Retard Bicalaccord Bicalutamide Bicillin LA BiCNU Bile and Liver Therapy	66 65 66 206 57 57 57 57 75 93 93 23
clioquinol Betamethasone valerate with fusidic acid Betaxolol Betnovate Betnovate .C. Betoptic Betoptic S Bezafibrate Bezalip Retard Bicalaccord Bicalutamide Bicillin LA BiCNU Bile and Liver Therapy	66 65 66 206 57 57 57 57 75 93 93 23
clioquinol Betamethasone valerate with fusidic acid Betaxolol Betnovate Betnovate-C Betoptic Betoptic S Bezafibrate Bezalip Retard Bicalaccord Bicalutamide Biclillin LA Bile and Liver Therapy Biltricide	66 .206 .206 .206 .206 .206 57 57 57 .175 93 .161 23 91
clioquinol Betamethasone valerate with fusidic acid Betaxolol Betnovate Betnovate .C. Betoptic Betoptic S Bezafibrate Bezalip Retard Bicalaccord Bicalutamide BicNU Bile and Liver Therapy Bitricide Bimatoprost	66 .206 .206 .206 .206 57 57 57 57 93 .161 23 91 .207
clioquinol Betamethasone valerate with fusidic acid Betaxolol Betnovate Betnovate C Betoptic S Bezafibrate Bezafibrate Bezalip Bezalip Retard Bicalutamide Bicalutamide Bicillin LA BicNU Bile and Liver Therapy Biltricide Bimatoprost Biodone	66 .206 .206 .206 .206 .206 57 57 57 57 57 93 .161 23 91 .207 .129
clioquinol Betamethasone valerate with fusidic acid Betaxolol Betnovate Betnovate-C Betoptic S Bezafibrate Bezafibrate Bezafibrate Bezafibrate Bezafibrate Bezafibrate Bezafibrate Bezafibrate Bezafibrate Bezafibrate Bezafibrate Bezafibrate Bicalutamide Bicalutamide Bicalutamide BicNU Biltacide Bithrcide Bimatoprost Biodone Biodone Extra Forte	66 .206 65 .206 .206 57 57 .175 93 .161 23 91 .207 .129 .129
clioquinol	66 .206 65 .206 .206 57 57 .175 .175 .175 93 .161 23 91 .207 .129 .129 .129
clioquinol	66 .206 .206 .206 .206 .206 57 57 57 .175 .175 .175 93 .161 23 91 .207 .129 .129 36
clioquinol	66 .206 .206 .206 .206 .206 .207 57 57 57 93 .161 23 91 .207 .129 .129 36 36 36 31
clioquinol	66 .206 65 .206 .206 .206 57 57 57 93 .161 91 .207 .129 91 .129 93 91 93 91
clioquinol	66 .206 .206 .206 .206 .206 .206 .207 57 57 57 93 93 91 207 .129 207 2129 223 36 353 67

Blood Colony-stimulating
Factors
Blood glucose diagnostic test
meter
Blood glucose diagnostic test
strip
Blood glucose test strips (visually
impaired)27
Blood ketone diagnostic test
meter
BNM
Boceprevir107
Bonjela
Boostrix
Bortezomib165
Bosentan
Bosvate53
Bplex
Brevinor 1/21
Brevinor 1/28
Brevinor 21
Bricanyl Turbuhaler
Brilinta44
Brimonidine tartrate207
Brimonidine tartrate with timolol
maleate 207
Brinzolamide207
Brolene205
Bromocriptine mesylate125
Brufen SR115
BSF Apo-Mirtazapine210
Buccastem139
Budesonide
Alimentary20
Respiratory198, 203
Budesonide with
eformoterol 199
Bumetanide56
Buprenorphine with
naloxone
Bupropion hydrochloride158
Burinex
Buscopan
Buspirone hydrochloride145
Busulfan161
Butacort Aqueous203
- C -

Cabergoline	89
Cafergot1	
Caffeine citrate20	04
Cal-d-Forte	38
Calamine	64

Calcipotriol70
Calcitonin79
Calcitriol
Calcitriol-AFT
Calcium carbonate20, 39
Calcium Channel Blockers
Calcium Disodium
Versenate
Calcium folinate
Calcium Folinate Ebewe
Calcium gluconate
Calcium Homeostasis
Calcium polystyrene
sulphonate
Sulphonate
Calcium Resonium
Calogen222
Calsource
Camptosar164
Candesartan cilexetil51
Candestar51
Canesten63
Capecitabine163
Capecitabine Winthrop163
Capoten50
Capsaicin
Musculoskeletal116
Nervous127
Captopril50
Carafate23
Carbaccord161
Carbamazepine134
Carbimazole84
Carbomer208
Carboplatin161
Carboplatin Ebewe
Carbosorb-X
Cardinol LA54
Cardizem CD55
CareSens
CareSens II
CareSens N
CareSens N POP26
Carmustine
Carvedilol
Catapres55
Catapres TTS 1
Catapres-TTS-155 Catapres-TTS-255
Catapres TTC 2
Catapres-TTS-3
CeeNU
Cefaclor monohydrate
Cefalexin
Cefalexin Sandoz91 Cefazolin91

Ceftriaxone	91
Ceftriaxone-AFT	91
Cefuroxime axetil	91
Celestone Chronodose	79
Celiprolol	53
Cellcept	
Celol	
Centrally-Acting Agents	55
Cephalexin ABM	91
Cerezyme	36
Cetirizine hydrochloride	.197
Cetomacrogol	
Cetomacrogol with glycerol	
Champix	159
Charcoal	210
Chemotherapeutic Agents	161
Chicken pox vaccine	
Chlorafast	
Chlorambucil	
Chloramphenicol	205
Chlorhexidine gluconate	
Alimentary	37
Dermatological	07
Chloroform	
Chlorothiazide	
Chlorpheniramine maleate	197
Chlorpromazine	
hydrochloride	
	1/0
Chlorsig	
Chlorsig Chlortalidone	205
Chlorsig	205
Chlorsig Chlortalidone [Chlorthalidone]	205 56
Chlorsig Chlortalidone [Chlorthalidone] Chlorthalidone	205 56 56
Chlorsig Chlortalidone [Chlorthalidone] Chlorthalidone Chlorvescent	205 56 56 49
Chlorsig Chlortalidone [Chlorthalidone] Chlorthalidone Chlorvescent Cholecalciferol	205 56 56 49 38
Chlorsig Chlortalidone [Chlorthalidone] Chlorthalidone Chlorvescent Cholecalciferol Cholestyramine	205 56 56 49 38
Chlorsig Chlortalidone [Chlorthalidone] Chlorthalidone Chlorvescent Cholecalciferol Cholestyramine Choline salicylate with	205 56 49 38 57
Chlorsig Chlortalidone [Chlorthalidone] Chlorthalidone Chlorvescent Cholecalciferol Cholestyramine	205 56 49 38 57
Chlorsig Chlortalidone [Chlorthalidone] Chlorthalidone Chlorvescent Cholecalciferol Cholestyramine Choline salicylate with cetalkonium chloride	205 56 49 38 57 37
Chlorsig Chlortalidone [Chlorthalidone] Chlorthalidone Chlorvescent Cholecalciferol Cholestyramine Choline salicylate with cetalkonium chloride Cholvastin	205 56 49 38 57 37 37
Chlorsig Chlortalidone [Chlorthalidone] Chlorthalidone Chlorthalidone Chlorvescent Cholecalciferol Cholestyramine Choline salicylate with cetalkonium chloride Cholvastin Ciclopirox olamine	205 56 49 38 57 37 57 63
Chlorsig Chlortalidone [Chlorthalidone] Chlorthalidone Chlorthalidone Chlorvescent Cholecalciferol Cholestyramine Choline salicylate with cetalkonium chloride Cholvastin Ciclopirox olamine Ciclosporin	205 56 49 38 57 57 57 63 195
Chlorsig Chlortalidone [Chlorthalidone] Chlorthalidone Chlorthalidone Chlorescent Cholecalciferol Cholestyramine Choline salicylate with cetalkonium chloride Cholvastin Ciclopirox olamine Ciclosporin Ciclosporin Cilazapril	205 56 49 38 57 57 57 63 195
Chlorsig Chlortalidone [Chlorthalidone] Chlorthalidone Chlorthalidone Cholescent Cholestyramine Cholestyramine Cholestyramine Cholestyramine chloride Cholvastin Ciclopirox olamine Ciclosporin Cilazapril Cilazapril with	205 56 49 38 57 57 63 195 50
Chlorsig Chlortalidone [Chlorthalidone] Chlorthalidone Chlorthalidone Cholescent Cholestyramine Cholestyramine Cholestyramine Cholestyramine chloride Cholvastin Ciclopirox olamine Ciclosporin Cilazapril Cilazapril with	205 56 49 38 57 57 63 195 50
Chlorsig Chlortalidone [Chlorthalidone] Chlorthalidone Chlorthalidone Cholecalciferol Cholestyramine Cholestyramine Choline salicylate with cetalkonium chloride Cholvastin Ciclopirox olamine Ciclosporin Cilazapril Cilazapril with hydrochlorothiazide	205 56 49 38 57 57 63 195 50 51
Chlorsig Chlortalidone [Chlorthalidone] Chlorthalidone Chlorthalidone Chlorescent Cholescliferol Cholestyramine Cholestyramine Cholestyramine Cholestyramine Cholvastin Ciclopirox olamine Ciclosporin Cilazapril Cilazapril with hydrochlorothiazide Cilicaine	205 56 49 38 57 57 63 195 50 51 94
Chlorsig Chlortalidone [Chlorthalidone] Chlorthalidone Chlorthalidone Cholrescent Cholescalciferol Cholestyramine Cholestyramine Choline salicylate with cetalkonium chloride Cholvastin Ciclosporin Ciclosporin Ciclosporin Cilazapril Cilazapril with hydrochlorothiazide Cilicaine Cilicaine VK	205 56 56 49 38 57 37 57 63 195 50 51 94 94
Chlorsig Chlortalidone [Chlorthalidone] Chlorthalidone Chlorthalidone Chlorescent Cholescliferol Cholestyramine Cholestyramine Cholestyramine Cholestyramine Cholvastin Ciclopirox olamine Ciclosporin Cilazapril Cilazapril Cilazapril with hydrochlorothiazide Cilicaine VK Ciloxan	205 56 56 49 38 57 57 63 195 50 51 94 94 94 205
Chlorsig Chlortalidone [Chlorthalidone] Chlorthalidone Chlorthalidone Chlorvescent Cholescalciferol Cholestyramine Cholestyramine Cholestyramine Cholvastin Ciclopirox olamine Ciclosporin Ciclosporin Cilazapril Cilazapril Cilazapril with hydrochlorothiazide Cilicaine VK Ciloxan Cipflox	205 56 56 49 38 57 57 63 195 50 51 94 94 94 205
Chlorsig	205 56 56 37 57 57 57 50 51 94 94 94 95
Chlorsig	205 56 56 37 57 57 57 50 51 94 94 94 95
Chlorsig	205 56 56 37 37 57 37 57 63 95 94 94 94 95 95
Chlorsig	205 56 56 38 57 38 57 57 57 57 94 95 94 95 95 95 95
Chlorsig	205 56 56 49 38 57 57 57 57 50 94 94 94 95 95 95 95 95 95 95
Chlorsig	205 56 56 38 57 57 57 50 95 94 94 95 95 95 95 95 95
Chlorsig	205 56 56 38 57 57 57 50 95 94 94 95 95 95 95 95 95

Cladribine163
Clarithromycin
Alimentary22
Infection
Clexane45
Climara 10082
Climara 5082
Clindamycin95
Clindamycin ABM95
Clinicians Renal Vit
Clobazam134
Clobetasol BNM65
Clobetasol propionate65, 71
Clobetasone butyrate65
Clofazimine100
Clomazol
Dermatological
Genito-Urinary
Clomiphene citrate90
Clomipramine hydrochloride
Clonazepam
Clonidine
Clonidine BNM55
Clonidine hydrochloride55
Clonidaria
Clopidogrel44 Clopine
Clopine
Clopixol
Clotrimazole
Dermatological63
Genito-Urinary76
Clozapine141
Clozaril141
Co-Renitec51
Co-trimoxazole95
Coal tar70
Coal tar with allantoin, menthol,
phenol and sulphur70
Coal tar with salicylic acid and
sulphur71
Coco-Scalp71
Codeine phosphate
Extemporaneous217
Nervous128
Cogentin125
Colaspase [L-asparaginase]165
Colchicine
Colestid57
Colestipol hydrochloride57
Colgout
Colifoam21
Colistin sulphomethate
Colistin-Link95
Collodion flexible

Colofac22
Coloxyl35
Combigan207
Comfort
Comfort Short31
Compound electrolytes48
Compound
hydroxybenzoate
Concerta
Condoms
Condyline72
Contact-D
Contraceptives - Hormonal74
Contraceptives -
Non-hormonal
Copaxone152
Cordarone-X
Corticosteroids and Related
Agents for Systemic Use
Corticosteroids Topical
Cosmegen166
Cosopt207
Cosopi207 Coumadin47
Creon 10000
Creon 25000
Crixivan
Crotamiton
Crystaderm63
Curam
Curam Duo
Cvite
Cyclizine hydrochloride139
Cyclizine lactate
Cyclogyl208
Cyclopentolate
hydrochloride
Cyclophosphamide161
Cycloserine
Cyklokapron43
Cyproterone acetate80
Cyproterone acetate with
ethinyloestradiol
Cytarabine163
Cytotec
Cytoxan161
- D -
D-Penamine116
d4T110
Dabigatran46
Dacarbazine166
Dactinomycin [Actinomycin
D] 166
Daivobet70

Daivonex70 Daktarin64
Dalacin C95
Dalteparin sodium45
Danazol90
Dantrium123
Dantrolene123
Daonil25
Dapa-Tabs57
•
Dapsone100
Daraprim96
Darunavir110
Dasatinib169
Dasaunio
Daunorubicin166
DBL Acetylcysteine210
DBL Aminophylline203
DBL Bleomycin Sulfate165
DBL Carboplatin161
DBL Cisplatin161
DBL Docetaxel166
DBL Doxorubicin166
DBL Doxorubicin S29166
DBL Epirubicin
Hydrochloride
DBL Ergometrine76
DBL Gemcitabine164
DBL Leucovorin Calcium
DBL Morphine Sulphate129
DBL Pethidine
Hydrochloride 130
DBL Tobramycin
DDI109
De Nol23
De-Worm91
De-Worm
Decozol
Decozol37 Deferasirox210
Decozol
Decozol 37 Deferasirox 210 Deferiprone 211 Deoxycoformycin 168 Depo-Medrol 80 Depo-Medrol with Lidocaine 80 Depo-Provera 75 Depo-Testosterone 80 Deprim 95 Dermol 71 Desferal 211 Desferioxamine mesilate 211 Desmopressin acetate 89
Decozol 37 Deferasirox 210 Deferiprone 211 Deoxycoformycin 168 Depo-Medrol 80 Depo-Medrol with Lidocaine 80 Depo-Provera 75 Depo-Testosterone 80 Deprim 95 Dermol 71 Desferal 211 Desferioxamine mesilate 211 Desmopressin acetate 89
Decozol
Decozol
Decozol
Decozol
Decozol
Decozol

Dexamethasone phosphate	79
Dexamethasone with framycetin	
and gramicidin	. 205
Dexamethasone with neomycin	
sulphate and polymyxin B	
sulphate	. 206
Dexamfetamine sulfate	
Dexmethsone	79
Dextrochlorpheniramine	
maleate	
Dextrose	48
Dextrose with electrolytes	
DHC Continus	
Diabetes	
Diabetes Management	
Diacomit	137
Diamide Relief	
Diamox	
Diaphragm	
Diasip	
Diason RTH	
Diazepam133	
Diazoxide	
Dicarz	
Diclax SR	
Diclofenac Sandoz	115
Diclofenac sodium	
Musculoskeletal	115
Sensory	206
Didanosine [DDI]	
Differin	
Difflam	
Diflucan	
Diflucan S29	
Diflucortolone valerate	65
Digestives Including	~ 4
Enzymes	34
Digoxin	
Dihydrocodeine tartrate	
Dilantin	
Dilantin Infatab	
Diltiazem hydrochloride	
Dilzem	
Dimethicone Dimethyl fumarate	145
Dipentum Diphtheria, tetanus and pertussis	21
	040
vaccine	. 249
Diphtheria, tetanus, pertussis	050
and polio vaccine	. 200
Diphtheria, tetanus, pertussis, polio, hepatitis B and	
haemophilus influenzae type B	
naemophilus iniluenzae type D	

vaccine	250
Diprosone	65
Diprosone OV	65
Dipyridamole	44
Disinfecting and Cleansing	
Agents	66
Disopyramide phosphate	52
Disulfiram	158
Diuretics	56
Diurin 40	56
Docetaxel	166
Docetaxel Sandoz	166
Docusate sodium	35
Docusate sodium with	
sennosides	35
Domperidone	
Donepezil hydrochloride	157
Donepezil-Rex	
Dopergin	125
Dopress	
Dornase alfa	
Dorzolamide hydrochloride	207
Dorzolamide with timolol	207
Dostinex	<u>207</u> 80
Dothiepin hydrochloride	131
Doxazosin	
Doxepin hydrochloride	131
Doxine	101 Q4
Doxorubicin Ebewe	166
Doxorubicin hydrochloride	166
Doxy-50	100 94
Doxycycline	
Doxycycline DP Fusidic Acid Cream	
DP Lotion	
DP Lotn HC	
DP-Anastrozole	177
Dr Reddy's Omeprazole	23
Dr Reddy's Ondansetron	139
Dr Reddy's Terbinafine	99
Drugs Affecting Bone	
Drugs Affecting Bone Metabolism	117
Dulcolax	
Duocal Super Soluble	
Powder	221
Duolin	
Duolin HFA	
Durex Confidence	201 73
Durex Extra Safe	70 73
Duride	
Dynacirc-SRO	55 55
•	
- E - e-chamber La Grande	004
e-chamber Mask	204

e-chamber Turbo204
E-Mycin
E-WIYCHT
Ear Preparations205
Ear/Eye Preparations205
Easiphen Liquid235
EasyCheck77
Econazole nitrate64
Efavirenz109
Efavirenz with emtricitabine and
tenofovir disoproxil
fumarate110
Efexor XR133
Effient44
Eformoterol fumarate199
Efudix72
Egopsoryl TA70
Elecare
Elecare LCP
Eligard89
Elocon
Elocon Alcohol Free66
Eloxatin162
Eltrombopag42
Eltroxin
Emend Tri-Pack
EMLA127
Emtricitabine110
Emtricitabine with tenofovir
Emtricitabine with tenofovir disoproxil fumarate
Emtricitabine with tenofovir disoproxil fumarate 110 Emtriva 110 Emulsifying ointment 67 Enalapril maleate hydrochlorothiazide 51 Endrel 178 Endocrine Therapy 161 Enerlyte 48 Enfuvitide 111 Ensure 231 Ensure Plus 230 Ensure Plus RTH 230
Emtricitabine with tenofovir disoproxil fumarate 110 Emtriva 110 Emulsifying ointment 67 Enalapril maleate 50 Enalapril maleate with hydrochlorothiazide 51 Enbrel 178 Endocrine Therapy 175 Endoxan Enerlyte 48 Enfuviride 111 Enoxaparin sodium 45 Ensure Plus 231 Ensure Plus HN 230 Ensure Plus RTH 230 Entacapone
Emtricitabine with tenofovir disoproxil fumarate 110 Emtriva 110 Emulsifying ointment
Emtricitabine with tenofovir disoproxil fumarate 110 Emtriva 110 Emulsifying ointment
Emtricitabine with tenofovir disoproxil fumarate 110 Emtriva 110 Emulsifying ointment 67 Enalapril maleate hydrochlorothiazide 51 Enbrel 178 Endocrine Therapy Endoxan 161 Enerlyte 48 Ensure 231 Ensure Plus 231 Ensure Plus RTH 230 Entapone 125 Entapone 125 Entacovir 102 Entocort CIR
Emtricitabine with tenofovir disoproxil fumarate 110 Emtriva 110 Emulsifying ointment 67 Enalapril maleate 50 Enalapril maleate with hydrochlorothiazide hydrochlorothiazide 178 Endocrine Therapy 175 Endocrine Therapy 175 Endoxan 161 Enerlyte
Emtricitabine with tenofovir disoproxil fumarate 110 Emtriva 110 Emulsifying ointment 67 Enalapril maleate hydrochlorothiazide 51 Enbrel 178 Endocrine Therapy Endoxan 161 Enerlyte 48 Ensure 231 Ensure Plus 231 Ensure Plus RTH 230 Entapone 125 Entapone 125 Entacovir 102 Entocort CIR
Emtricitabine with tenofovir disoproxil fumarate 110 Emtriva 110 Emulsifying ointment
Emtricitabine with tenofovir disoproxil fumarate 110 Emtriva 110 Emulsifying ointment 67 Enalapril maleate bill hydrochlorothiazide 51 Endrel Endocrine Therapy 111 Enorel Endryte 48 Enfuvirtide Ensure 231 Ensure Plus 232 Ensure Plus HN 230 Ensure Plus RTH 230 Entacapone 125 Entacone 215 Entacorir 102 Entocort CIR 200 Epilim Crushable 136 Epilim IV
Emtricitabine with tenofovir disoproxil fumarate 110 Emtriva 110 Emulsifying ointment

Epirubicin Ebewe166
Epirubicin hydrochloride
Epirubiciii fiyufochionae
Epoetin alfa [Erythropoietin
alfa] 42
Eprex42
Eptacog alfa [Recombinant factor
VIIa]
ERA92
Ergometrine maleate76
Ergotamine tartrate with
caffeine
Erlotinib
Erythrocin IV
Erythromycin ethyl succinate92
Erythromycin lactobionate
Erythromycin stearate
Erythropoietin alfa41
Escitalopram132
Eskazole91
Estradot82
Estrofem82
Etanercept178
Ethambutol hydrochloride101
Ethics Aspirin127
Ethics Aspirin EC44
Ethics Enalapril
Ethics Lisinopril
Ethinyloestradiol83
Ethinyloestradiol with desogestrel
desogestrei
Ethinyloestradiol with
levonorgestrel74
Ethinyloestradiol with
norethisterone75
Ethosuximide134
Etidronate disodium118
Etopophos167
Etoposide166
Etoposide phosphate167
Etravirine
Eumovate65
Everet
Everolimus195
Evista119
Exelon
Exemestane
Exjade
Extemporaneously Compounded
Preparations and
Galenicals 217
Eye Preparations205
Ezemibe57
Ezetimibe57

Ezetimibe with simvastatin	58
Factor eight inhibitor bypassing	
fraction	43
Febuxostat	123
Feed Thickener Karicare	
Aptamil	233
FEIBA NF	43
Felodipine	
Fenpaed	115
Fentanyl	
Fentanyl Sandoz	128
Ferodan	40
Ferriprox	
Ferro-F-Tabs	
Ferro-tab	
Ferrograd	40
Ferrograd F	
Ferrous fumarate	39
Ferrous fumarate with folic	
acid	39
Ferrous sulphate	40
Ferrous sulphate with folic	
acid	
Ferrum H	40
Fexofenadine hydrochloride	
Fibro-vein	
Filgrastim	
Finasteride	
Fingolimod	14/
Finpro	
Firazyr	197
Flagyl	
Flagyl-S	
Flamazine	
Flecainide acetate Fleet Phosphate Enema	
Flixonase Hayfever &	30
Allergy	203
Flixotide	
Flixotide Accuhaler	
Floair	
Florinef	
Fluanxol	
Fluarix	
Flucloxacillin	
Flucloxin	
Fluconazole	
Fludara	
Fludara Oral	
Fludarabine Ebewe	
Fludarabine phosphate	
Fludrocortisone acetate	

Fluids and Electrolytes48
Flumetasone pivalate205
Fluocortolone caproate with
fluocortolone pivalate and
cinchocaine
Fluorometholone
Fluorouracil
Fluorouracil Ebewe
Fluorouracil sodium
Fluoxetine hydrochloride
Flupenthixol decanoate
Fluphenazine decanoate
Flutamide
Flutamin
Fluticasone
Fluticasone propionate
Fluticasone with salmeterol200
FML206
Foban63
Folic acid42
Food Thickeners233
Foods And Supplements For
Inborn Errors Of
Metabolism234
Foradil199
Forteo119
Fortini225
Fortini Multi Fibre225
Fortisip231
Fortisip Multi Fibre232
Fosamax
Fosamax Plus118
Fragmin45
Framycetin sulphate
Freestyle Optium
Freestyle Optium Ketone
Freestyle Optium Neo
Frisium
Frumil
Frusemide
Frusemide-Claris
Fucicort
Fucidin
Fucithalmic205
Fungilin
Furosemide [Frusemide]56
Fusidic acid
Dermatological63
Infection95
Sensory205
Fuzeon111
- G -
Gabapentin134

Gacet128
Ganciclovir205
Gardasil251
Gastrosoothe22
Gaviscon Double Strength20
Gaviscon Infant20
Gefitinib171
Gemcitabine Ebewe164
Gemcitabine hydrochloride164
Gemfibrozil
Gemzar164
Genoptic205
Genox177
Gentamicin sulphate
Infection95
Sensory205
Gilenya147
Ginet76
Glatiramer acetate152
Glibenclamide25
Gliclazide25
Glipizide25
Glivec171
Glizide25
Glucagen Hypokit24
Glucagon hydrochloride24
Glucerna Select223
Glucerna Select RTH223
Glucobay25
Glucose [Dextrose]48
Gluten Free Foods233
Glycerin with sodium
saccharin217
Glycerin with sucrose217
Glycerol
Alimentary35
Extemporaneous217
Glyceryl trinitrate
Alimentary22
Cardiovascular58
Glycopyrronium202
Glycopyrronium bromide22
Glytrin58
Gold Knight73
Gopten
Goserelin acetate88
Granirex139
Granisetron139
Gutron53
Gynaecological
Anti-infectives
- H -
Habitrol159

Haemophilus influenzae type B	
vaccine	250
Haldol	143
Haldol Concentrate	143
Haloperidol	141
Haloperidol decanoate	143
Hamilton Sunscreen	71
Havrix	
Havrix Junior	
HBvaxPRO	
healthE Dimethicone 10%	67
healthE Dimethicone 5%	67
healthE Fatty Cream	07
healthE Glycerol BP	217
healthE Urea Cream	217
Healtheries Simple Baking	07
Mix	000
Hemastix	
Heparin sodium	
Heparinised saline	40
Heparinised saline	40
Heparon Junior	224
Hepatitis A vaccine	250
Hepatitis B recombinant	
vaccine	
Hepsera	
Herceptin	193
Hexamine hippurate	
Hiprex	
Histaclear	
Histafen	
Holoxan	
Horleys Bread Mix	
Horleys Flour	234
Hormone Replacement Therapy	-
Systemic	81
HPV	
Humalog	25
Humalog Mix 25	
Humalog Mix 50	24
Humatin	96
Humira	184
HumiraPen	
Humulin 30/70	
Humulin NPH	
Humulin R	
Hyaluronic acid	
Hybloc	
Hydralazine	
Hydralazine hydrochloride	50 50
Hydrea	167
Hydrocortisone	107
Dermatological	65
Hormone	
Hormone	00

Hydrocortisone acetate21
Hydrocortisone and paraffin
liquid and Ianolin 65
Hydrocortisone butyrate65, 71
Hydrocortisone with
cinchocaine 22
Hydrocortisone with
miconazole 66
Hydrocortisone with natamycin
and neomycin 66
Hydrogen peroxide
Alimentary
Dermatological63
Hydroxocobalamin38
Hydroxychloroquine116
Hydroxyurea167
Hygroton56
Hylo-Fresh208
Hyoscine hydrobromide139
Hyoscine N-butylbromide22
Hypam153
Hyperuricaemia and
Antigout 122
Hypnovel153
Hypromellose208
Hypromellose with Dextran
Hysite207
-1-
- I - Ibiamox93
Ibiamox93 Ibugesic115
Ibiamox
Ibiamox 93 Ibugesic 115 Ibuprofen 115 Icatibant 197
Ibiamox 93 Ibugesic 115 Ibuprofen 115 Icatibant 197 Idarubicin hydrochloride 167
Ibiamox 93 Ibugesic 115 Ibuprofen 115 Icatibant 197 Idarubicin hydrochloride 167
Ibiamox 93 Ibugesic 115 Ibuprofen 115 Icatibant 197 Idarubicin hydrochloride 167
Ibiamox 93 Ibugesic 115 Ibuprofen 115 Icatibant 197 Idarubicin hydrochloride 167 Ifosfamide 161 Ikorel 59 Iloprost 61
Ibiamox 93 Ibugesic 115 Ibuprofen 115 Icatibant 197 Idarubicin hydrochloride 167 Ifosfamide 161 Ikorel 59 Iloprost 61 Imatinib mesilate 171
Ibiamox 93 Ibugesic 115 Ibuprofen 115 Icatibant 197 Idarubicin hydrochloride 167 Ifosfamide 161 Ikorel 59 Iloprost 61
Ibiamox 93 Ibugesic 115 Ibuprofen 115 Icatibant 197 Idarubicin hydrochloride 167 Ifosfamide 161 Ikorel 59 Iloprost 61 Imatinib mesilate 171 Imatinib-AFT 171 Imiglucerase 36
Ibiamox 93 Ibugesic 115 Ibuprofen 115 Icatibant 197 Idarubicin hydrochloride 167 Ifosfamide 161 Ikorel 59 Iloprost 61 Imatinib mesilate 171 Imatinib-AFT 171 Imiglucerase 36 Imipramine hydrochloride 131
Ibiamox 93 Ibugesic 115 Ibuprofen 115 Icatibant 197 Idarubicin hydrochloride 167 Ifosfamide 161 Ikorel 59 Iloprost 61 Imatinib mesilate 171 Imatinib-AFT 171 Imiglucerase 36
Ibiamox 93 Ibugesic 115 Ibuprofen 115 Icatibant 197 Idarubicin hydrochloride 167 Ifosfamide 161 Ikorel 59 Iloprost 61 Imatinib Mesilate 171 Imatinib-AFT 171 Imiglucerase 36 Imipramine hydrochloride 131 Imiquimod 71 Immune Modulators 111
Ibiamox 93 Ibugesic 115 Ibuprofen 115 Icatibant 197 Idarubicin hydrochloride 167 Ifosfamide 161 Ikorel 59 Iloprost 61 Imatinib mesilate 171 Imatinib-AFT 171 Imiglucerase 36 Imipramine hydrochloride 131 Imiquimod 71
Ibiamox 93 Ibugesic 115 Ibuprofen 115 Icatibant 197 Idarubicin hydrochloride 167 Ifosfamide 161 Ikorel 59 Iloprost 61 Imatinib mesilate 171 Imiglucerase 36 Imipramine hydrochloride 131 Immunod 71 Immune Modulators 111 Immunosuppressants 177 Imuran 177
Ibiamox 93 Ibugesic 115 Ibuprofen 115 Icatibant 197 Idarubicin hydrochloride 167 Ifosfamide 161 Ikorel 59 Iloprost 61 Imatinib mesilate 171 Imiguerase 36 Imiquimod 71 Immune Modulators 111 Immuran 177 Invara 177 Indacaterol 199
Ibiamox 93 Ibugesic 115 Ibuprofen 115 Icatibant 197 Idarubicin hydrochloride 167 Ifosfamide 161 Ikorel 59 Iloprost 61 Imatinib mesilate 171 Imiglucerase 36 Imipramine hydrochloride 131 Immunod 71 Immune Modulators 111 Immunosuppressants 177 Imuran 177
Ibiamox 93 Ibugesic 115 Ibuprofen 115 Icatibant 197 Idarubicin hydrochloride 167 Ifosfamide 161 Ikorel 59 Iloprost 61 Imatinib 71 Imatinib-AFT 171 Imiglucerase 36 Imipramine hydrochloride 131 Imiquimod 71 Immune Modulators 111 Imuran 177 Indacaterol 199 Indapamide 57 Indinavir 110
Ibiamox 93 Ibugesic 115 Ibuprofen 115 Icatibant 197 Idarubicin hydrochloride 167 Ifosfamide 161 Ikorel 59 Iloprost 61 Imatinib mesilate 171 Imiglucerase 36 Imipramine hydrochloride 131 Imiquimod 71 Immune Modulators 117 Indapamide 57 Indapamide 57 Indinavir 110 Infanrix IPV 250
Ibiamox 93 Ibugesic 115 Ibuprofen 115 Icatibant 197 Idarubicin hydrochloride 167 Ifosfamide 161 Ikorel 59 Iloprost 61 Imatinib mesilate 171 Imiglucerase 36 Imipramine hydrochloride 131 Imiquimod 71 Immune Modulators 111 Indapamide 57 Indapamide 57 Indinavir 110 Infanrix IPV 250 Infanrix IPV 250
Ibiamox 93 Ibugesic 115 Ibuprofen 115 Icatibant 197 Idarubicin hydrochloride 167 Ifosfamide 161 Ikorel 59 Iloprost 61 Imatinib mesilate 171 Imatinib-AFT 171 Imiguerase 36 Imipramine hydrochloride 131 Imiquimod 71 Immune Modulators 111 Immunosuppressants 177 Indaparvic 179 Indaparvic 170 Infanrix IPV 250 Infantrix IPV 250 Infantrix IPC 250 Infant Formulae 235
Ibiamox 93 Ibugesic 115 Ibuprofen 115 Icatibant 197 Idarubicin hydrochloride 167 Ifosfamide 161 Ikorel 59 Iloprost 61 Imatinib mesilate 171 Imatinib-AFT 171 Imiguerase 36 Imipramine hydrochloride 131 Imiquimod 71 Immune Modulators 111 Immunosuppressants 177 Indaparvic 179 Indaparvic 170 Infanrix IPV 250 Infantrix IPV 250 Infantrix IPC 250 Infant Formulae 235
Ibiamox 93 Ibugesic 115 Ibuprofen 115 Icatibant 197 Idarubicin hydrochloride 167 Ifosfamide 161 Ikorel 59 Iloprost 61 Imatinib mesilate 171 Imiglucerase 36 Imipramine hydrochloride 131 Imiquimod 71 Immune Modulators 111 Indapamide 57 Indapamide 57 Indinavir 110 Infanrix IPV 250 Infanrix IPV 250

Inhaled Long-acting
Beta-adrenoceptor
Agonists 199
Inset 3031
Inset II32
Insulin aspart25
Insulin aspart with insulin aspart
protamine24
Insulin glargine25
Insulin glulisine25
Insulin isophane24
Insulin isophane with insulin
neutral 24
Insulin lispro25
Insulin lispro with insulin lispro
protamine24
Insulin neutral24
Insulin pen needles28
Insulin pump28
Insulin pump accessories29
Insulin pump infusion set (steel
cannula)
Insulin pump infusion set (teflon
cannula, angle insertion with
insertion device)
Insulin pump infusion set (teflon
cannula, angle insertion)
Insulin pump infusion set (teflon
cannula, straight insertion with
insertion device)
Insulin pump infusion set (teflon
cannula, straight insertion)
Insulin pump reservoir
Insulin syringes, disposable with
attached needle
Intal Forte CFC Free202
Intal Spincaps202
Intelence
Interferon alfa-2a112
Interferon alfa-2b112
Interferon beta-1-alpha152
Interferon beta-1-beta153
Intra-uterine device73
Intron-A112
Invega Sustenna143
IPOL
Ipratropium bromide201, 203
Iressa171
Irinotecan Actavis 100164
Irinotecan Actavis 40164
Irinotecan hydrochloride164
Irinotecan-Rex164
Iron polymaltose40

Isentress111	1
Ismo 2059	9
Isoniazid101	
Isoprenaline59	
Isoptin55	5
Isopto Carpine207	
Isosorbide mononitrate59	
Isosource Standard230)
Isosource Standard RTH230	
Isotane 10	
Isotane 20	
Isotretinoin	2
Isradipine55 Isuprel	0
Itch-Soothe64	
Itraconazole	
Itrazole	
lvermectin	
- J -	5
Jadelle	5
Jevity	
Jevity HiCal RTH230	n
Jevity RTH230	0
- K -	Č
Kaletra110	n
Kemadrin	
Kenacomb205	
Kenacort-A 1080	
Kenacort-A 4080	
Kenalog in Orabase	
Ketocal 3:1238	
KetoCal 4:1238	
Ketoconazole	
Dermatological71	1
Infection	
Ketogenic Diet238	8
Ketone blood beta-ketone electrodes	
electrodes 26	6
Ketoprofen115	5
Ketostix	
Kindergen	
Kinson	
Kivexa	
Klacid	
Kliogest	
Kliovance	3
Konakion MM43	s S
Konsyl-D	
-I -	5
L-asparaginase165	-

Labetalol53
Lacosamide135
Lactulose35
Laevolac35
Lamictal136
Lamivudine103, 110
Lamivudine Alphapharm110
Lamotrigine136
Lamprene100
Lanoxin
Lanoxin PG52
Lansoprazole23
Lantus25
Lantus SoloStar25
Lanvis164
Lanzol Relief23
Lapatinib ditosylate172
Largactil140
Lasix
Latanoprost207
Lax-Sachets
Lax-Suppositories
Lax-Tab
Laxatives35
Laxsol
Leflunomide116
Lenalidomide167
Letraccord177
Letrole
Letrozole177
Leukeran FC161
Leukotriene Receptor Antagonists
Leunase
Leuprorelin
Leustatin163
Levetiracetam136
Levetiracetam-Rex136
Levobunolol206
Levocabastine206
Levodopa with benserazide125
Levodopa with carbidopa125
Levomepromazine maleate141
Levonorgestrel
Genito-Urinary75–76
Hormone83
Levothyroxine
Levothyroxine (mercury
pharma)
Lidocaine
[Lignocaine] 126–127
Lidocaine [Lignocaine]
hydrochloride

Lidocaine [Lignocaine] with
chlorhexidine127
Lidocaine [Lignocaine] with
prilocaine
Lidocaine-Claris126
Lifestyles Flared73
Lignocaine Hormone80
Nervous126. 127
Link Healthcare
Lioresal Intrathecal
Lipazil
Lipid-Modifying Agents57
Liquigen
Lisinopril50
Lisuride hydrogen maleate125
Lithicarb FC141
Lithium carbonate141
Livostin206
LMX4127
Locacorten-Viaform ED's205
Local preparations for Anal and
Rectal Disorders
Locasol236 Locoid65, 71
Locoid Crelo65
Locoid Lipocream65
Locorten-Vioform
Lodoxamide
Logem
Lomide206
Lomustine161
Loniten59
Loperamide hydrochloride20
Lopinavir with ritonavir110
Lopresor53
Loprofin
Loprofin Mix
Lorafix
Loratadine
Lorazepam145
Lormetazepam
Losartan Actavis
Losartan potassium52
Losartan potassium with
hydrochlorothiazide52
Lovir104
Loxamine132
Lucrin Depot PDS89
Ludiomil
Lumigan
Lycinate58

Lyderm	70
- M -	
m-Eslon	129
M-M-R II	253
m-Nystatin	37
Mabthera	
Madopar 125	
Madopar 250	125
Madopar 62.5	
Madopar HBS	
Madopar Rapid	017
Magnesium hydroxide	
Magnesium sulphate	40
Malathion with permethrin and	70
piperonyl butoxide	
Maprotiline hydrochloride	
Marevan	47
Marine Blue Lotion SPF 50+	
Marquis Black	73
Marquis Conforma	73
Marquis Protecta	
Marquis Selecta	
Marquis Sensolite	
Marquis Supalite	73
Marquis Titillata	73
MarquisTantiliza	
Marvelon 28	74
Mask for spacer device	204
Mast Cell Stabilisers	202
Max Health	
Alimentary	22
Hormone	79
Maxidex	206
Maxitrol	206
MCT oil (Nutricia)	222
Measles, mumps and rubella	
vaccine	253
Mebendazole	
Mebeverine hydrochloride	22
Medrol	
Medroxyprogesterone acetate	
Genito-Urinary	75
Hormone	82 84
Mefenamic acid	
Megestrol acetate	
Meloxicam	
Melphalan	
Menactra	
Meningococcal (groups A, C, Y	200
and W-135) congugate	
anu w-100/conyuyate	050
vaccine	203
vaccine	050
vaccine	253

Mercaptopurine164
Mercilon 2874
Mesalazine21
Mesna167
Mestinon115
Metabolic Disorder Agents
Metamide
Metchek25
Meterol199
Metformin hydrochloride25
Methadone hydrochloride
Extemporaneous217
Nervous129
Methatabs129
Methopt208
Methotrexate164
Methotrexate Ebewe164
Methotrexate Sandoz164
Methyl hydroxybenzoate217
Methylcellulose217
Methylcellulose with glycerin and
sodium saccharin
Methylcellulose with glycerin and
sucrose
Methyldopa55
Methylphenidate
hydrochloride
Methylphenidate hydrochloride
extended-release
Methylprednisolone80
Methylprednisolone (as sodium
succinate)
succinate)
succinate) 80
succinate)
succinate) 80 Methylprednisolone 65 Methylprednisolone acetate 80 Methylprednisolone acetate with 80 Idocaine [Lignocaine] 80 Methylxanthines 203 Metoclopramide 139 Metopirone 90 Metoprolol - AFT CR 53 Metoprolol succinate 53
succinate) 80 Methylprednisolone 65 Methylprednisolone acetate 80 Methylprednisolone acetate with 10 Iidocaine [Lignocaine] 80 Methylxanthines 203 Metoclopramide 139 Metoplazone 56 Metoprolol - AFT CR 53 Metoprolol succinate 53
succinate) 80 Methylprednisolone 65 Methylprednisolone acetate 80 Methylprednisolone acetate with 11 Iidocaine [Lignocaine] 80 Methylprednisolone acetate with 11 Metoclopramide 139 Metolazone 56 Metoprolol - AFT CR 53 Metoprolol succinate 53 Metoprolol succinate 53 Metoprolol tartrate 53 Metornold zole 100
succinate) 80 Methylprednisolone 65 Methylprednisolone acetate 80 Methylprednisolone acetate with 11 Iidocaine [Lignocaine] 80 Methylprednisolone acetate with 139 Metoclopramide 139 Metolazone 56 Metoprione 90 Metoprolol - AFT CR 53 Metoprolol succinate 53 Metoprolol zone 100 Metyrapone 90
succinate) 80 Methylprednisolone 65 Methylprednisolone acetate 80 Methylprednisolone acetate with 1 lidocaine [Lignocaine] 80 Methylprednisolone acetate with 1 lidocaine [Lignocaine] 80 Methylprednisolone acetate with 139 Metolopramide 139 Metolazone 56 Metopirone 90 Metoprolol - AFT CR 53 Metoprolol succinate 53 Metoprolol tartrate 53 Metyrone 90 Mexiletine hydrochloride 90
succinate) 80 Methylprednisolone 65 Methylprednisolone acetate 80 Methylprednisolone acetate with 1 lidocaine [Lignocaine] 80 Methylprednisolone acetate with 80 Methylprednisolone acetate 90 Metoclopramide 139 Metolazone 56 Metoprolol - AFT CR 53 Metoprolol succinate 53 Metorolol tartrate 53 Metronidazole 100 Metyrapone 90 Mexiletine hydrochloride 52 Mexiletine Hydrochloride 52
succinate) 80 Methylprednisolone 65 Methylprednisolone acetate 80 Methylprednisolone acetate with 1 lidocaine [Lignocaine] 80 Methylprednisolone acetate with 1 lidocaine [Lignocaine] 80 Methylprednisolone acetate with 139 Metolopramide 139 Metolazone 56 Metopirone 90 Metoprolol - AFT CR 53 Metoprolol succinate 53 Metoprolol tartrate 53 Metyrone 90 Mexiletine hydrochloride 90

Micolette36	
Miconazole37	
Miconazole nitrate	
Dermatological64 Genito-Urinary	
Genito-Urinary76	
Micreme76	
Micreme H66	
Microgynon 3074	
Microlut	
Midazolam153	
Midodrine53	
Minerals	
Mini-Wright AFS Low Range204	
Mini-Wright Standard204	
Minidiab25	
Minirin	
Mino-tabs94	
Minocycline hydrochloride94	
Minocycline nydrochlonde	
Minomycin94 Minor Skin Infections	
Minor Skin Infections	
Minoxidil59	
Mirena83	
Mirtazapine132	
Misoprostol22 Mitomycin C167	
Mitomycin C167	
Mitozantrone167	
Mitozantrone Ebewe167	
Mixtard 3024	
Moclobemide132	
Modafinil157	
Modavigil157	
Modecate143	
Moduretic56	
Mogine136	
Mometasone furoate66	
Monogen224	
Montelukast202	
Moroctocog alfa [Recombinant	
factor VIII1	
factor VIII]43 Morphine hydrochloride129	
Morphine sulphate129	
Morphine tartrate129	
Motetis	
Mouth and Throat37	
Moxifloxacin95	
MSUD Maxamaid235	
MSUD Maxamum235	
Mucilaginous laxatives with	
stimulants	
Sumulatus	
Mucolytics203 Multiple Sclerosis	
Multiple Scierosis Treatments145	
Ireatments	
Multivitamin renal38	

Multivitamins	39
Mupirocin	63
Muscle Relaxants	123
Mvite	39
Myambutol	101
Mycobutin	101
MycoNail	
Mycophenolate mofetil	177
Mycostatin	64
Mydriacyl	208
Mylan Atenolol	
Mylan Melphalan	161
Mylan-Bosentan	60
Mylanta P	20
Myleran	
Myocrisin	117
Myometrial and Vaginal Hormone	
Preparations	76

- N -

Nadolol	54
Nalcrom	
Naloxone hydrochloride	210
Naltraccord	
Naltrexone hydrochloride	
Naphazoline hydrochloride	209
Naphcon Forte	209
Naprosyn SR 1000	
Naprosyn SR 750	116
Naproxen	
Nardil	131
Nasal Preparations	203
Natalizumab	148
Natulan	168
Nausicalm	139
Nauzene	139
Navelbine	169
Nedocromil	202
Nefopam hydrochloride	127
Neisvac-C	253
Neo-B12	
Neo-Mercazole	84
Neocate Advance	
Neocate Gold	
Neocate LCP	236
Neoral	
Neostigmine metilsulfate	
Nepro HP (strawberry)	
Nepro HP (vanilla)	226
Nepro HP RTH	
Nerisone	65
Neulactil	
Neulastim	
Neurontin	134

NeuroTabs	
Nevirapine	.109
Nevirapine Alphapharm	
Nicorandil	
Nicotine	
Nicotinic acid	57
Nifedipine	55
Nifuran	
Nilotinib	.172
Nilstat	
Alimentary	37
Genito-Urinary	76
Infection	98
Nipent	.168
Nitrados	.153
Nitrates	58
Nitrazepam	.153
Nitroderm TTS	58
Nitrofurantoin	
Nitrolingual Pump Spray	58
Nizoral	
Noctamid	.153
Nodia	
Noflam 250	
Noflam 500	
Non-Steroidal Anti-Inflammatory	
Drugs	115
New years of the ID and the set	
Nonacod alta i Recomplinant	
Nonacog alfa [Recombinant factor IX]	
factor IX]	
factor IX] Norethisterone	43
factor IX] Norethisterone Genito-Urinary	43 75
factor IX] Norethisterone Genito-Urinary Hormone	43 75 84
factor IX] Norethisterone Genito-Urinary Hormone Norflex	43 75 84 .124
factor IX] Norethisterone Genito-Urinary Hormone Norflex Norfloxacin	43 75 84 .124 .114
factor IX] Norethisterone Genito-Urinary Hormone Norflex Norfloxacin Noriday 28	43 75 84 .124 .114 75
factor IX] Norethisterone Genito-Urinary Hormone Norflex Norfloxacin Noriday 28 Norimin	43 75 84 .124 .114 75 75
factor IX] Norethisterone Genito-Urinary Hormone Norflex Norfloxacin Noriday 28 Norimin Normacol Plus	43 75 84 .124 .114 75 75 35
factor IX] Norethisterone Genito-Urinary Hormone Norflex Norfloxacin Noriday 28 Norimin Normacol Plus Normison	43 75 84 .124 .114 75 75 35 .153
factor IX] Norethisterone Genito-Urinary Hormone Norflex Norflex Norfloxacin Noriday 28 Normin Normacol Plus Normison Norpress	43 75 84 .124 .114 75 75 35 .153 .131
factor IX] Norethisterone Genito-Urinary Hormone Norflex Norflex Noriday 28 Norimin Normacol Plus Normison Norpress Nortriptyline hydrochloride	43 75 84 .124 .114 75 75 35 .153 .131 .131
factor IX] Norethisterone Genito-Urinary Hormone Norflex Norfloxacin Noriday 28 Norimin Normacol Plus Normison Norpress Nortriptyline hydrochloride Norvir	43 75 84 .124 .114 75 75 35 .153 .131 .131 .111
factor IX] Norethisterone Genito-Urinary Hormone Norflex Norfloxacin Norfloxacin Noriday 28 Norimin Normacol Plus Normison Norpress Nortriptyline hydrochloride Norvir NovaSource Renal	43 75 84 .124 .114 75 75 35 .153 .131 .131 .111 .226
factor IX] Norethisterone Genito-Urinary Hormone Norflex Norfloxacin Noriday 28 Noriday 28 Normacol Plus Normacol Plus Normison Norpress Nortriptyline hydrochloride Norvir NovaSource Renal Novatretin	43 75 84 .124 .114 75 75 35 .153 .131 .131 .111 .226 70
factor IX] Norethisterone Genito-Urinary Hormone Norflex Norfloxacin Noriday 28 Noriday 28 Norimin Normacol Plus Normison Normison Norpress Nortriptyline hydrochloride Nortriptyline hydrochloride NovaSource Renal NovaRapid	43 75 84 .124 .114 75 35 35 31 .131 .131 .111 .226 70 25
factor IX] Norethisterone Genito-Urinary Hormone Norflex Norfloxacin Noriday 28 Noriday 28 Noriday 28 Noriday 28 Noriday 28 Norimin Normison Normison Normison Norpress Nortriptyline hydrochloride Nortriptyline hydrochloride NovaSource Renal NovaSource Renal NovaRapid NovoRapid	43 75 84 .124 .114 75 35 .131 .131 .131 .111 .226 70 25
factor IX] Norethisterone Genito-Urinary Hormone Norflex Norfloxacin Noriday 28 Noriday 28 Norimin Normison Normison Normison Normison Norpress Nortriptyline hydrochloride Nortriptyline hydrochloride Nortriptyline hydrochloride NovaSource Renal NovaSource Renal NovaRapid NovoRapid FlexPen NovoRapid Penfill	43 75 84 .124 .114 75 35 .131 .131 .131 .111 .226 70 25 25
factor IX] Norethisterone Genito-Urinary Hormone Norflex Norfloxacin Noriday 28 Noriday 28 Noriday 28 Norimin Normacol Plus Normison Normison Norpress Nortriptyline hydrochloride Nortriptyline hydrochloride Nortriptyline hydrochloride NovaSource Renal NovaSource Renal NovaRapid NovoRapid FlexPen NovoRapid Penfill NovoSeven RT	43 75 84 .124 .114 75 35 .153 .131 .131 .131 .131 .226 25 25 25 42
factor IX] Norethisterone Genito-Urinary Hormone Norflex Norfloxacin Noriday 28 Noriday 28 Noriday 28 Norimin Normison Normison Normison Normison Nortriptyline hydrochloride Nortriptyline hydrochloride Nortriptyline hydrochloride Nortriptyline hydrochloride Novasource Renal NovaSource Renal NovaRapid FlexPen NovoRapid Penfill NovoSeven RT Noxafil	43 75 84 .124 .114 75 35 .153 .131 .131 .131 .131 226 25 25 25 42 98
factor IX] Norethisterone Genito-Urinary Hormone Norflex Norfloxacin Noriday 28 Noriday 28 NovoRapid NovoRapid Penfill NovoRapid Penfill NovoRaji Novafil	43 75 84 .124 .114 75 35 .153 .131 .131 .131 70 25 25 25 298 42
factor IX] Norethisterone Genito-Urinary Hormone Norflex Norflex Noriday 28 Normin Normacol Plus Normacol Plus Normison Norpress Nortriptyline hydrochloride Nortriptyline hydrochloride NovaSource Renal NovaSource Renal NovaSeretin NovoRapid FlexPen NovoRapid Penfill NovoSeven RT NovaSali Nozinan Nozinan	43 75 84 .124 .114 75 35 .153 .131 .131 .131 70 25 25 225 42 98 .141 .203
factor IX] Norethisterone Genito-Urinary Hormone Norflex Norflex Noriday 28 Normin Normacol Plus Normison Normison Norpress Nortriptyline hydrochloride Nortriptyline hydrochloride NovaSource Renal NovaSource Renal NovaSource Renal NovaSource Renal NovaSource Renal NovaRapid FlexPen NovoRapid PlexPen NovoRapid Penfill NovaSeven RT Noxafil Nozafia Nozalian Nuelin	43 75 84 .124 .114 75 35 .153 .131 .131 .131 .111 .226 25 25 42 98 .141 .203 .203
factor IX] Norethisterone Genito-Urinary Hormone Norflex Norflex Noriday 28 Normin Normacol Plus Normacol Plus Normison Norpress Nortriptyline hydrochloride Nortriptyline hydrochloride NovaSource Renal NovaSource Renal NovaSeretin NovoRapid FlexPen NovoRapid Penfill NovoSeven RT NovaSali Nozinan Nozinan	43 75 84 .124 .114 75 35 .131 .131 .131 226 25 42 98 41 .203 .203 .134

Nutrient Modules220
Nutrini Energy Multi Fibre
Nutrini Energy RTH225
Nutrini Low Energy Multi Fibre
227
Nutrini RTH225
Nutrison Concentrated233
Nutrison Energy230
Nutrison Energy Multi Fibre230
Nutrison Multi Fibre230
Nutrison Standard RTH230
Nyefax Retard
Nystatin
Alimentary37
Dermatological64 Genito-Urinary76
Infection98
NZB Low Gluten Bread Mix234
- 0 -
O/W Fatty Emulsion Cream67
Octocog alfa [Recombinant factor
VIII]
Octreotide
Octreotide LAR (somatostatin
analogue) 176
Oestradiol
Oestradiol valerate82
Oestradiol with
norethisterone83
Oestriol
Genito-Urinary76
Hormone83
Oestrogens
Oestrogens with
medroxyprogesterone
Oil in water emulsion67
Olanzapine141, 143
Olbetam
Olopatadine209
Olsalazine21
Omalizumab191
Omeprazole23
Omezol Relief23
Omnitrope85
Onbrez Breezhaler
Oncaspar168
OncoTICE
Ondansetron
Ondansetron ODT-DRLA
One-Alpha
Onelink
Onrex
Ora-Blend218

Ora-Blend SF	.218
Ora-Plus	
Ora-Sweet	.217
Ora-Sweet SF	.217
Orabase	37
Oral Supplements/Complete Diet	
(Nasogastric/Gastrostomy	
Tube Feed)	223
Oratane	62
Orgran	.234
Ornidazole	
Orphenadrine citrate	.124
Ortho All-flex	
Ortho-tolidine	78
Oruvail SR	
Osmolite	.230
Osmolite RTH	
Ospamox	93
Other Endocrine Agents	89
Other Oestrogen	
Preparations	83
Other Progestagen	
Preparations	83
Other Skin Preparations	72
Ovestin	
Genito-Urinary	
Hormone	
Ox-Pam	
Oxaliccord	.162
Oxaliplatin	.162
Oxaliplatin Actavis 100	.162
Oxaliplatin Actavis 50	.162
Oxaliplatin Ebewe	.162
Oxazepam	.145
Oxis Turbuhaler	.199
Oxpentifylline	59
Oxybutynin	77
Oxycodone ControlledRelease	
Tablets(BNM)	130
Oxycodone hydrochloride	
Oxycodone Orion	
OxyContin	.130
OxyNorm	
Oxytocin	
Oxytocin BNM	76
Oxytocin with ergometrine	
maleate	
Ozole	97
- P -	
Pacifen	.123
Pacific Buspirone	.145
Paclitaxel	.168
Paclitaxel Actavis	.168

			INDEX
Generic	Chemicals	and	Brands

Paclitaxel Ebewe168
Paediatric Seravit
Paliperidone143
Pamidronate disodium119
Pamisol119
Panadol128
Pancreatic enzyme
Pantoprazole23
Pantoprazole Actavis 2023
Pantoprazole Actavis 4023
Panzytrat
Papaverine hydrochloride
Para Plus70
Para-amino salicylic acid101
Paracare128
Paracare Double Strength128
Paracetamol128
Paracetamol + Codeine
(Relieve)130
Paracetamol with codeine130
Paradigm 52228
Paradigm 722
Paradigm Mio MMT-92132
Paradigm Mio MMT-92332
Paradigm Mio MMT-925
Paradigm Mio MMT-941
Paradigm Mio MMT-943
Paradigm Mio MMT-94532
Paradigm Mio MMT-96532
Paradigm Mio MMT-97532
Paradigm Quick-Set
MMT-386 33
Paradigm Quick-Set
MMT-387
Paradigm Quick-Set
MMT-396 33
Paradigm Quick-Set
MMT-397
Paradigm Quick-Set
MMT-398
Paradigm Quick-Set
MMT-399 33
Paradigm Silhouette
MMT-368 31
Paradigm Silhouette
MMT-377
Paradigm Silhouette
MMT-378 31
Perediam Silbouotto
Paradigm Silhouette
MMT-381
Paradigm Silhouette
MMT-382 31
Paradigm Silhouette

MMT-383	
Paradigm Silhouette	
MMT-384	
•	
•	
•	
Paraffin	
Paraffin liquid with soft white	
paraffin	
Paraffin liquid with wool fat .	
Paraldehyde	133
Parasiticidal Preparations	68
Parnate	131
Paromomycin	96
Paroxetine hydrochloride	
Paser	
Patanol	
Paxam	
Pazopanib	
Pack flow motor	
Peak flow meter	204
Pedialyte - Bubblegum	
Pediasure	
Pediasure RTH	
Pegaspargase	
Pegasys	112
Pegasys RBV Combination	
Pack	112
Pegfilgrastim	47
Pegylated interferon alfa-2a	112
Penicillamine	
PenMix 30	
PenMix 40	24
PenMix 50	
Pentasa	
Pentostatin	
[Deoxycoformycin]	169
Pentoxifylline [Oxpentifylline]	
Pepti Junior Gold Karicare	007
Aptamil	
Peptisoothe	
Peptisorb	
Perhexiline maleate	55
Pericyazine	
Perindopril	
Permethrin	70
Persantin	44
Peteha	101
Pethidine hydrochloride	130
Pevaryl	
Pexsig	

Pharmacare	
Pharmacy Services	
Phenelzine sulphate	131
Phenobarbitone	
Phenobarbitone sodium	
Extemporaneous	218
Nervous	150 1 2
Phenoxybenzamine	100
hydrochloride	50
Phenoxymethylpenicillin	04
(Penicillin V)	
Phenytoin sodium	.134, 136
Phlexy 10	
Phosphate-Sandoz	49
Phosphorus	
Phytomenadione	
Pilocarpine hydrochloride	
Pimafucort	66
Pindolol	
Pinetarsol	
Pioglitazone	
Piportil	144
Pipothiazine palmitate	144
Pizaccord	25
Pizotifen	
PKU Anamix Infant	
PKU Anamix Junior	
PKU Anamix Junior LQ	
PKU Lophlex LQ 10	
PKU Lophlex LQ 20	235
Plaquenil	116
Plendil ER	51
pms-Bosentan	
Pneumococcal (PCV13)	00
vaccine	054
Pneumococcal (PPV23) polysaccharide vaccine	054
Pneumovax 23	
Pheumovax 23	
Podophyllotoxin	
Polaramine	
Poliomyelitis vaccine	
Poloxamer	35
Poly-Gel	208
Poly-Tears	
Poly-Visc	
Polycal	220
Polyvinyl alcohol	208
Ponstan	115
Posaconazole	98
Postinor-1	
Potassium chloride	48–49
Potassium citrate	77
Potassium iodate	39

Povidone iodine68
Pradaxa46
Pramipexole hydrochloride
Prasugrel
Pravastatin
Praziquantel91
Prazosin
Pred Forte206
Pred Mild206
Prednisolone80
Prednisolone acetate206
Prednisolone sodium
phosphate 206
Prednisone80
Pregnancy Tests - hCG Urine77
Premarin
Prevenar 13254
Prezista110
Priadel141
Primacin100
Primaguine phosphate100
Primidone
Primolut N84
Probenecid
Probenecid-AFT
Procaine penicillin
Procarbazine hydrochloride
Prochlorperazine
Proctosedyl
Procur
Procyclidine hydrochloride
Procytox
Prodopa55
Progesterone84
Proglicem24
Proglicem24
Proglycem24
Progynova82
Prokinex139
Promethazine hydrochloride198
Promethazine theoclate140
Promod222
Propafenone hydrochloride52
Propamidine isethionate205
Propranolol54
Propylene glycol218
Propylthiouracil84
Protamine sulphate46
Protaphane24
Protaphane Penfill24
Protifar
Protionamide
Provera
1 10101002, 04

Psoriasis and Eczema

Preparations	
PTU	84
Pulmicort Turbuhaler	198
Pulmocare	223
Pulmozyme	203
Puri-nethol	164
Pyrazinamide	101
Pyridostigmine bromide	115
Pyridoxine hydrochloride	38
Pyrimethamine	96
Pytazen SR	

- Q -

Q 300	100
Questran-Lite	57
Quetapel	141
Quetiapine	141
Quick-Set MMT-390	33
Quick-Set MMT-391	33
Quick-Set MMT-392	33
Quick-Set MMT-393	33
Quinapril	51
Quinapril with	
hydrochlorothiazide	51
Quinine sulphate	100
Qvar	198

- R -

RA-Morph	129
Raloxifene hydrochloride	119
Raltegravir potassium	111
Ramipex	
Ranbaxy-Cefaclor	91
Ranitidine	
Ranitidine Relief	22
Ranmoxy	
Rapamune	
Reandron 1000	
Recombinant factor IX	43
Recombinant factor VIIa	
Recombinant factor VIII	
Rectogesic	
Redipred	80
Refresh Night Time	209
Renilon 7.5	
Resonium-A	
Resource Beneprotein	
Resource Diabetic	223
Respigen	200
Respiratory Devices	
Respiratory Stimulants	
Retinol palmitate	
ReTrieve	62

Retrovir	110
Reutenox	
Revlimid	
Revolade	42
Rexacrom	
RexAir	
Reyataz	110
Ridaura s29	
Rifabutin	
Rifadin	101
Rifampicin	
Rifaximin	
Rifinah	
Rilutek	126
Riluzole	
Riodine	68
Risedronate Sandoz	119
Risedronate sodium	
Risperdal Consta	
Risperdal Quicklet	142
Risperidone	142, 144
Risperon	
Ritalin	
Ritalin LA	
Ritalin SR	155
Ritonavir	
Rituximab	
Rivaroxaban	
Rivastigmine	
Rizamelt	
Rizatriptan	
Roferon-A	
Ropinirole hydrochloride	105
RotaTeq	120
Rotavirus live reassortant oral	
vaccine	
Roxane	
Roxane	
Roxithromycin	
Rubifen	
Rubifen SR	
Rythmodan	
Rytmonorm	
-S-	
Sabril	197
SalAir	200
Salamol	
Guiui 101	

Salazopyrin21 Salazopyrin EN21 Salbutamol200 Salbutamol with ipratropium

bromide 201

Salicylic acid71
Salmeterol199
Sandomigran138
Sandostatin LAR176
Scalp Preparations71
Scopoderm TTS139
Sebizole71
Sedatives and Hypnotics153
Sedatives and Hyphotics
Seebri Breezhaler202
Selegiline hydrochloride125
Senna
Senokot
SensoCard27
Serenace141
Seretide200
Seretide Accuhaler200
Serevent199
Serevent Accuhaler
Cerembana 00
Serophene90
Sertraline132
Sertraline Actavis132
Sevredol129
Sex Hormones Non
Contraceptive
Shield 49
Shield Blue73
Shield XL73
SII-Onco-BCG184
Sildenafil60
Silhouette MMT-37131
Silhouette MMT-373
Silver sulphadiazine63
Simethicone20
Simvastatin
Sinemet125
Sinemet CR125
Singulair
Sirolimus195
Slow-Lopresor53
Sodibic
Sodium acid phosphate
Sodium alginate
Sodium aurothiomalate117
Sodium bicarbonate
Blood48-49
Extemporaneous218
Sodium calcium edetate211
Sodium
carboxymethylcellulose
Sodium chloride
Blood48
Respiratory203
Sodium citrate with sodium lauryl
···· /

sulphoacetate	36
Sodium citro-tartrate	78
Sodium cromoglycate	
Alimentary	21
Respiratory	202
Sensory	202
Sodium fluoride	200
Sodium hyaluronate [Hyaluronic	
	000
acid]	
Sodium nitroprusside	26
Sodium polystyrene	
sulphonate	49
Sodium tetradecyl sulphate	43
Sodium valproate	
Sofradex	
Soframycin	205
Solian	140
Solifenacin succinate	
Solox	23
Solu-Cortef	80
Solu-Medrol	
Somatropin (Omnitrope)	85
Sotacor	
Sotalol	
Spacer device	
Span-K	
Spiractin	4 3 56
Spiriva	202
Spironolactone	56
Sporanox	00
Sprycel	160
Staphlex	109
Stavudine [d4T]	110
Stelazine	
Stemetil	
Stesolid	133
Stimulants/ADHD	
Treatments	. 154
Stiripentol	
Stocrin	
Stomahesive	
Strattera	
Stromectol	
Suboxone	
Sucralfate	
Sulfadiazine sodium	
Sulindac	
Sulphasalazine	21
Sulphur	71
Sumatriptan	138
Sun Pharma	138
Sunitinib	
Sunscreens	71

1
0
0
0
0
0
0
3
1
1
3
9
9
9
5
9
0
0
4
6
8
8

Tacrolimus195 Tacrolimus Sandoz195 Tambocor52 Tambocor CR52 Tamoxifen citrate177 Tamsulosin hydrochloride77 Tamsulosin-Rex77 Tap water218 Tar with triethanolamine lauryl sulphate and fluorescein71 Tarceva170 Tasigna172 Tasmar125 Taxotere166 Tecfidera145 Tegretol134 Tegretol CR134 Telfast198 Temaccord168 Temazepam153 Temozolomide168 Tenofovir disoproxil fumarate 105 Tenoxicam116 Tepadina162 Terazosin50 Terbinafine99

Terbutaline sulphate	
Teriflunomide	
Teriparatide	119
Testosterone	
Testosterone cypionate	80
Testosterone esters	81
Testosterone undecanoate	
Tetrabenazine	126
Tetrabromophenol	120
Tetracosactrin	
Tetracyclin Wolff	
Tetracycline	
Teva	
Thalidomide	
Thalomid	
Theophylline	
Thiamine hydrochloride	38
THIO-TEPA	
Thioguanine	164
Thiotepa	
Thymol glycerin	37
Thyroid and Antithyroid	
Agents	84
Ticagrelor	44
Tilade	
Timolol	
Cardiovascular	54
Sensory	
Timoptol XE	207
Tiotropium bromide	202
TMP	
TOBI	
	97
Tobramycin Infection	07
Sensory	
Tobrex	
Tofranil	
Tofranil s29	131
Tolcapone	
Tolterodine	
Tolvon	
Topamax	137
Topical Products for Joint and	
Muscular Pain	116
Topiramate	137
Topiramate Actavis	137
T · · · · · · · · · ·	
(TPN)	48
TPN	
Tracleer	
Tramadol hydrochloride	130
Tramal SR 100	120
Tramal SR 150	120
II aIII aI JT 100	

Tysabri	148
TykerD	1 1 0
	172
Tykerb	
Two Cal HN RTH	∠33 222
Truvada Two Cal HN	
Trusopt	
Tropicamide	
Trophic Hormones	.85
Trisul	.95
Trisequens	.83
Trimethoprim	
Trimeprazine tartrate	
hydrochloride	142
	140
Trifluoperazine	.00
Trichozole	
Trichozole	
Triazolam	
Sensory	
Dermatological	
gramicidin, neomycin and nystat	in
Triamcinolone acetonide with	.00
Hormone	
Dermatological	
Alimentary	37
Triamcinolone acetonide	104
Trexate	
Oncology	
Dermatological	62
Tretinoin	.55
Trental 400	50
Dependence	157
Treatments for Substance	107
Treatments for Dementia	157
Travoprost	
Travatan	207
Trastuzumab	102
Tranylcypromine sulphate	121
Tranexamic acid	10.
Trandolapril	
Trandate	
Tramal SR 200	

Ultraproct	21
Univent2	01, 203
Ural	78
Urea	67
Urex Forte	56
Urinary Agents	77
Urinary Tract Infections	114
Uromitexan	167
Ursodeoxycholic acid	34
Ursosan	34

Utrogestan	84
- V -	
Vaccinations	040
Vaclovir	
Valaciclovir	
Valcyte	
Valganciclovir	104
Vallergan Forte	109
Valtrex	10/
Vancomycin	
Vannair	
Varenicline tartrate	
Varicella vaccine [Chicken pox	100
vaccine]	255
Varilrix	
Various	
Vasodilators	
Vasopressin Agonists	
Vedafil	
Velcade	
Venlafaxine	
Venomil	
Ventavis	
Ventolin	
Vepesid	
Verapamil hydrochloride	
Vergo 16	
Vermox	
Verpamil SR	
Vesanoid	
Vesicare	
Vexazone	
Vfend	
Viaderm KC	
Victrelis	107
Vidaza	162
Videx EC	
Vigabatrin	
Vimpat	135
Vinblastine sulphate	
Vincristine sulphate	169
Vinorelbine	169
Vinorelbine Ebewe	169
Viramune Suspension	109
Viread	105
Virgan	
Vistil	208
Vistil Forte	208
VitA-POS	
Vitabdeck	
Vitadol C	38
Vital	227
Vitamin A with vitamins D and	

С	38
Vitamin B complex	38
Vitamins	
Vivonex Pediatric	
Vivonex TEN	227
Volibris	60
Voltaren	115
Voltaren D	115
Voltaren Ophtha	206
Volumatic	204
Voriconazole	99
Vosol	205
Votrient	
Vttack	99
- W -	
Warfarin sodium	47
Wart Preparations	71
Wasp venom allergy	
treatment	197
Water	
Blood	48
Extemporaneous	218
Wool fat with mineral oil	67
Wool fat with mineral oil	67
	145

Xifaxan XMET Maxamum Xolair XP Maxamaid XP Maxamum Xylocaine Viscous Xylocaine Viscous	234 191 235 235 126
Xyntha	
-Z-	
Zantac	22

Zantac	
Zapril	50
Zarator	57
Zarontin	134
Zaroxolyn	56
Zarzio	47
Zavedos	167
Zeffix	103
Zeldox	142
Zerit	
Zetop	197
Ziagen	109
Zidovudine [AZT]	
Zidovudine [AZT] with	
lamivudine	
Zimybe	58
Zinc and castor oil	

Zinc sulphate	40
Zincaps	40
Zinnat	
Ziprasidone	142–143
Zithromax	92
Zoladex	88
Zoledronic acid	
Hormone	79
Musculoskeletal	120
Zometa	79
Zopiclone	153
Zopiclone Actavis	153
Zostrix	116
Zostrix HP	127
Zovirax	205
Zuclopenthixol decanoate	144
Zuclopenthixol	
hydrochloride	143
Zusdone	142
Zyban	
Zypine	141
Zypine ODT	
Zyprexa Relprevv	143
Zytiga	175